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Colorectal cancer (CRC) is a leading cause of cancer-related deaths, being the 
secondary most lethal cancer type in UK and the third worldwide. In the recent years, 
detection methods and therapies have improved overall survival and life quality of patients 
diagnosed with CRC but it is still a major health problem. There are a few signalling pathways 
whose alteration are hallmarks for CRC such as the WNT signalling pathway, RAS, TGFβ and 
the TP53 gene related signalling. For instance, the Apc gene, the core negative regulator of 
the WNT signalling pathway, is mutated in over 85% of total sporadic CRC cases and it is 
considered an initiating event for tumour formation. Targeting any of these pathways is the 
paradigm for conventional anticancer treatments. However, off-target effects or the 
development of resistance urge for additional treatments. Using multidrug therapies to 
tackle resilient cells or drugs affecting downstream pathway activation could be promising 
strategies to overcome treatment failure. 
Many molecular processes are altered during cancer evolution in order to favour 
tumour survival. One that has caught the attention of cancer researchers over the past 
decades is alternative splicing. Alternative-produced isoforms of proteins have been 
observed overexpressed in a wide spectrum of tumour types compared to non-tumoral 
healthy tissues and oncogenic properties have been attributed to many of them. RAC1B is an 
example of an alternative spliced isoform, which was firstly discovered in colorectal cancer 
cells. Since then, it has been associated with tumour-related functions. Its canonical protein 
product is RAC1, a small Rho GTPase protein which cycles from active to inactive states and 
drives cell migration and invadopodia formation, among other functions. Interestingly, Rac1 
signalling, but not its expression, has been detected overactivated in tumours, suggesting an 
oncogenic role for those proteins that promote its GTP-bound state. RAC1B is the result of 
the insertion of 19 amino acids within the switch II domain, which is responsible for the 
conformational change during its cycling from GTP to GDP. Consequently, RAC1B remains in 
a GTP bound state and it is considered a constitutive active version of RAC1. Since it was first 
discovered in breast and colon cancer cells, it has been assigned a tumour-related role. 
However, little is known about its downstream activated pathways and its function in both 
homeostasis and cancer.  





The goal of the present thesis was to describe RAC1B role in the intestine, either 
within a neoplastic context or during normal conditions. Besides, I aimed to characterise 
RAC1B relevance in tumour formation and to elucidate its potential as a therapeutic target. 
Initially, RAC1B tumour expression was studied through analysis of The Cancer 
Genome Atlas (TCGA) dataset. Interestingly, it was detected highly expressed in many cancer 
types such as lung, pancreas, thyroid and gastric-related cancers. Moreover, patients with 
high levels of RAC1B have a worse overall survival and disease-free survival. CRC can be 
divided into four different subtypes, the CMS subtypes. Curiously, even though RAC1B 
correlated with the canonical/WNT-related subtype, which has one of the best prognosis 
(CMS2), patients within this group with high RAC1B expression had a survival rate 
comparable to those with the most malignant subtype, CMS4. Therefore, these data indicate 
that RAC1B expression correlates with a worse overall prognosis for CRC patients. 
I then studied both its tumour promoter role and its requirement to drive 
tumorigenesis by modulating its expression in tamoxifen-inducible mouse models, which 
emulated different stages across tumour evolution. Other than survival and tumorigenesis 
data, intestinal tissue was used for histologic and molecular analysis, as well as for extraction 
of intestinal stem cells to culture in a 3D organoid system for following functional analysis. A 
benign adenocarcinoma model driven by heterozygous loss of Apc (APC) and an invasive 
tumour model with Apc and TP53 co-deletion (APC P53) showed the most interesting results 
and provided most information about Rac1b-related signalling pathways. 
On one side, Rac1b depletion in the APC model prolonged mice survival by decreasing 
tumorigenesis. Phenotypically, these tumours were less proliferative and RNAseq analysis 
demonstrated a strong WNT-driven phenotype, since most of its target genes were depleted 
in the co-deleted group. Moreover, a protein interactome analysis by BioID showed a large 
interactive network, with EGFR and ErbB2 receptors and other RTK and proteins involved in 
the EGFR signalling pathway. Functional analysis using a colorectal 2D cell line validated its 
interaction and presented a decreased EGFR activation when Rac1b was deleted. 
Interestingly, APC-derived organoids with Rac1b deletion were more sensitive to the 
treatment with an EGFR inhibitor drug than organoids with wild type Rac1b expression, 
indicating a synergistic effect. Moreover, tumours from the aging cohort also presented a 
downregulation in two transcriptional targets of the ERK pathway, suggesting that depletion 
of Rac1b was modulating both WNT and EGFR signalling pathways to diminish tumorigenesis. 





On the other side, the opposite effect was observed when Rac1b was overexpressed. 
The APC P53 model was used in order to model tumour invasion, although these mice 
presented a rapid tumour initiation phenotype rather than long-developed invasive tumours.  
RAC1B overexpression drove an increased tumorigenesis in the small intestine which led to 
a significant decrease in mice survival. Promotion of tumorigenesis was also observed when 
RAC1B was overexpressed in a pre-tumorigenic APC P53 model, which developed 
significantly more micro lesions or early adenomas compared to the control mice. 
Intriguingly, these microadenomas presented a marked decrease in the percentage of 
apoptosis. Transcriptome and functional analysis on the organoids derived from these mice 
revealed a decreased TGFβ-induced apoptosis, potentially through downregulation of its pro-
apoptotic target gene Bim and its signal transductor SMAD4. Histoscore quantification of 
endpoint aging tumours stained for SMAD4 antibody demonstrated a significant reduction in 
immune positivity in the group with RAC1B overexpression, pointing to SMAD4 as a potential 
Rac1b downstream mediator to regulate cell death and TGFβ tumour suppressor role. 
Altogether, this thesis provides evidence for a tumour promoter role of Rac1b. Given 
that its expression positively correlates with a worse patient prognosis, therapeutic targeting 
of RAC1B in combination with other anticancer treatments could efficiently amplify their 
effect. Nonetheless, cellular context and tumour stage might vary its downstream function, 

















The human body is composed by more than thirty trillion cells, which grow and divide 
under tightly regulated controls to avoid any cell damage or mutations. When these adverse 
events occur, our control system detects those altered cells and eliminates them from our 
body. However, if there is a dysregulation of our check-point controls, mutated cells will 
accumulate and grow uncontrollably, forming a tumoral mass and giving rise to cancer. 
Tumours might be seen as parasites, since they will take advantage of normal physiological 
processes to their own benefit to ultimately spread across different tissues. 
Cells contain our genetic information within DNA molecules, which work as an 
instruction manual for their proper functioning. However, the molecules to conduct their 
function are not DNA but proteins, which are the result of molecular processes derived from 
DNA. Different proteins can be originated from a same DNA sequence by the so-called 
process of splicing. Usually, splicing provides a predominant type of protein but, under 
certain circumstances, alternative proteins are derived from the same DNA sequence. This 
process is referred to as alternative splicing and its protein products have been an interesting 
topic of study in some diseases such as cancer. It is believed that these alternative proteins 
can provide advantages to the tumours compared to their canonical counterparts. Besides, 
they are usually more abundant in tumours than in adjacent healthy tissues, providing an 
interesting therapeutic target. 
The present project focuses in the study of an alternative splicing protein product 
named RAC1B. RAC1B has been predominantly seen in tumour tissues compared to its not 
alternative protein analogue, RAC1. RAC1 is ubiquitously expressed in all tissues and it has 
functions related with cell movement and organization of cellular compartments. RAC1 
cycles from active to inactive states as a self-regulator of its function. In contrast, RAC1B is 
almost constantly maintained on its active state, which translates into a continuous 
functioning, and this lack of regulation suggests a tumoral role. However, little is known 
about its function in both normal tissue and tumours. In order to gain knowledge about its 
role, I used mouse models for colorectal cancer (CRC) whose RAC1B expression was either 
eliminated or expressed at high levels and studied its function and the effects in these mice. 





Initially, I made use of a large human tumour data set to study RAC1B levels across a 
wide spectrum of tumour types. I observed that RAC1B was mostly expressed in tumours and 
that colorectal cancer patients with high levels of RAC1B had a worse prognosis and lower 
overall survival. Besides, RAC1B expression correlated with other cancer driver genes 
relevant in a vast range of tumours, supporting the hypothesis of a tumour-related role for 
RAC1B. 
I then made used of CRC mouse models which emulated either a benign colorectal 
carcinoma or an invasive tumour and I observed two main results. Firstly, when Rac1b was 
deleted in the less aggressive model, mice survival was improved and they developed less 
tumours compared to mice with normal Rac1b levels. This was due to a reduced activity in 
two cancer-related process (WNT and EGFR signalling), which are usually targeted for 
anticancer treatments. Interestingly, patients treated with this treatment (inhibitor for EGFR 
signalling pathway) commonly develop resistances, leading to tumour reappearance and 
more aggressive secondary disease. However, if the treatment is combined with another 
drug that reduces Rac1b levels, the overall effect is improved. Secondly, when RAC1B levels 
were overexpressed compared to normal levels in an invasive tumour mice model, survival 
was reduced and tumour formation was increased, worsening mice performance. Following 
analysis revealed that RAC1B was acting in a process responsible for eliminating mutated 
cells, namely apoptosis, which works as a protector for tumour formation. My results indicate 
that high RAC1B expression suppresses its function, which in turn leads to the survival of 
mutated cells and tumour formation. 
Altogether, this thesis provides evidence of a tumour promoter role for RAC1B. I have 
elucidated processes and molecular partners RAC1B interacts with, suggesting unknown 
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Chapter 1: Introduction 
1.1 Colorectal cancer 
Colorectal cancer (CRC) is the development of cancer in the colon or rectum. It 
proceeds with the outgrowth and transformation of benign polyps into adenocarcinoma, 
which acquire the potential to invade through submucosal layers. If untreated, invasive 
tumoral cells will eventually penetrate into blood vessels and colonise other tissues by the 
so-called process of metastasis, which is responsible of the vast majority of CRC-related 
deaths. Worldwide, CRC is the second most deadly type of cancer although large advances in 
detection and treatment have improved its overall survival rate. Colorectal cancer refers to 
cancers developed in both the colon and rectum. Even though anatomic, aetiologic and 
prognostic differences exist between them, its main traits and characteristics will be next 
described as a joint cancer type unless stated. The following section will outline the current 
knowledge in CRC regarding influential factors, classification, cancer driver genes and 
signalling pathways responsible for its malignancy.  
 
1.1.1 Statistics 
Bowel or colorectal cancer (CRC) is cancer originated in the intestine, more frequently 
developed in the large intestine or colon. It is the third commonest type of cancer worldwide 
in both, men and women, after lung and breast cancer. However, it is the second leading 
cause of cancer death only surpassed by lung cancer, accounting for 9.2% of total cancer-
derived deaths1. In the UK, CRC accounts for the second most common cause of cancer death 
but it classifies as third when statistics are split according to sex, accounting for 10% of all 
males and females cancer-related deaths, surpassed by prostate and breast cancer 
respectively. CRC incidence and mortality are higher in men, since 54% of all CRC deaths are 
males and 46% are females. Over the last 50 years, CRC mortality has substantially decreased 
in the UK, reducing by about 44% and by around 14% in the last decade alone. It is one of the 
cancer types with better treatment response at early diagnosis, since 77% of men and 74% 
of women survive for one year and about 58% survive for more than five years. The tumoral 
stage at diagnosis is an important indicator of survival rate, since up to 98% and 90% of 
patients diagnosed at stage I and II respectively survive, whereas only 40% have good 





prognosis when diagnosed at advanced and/or metastatic stages (stage IV)2. Still, there has 
been an improvement of 30% in one-, five-, and ten-years survival over the last fifty years 
and it is predicted to keep progressing at this rate. However, these numbers might vary 
largely depending on the country or place of living. For instance in UK, people that live in 
deprived areas with poor access to health care are diagnosed later and therefore have a 
worse survival rate (although this has only been demonstrated in men). Worldwide, regions 
that have less incidence of CRC due to their lifestyle and diet differences, have the same 
mortality rates to countries with high incidence as a result of limited access to medical 
controls and the lack of screening programs which prevent a late diagnosis. 
Overall, although its incidence has increased over the last years due to environmental 
risk factors, it is a fairly treatable cancer and improvement in early diagnosis and general 
awareness have substantially decreased its mortality rate. 
 
1.1.2 Influential factors for CRC onset 
A family history of disease (first- and second- degree relatives with CRC) and mutations 
in CRC-related syndrome genes are the main criteria for an individual being entered into 
screening detection programs regardless to their age or other risk factors. However, only 
about 30% of all CRC cases have a hereditary origin and environmental factors highly 
contribute to sporadic CRC cancer aetiology3. Population criteria selection for screening is 
still under debate and some risk factors that influence CRC incidence do not alter selection 
parameters (as for example obesity or alcohol consumption). It is estimated that 1 in 15 and 
1 in 18 men and women respectively in UK will be diagnosed with CRC on their lifetime, 54% 
of whose cases could be preventable4. Hence, acknowledging its risk and preventive factors 
could positively modify the chances of developing CRC. 
 
1.1.2.1 Risk factors 
Age is the main CRC risk factor with risk steeply rising from 50 years onwards and 
peaking at its highest incidence risk from 70 to 75 years old. Notably, sex difference is more 
noticeable at older ages, men being 1.7 times more likely to experience CRC than women 





from 65 to 69 years old in UK. Therefore, the majority of screenings programs start at 50-55 
years old unless a positive family history is stated5.  
Food digestion and nutrient absorption is carried out in the intestine and the type of 
food and nutritional properties that pass through the gastrointestinal tract (GI) confers a 
huge difference and long-term consequences. Red and processed meat consumption has 
long been associated with CRC risk although studies were never concordant nor definitive. 
However, in 2015, the World Health Organization (WHO) categorised processed meat within 
the group 1 (carcinogenic to humans) and red meat into group 2A (probably carcinogenic to 
humans)6. 100g per day of red meat and 50g per day of processed meat increases CRC risk 
17% and 18% respectively, mainly due to its cooking (grilled or over-cooked) and processing 
methodology and the genotoxic metabolites that are generated (H-nitroso-compounds – 
NOC-, polycyclic aromatic hydrocarbons -PAH- and heterocyclic aromatic amines -HAA-). 
Association was also observed in other cancers such as pancreas or prostate cancer and 
relative abundance of these type of meats in some diets contribute to the differential 
geographic incidence of CRC.  
A similar correlation occurs related to alcohol consumption. Moderate (50g/day) and 
heavy drinking (>50g/day) is associated with CRC risk compared to light or non-drinkers, with 
a stronger association in men than in women7. Indeed, there seems to be a non-linear dose-
response to alcohol consumption, with a CRC risk considered for intakes over 30g/day (about 
2 drinks)8. Carcinogenic mechanisms of action for alcohol include production of both reactive 
oxygen species (ROS) and acetaldehyde from ethanol oxidation and its role as a solvent to 
facilitate cellular penetration of other carcinogens (such as tobacco)9.  Other than CRC, 
alcohol negatively contributes to other cancer types and malignancies and its socially 
accepted excessive use is a major unappreciated health problem.  
Obesity is another parameter that negatively affects CRC and this is evaluated by the 
body mass index (BMI), waist circumference (WC) and waist-hip ratio. An excess in any of 
these three measurements increases the risk of CRC, thought to account for ~11% of all CRC 
cases in UK compared to normal weight individuals4. Meta-analysis studies have classified a 
BMI over 5kg/m2 and a WC increased over 10cm as a significant CRC risk8,10. Body adiposity 
causes endocrine abnormalities and metabolic changes, acting as a chronic inflammatory 
mass and altering pathways such as insulin-like growth factor (IGF) signalling, which 





promotes cell growth and inhibits apoptosis11. Therefore, lowering overall body adiposity 
lowers the incidence of most cancer types and improves patient performance during disease. 
Interestingly, height is as an unmodifiable CRC risk factor. Compelling investigations 
have demonstrated a positive correlation with tall people and bowel cancer, with incidence 
increasing by 5% per every 5 centimetres in height12. Potential reasons accounting for this 
include life factors during childhood such as greater exposure to growth factors and IGF, as 
well as anatomical reasons (longer intestines and greater number of cells). However, 
prevention screenings do not consider height parameter as a selection criteria. 
Other predisposing factors which do influence screening recommendations are 
inflammatory bowel diseases (IBD). Ulcerative colitis (UC) and Crohn’s disease (CD) accounts 
for the most common and well-documented intestinal disorders that promote CRC. They 
consist in the combination of an exacerbated inflammatory response to an altered intestinal 
microbiota or dysbiosis, accompanied by external insults (stress, smoking, diet, etc) and a 
susceptible genetic make-up of the host13. Twins and familial aggregation studies point to a 
substantial hereditary load for IBD, since 2%-5% and 5%-8% of UC and CD patients 
respectively will have IBD family history14. Moreover, both diseases could be developed 
within the same family, suggesting common and shared genetic loci. Their major difference 
though is their site of origin; CD can develop anywhere in the GI (although it’s usually more 
common in the ileum and colon), whereas UC is specific to the most distal parts of the large 
intestine. Difference also exist on their location within the intestinal epithelia; while CD 
inflammation is frequently transmural, UC is confined to the most superficial layers. An early 
disease onset is displayed in both disorders, usually ranging from 15 to 30 years old15. Their 
symptomatology is chronically discontinuous, with pause and relapse episodes that might 
mislead the need for eradication. Its cumulative, extended and prolonged inflammation 
burden is a major risk for CRC development. It accounts for 1-2% of all CRC cases and IBD 
patients have 70% higher risk of CRC than general population16. After 8 to 10 years of initial 
diagnosis patients are under close and regular surveillance and CRC incidence is 1% higher 
every year after 20 years of IBD diagnosis. Usually, IBD-related cancers appear at younger 
age compared to sporadic cancer, about 15-20 years earlier. Their genetics are different to 
sporadic cancer and carcinoma is preceded by a series of low- and high-grade dysplasia which 
ultimately culminate in neoplasia, usually multifocal17. There is more investigation in UC 





compared to CD-associated cancer, although it is believed that both lead to an equivalent 
cancer risk18. 
Diabetes mellitus type II is an example of non-intestinal disease linked with CRC risk. 
There is a 30% higher risk of CRC and 70% increased incidence in proximal/right colon cancer 
in diabetic patients19. Mechanistically, the resulted chronic hyperinsulinemia causes elevated 
insulin and IGF levels which are promoters of tumour proliferation. Controversially, some 
studies have shown that certain insulin sensitizer anti-diabetic drugs have protective effects 
for CRC, such as metformin, while insulin secretagogues worsen CRC incidence20. Thence, 
overall CRC risk can be positively and negatively modified depending on the therapy of use.  
Finally, economic status is a social factor which influences CRC incidence. Human 
development index (HDI) accounts for countries whose population have high indexes of life 
expectancies, education and capital incomes. It is shown that higher HDI countries have more 
probabilities to develop CRC than countries with low HDI. However, mortality does not follow 
the same trend, given that better health care facilities and surveillance programs improve 
survival rate in the richest countries21. According to IARC published data from 2018, there is 
a 72% mortality among all CRC cases developed in low HDI countries, against 45% in high and 
very high HDI countries, even though there were 40 times more cases in the latter22. This 
disproportional disparity in CRC incidence is independent to the risk factors aforementioned 
and urge for a global vision when addressing treatment and prevention.  
 
1.1.2.2 Protective factors 
Given the high environmental component that enhances CRC onset, there are 
numerous positive factors which have been demonstrated to be beneficial for high risk 
individuals and contribute to a healthy lifestyle. 
As discussed above, diet plays a major role in CRC incidence. Likewise, evidence exists 
for some types of foods that counteract other negative stimuli and have cancer preventive 
properties. Initial interest came after Burkitt’s observation of low CRC incidence in African 
populations, who have a diet based on high-fibre foods23. Dietary fibre might lower intestinal 
diseases and cancer through diverse mechanisms24. First, it forms short-chain fatty acids as a 
result of its fermentation by the intestinal microbiota. One of them is butyrate, which has 
already been shown to bear anti-proliferative properties. Additionally, it reduces food transit 





time and enlarges stool bulk, therefore diminishing the chances for residual mutagens to 
interact with the lining of the large intestine. It has also been shown to prevent insulin 
resistance, another risk factor for CRC, and it is a source of bioactive compounds with 
potential anti-cancer properties such as vitamin C, copper and phenolic compounds. Diverse 
meta-analysis studies have been conducted to study association with dietary fibre and CRC 
risk. There is a large amount of heterogeneity and a significant correlation was observed 
when population was stratified by sex, proving a significant association comparing consumers 
with high- vs low-fibre diets, regardless of the type of fibre origin25.  Among the foods with 
high fibre content are the wholegrains. There is a 17% reduced CRC incidence per 90 grams 
of wholegrain consumption per day, a meta-analysis from the Continuous Update Project 
Report (CUP) showed8, pointing to a protective role for CRC. Another rich source are fruits 
and non-starchy vegetables. A fruit intake above 300g per day (the equivalent of two average 
apples) significantly decreases CRC risk, while there is a positive correlation for intakes below 
100g per day8. Other than the aforementioned fibre properties, fruits are a source of vitamins 
C and E, as well as for bioactive compounds like folic acid or flavonoids. Non-starchy or 
resistant starch aliments refers to those foods that escape small bowel digestion and pass 
straight to the colon for fermentation and consequent formation of short-chain fatty acids. 
Reduced tumorigenesis has been proven in mice fed with resistant starch, as well as a 
diminished proliferation at the top colonic crypts26. A meta-analysis with eleven studies 
demonstrated that 100 grams per day of non-starchy vegetables reduced CRC risk by 2% and 
an inverse correlation was observed for intakes below 100g/day8. Aside from dietary fibre 
advantages, resistant starch vegetables contain a set of anti-tumoral agents whose 
combination lessen CRC incidence (folic acid, carotenoids, flavonoids and so on).  
Other components with CRC preventive properties include foods with vitamin C, D, as 
well as multivitamin supplements. Vitamin D is mainly known by its role in regulating calcium 
homeostasis and bone mineral metabolism. However, an anti-carcinogenic function has been 
gaining prominence after investigating the associated targeted genes of its nuclear receptor 
VDR, which might modulate colonic mucosa integrity and immunity27, among other 
functions.  A pooling project conducted by McCullough and colleagues demonstrated a 19% 
and 27% lower CRC risk with 75nm/L and 100nm/L of circulating vitamin D, respectively28. 
There was no higher improvement at concentrations above 100nm/L, and the opposite 
outcome was observed for concentrations under 30nm/L, increasing the risk up to 31%. 
Protective concentrations are over those recommended by IOM (Current Institute of 





Medicine) (65,2nm/L), which only take into consideration the amount needed for a proper 
bone health. Interestingly, they found a better association with women compared to men, 
probably due to the influence of oestrogen vitamin D activity. Therefore, vitamin D deficiency 
associates with an increased incidence in cancer, and CRC is the top cancer type with greatest 
risk according to a report from the WHO29. Moreover, it was recently demonstrated that 
vitamin D levels fall after CRC surgery and this drop predicts a worse patient outcome, 
suggesting a possible benefit in survival outcome if vitamin D is supplemented after surgery30. 
However, less conclusive information is available regarding the potential protective role for 
vitamin C or ascorbic acid. It is considered a potent antioxidant and mice experiments have 
shown an increased uptake in mutated tumoral cells of the oxidized form of vitamin C 
compared to normal cells, leading to oxidative stress and tumoral cell death31. Some clinical 
trials exploring ascorbic acid therapeutic potential alone or in combination with other 
chemotherapeutics have shown positive results and apparently, its administration route 
causes substantial differences on the outcome, with intravenous infusion the most 
efficient31,32. Nevertheless, data regarding its role as a CRC preventive is still limited. Similarly, 
an inverse correlation exists for multivitamin supplement users compared to non-users, a 
meta-analysis showed33. Overall, additional vitamin supplementation to diet seems to 
provide beneficial anti-neoplastic results, but a better understanding of its underlying 
mechanisms would help clarify its contribution and guide therapeutic doses. 
Along with vitamin D, calcium has been shown to possess protective functions against 
CRC. Mechanistically, calcium is able to bind proinflammatory secondary bile acids and 
ionized fatty acids, as well as reducing cell proliferation and promoting differentiation. The 
major sources for calcium are dairy products, which also have lactic acid-producing bacteria, 
casein and lactose that can increase calcium bioavailability26,34. Meta-analysis studies from 
the CUP demonstrate a significant reduction in CRC risk for dairy products (15% decrease per 
400g/day), milk (10% for intakes of 200g/day) and dietary calcium (6% per 200mg/day)8. 
However, beneficial role for cheese is limited. Cheese, a rich calcium source, is a double-edge 
sword due to its high fat content and there is not a significant inverse association with cheese 
consumption and CRC risk. However, overall, food high in dietary calcium are likely to reduce 
CRC risk.  
A convincing protective factor for CRC is physical activity. Consistently, a number of 
meta-analysis studies conducted in the last years have shown significant relative risk ratio for 





CRC risk in both total and recreational physical activity35,36. Numbers range from 20% to 30%, 
varying with sex or colonic region stratification. Mechanisms associated are a possible 
reduction in insulin resistance and inflammation and its consequent body weight loss after 
prolonged high physical activity. However, further studies are needed to validate its 
protective effect when there is not loss of body weight. Moreover, exercices stimulates 
colonic motility and reduces transit time, additional factors that contribute to decline CRC 
incidence26,36.  
Finally, an interesting result is the inverse association with non-steroidal anti-
inflammatory agents (NSAIDs), such as aspirin. Through cyclooxygenase-2 enzyme (COX2) 
inhibition, NSAIDs are potent anti-inflammatory agents. Besides, aspirin has been 
demonstrated to have colonic specific functions like cell proliferation inhibition by NF-κB and 
β-catenin signalling interruption and promotion of apoptosis by inducing caspase 8 and 937,38. 
Specifically in CRC cells, aspirin also inhibits cell proliferation by inducing AMPK/mTOR-
dependent autophagy39. Given the high expression of COX2 in CRC, attention arose for the 
use of NSAIDs as anti-cancer or preventive treatment. Meta-analysis trials with low daily 
aspiring doses (75-300mg) for 5 years revealed a reduction in CRC risk by about 30%40. 
Importantly, at these doses there was a substantial reduction of secondary cardiovascular 
complications. Recently, it has been shown that aspirin doses administered for anti-
cardiovascular and anti-cancer endings should be tailored based on patient’s body weight 
and height for an improved outcome41. For CRC chemoprevention, aspirin has been the first 
agent accepted by the U.S. Preventive Services Task Force (USPSTF) to be routinely used 
within individuals from 50 to 69 years with no high CRC risk but a specific cardiovascular risk 
profile42. 
In summary, numerous modifiable factors seem to have, to some extent, a positive 
and a negative effect on either preventing CRC onset or improving disease course. Expanding 
general population awareness for a healthy lifestyle against cancer and other diseases is 
essential, albeit a further elucidation and a comprehensive description of its mechanism of 

















Table 1.1: Risk and protective factors for colorectal cancer. Adapted from “The Continuous 










Decreases risk Increases risk 
Strong evidence 
Convincing   Physical activity 
  Age 
  Processed meat 
  Alcoholic drinks 
  Body fatness 
  Adult attained height 
  Chronic inflammatory bowel disease (IBD) 
Probable 
  Wholegrains   
  Foods containing dietary fibre   Red meat 
  Dairy products   Diabetes mellitus type II 
  Calcium supplements   





    Foods containing dietary fibre   
Limited-   Fish   Low intake non-starchy vegetables 
suggestive   Vitamin D   Low intake of fruits 
    Multivitamin supplements   
Limited-   Cereals, fatty acid composition, legumes, garlic, non-dairy sources of serum, 
no conclusion   sugar, coffee, tea, retinol, …   





1.1.3 Hereditary CRC 
Genetics factors are an important factor contributing to CRC risk, believed to account 
for up to 30% of all cases. However, only 10% of these correspond to known genetic CRC 
syndromes. The most characteristic trait of hereditary CRC is an early onset, from 25 to 45 
years old. Aside from the syndromes described below (Table 1.2), there is a high familial risk 
if first- or second-degree relatives have developed either cancer or polyposis, which points 
to a related inheritance whose genetic drivers are mostly still unknown. The major 
prevention measure to avoid early cancer-related death is a prompt detection and diagnosis, 
usually by colonoscopy surveillance (easy for polyposis syndromes) or histological/genetic 
analysis profile of biopsies (non-polyposis)43. Below some of the most common bowel cancer 
syndromes will be described. 
 
1.1.3.1 Lynch syndrome 
Also known as hereditary non-polyposis colorectal cancer or HNPCC, Lynch syndrome 
(LS) is an autosomal dominant condition which causes defects in mismatch repair (MMR) 
genes and predisposes to cancer in the colon and other organs such as endometrium or 
brain44. Families carrying MMR mutations may develop different primary tumour types 
segregated within different family members and their detection will facilitate LS diagnosis45. 
Tumours are more commonly developed at the most proximal/right-sided part of the colon 
and it presents an accelerated carcinogenesis compared to sporadic cancer. Its CRC incidence 
ranges from 2.5% to 5% of all CRC cases (most frequent inherited CRC type) and has a 
cumulative lifetime risk of about 40%46. LS patients are symptomatic of disease at 30-45 
years, slightly later than FAP carriers (Familial Adenomatous Polyposis, described below). 
Since it belongs to the non-polyposis syndrome group, its diagnosis is more complicated but 
equally managed by periodic colonoscopy surveillance, yet in some cases subtotal colectomy 
can be contemplated47.  
Even though it is an autosomal dominant disease, homozygosity is required for an 
MMR deficient phenotype48. This type of malignancy is characterised by a high mutational 
rate, rendering a mutator phenotype on affected individuals. This in turn facilitates the 
acquisition of second hits during tumorigenesis. Microsatellite instability (MSI) is also present 
in LS tumours as a direct consequence of the lack of repair due to MMR mutations. Germline 





mutations in at least one of the five MMR genes described comprises LS genetics: MLH1, 
MSH2, MSH6, PMS2 and EpCAM. Immunohistochemistry to identify loss of any of these gene 
protein products, especially MLH1 and MSH2, is an easy and rapid method for LS detection. 
Mutations in MLH1 and MSH2 accounts for up to 90% of all LS, while only 10% are due to 
mutations in MSH6 and rarely, mutations occur in PMS245. EpCAM deletion can lead to 
methylation of the MSH2 promoter but it is also regarded as a rare event49.  
 
1.1.3.2 Familial adenomatous polyposis 
Within the polyposis syndrome subtype, familial adenomatous polyposis (FAP) is 
characterised by the emergence of up to thousands of small polyps, predominantly in the 
most distal region of the large intestine in an autosomal-dominant inheritance fashion45. 
Initial appearance of polyps has an early onset (preteen and adolescents years) and CRC 
occurs at an average age of 35 years, with an incidence of less than 1% of all CRC cases. Given 
the large number of polyps, chances that at least one of them accumulates additional 
mutations and transforms into an adenocarcinoma are high, and therefore CRC penetrance 
of FAP is up to 100%. Genetically, FAP is the result of truncating germline mutations in the 
tumour suppressor gene Adenomatous polyposis coli (APC) and the inactivation of the 
remaining allele by additional somatic mutation or loss of heterozygosity (LOH). As well as of 
characterising FAP syndrome, loss of APC is the main initiating event in the vast majority of 
sporadic cancer. It is a tumour suppressor gene due to its negative regulatory role of the WNT 
signalling pathway and following sections will further describe its role.  
Extracolonic manifestations are also seen in FAP patients, which are less frequent and 
led by different type of mutations in APC48. Detection of more than 100 polyps confirms FAP 
diagnosis. An attenuated version form of FAP (AFAP) exists, characterised by developing 
fewer benign adenomas (hundreds instead of thousands). Consequently, CRC risk is also 
reduced (up to 70%)50. The onset of AFAP is delayed in comparison to the non-mild version 
(polyposis begins at an average age of 40 years) and its distribution is more proximal rather 
than left-sided. Diagnosis of AFAP is attributed when less than 100 polyps are detected and 
its incidence is unknown, although likely ranging from 5% to 10% of all FAP patients51. 
Predominantly, truncating 5’ mutations in APC occurs, which permits restart of translation 
and results in a shorter APC protein with constricted functions. Alternatively and less 
frequently, in-frame deletions due to splice-site mutations derive into hypomorphic APC 





protein48. However, Apc mutations partially explain AFAP genetics and the role of modifier 
genes for Apc function has also been investigated. For instance, there is evidence of some 
genes located at the 1p35-36 loci and 18q21-23 that attenuates the function of mutated APC 
by suppressing tumour formation51. FAP is clinically managed by periodic colonoscopies 
according to the tumour burden. Unfortunately, as disease advances, these procedures 
become more challenging and colectomy surgery is used as CRC prevention strategy. 
Interestingly, chemoprevention trials using aspirin or natural COX2-inhibitors such as 
curcumin have shown to be a potential option for AFAP patients whom surgery is avoidable, 
on top of delaying and preventing new surgeries in FAP patients52.  
 
1.1.3.3 MUTYH-associated polyposis 
Another hereditary condition predisposing to CRC is MUTYH-associated polyposis, 
which is caused by mutations in the base excision repair (BER) gene MUTYH. MYH (MUTYH 
protein) prevents G:C to T:A transversions, and mutations in this gene causes proximal 
colonic polyposis and an increased risk of CRC53. Genetic testing for MUTYH is conducted in 
patients with over 15 polyps and no identified germline mutations in Apc54. It is estimated 
that up to 30% patients with 10 to 100 polyps harbour biallelic/homozygous MUTYH 
mutations, and 7% to 29% are associated with individuals with 100 to 1000 polyps55, which 
could explain a portion of FAP and AFAP patients without detected Apc mutations. Overall, 
MUTYH deficiency predisposes for CRC, with an almost complete penetrance for late-onset 
disease (over 60 years) and it represents 0.54% of all CRC cases56. 
 
1.1.3.4 Hamartomatous polyposis syndromes 
The vast majority of polyps detected in endoscopies have epithelial origins, which 
comprises FAP, hyperplastic and adenomatous polyps, among other types. However, polyps 
can also arise within other intestinal compartments. Hamartomatous polyps are those whose 
origin is mostly from the mucosal layers and have a disordered tissue growth from in-site 
cells. Four types of syndromes are characterised by this type of polyp morphology: Peutz-
Jeghers syndrome (PJS), familial juvenile polyposis syndrome (JPS), Cowden’s disease and 
Banayan-Ruvalcaba-Riley syndrome. These are rare syndromes although are the most 
common type among children57. They have an autosomal dominant inheritance and only 





PTHS and juvenile polyposis are associated with increased CRC incidence. Genetically, PTHS 
is caused by mutations in the tumour suppressor gene LKB1, involved in the mTOR pathway, 
while juvenile polyposis has silencing mutations in TGFβ-related genes (SMAD4 and 
BMPR1A)45,48. Given the unclassified penetrance of these mutations, their contribution to 
familial or sporadic CRC is debatable48. Similar situation occurs for Cowden’s disease, whose 
malignant transformation is extremely rare but it is likely to enhance sporadic cancer risk 






















hMLH1, hMLH2, hMSH6,  
hPMS2, EpCAM 
A.D. 30-45 non-polyposis 40 
Familial adenomatous polyposis (FAP) APC A.D. 35 100-1000 100 
Attenuated FAP (AFAP) APC A.D. 40 <100 70 
MUTYH-associated polyposis MUTYH A.R. 60 10-1000 80 
Peutz-Jeghers syndrome (PTHS) LKB1 A.D. 20 1-100 39 
Familial juvenile polyposis SMAD4, BMPR1A A.D. 42 1-100 39 
Cowden's disease PTEN A.D. 20 - - 
Bannayan-Ruvalcaba-Riley sindrome PTEN A.D. 20 - - 





1.1.4 Sporadic CRC 
CRCs that arise in patients without a family history or genetic predisposition are 
termed sporadic CRC. Sporadic CRCs occurs mostly in older patients (above 50-55 years), and 
arise from benign polyp lesions which transform to malign adenocarcinomas after the 
accumulation of a series of mutations during a long period of time. Up to three quarters of 
all CRC cases are sporadic tumours whose origin is distinguished by two main routes: the 
adenoma-carcinoma sequence and the serrated pathway (Figure 1.1).  
 
1.1.4.1 Adenoma-carcinoma sequence 
Colorectal cancer was one of the first tumour types characterised at the molecular 
level, described by Fearon and Vogelstein in 199059. Commonly referred to as the Vogelstein 
model, it describes the progressive stepwise accumulation of well-defined genetic alterations 
in initially benign adenomatous polyps up to the formation of malignant and invasive 
adenocarcinomas.  
 A preferred order was proposed to exist in the acquisition of oncogenic mutations that 
leads to tumour formation. Through comparison of mutation frequency on the most mutated 
chromosomal regions according to tumoral stage (defined by tumour size), they observed a 
linear sequential pattern of four to five core events which are potentially responsible to drive 
adenoma progression via clonal expansion of mutated cells59. Despite subsequent tumour 
sequencing projects making major contributions in identifying mutated driver genes, the 
Vogelstein model is still regarded as the paradigm for understanding sporadic colorectal 
cancer progression.  
Somatic mutations or loss in the Adenomatous polyposis coli (APC) gene are the first 
event in the adenoma-carcinoma sequence, giving rise to a hyperproliferative tissue and 
leading to the initiation of adenomas in about 80% of all CRC cases60. APC is located on 
chromosome 5q and germline heterozygous mutations of APC are observed in FAP patients. 
Its product is a large protein of 2843 amino acids, initially thought to mediate its tumour 
suppressor role through cell adhesion mechanisms but soon after its predominant function 
was described as a negative regulator of the WNT signalling pathway61. In normal conditions, 
APC ensembles as a complex with the Axin1, Axin2, GSK3β and CK1 proteins to prompt 
phosphorylation of the core protein β-catenin and direct its targeting to ubiquitin-dependent 





proteasome degradation62. However, truncated APC is unable to form the degradation 
complex and therefore β-catenin is stable in the cytoplasm and able to translocate to the 
nucleus and initiate transcription of its target genes. Aberrant WNT signalling activation is a 
hallmark for CRC initiation and it will be further described in more detail. An alternative 
function is attributed to APC associated with chromosome segregation and the resulting 
chromosome instability (CIN). This hypothesis is based on a direct and indirect interaction of 
APC with the microtubules responsible for a proper assembly of the mitotic spindle63,64. 
Chromosomal segregation errors in still dividing cells promotes tumorigenesis through CIN. 
An increase in CIN has been observed in APC-deficient tumours65, as well as a result of 
abnormal WNT signalling activity66. Both dual roles, WNT signalling and chromosomal 
segregation regulation, contributes to its tumours suppressive role and to its function as a 
“gatekeeper” gene for normal cells in early adenoma formation. 
DNA hypomethylation is the second event in the Vogelstein model59. DNA methylation 
is an epigenetic modification that modulates expression of certain genes. The global trend 
observed in colonic tumours is hypomethylation of key regulatory genes, which also 
contributes to chromosomal instability67. However, in some tumour cells hypermethylation 
leads to gene silencing, especially on the promoter regions of tumour suppressor genes and 
DNA mismatch repair (MMR) genes. Highly hypermethylated tumours have been further and 
separately subclassified as CIMP, CpG island methylator phenotype68. They associate with 
microsatellite instability (MSI) and characterise the alternative pathway for sporadic CRC 
tumours, the sessile serrated adenomas (SSA), and the previous explained hereditary Lynch 
tumours.  
K-RAS is the most mutated small GTPase protein of the Ras superfamily. Acting as a 
molecular switch downstream of growth factor receptors, such as Epidermal Growth Factor 
Receptor (EGFR), it stimulates cell proliferation through the MAPK signalling pathway69. 
Activating mutations, mostly occurring at codon 12, are found in about 40% of all CRCs70. 
Although it is present at a high incidence percentage, it is less common in small dysplastic 
adenomas (less than 1cm) compared to larger lesions. K-RAS mutation is suggested to appear 
during the transition from early to intermediate adenoma, driving clonal expansion following 
APC deletion59,71. However, likely due to its inability to increase the stem cell pool72, it is not 
required for adenoma initiation. In recent years, K-RAS mutations have also been associated 
to drive  metabolic reprogramming in tumours through overexpression of some glucose 





receptors and enhancement of glucose uptake73,74. Overall, mutations in K-RAS render a 
proliferative advantage in tumours and contribute to their malignant behaviour. 
Loss of heterozygosis (LOH) in regions within chromosomes 17q and 18q are 
considered the next genetic event59. LOH in 18q occurs at a high frequency in all CRC cases 
(about 70% in all CRC tumours)75. While it is infrequent in early or small adenomas, allelic loss 
of 18q is present in most advanced adenomas and present in virtually all liver metastasis76. 
Originally, the tumour suppressor gene localized in 18q was identified as Deleted in colorectal 
cancer (DCC). DCC encodes for a transmembrane glycoprotein that mediates the effects of 
its ligand netrin-1, involved in neuronal cell migration, apoptosis and axon guidance77. Even 
though decreased expression of DCC seemed to correlate with 18q LOH in colorectal cancer, 
as well as in other cancer types, loss-of-function (LOF) experiments in mice failed to 
consolidate its tumour suppressor role78. Instead, a conditional suppressive function for DCC 
depending on its ligand availability rather than a leading tumour inhibition role appears more 
likely to occur79. Further research on genes residing in this locus aside DCC identified the 
SMAD family member 4, SMAD480. This is a cytoplasmic transducer of the Transforming 
Growth Factor Beta (TGFβ) signalling pathway, whose inhibition promotes cell proliferation 
and resistance to death81. 10 to 15% of advanced adenocarcinomas harbour inactivating 
mutations in SMAD470, and germline mutations in SMAD4 are the cause of inherited juvenile 
polyposis syndrome45 further supporting the role SMAD4 as a driver tumour suppressor gene. 
Allelic loss on chromosome 17q occurs at a similar rate to 18q LOH and it mainly affects 
the TP53 gene70. TP53 is a transcription factor for a plethora of target genes and is involved 
in many cellular processes mainly related in cell cycle check points and cell death82. 
Alterations in TP53 cause genome instability, promoting tumorigenesis. It is the most 
mutated gene in all cancers83 and about 50% of CRC tumours present TP53 mutations84. A 
higher proportion of de novo mutations and loss of TP53 at adenocarcinomas and invasive 
foci compared to early adenomas classifies TP53 as one of the later events during adenoma 
to carcinoma transition59,85. Thence, mutations in TP53 favour cell division and survival 
against the cellular stress signals surrounding tumoral cells at late stages.  
Finally, additional evidence has led to a further oncogenic pathway incorporated into 
the original Vogelstein sequence, the PI3K signalling pathway. Phosphoinositide 3-kinases 
(PI3K) are responsible for the production of phosphatidylinositol-3-4-5-triphosphate (PIP3), 
an intracellular second messenger which drives activation of cell growth cues, such as its 





canonical and most well-known activation of the pro-survival AKT signalling86. The gene that 
encodes for the catalytic subunit of PI3K, PIK3CA, is the second most mutated gene in all 
cancer types following TP53, with an incidence higher than 10%83. Activating mutations in 
PIK3CA are seen in about 15% to 25% in CRC, leading to an activation of the pathway 
independently from its upstream receptor tyrosine kinase (RTK)70,87. In addition, the negative 
regulator of this pathway, the PIP3 phospholipid phosphatase PTEN, is a well-established 
tumour suppressor87. Mostly inactivated by biallelic mutations, PTEN loss is observed in 10% 
of all CRC tumours, including the rare familial Cowden’s disease and in a small percentage of 
JPS cases58,88. The requirement of high WNT activation levels for driving adenoma 
transformation and its high invasive tumours incidence, both in PTEN-deficient mice89, plus 
the association between PIK3CA and tumour invasion90, have classified mutations in this 
pathway to be relevant for the last steps during carcinoma transition.  
Accounting for up to 85% of all sporadic CRC, the stepwise sequence progression for 
carcinoma formation is the cornerstone for the understanding of CRC genetics. Signalling 
pathways whereby the aforementioned oncogenes and tumour suppressor genes undertake 
their functions are the top molecular processes investigated and addressed when designing 
therapeutic strategies. However, further investigations have underscored some drawbacks 
of this model and suggested new perspectives to consider when studying colonic neoplastic 
processes, which will be outlined below.  
 
1.1.4.2 The serrated pathway 
For a long time, it was believed that the traditional adenoma-carcinoma sequence was 
the unique pathway for CRC carcinogenesis. However, a subset of polyps different to the 
conventional adenomas (tubular and tubulovillous adenomas) with a distinguishable 
histologic and molecular features exist, the so-called sessile serrated polyps. Longacre and 
Fenoglio-Preiser in 1990 first described lesions with a mixture of features from hyperplastic 
and adenomatous polyps that had a serrated glandular pattern and different morphological 
characteristics, which suggested a distinct neoplastic origin91. Extensive investigation has 
been made in these lesions and it was not until 2010 when the WHO officially classified these 
polyps into three subtypes: the sessile serrated adenoma/polyp (SSA/P), the traditional 
serrated adenoma (TSA) and the hyperplastic polyps (HPs)92.  HPs are the commonest lesions 
among the serrated polyps (80-90%) and are further subdivided depending on their mucin 





content93. In most of the cases, HPs are benign lesions and difficult to detect in endoscopic 
surveillance due to their small size, usually less than 5mm. TSA are the rarest serrated lesions 
(1-6%) with a sessile or pedunculated morphology, normally bigger than 5mm. Both HP and 
TSA originate in the distal/left colon which accompanies molecular characteristics with less 
malignant potential94. However, SSA/P (15-20%) are the unique serrated lesions located on 
the proximal colon, their size is larger than 5mm and are considered the main serrated 
carcinoma precursors95. In the last couple of decades, the serrated pathway has been 
established and well-accepted as an alternative pathway through which carcinomas develop, 
accounting for up to 30% of all colon cancers.  
Cytosine-guanine residues (CpGs) are prone to methylation, which increases risk of 
cytosine deamination to thymine. As a protective evolutionary mechanism, the genome 
harbour low frequency of small CpG repeats except for CpG-rich regions in the promoter of 
some genes, known as CpG islands68. Methylation in CpG islands translates into gene 
silencing of the promoter product, and this can affect tumour suppressor genes. Aberrant or 
hypermethylation of these regions in a subset of tumours is referred to as CIMP (CpG island 
methylator phenotype) and classifying them into the serrated route for tumorigenesis96. 
CIMP accounts for up to 30% of all CRC and it is the main characteristic of tumours that 
originate through the serrated pathway97. Depending on the levels of methylation, CIMP is 
graded as CIMP-L (low), CIMP-H (high) and CIMP-0 (negative), which accompanies a series of 
specific and distinguishable features. SSA tumours are CIMP-H, develop mostly in the 
proximal/right colon and are gender-specific (more common in women). CIMP associates 
with MSI given hMLH1 hypermethylation. Since both phenotypes cluster in right sided 
lesions, a proposed mechanism suggests that MSI is a result of CIMP which would eventually 
lead to carcinogenesis through MMR deficiency94. MSI is mostly observed in serrated 
tumours and CIMP-O and CIMP-L tumours have an MSS phenotype. However, although 
important, MSI is not an essential mechanism for SSA transformation to carcinomas98. 
Tumours can be classified into a CIMP group according to the hypermethylation status of a 
previously defined set of genes. Indeed, recent large-scale methylation studies using TCGA 
data have further subclassified CRC into 5 distinct subgroups, mostly differentiating high 
CIMP tumours with either K-RAS or BRAF mutations99. 
MAPK pathway overactivation is the second characteristic trait for serrated tumours. 
Activating BRAF mutations is considered the initiating event of serrated carcinogenesis100 and 





deletions in chromosome arm 5q (APC) are very rare. However, SSAs with acquired dysplasia 
on their malignant transition show WNT activation through missense APC mutations or other 
mutations in the pathway such as CTNNB1, both events uncommon in the adenoma-
carcinoma sequence101. Given the mutual exclusivity with BRAF mutations71, K-RAS mutations 
are found more often in CIMP-L or CIMP-O. Likewise, tumours with MMR-deficiency 
associate with high BRAF-mutation and low K-RAS-mutation frequency98. 
Different paths can be undertaken by a serrated lesion during its evolution towards a 
malignant carcinoma. Still, the molecular traits most commonly seen in these tumours, which 
constitute the so-called serrated pathway, are MSI in proximal/right lesions with initiating 
mutations in BRAF and a CpG island methylator phenotype, ultimately leading to carcinoma 
formation.  
 
1.1.4.3 New insights onto tumour origin 
The preconceived way to understand tumorigenesis requires a monoclonal initiating 
event that through chromosome instability or high mutational rate will facilitate the 
accumulation of additional driver mutations. Selective pressure within newly acquired 
mutations and clonal expansion from successful selected subclones will configure the final 
genetic profile of the transformed tumour. In this regard, the molecular and histological 
characteristics of colorectal cancer constitute a cornerstone for this principle. However, the 
study of early and driver mutations that prompt tumour initiation is of great difficulty given 
the advanced natural origin of human tumour samples. When considering tumour growth as 
an evolutionary process, one can assume that late sampled tumours would harbour 
information from early-originated mutations. Hence, evolution of tumour growth and the 
origin of its intra tumour heterogeneity (ITH) can be assessed at the genomic level. Data 
obtained from next-generation sequencing (NGS) analysis led to the development of a new 
model for understanding tumorigenesis (Figure 1.1). Based on the analysis of single tumour 
glands by multiple genomic techniques, the Big Bang model relies on the assumption that 
mutations in a tumour do not arise in a linear-sequential manner following clonal expansion, 
but rather at the initiation of tumour transformation102. Presumably, there is an initial 
transformation with intermixed tumour subclones that will grow as a single expansion. Two 
types of mutations define these clones: public or clonal, those that will be present in all 
tumours, and private or subclonal, those that will be pervasive but not dominant. New  








Figure 1.1: Colonic tumorigenesis according its mutational route. According to the clonal 
expansion model, sequential mutations arise driven by selective pressure. Two tumorigenic 
routes exist depending on their initiating event (Apc loss or MSI), the so-called adenoma-
carcinoma sequence or the serrated pathway. However, recent advances and data generated 
by next-generation sequencing (NGS) have allowed the characterisation of a new 
tumorigenesis theory. The Big Bang or single expansion model postulates that an initial burst 
of inter-mixed mutated clones arises early on tumorigenesis, which grow without selective 
sweeps. In both routes, time is the limiting factor.  
Mutations presented in the single expansion model are symbolic, based on their percentage 
of mutations in CRC.  
Top figure representing intestinal tumorigenic stages is adapted from “The molecular 










private mutations will arise as the tumour progresses due to high mutational rate and 
replication errors, but these will only be limited to certain subpopulations. According to the 
model, there are no clonal expansions when new private mutations originate. Even though 
these mutations might increase tumour fitness, they are not fixed in a selective fashion given 
that the time of origin prevails over selective pressure102. ITH found in most of the tumours 
supports this model. Previously, it was assumed that heterogeneity was the result of the 
transition to new driver mutations being fixed. However, the high ITH observed in carcinoma 
cells does not correlate with a dynamic of linear stepwise selection and selective sweeps. 
Hence, the model implies that ITH arises early and given the rapid tumour growth rate, 
fixation of newly formed mutations is a rare event. Besides, it also suggests that aggressive 
mutations that will provide future advantages on the tumour are already present at early 
stages, opening a new therapeutic angle. For example, resistance to EGFR inhibitor (EGFRi) 
treatment is almost unavoidable in virtually all initially responsive patients due to acquired 
mutations in K-RAS103 and two independent parallel studies found that those mutations were 
already detectable at low levels in the presumed K-RASWT patients, supporting the Big Bang 
model for early transformation104,105. Moreover, recent exome-sequencing data from paired 
CRC primary tumours and metastasis demonstrated a low genomic divergence and an early 
dissemination of metastatic subclones, even when carcinoma is clinically undetectable106. 
Thus, metastatic-associated driver genes are present in early clones and could serve as 
biomarkers for detection of metastatic-prone tumours. This suggests that understanding ITH 
in each tumour can be an informative and useful predictor of its future behaviour. The nearly 
neutral evolution of the Big Bang model for tumorigenesis has been supported by other 
studies and in cancer types other than colorectal cancer107,108. Indeed, studies prior to the Big 
Bang model already suggested scenarios such as the ones described. For instance, it was 
generally accepted that some initial intrinsic characteristics of the tumour would anticipate 
its malignancy such as an increased sensitivity to immune-check blockade in MMR-deficient 
CRC in contrast to MSS and low-hypermutated tumours109,110. Moreover, data generated 
from the TCGA analysis further supports this model.  
Interestingly, exome-sequencing analysis of TCGA data set shows that early-stage 
tumours present high levels of mutations which are proposed to arise at late stages according 
to the linear sequence, such as TP53 or SMAD4, indicating that tumour origin might not be 
monoclonal or that an alternative model to the Vogelstein model may exist. Furthermore, 
William et al. developed a statistical test to validate the model on the TCGA data set107. One-





third of TCGA tumours demonstrated a neutral evolution, although the model had a few 
caveats due to simplistic assumptions needed to be assumed for conducting the test111. After 
improvements on their test, they argue that neutrality is essential for understanding tumour 
heterogeneity albeit selection remains the main force for adaptation112.  
Even though the Big Bang model has been proven in different settings and it is 
endorsed by a body of evidence, clonal expansion and selective pressures as driving forces 
for tumorigenesis should not be discarded. Indeed, the model also suggests that external 
pressures such as treatment might switch tumour dynamics to a Darwinian evolution to 
select for treatment-resistant clones113. Besides, colorectal cancer mouse models have 
demonstrated how the addition of certain mutations confers invasive behaviour compared 
to others and the ability of some mutations themselves to initiate tumorigenesis114. Likewise, 
sophisticated organoid experiments have demonstrated the ability to transform healthy 
human intestinal epithelium into a carcinoma by stepwise-directed mutagenesis115,116, and 
an orthotopic organoid experiment modelled the sequential addition of mutations and the 
gradual increase of malignant features117, supporting the contribution of each mutation 
during CRC progression. 
Whether tumorigenesis is preceded by single or clonal expansion, or whether genetic 
drift or selection pressures are responsible for a subclone predominance is still uncertain. 
The tissue of origin and initiating genetic event might be highly responsible for the route 
taken during tumorigenesis. Great efforts are currently being employed to unravel the 
evolutionary history of tumours, unmasking intricate phylogenetic mutational trees and 
complex ITH. Despite this valuable information, the requirement of single cell analysis to 
conduct these studies might be impractical for routine clinical practice. Hence, the 
expectations of this model in personalising anti-cancer treatment might be challenged by the 










1.1.5 Physiology of the intestine 
The intestine is the largest structure in the body. In humans it is up to 8 meters in 
length and has a surface area of over 30m2 118. It constitutes a physical and biochemical 
barrier separating the intestinal luminal content from the underlying immune tissue, on top 
of controlling the intestinal microbiota by segregating commensal bacteria and integrating 
their microbial signals. Apart from ingestion, it controls all digestive functions, ranging from 
nutrient absorption to metabolic activities. It consists of the small and large intestine or 
bowel, the former being further subdivided into three morphological and functional different 
compartments. The first and smallest section, the duodenum, is in contact with the stomach 
and harbours the longest villus for nutrient absorption. This is followed by the jejunum and 
ileum, with villus length decreasing the more distal and closer to the large intestine and 
mucus secretion increasing for better lubrication of the food bulk towards the colon. The 
small intestinal wall is composed by four distinguished layers. The mucosa is the innermost 
layer which secretes digestive enzymes and hormones. It is supported by the connective 
tissue of the submucosa which connects it to the muscularis layer, in charge of the peristalsis 
or gut contraction and relaxation movements for digestion. The serous fluid secreted by the 
serosa, the outermost intestinal layer, lubricates the peristaltic movements from the 
muscularis119. 
The intestinal villi are finger-like projections from the mesenchyme into the intestinal 
lumen with the main objective of increasing and maximising the area of nutrient absorption. 
They are covered by a single cell layer of post-mitotic epithelium and underlined by blood 
vessels to facilitate nutrient absorption into the organism. Villi are intrinsic of the small 
intestine, being larger on the most proximal regions. In contrast, the colon is a flat luminal 
surface lacking villi, given its main function of compacting and excreting stool. Aside from 
enlarging absorption, villi are exposed to high levels of stress and environmental insults and 
a quick turnover of their adult intestinal cells protects and decreases the risk of damage 
exposure to underlying tissue120. Each villus is circumscribed at the base by at least six crypts 
of Lieberkühn121, which are the niche for the stem and progenitors cells that fuel self-renewal 
of the epithelium. Stem cells, the so-called crypt base columnar (CBC) cells, give rise to six 
different epithelial cell types which all except one migrate upwards along the crypt-villus axis.  
 





1.1.5.1 Cell populations 
The major characteristic of the intestinal epithelium is its rapid turnover of the adult 
differentiated cell compartment, which is able to self-renew every 3 to 6 days. This requires 
a daily generation of over 300 million new epithelial cells121, which is sustained by the stem 
cells residing at the crypt bottom. There is only one adult cell lineage whose renewal is 
slower, the Paneth cells, ranging from 3 to 6 weeks122. The six differentiated intestinal cell 
types are comprised of enterocytes, goblet, enteroendocrine, Tuft, Paneth and M cells 
(Figure 1.2). Indeed, they can be classified according to whether they have an absorptive 
(enterocytes and M cells) or secretory (Paneth, goblet, enteroendocrine and Tuft cells) 
function.  
The absorptive lineage is the most abundant in the villus epithelium. Enterocytes 
process the uptake of nutrients, as well as constituting a cohesive epithelial monolayer for 
permeability protection. These develop microvilli structures at their apical region, which 
allow approximately 10- to 20-fold increase of their surface area and establish the so-called 
brush border, with specialized digestive functions123. M cells are localised over the immune 
cell Peyer’s patches and are in charge of internalising luminal antigens from intestinal 
microbiota and trigger mucosal immunity by the induction of immunoglobulin A (IgA)124. 
Although originally considered secretory cells, Tuft cells may not enter into the full secretory 
criteria due to the lack of an expressing marker that characterises the rest of secretory cells, 
ATOH1125. They are rare intestinal cells that function as a chemosensory cells given their 
multiple expression of taste receptors signalling members and the presence of a long 
microvilli at the top. Enteroendocrine cells constitute a small population of the intestinal 
epithelium, less than 1%, but the largest population of hormone-producing cells in the body. 
They are able to sense the luminal content and release peptide hormones accordingly, as a 
coordinated system for gut metabolic functions like insulin secretion or appetite126. The 
morphological cup-like appearance gives the name of goblet cells, which are specialised in 
mucus secretion. Mucins and trefoil factors are the main components of the intestinal mucus, 
which serves as a chemical and physical protection from shear stress. These cells are more 
predominant in the colon and ileum, where mucus properties are beneficial to lubricate the 
passage of feces127. Finally, the Paneth cell linage has a protective function by secretion of 
hydrolytic enzymes like lysozyme and antimicrobial substances like defensins. The colon is 
devoid of Paneth cells but instead, other cells positive for Reg4+ marker undertake their 





analogous function128. All six differentiated cell types originate from the intestinal stem cells 
residing at the crypt bottom and distinct molecular signalling inputs dictate their lineage fate. 
Transit-amplifying cells are an intermediate cell type between stem and differentiated cells 
with a high proliferative rate. They reside in the crypt just above the stem cell niche and are 
capable of differentiating into all functional lineages except Paneth cells, which originate 
directly from CBC stem cells. Differentiated or mature cells then follow an upwards migration 
along the crypt-villus axis and cell replacement occurs when “old” cells reach the villus tip by 
anoikis-dependent cell death. Of note, Paneth cells are the only intestinal differentiated cell 
type that migrates in a downwards fashion, staying at the crypt bottom interspersing stem 
cells and sustaining their niche. Given the lack of villus structures in the colon, differentiated 
cells remain in the top crypt and in the surface epithelium (Figure 1.2). 
The stemness criteria of a cell describes the capability to generate multiple lineages 
and to possess long-term self-renewal capacity. In the intestine, stem cells are constantly 
proliferating, generating undifferentiated daughter/transit-amplifying cells which divide and 
differentiate into different cell lineages. It has been largely known that pluripotency of the 
intestine resides at the crypt bottom, but the lack of advanced genetic tools made further 
characterization of potential intestinal stem cells challenging. Originally, two independent 
models attempted to explain their intestine positioning. One of them argued that stem cells 
resided at the position +4, 0 being the central deepest crypt cell, and that Paneth cells resided 
from 0 to +3129. They demonstrated DNA label-retaining capacity of these cells but progeny 
linked to them could not be proven. Parallelly, Leblond and Cheng argued that CBC cells 
represented the intestinal stem cells due to their morphology and cycling activity130. 
However, it was not until twelve years ago that the first stem cell marker for this CBC cells 
was described using lineage tracing experiments131. By the tamoxifen induction of genetically 
modified mice carrying a LacZ and Cre-EGFP knock-in alleles in the Lgr5 gene, a WNT 
signalling target gene, Barker et al. were able track cell differentiation from the Lgr5+ cells. 
These cells were localised intermingled with the Paneth cells, at positions 0 to +2 and rarely 
at +4, as it was previously suggested. After five days of induction, the whole crypt-axis was 
monoclonal and labelled with its expression, containing cells from all lineages. Therefore, 
Lgr5 was revealed as a CBC stem cell marker for both small and large intestine. Nonetheless, 
extensive research has also demonstrated stem cell-like properties for the +4 label-retaining 
cells (LRC). The current belief for their function argues that they serve as quiescent stem cells 
which can restore Lgr5+ cells and replenish the crypt units following their loss upon 





injury132,133. Hence, certain circumstances require the LRC pool for proper tissue 
regeneration. However, it seems that normal tissue homeostasis does not rely on their 
proliferation, aside from being precursors of Paneth cells133. Furthermore, recent 
investigations have demonstrated that differentiated cells from distinct lineages, including 
secretory and enterocytes progenitors, can dedifferentiate and repopulate the crypt base, 
after Lgr5+ cells loss134,135. It is yet unknown whether dedifferentiation ability is marked by 
niche distance or progenitor stage, although a possible mechanism suggests that contact re-
establishment with Paneth cells might provide niche signals to gain stemness136,137. Indeed, 
the stemness of the stem cell zone is also partially maintained by the stem cell niche 
composed of subepithelial myofibroblasts associated to the crypt, which secrete growth 
factors and cytokines to sustain stem cell proliferation. It has also been suggested that 
epigenetic mechanisms might play a key role, given that for instance permissive open 
chromatin is maintained throughout differentiation and this can facilitate reprogramming138. 
Dedifferentiation plasticity is also observed in other tissues such as the lung or liver139,140, 
implying a shared differentiation dynamic with higher complexity to that of unidirectionality.  
In summary, the identification of stem cell markers has allowed their thorough study 
and the characterization of cell growth dynamics along the crypt-villus axis. The stem cell 
niche and the activity of certain signalling pathways preserve and restrict the stem cell zone 
at the crypt bottom, which gives rise to all the intestinal cell lineages. Interestingly, adult 
intestinal cells can cope with the loss of stem cells by self-reprogramming to dedifferentiated 
states. Despite large contributions, comprehensive mechanisms responsible for this cell 




















Figure 1.2: Small and large intestine architecture and their epithelium self-renewal 
dynamics. Taken from: “Adult intestinal stem cells: critical drivers of epithelial homeostasis 









1.1.5.2 Signalling pathways maintaining intestinal homeostasis 
With such complex dynamics to fulfil the rapid turnover for differentiation, a tight 
signalling network at the stem cell niche and in the transit-amplifying (TA) zone is needed for 
appropriate functioning and proliferation. Among the most relevant are the WNT, Notch, EGF 
and BMP signalling pathways, whose ligands are also used for in vitro organoid modelling of 
crypt growth141.  
The WNT signalling pathway and the gene expression profile activated through the β-
catenin cascade and TCF4/LEF1 transcription factors have been shown to be the master 
regulators of stem cells proliferation, as well as for maintaining the constant proliferation of 
the TA cells. Evidence reside on the disorganization of the stem cell niche and intestinal 
architecture destruction upon conditional deletion of some of its core elements or targeted 
genes, as well as on the resultant intestinal hyperplasia and uncontrolled grow when they 
are activated142–144. Binding of Wnt ligands to the Frizzled-LRP5-LRP6 complex and LGR4 and 
LGR5 receptors leads to dissociation of the β-catenin destruction complex, allowing its 
nuclear translocation from the cytoplasm, where association with TCF4/LEF1 transcription 
factors initiates their transcriptomic program (more detail of the pathway will be outlined in 
the next section). A gradient of WNT signalling activity is observed along the crypt axis, being 
higher at the bottom and decreasing as it reaches the villus tip. This activity gradient 
maintains the stem cell zone, which is restricted to the crypt bottom, and delimits high 
proliferative rate to a confined region. Ligand availability is responsible for this gradient, with 
WNT3A and R-spondin ligands the best described. WNT3A and other WNT ligands such as 
WNT2B are produced by Paneth cells and underlying mesenchyme, and it is likely other 
unknown sources also boost WNT ligands levels136,145. Likewise, intestinal R-spondin derives 
from PDGFRα+ subepithelial myofibroblast146. A gradient of WNT activity is created through 
the progressive loss of ligand-bound cells across CBC cell divisions, being almost non-existent 
at the topmost regions147. Besides, stem cells express high levels of LGR4 and LGR5 receptors 
compared to differentiated cells, both specific for R-spondin binding148. On top of regulating 
WNT activity, β-catenin also controls cell positioning through expression modulation of 
Ephrin ligands and their Eph tyrosine receptors. Receptor expression is restricted to the 
proliferative intestinal region whilst ligand expression is present in an antagonist pattern, 
decreasing towards the crypts149. This distribution is essential for correct localization of 





epithelial cells along the intestinal crypt/villus axis, given the observation that deletion of 
EphB3 in the murine intestinal epithelium causes Paneth cell mislocalization.  
A similar situation as with WNT and R-spondin ligands occurs for EGF ligand. Paneth 
cells produce EGF and TNFα ligands136, whose receptor (ERBB1) is highly expressed in CBC 
cells. The EGF signalling pathway participates in stem cell proliferation but high activity levels 
can be detrimental and lead to disease. With the aim of controlling a steady state of activity, 
stem and proliferative cells also express Lrig, its negative regulator of the pathway150. EGF is 
one of the indispensable factors to maintain crypt structures in vitro. However, although EGF 
is essential for their proliferation, it is not required for stem cell identity since stem cells are 
maintained in organoids upon EGF-depletion, albeit their proliferation is halted and they 
enter in a reversible quiescent state151. 
Ligands of the BMP family, which activate non-canonical SMAD signalling via the 
SMAD1/5/8 transcription factor complex, are also important. BMP2 and BMP4 ligands 
released by intercrypt and intervillus mesenchymal cells promote cell differentiation152. In 
order to protect stem cells from this pro differentiation activity, the stem cell niche expresses 
high levels of BMP inhibitors such as Gremlin 1, Gremlin 2 and Noggin153. 
Finally, Notch signalling controls CBC cells fate through its lateral inhibition and direct 
membrane cell contact for activation. When a Notch-activated cell expresses its target gene 
HES1, this in turn inhibits Notch activity on its neighbouring cells through repression of 
ATOH1 expression, whereby Notch signalling is also repressed154. Notch signalling blocks the 
secretory lineage differentiation, hence regulating a constant rate of secretory/absorptive 
differentiated cells through this binary fate. 
In summary, generation of the highly diverse specialised intestinal cells and 
maintenance of the stem cell population is the result of tightly control signalling cascades, 










1.1.6 Cancer driver genes and their signalling pathways 
Transformed cells are characterised by presenting aberrant activation of normal 
functioning signalling pathways. In the intestine, pathways responsible for tissue 
homeostasis and cell proliferation are hotspots for deregulation, facilitating unrestricted cell 
overgrowth throughout the tissue. The TCGA revealed the signalling pathways with most 
recurrently mutated genes in the majority of sporadic CRCs, which include the WNT, 
RAS/mitogen-activated protein kinase (MAPK), transforming growth factor beta (TGF-β) and 
TP53 signalling155.  A brief overview on the biochemical characteristic of these pathway will 
be provided. 
 
1.1.6.1 The WNT signalling pathway 
WNT signalling is a conserved pathway with functions in morphogenesis and 
proliferation during both development and adult tissue homeostasis. There are two 
functionally distinguishable types with shared receptors but divergent downstream cascades, 
the canonical or WNT/β-catenin and the non-canonical or planar cell polarity (PCP) pathway. 
Its activation is driven by WNTs and R-spondin ligands upon binding to Frizzled-LRP5/6 
complexes and LGR4/5 receptors. 
WNTs are growth factors that promote proliferation through WNT signalling 
activation. There are nineteen different ligands in humans with likely distinct functions given 
the phenotypes observed in LOF experiments and their conserved orthologs in other species, 
albeit their signalling outputs are fairly similar156. They are usually co-expressed in the same 
tissue, as for example in the intestine where six different WNTs are expressed. Differences 
might reside on their specificity to activate either the canonical or the non-canonical 
signalling, although their cooperation and cross-reactivity has demonstrated that virtually all 
WNTs can ultimately activate the β-catenin cascade157. In parallel, the other main type of 
ligand are R-spondins. These are secreted proteins and four different types exist in humans. 
They promote WNT signalling by both potentiating WNT-driven activation and binding to 
their specific receptors148,158. Interestingly, WNTs and R-spondin ligands have distinct but 
cooperative functions for WNT-dependent maintenance of Lgr5+ stem cells: R-spondin 
induces their self-renewal and stem-cell proliferation, whereas WNT ligands induce LGR5, 
RNF43 and ZNRF3 expression to sustain R-spondin activity159. 





Heterodimers of Frizzled proteins (FZDs) with their co-receptors, low-density 
lipoprotein receptor-related protein 5 and 6 (LRP5/6), are the primary receptors for WNT 
ligands, although R-spondins can also signal through them by binding to LRP6. Association of 
WNT to FZD leads to LRP5/6 dimerization and a conformational change that induces both 
phosphorylation of the cytoplasmic LRP5/6 tail and recruitment of the positive WNT 
regulator Dishevelled (DVL) protein on the cytoplasmic region of FZD. DVL stabilises receptor 
heterodimerization and along with the LRP5/6 phosphorylated sites recruits the scaffolding 
protein Axin for initiating the signalling cascade160. On the other side, LRG4/5 receptors are 
the main binding partners for R-spondin ligands. LRG5 was firstly discovered as a WNT target 
gene and as a marker for intestinal stem cells131. Both, LGR4 and LGR5 are co-expressed in 
the intestine but LGR4 is more broadly expressed along the crypt-villus axis. Upon R-spondin 
binding, LGR4/5 receptors interact with FZD-LRP5/6 complex and trigger WNT signalling, as 
well as enhancing WNT ligands signals161. Alongside receptors, potent membrane negative 
regulators for WNT signal exists. RNF43 and ZNRF3 are E3 ligases that ubiquitinate 
cytoplasmic loops of FZDs and LGR4/5 receptors, inducing their proteasomal degradation. 
They are also WNT target genes, therefore acting as a negative feedback loop. Interestingly, 
R-spondin can also bind to ZNRF3 and RNF43, releasing WNT receptors from their negative 
pressure, thereby indirectly inducing WNT activation162. Besides, a dual function for DVL was 
recently discovered, whereby it can mediate ZNRF3/RNF43-dependent ubiquitination of FZD 
receptors, hence acting as a positive and a negative regulator of the WNT pathway to ensure 
proper signalling activity163.  
Signal and gene transcription activation is mediated by the activity of a cytoplasmic 
destruction complex (DC) and the nuclear translocation of the transcriptional coactivator 
protein β-catenin. The DC is integrated by the tumour suppressor protein APC, the two 
constitutively active serine-threonine kinases CK1 and GSK3 and the complex scaffolding 
protein Axin. Under ligand-free conditions, the DC efficiently captures β-catenin by direct 
binding to Axin. Thence, sequential phosphorylations by the CK1 and GSK3 kinases in its 
amino terminal region function as docking sites for the E3 ubiquitin ligase β-Trcp, which 
targets β-catenin for proteasomal degradation and maintains low levels of β-catenin in the 
cytoplasm. However, upon ligand binding, Axin localises at the membrane, recruited by 
phosphorylated LRP6 and DVL, which destabilises the DC and dissociates β-Trcp from the 
complex. Phosphorylated β-catenin uncapable of being ubiquitinated is accumulated in the 
DC, which saturates the complex and newly synthetized free β-catenin starts to accumulate 





in the cytoplasm164 (Figure 1.3). Previous models suggested that cytoplasmic β-catenin 
accumulation was due to an inability to form the DC and hence a lack of phosphorylation 
sites for ubiquitin ligase recognition165. However, they were based on overexpression analysis 
and this updated model was the first based on studying the complex dynamics at endogenous 
levels. Free cytoplasmic β-catenin is then able to translocate to the nucleus, displace the 
repressor protein Groucho and engage transcription by binding to the DNA-bound T cell 
factor/lymphoid enhancer factor (TCF/LEF) family of proteins. This initiates a signalling 
cascade of genes involved in embryonic and adult stem cell proliferation, whose 
overactivation leads to the transformation of intestinal epithelial cells166. 
Inactivating mutations in the APC gene is the principal mechanism of WNT signalling 
deregulation and as it was mentioned in the previous section, its loss is present in the vast 
majority of CRC. Other less frequent mutations within the pathway include the β-catenin 
encoding gene CTNNB1, AXIN2, AMER1 or TCF7155,167. Alternative mechanisms to activate 
WNT signalling also include overexpression of WNT ligands168,169 or silencing of natural WNT 
antagonist through hypermethylation of their promoter, such as for SFRPs (secreted frizzled-
related proteins)170. Despite diversity existing as to the precise mechanism via which WNT 
activation is achieved, it is recognised as a hallmark of CRC171. However, its therapeutic 








Figure 1.3: The Wnt signalling pathway. In the absence of ligand (left), β-catenin is efficiently 
degraded through ubiquitination and the pathway remains switch off. However, in the 
presence of ligand (right), the DC localises at the membrane where the βTrCP cannot bind. 
The excess of unphosphorylated cytoplasmatic β-catenin translocates to the nucleus and 
activates its signalling program. Illustration taken from “Wnt Signaling through Inhibition of 
β-Catenin Degradation in an Intact Axin1 Complex” (Li et al., 2012). 





1.1.6.2 RAS/mitogen-activated protein kinase (MAPK) pathway 
Signalling activated by MAP kinase proteins constitute a sequential phosphorylation 
cascade that responds to extracellular stimuli such as growth factors, cellular stress and 
inflammation. Signals are integrated by a set of receptors tyrosine kinases (RTK), which 
recruit the adaptor protein GRB2 and the RasGEF SOS to activate the Ras small GTPase at the 
membrane. GTP-bound Ras recruits Raf and initiates the kinase cascade, leading to a range 
of biological responses such as proliferation, differentiation, apoptosis or inflammation172. 
Four different cascades exist which are commonly referred to by the last kinase member: 
ERK1/2, JNK, p38 and ERK5. The ERK1/2 (also termed p42/p44) MAPK cascade is the best 
characterised, especially its Raf-MEK-ERK activation route173 (Figure 1.4). Activated ERK1/2 
translocates to the nucleus for phosphorylation-dependent transactivation of TFs, mainly 
involved in cell proliferation and differentiation. The JNK cascade is mainly induced in 
response to cytokines, pathogens, environmental stress or genotoxins. At least fifty JNK 
substrates have been identified this far, including c-Jun, p53, c-Myc, Bim and MCL1, indicating 
that proliferation and apoptosis regulation are among its biological functions174. 
Phosphorylated c-Jun can dimerize with JunB, JunD or c-Fos to jointly constitute the 
transcription factor activator protein 1 (AP-1). Cellular stress can also activate the p38 MAPK 
kinase, especially stimuli such as UV light, heat or osmotic shock, as well as growth factors 
like insulin in a cell-dependent manner175. Consequently, stress-related responses are 
activated by this kinase such as Cdc42-induced cell cycle arrest and NF-κB regulation. Besides, 
it also promotes phosphorylation of other kinases in the cytoplasm like the mitogen-
activated protein kinase-activated protein (MAPKAPK). ERK5 is more poorly described but 
equally important for growth factors and stress response. With a more limited set of 
substrates, its activation translates in an enhanced c-Jun expression176. 
Epidermal growth factor receptor (EGFR) is the best known RTK that associates 
extracellular factors with the MAPK signalling pathway. EGFR or ERBB1 is a member of the 
ERBB family of receptors. Upon ligand binding, EGFR mono or heterodimerises with other 
members of the family, preferentially ERBB2, and auto-phosphorylates on its tyrosine 
residues, allowing the association of adaptor proteins like Grb2 and the RasGEF SOS for Ras 
activation and membrane recruitment of the first MAPKKK. During intestinal homeostasis, 
EGFR ligands released by the stem cell niche activate proliferative responses through ERK 
signalling136. Indeed, MAPK activity also shows a gradient across the intestinal epithelial cells, 





being higher at the crypts and lower at the villi to promote differentiation177. Thence, 
overactivation and expansion of ERK1/2 activity leads to rapid proliferation of 
undifferentiated cells, promoting cell transformation. An increase in the abundance of EGFR 
ligands and activating mutations in either EGFR or in the recruited Ras small GTPases confers 
a cell-autonomous activation of ERK69. Three different forms of Ras GTPases exist in humans 
for RTK downstream activation: K-RAS, N-RAS or B-RAF, which in CRC are mutated at an 
incidence of 45%, 5% and 10% respectively69,155. K-RAS and B-RAF mutations are mutually 
exclusive and they associate with distinct tumorigenic routes71. All mutations translate into 
hyperactivity of ERK1/2 signalling but dissecting their mutational profile is of paramount 
importance for addressing therapeutic strategies, as for instance the benefit of using MEK1/2 













Figure 1.4: The MAPK signalling pathway. The picture illustrates the major 
downstream EKR1/2 targets, both cytosolic proteins and nuclear transcription factors. 
Image taken from “Targeting ERK, an Achille’s Hell of the MAPK pathway, in cancer 
therapy” (Liu et al., 2018).  
 





1.1.6.3 The TGF-β signalling pathway 
The transforming growth factor-beta (TGF-β) signalling pathway is a superfamily of 
TGF-β receptors and proteins that are involved in a plethora of cellular processes, such as cell 
proliferation, apoptosis, differentiation, morphogenesis and migration179. It is comprised of 
33 different ligands from diverse families (TGF-β, Bone Morphogenic proteins -BMPs-, 
Activin, and so on) that bind to multimers of TGFβ-1 and -2 serine/threonine kinase receptors 
(TβRI and TβRII) or BMP receptors (BMPR) and activate either canonical or non-canonical 
cues. In the canonical pathway, SMAD2/3 are phosphorylated by receptors of the TGF-β 
family whilst SMAD1/5/8 are activated by BMP receptors. These receptor-activated SMADs 
then form a trimeric cytoplasmic complex with SMAD4, which facilitates translocation to the 
nucleus for initiating the transcription of targeted genes81. In parallel, the non-canonical 
pathway includes a SMAD-independent activation of the MAPK signalling, among other 
pathways such as PI3K or mTOR, through recruitment of Grb2 and SOS on TβRI/II tyrosine 
phosphorylated sites. Ras and Rho small GTPases and TGF-β-activated kinase 1 (TAK1) 
associate to the phosphorylated receptors and trigger the ERK1/2, JNK and p38 cascades to 
ultimately enhance gene transcription180.  
Although TGF-β was first described for its role during embryonic development, current 
literature mainly focusses on its function in cancer and its switchable dual role. Suppression 
of the pathway has been observed at early stages of cancer in order to overcome the role of 
TGF-β signalling in cell growth inhibition and promotion of apoptosis. This can occur by 
induction of the cyclin-dependent kinase inhibitor p21 or the pro-apoptotic protein Bim181. 
However, in a context and time dependent manner, TGF-β activity changes to a pro-
oncogenic function by induction of EMT and inflammation. Cell-autonomous genomic and 
epigenomic changes in the tumour cell genome might tailor TGF-β anti- or pro-oncogenic 
functions, such as mutations in TP53, loss of SMAD4 or oncogenic activations in the RAS-
MAPK pathway182. The TCGA data shows that inactivating mutations in SMAD4 are present 
in up to 20% of CRCs, along with less frequent mutations in SMAD2/3 and TGF-β and activin 
receptors155,183. However, given its promotion of the EMT process and the highly 
undifferentiated morphology of tumoral cells when TGF-β is activated, high levels of TGF-β 
ligands within the tumour or surrounding stroma indicates patient poor prognosis184. 
Consequently, its therapeutic targeting has been hindered by the lack of understanding of its 
double-edged function and its activity is rather used as a marker for tumour stratification185.  





1.1.6.4 p53 signalling 
First cloned in 1983, the p53 protein (encoded by the TP53 gene) is a transcription 
factor that regulates cell cycle progression and apoptosis. These functions can also be 
regulated at the cytoplasmic level given its ability to interact with protein members of the 
Bcl2 family186. p53 activity is inhibited by its interacting protein MDM2, which prevents its 
function either by promoting p53 ubiquitination or by blocking its trans-activation domain. 
In normal cells, p53-MDM2 constitute a negative feed-back loop whereby p53 induces 
MDM2 expression to self-control its function, maintaining low p53 levels187. Its activity is also 
modulated by MDMX, a family member of MDM2 that contributes to MDM2-dependent 
ubiquitination188. Upon DNA damage or cellular stress, MDM2 dissociates and p53 levels 
increase in order to halt cell cycle and drive apoptosis on damaged cells. Furthermore, 
regulation of autophagy and induction of senescence are also other mechanisms p53 utilise 
for suppressing cell growth189. Given its critical function, p53 has been designated as the 
“guardian of the genome” and its proper activity is paramount to keep an organism free from 
damaged cells190. Therefore, it is not surprising that tumours lose its activity to expand clones 
of transformed tumoral cells. 
TP53 is the most mutated gene in all cancer types83, and the second-most in CRC. It is 
believed that mutations in TP53 drives invasion of tumours, although some types of CRC may 
present p53 loss as the initiating mutational event, such as cancers derived from chronic 
inflammation191. Interestingly, a high percentage of these mutations (74%) are missense 
mutations, which give rise to a mutant protein that is efficiently expressed in tumour cells 
and leads to a decrease in wild type p53 activity192. Mutant TP53 is detectable by 
immunohistochemistry (IHC) in human tumours, which shows a more aggressive morphology 
and early cancer onset compared to those mutations that cause loss of TP53 expression193,194. 
Genetically modified mice with either deletion of TP53 or expression of mutant TP53 
conditionally in the intestine have shown that the latter presents a gain-of-function (GOF) 
phenotype and induces invasion of intestinal adenocarcinomas195. However, a recent study 
has demonstrated that missense mutations in TP53 lead to a dominant-negative effect (DNE) 
rather than GOF activities, equivalent to that of p53 inactivation196. In both scenarios, mutant 
TP53 is clonally selected over wild type TP53. Therefore, restoration of normal p53 is not a 
feasible therapeutic approach and further elucidation of mutant p53 mechanisms are 
necessary.  





1.1.7 Stratification of CRC tumours 
One of the outcomes from the TCGA project was to facilitate the classification of 
cancer types into subtypes197,198. Typically, initial classifications of CRC have been made 
according to whether tumours displayed microsatellite instability (MSI) or not (MSS) and by 
their mutational rate199. MSI and hypermutated tumours, mostly correlating with MLH1 
silencing, featured a group that represented 15% of all CRCs. Over time and with the 
acquisition of data from large sequencing programs such as TCGA, it became apparent that 
tumours harbour further molecular differences which would allow further subclassification. 
For instance, it was described that within the MSI group, over 37% of these tumours did not 
have MLH1 hypermethylation and presented high WNT activity due to APC and K-RAS 
mutation, in contrast to the other 63% that showed high frequency of BRAFV600E mutations 
and low WNT  signalling200. As the TCGA and other efforts progressed, different groups 
attempted to describe complex and standardised gene-based classifications but there was a 
lack of both concordance among all of them and feasible utility for clinical treatment201–204. 
With the aim of using the similarities from each previous approach and to build from them a 
consistent molecular CRC classification, the CRC Subtyping Consortium was created (CRCSC). 
It was formed by six different expert groups which had an independent algorithm that 
previously was used as an approach to subdivide CRC. The CRCSC took eighteen different CRC 
data sets and normalised their raw data format for these groups to analyse with their 
algorithm. Each one obtained a number of subgroups, whose association was studied and 
looked for robust substructures that would suggest clusters between the groups. They then 
identified four significant clusters, the so-called consensus molecular subtypes (CMSs) 
(Figure 1.3)185. Based on additional molecular data from the cohorts used to establish the 
CMSs, it was possible to outline the main characteristics for each of the four categories. The 
CMS1 comprises most of the MSI and hypermutated tumours, it has the highest proportion 
of B-RAF mutations (characteristic of serrated polyps) and an enriched immunological 
signature. On the other side, CMS2 is the most prevalent and it is considered the canonical 
CRC subtype. It is enriched with mutations in the WNT/β-catenin signalling pathway and it is 
mainly MSS. It has the lowest proportion of hypermutated tumours but the highest somatic 
copy number alteration (SCNA) count, especially in oncogenes. In contrast, CMS3 is 
considered the metabolic subtype with a high prevalence of KRAS mutations and an 
intermediate MSI phenotype. Last but not least, CMS4 accounts for the subtype with the 
worst prognosis due to its upregulation in genes implicated in TGF-β and EMT signature. Like 





CMS2, it is MSS and infrequently hypermutated and it has a high inflammatory signature as 
a result of its stromal infiltration. CMS4 is usually diagnosed at advanced stages and presents 
the worst overall survival and relapse-free survival. CMS1 survival is poor after treatment 
relapse and CMS2 along with CMS3 shows the best disease-free survival.  
Since then, CMS stratification has been implemented in both research and clinic as the 
“gold-standard” method for characterising tumours based on molecular and prognosis 
features. However, an evident drawback of analysing whole-tumour expression profile is the 
joint analysis of tumour and stroma. Evidence exists for a role of the tumour stroma on 
driving some of the features associated with poor prognosis and invasion, such as the 
mesenchymal and stem-like traits of the CMS4 and the inflammatory profile of CMS1 and 
CMS4205,206. With the intention of avoiding the stromal bias potentially derived by bulk 
tumour transcriptome, a new subtyping classification was created. The colorectal cancer 
intrinsic subtypes (CRIS) consists of the transcriptomic analysis of a large set of patient-
derived xenografts using human microarrays, hence differentiating expression of intrinsic 
only-tumour cells from the stromal gene expression with murine origin205. They identified 
five different subtypes with little overlap with those from the CMS consortium. MSI tumours 
clustered two major types, CRIS-A and to some extent CRIS-B, which presented an enriched 
CIMP and hypermutated phenotype compared to the other three subtypes, although MSS 
samples with a MSI-like phenotype were also present in the CRIS-A group. In contrast, CRIS-
B, CRIS-C and CRIS-D were CIN and enriched for WNT activity. Major characteristics 
associated for each subgroup included B-RAF and K-RAS mutations with metabolic phenotype 
for CRIS-A, inflammatory phenotype with high TGF-β signalling and EMT phenotype in the 
CRIS-B, high EGFR signalling dependency with K-RAS wild type tumours in CRIS-C, 
amplification of IGF2 and high WNT/stem signalling in CRIS-D, and Paneth-like phenotype 
with TP53 mutations in CRIS-D. Hence, major traits from the CMS subtypes were spread into 
different CRIS groups but the later were absent of stromal content, implying intrinsic tumoral 
gene profile responsible for driving these phenotypes. Transcriptomes from the xenografts 
was also validated on their corresponding primary tumours with high fidelity and treatment 
prediction was identified, such as the significant sensitivity on the CRIS-C group to cetuximab 
due to their dependence on EGFR signalling and lack of genetic markers of EGFRi-driven 
resistance. In spite of the novelty of this approach to discern between tumoral and stromal 
gene expression, bias resultant of the xenotransplantation cannot be completely discarded. 





Further clinical validation using this stratification is required and to date it has not had as 
broad an impact and comprehensive validation as the CMS subclassification.  
 The CMS subtyping has become highly informative in different settings, albeit current 
biomarkers used in clinic for tumour prognosis and treatment prediction include as few as 
MSI and mutational status of RAS or B-RAF207. Incorporation of variables that were not fully 
integrated in the initial CMS design such as intra-tumour heterogeneity or stromal content, 
plus other factors that might have biased tumour sample collection like colonic location or 
tumour treatment might improve the accuracy of the stratification and allow its efficient 





Figure 1.5: Schematic representation of CRC consensus subtypes. Taken from: “Consensus 
molecular subtypes and the evolution of precision medicine in colorectal cancer (Dientsmann 












1.1.8 Therapeutic approaches for CRC 
The therapeutic route taken upon CRC diagnosis varies largely depending on the 
disease stage at diagnosis. If detection occurs at early stages, surgery is the first option and 
adjuvant chemotherapy would be administered according to tumoral stage, especially for 
tumours at stage II and III (with local invasion or with regional lymph-node metastasis)210. For 
metastatic CRC (mCRC), resection of metastasis by surgery is also the best option but 
unfortunately, the majority of metastasis are unresectable. In that scenario, combination of 
different chemotherapeutic agents along with the addition of monoclonal antibodies have 
substantially improved overall survival of mCRC patients up to 30 months in the last 20 years, 
in comparison to the 12 months expectancy when single chemotherapeutic agent was 
administered211. Hence, a positive change in cancer treatment is observed after the 
introduction of targeted therapies. 
Fluoropyrimidines, especially 5-fluorouracil (5-FU), was initially the standard of care 
for CRC treatment212. Other chemotherapeutic agents also include irinotecan, oxaliplatin and 
trifluridine/tipiracil. Over time, different regimens of agent combinations emerged, being 
FOLFOXIRI the one that showed greater anti-tumour activity (triple combination of 5-FU, 
oxaliplatin and irinotecan)213. Indeed, adjuvant chemotherapy with FOLFOXIRI has 
demonstrated to increase overall survival of patients with stage II to III CRC214. However, 
advances in the molecular staging system have evinced the high levels of intra tumour 
heterogeneity in CRC and have slowly introduced targeted therapeutic approaches as the 
paradigm for anti-cancer treatments. Their efficiency relies on accurate patient stratification 
according to their potential response to therapies, which is achieved by the identification of 
treatment resistance/sensitivity biomarkers. To date, the genetic alteration most used in 
clinic for treatment decision making is K-RAS mutational status, which allows patient 
stratification for EGFRi treatment215. Indeed, the latest review from the national 
comprehensive cancer network dictates that all mCRCs patients should be genotyped for 
mutations in the RAS loci (for K-RAS or N-RAS) and, if positive, they should not receive EGFRi 
monoclonal antibodies treatment (such as cetuximab or panitumumab)207. Moreover, if they 
are wild type but present B-RAFV600E mutation, EGFRi should be combined with B-RAF 
inhibitor such as vemurafenib, although its efficiency in CRC is still debated and the clinical 
trial for this treatment is still ongoing216. Another biomarker regularly used is MMR 





deficiency, given that stage II tumours with MSI-H do not benefit from 5-FU adjuvant 
therapy217. 
Efficiency of combined chemotherapeutic agents is increased by additional treatment 
with cetuximab or panitumumab218,219 (anti-EGFR antibodies, for RAS wild type tumours) or 
with bevacizumab220 (an anti-VEGFR antibody, for RAS-mutated tumours).  As an example, a 
clinical trial demonstrated that FOLFOXIRI treatment alone on mCRC patients resulted on a 
median of progression-free survival of 9.7 months, while combination with bevacizumab 
extended it to 12.1 months211. Therefore, the best current adjuvant therapeutic option is the 
combination of a cocktail of chemotherapeutic agents along with monoclonal antibodies 
against non-mutated signalling pathways221. Unfortunately, this recipe has limited benefit 
given that a large proportion of treated tumours relapse. Therefore, there is a pressing need 
to develop more accurate biomarkers to better anticipate tumour response and increase the 
chances of success. However, as our knowledge in tumour biology expands, so it does its 
complexity and the level of personalization for the treatment to be efficient. This is 
accompanied by expensive screenings and high cost techniques which might not be doable 
to undertake at large scale. In spite of this, the benefit of these approaches might be manifold 
compared to current chemotherapy and screening standardization and identification of 
easily detectable new biomarkers will hopefully turn personalised medicine into the future 















1.2 Rho GTPases 
The Ras superfamily encompasses a large number of small GTPases which influence 
cell organization and signalling upon stimuli and binding to their associated regulators and 
effectors. With highly evolutionary conserved orthologs in both unicellular and multicellular 
organisms, Ras superfamily proteins are divided into 5 main subfamilies: Ras, Rho, Arf/Sar, 
Ran and Rab222. All of them share a common G structural domain which renders all members 
of the superfamily highly similar but still allows binding and affinity to specific protein 
effectors. This domain consists of a set of conserved G boxes (G1-G5) that directs their 
binding and hydrolysis of GTP/GDP, acting as molecular switches for a plethora of 
intracellular pathways. When bound to GTP, they are in an active state with high affinity for 
their downstream targets, whereas GTP hydrolysis confers an inactive GDP-bound state. This 
conformational switch is facilitated by two loop regions, switch I (residues 30 to 38) and 
switch II (residues 59-67) regions, whose reorientation modifies their affinity for their 
effectors223. There is also an effector core domain located within the switch I region (in 
residues 32-40) which has proven critical for their direct effector association and 
specificity224. Although simplistic, this process is tightly regulated by guanine nucleotide 
exchange factors (GEFs), which catalyse GDP to GTP exchange in the membrane, by GTP-
activating proteins (GAPs), which accelerates their low intrinsic GTPase hydrolysis activity, 
and by guanine nucleotide dissociation inhibitors (GDIs), which sequester GDP-bound 
GTPases in the cytoplasm to avoid binding to GEFs. Besides, additional spatiotemporal 
regulation exists at the post-translational level in some cellular contexts, that modulates their 
activation as well as their cellular targeting223,225. For example, membrane targeting of Ras 
proteins is conducted by lipid post-modification on a C-terminal CAAX motif, shared in the 
majority of Ras and Rho family members. Prenylation (farnesylation or geranylgeranylation) 
on the cysteine residues of their CAAX box and/or palmitoylation, the covalent binding of 
fatty acids, allows stable membrane positioning and Ras activation through GTP binding226. 
Indeed, GDI proteins, specific negative regulators of the Rho and Rab subfamily, carry out 
their cytoplasmic block through masking of the prenyl modification227. However, some 
proteins might undergo phosphorylation for cytosol translocation or ubiquitylation such as 
RhoA228. 
In humans, the Ras superfamily comprises over 150 different members. Although their 
biochemical function as GTPases is mostly shared across all members, differences on their G 





boxes sequences and specific functions allow their further functional classification in the 
aforementioned five branches. Besides, GDP/GTP-bound regulation through post-
translational modification and through binding to GEFs/GAPs are also specific for each 
subfamily. Phylogenetically, recent research points to the Arf subgroup as the root for the 
rest of the superfamily, contrary to the initial belief of Ras proteins as founding members222. 
Given the primordial role of Arf GTPases as membrane trafficking regulators, it underlies the 
evolutionary sophisticated function of Ras as modulators of cellular processes. The most 
functionally diverse group is the Ras subfamily, firstly known as viral oncogenes and now 
described with manifold roles in cell proliferation, survival, differentiation and gene 
expression control229. Rab and Arf are mainly involved in membrane and vesicular transport 
of proteins, whereby they can also transduce signalling cues230,231. The Ran subfamily 
encompasses the most abundant small GTPases in the cell and are regarded as a subgroup 
of the Rab family, becoming specialised in nuclear transport of RNA and proteins222, in 
addition they have a role in coordinating nuclear envelope and spindle apparatus assembly 
during mitosis232. Rho GTPases are closely related to the Ras subfamily and are characterised 
by their role in actin cytoskeleton organization, through which they can modulate cell 
polarity, morphology, migration and adhesion233. In turn, they also modulate a wide range of 
cell proliferation and survival processes via direct or indirect regulation of targeted gene 
expression. The best characterised members of this family are Rac1, RhoA and Cdc42, and 
given the central interest of this thesis, a comprehensive description in the Rho subfamily 
followed by an in-depth depiction of Rac1 will be provided. 
The Rho (Ras homologous) family constitutes a group of 20 small GTPases divided into 
8 subfamilies234. Rho was the first and serendipitously discovered in 1985, whose encoding 
gene was isolated from the sea snail Aplysia235. Short after, in 1989, Rac1 and Rac2 were 
identified as substrates for the botulinum toxin C3 ADP-ribosyltransferase236 and Cdc42 was 
elucidated in 1990 after cloning the formerly known G25K gene237. All of them presented high 
homology to the already described Ras gene (previous p21ras) but shared higher similarity 
between them, hence were considered to belong to the same subfamily. Almost all of the 
Rho proteins function as canonical GTPases cycling from active GTP-bound to inactive GDP-
bound states, working as molecular switches for signalling modulation. However, eight 
members of this family are regarded as “atypical” Rho proteins. These remain in constant 
activation due to key amino acid substitutions that either prevent GAP binding or cause high 





intrinsic nucleotide exchange activity, relying on their expression levels or post-translational 
modifications for their function regulation233.  
GEFs and GAPs are the major regulators for downstream Rho functions, along with 
GDIs (Figure 1.4). To date, there are over 80 RhoGEFs and RhoGAPs and 3 different RhoGDIs 
described. GEFs subclassify according to two unrelated carrying domains: Dbl-homology 
(DH), the most abundant with over 70 members in humans, TIAM1 being an example238, or 
Dock homology region (DHR) domains, a family with 11 members specifics for the Rac and 
Cdc42 subfamily. In contrast, a unique catalytic BCR homology (BH) domain exists for the 
described RhoGAPs239  which is unrelated to the other GAPs from the Ras superfamily. Given 
the very slow intrinsic hydrolysis activity of small GTPases, GAP binding is essential for tuning 
the signalling cascade to the cellular signal dynamics. Rho family functions are pleiotropic 
and the large number of different GEFs and GAPS are partially responsible for their broad 












Figure 1.6: Regulation of Rho GTPase activation. Most of the Rho GTPase proteins cycle from 
GDP-bound (inactive) to GTP-bound (active) states. This process is regulated by GEFs and 
GAPs proteins, as well as by post-translational modifications that allow their membrane 
targeting. GDI act as negative regulators by retaining RhoGTPase in the cytoplasm. Figure 
taken from “Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in 
development and disease” (Cook et al, 2014). 





Rho proteins are activated through stimuli transduced by growth factor receptors and 
integrins, among others240. Intensive research has been made in the last years to draw a 
better and more complete picture of the downstream functions of each Rho subfamily. Most 
of the current knowledge has been gained through analysis of cellular changes upon 
microinjection studies of dominant negative forms of RhoA, Rac or Cdc42, as well as with in 
vivo and in vitro experiments with constitutive active or dominant negative forms of each 
GTPase. Regarding actin dynamics and remodelling, the distinguishable traits for the most 
well-studied Rho protein subfamily are stress fibre formation and focal adhesion (FA) 
assembly for RhoA, the promotion of lamellipodium and membrane ruffling for Rac1 and the 
filopodium formation for Cdc42234. Hitherto, up to fifty different effectors for these three Rho 
proteins have been identified, embracing a broad set of signalling pathways including cell-
cycle progression, axonal guidance and chemotaxis, the alteration of which is of relevance 
for many diseases. 
Three highly homologous isoforms, with about 88% of shared sequence, comprise the 
Rho proteins: RhoA, RhoB and RhoC. All of these are capable of inducing stress-fibre and FA 
formation, which consist of bundles of contractile actin filaments emanating from 
extracellular matrix and cell membrane assemblies241. In comparison to Rac and Cdc42, Rho 
act at the rear part of the cells to promote detachment for cell locomotion242. At the 
molecular level, Rho activates the serine/threonine kinases ROCK1 and ROCK2 for myosin 
light-chain (MLC) phosphorylation and Myosin II activation, which interact with actin 
filaments from FAs, thereby enhancing contractility and modulating adhesion cell 
attachment traction (Figure 1.5)243. Likewise, Rho interacts with protein kinase C-related 
kinases (PRKs) and with the formin protein mDia, the latter in charge of promoting actin 
polymerization as well as of microtubule stability regulation244. Given that the three Rho 
proteins have a highly conserved core effector domain, it was presumed that they would also 
share most of their effectors; explaining why a large proportion of functional studies were 
initially conducted using RhoA as a model. However, different cellular location due to distinct 
post-translational modifications indicate specific targeted proteins and effectors, as it has 
been demonstrated in the last decade. While RhoA and RhoC are predominantly in the 
cytosolic compartment, RhoB localizes at the plasma membrane and at the endosomes245. 
This has been translated into substantial differences on their roles in cancer. Functional in 
vivo experiments and human tumour expression analyses have established RhoA and RhoC 
as consolidated oncogenes, with RhoC having a role as a metastatic driver244,246. On the 





contrary, RhoB is mainly considered a tumour suppressor gene since it inhibits cell growth 
and promotes apoptosis. However, some stimuli might induce its expression such as DNA 
damage or growth factors, indicating that its role in tumours might be context dependent. In 
fact, it has been shown to regulate endosome trafficking of growth factor receptors such as 
EGFR, hampering their recycling and therefore, indirectly modulating their signal 
positively247,248. Nevertheless, in most scenarios, RhoB acts as a tumour suppressor gene249 
and its downregulation negatively correlates with patient prognosis.  
Initially discovered as an essential factor for yeast budding and cell polarity, Cdc42 
(sharing 80% homology with the Rho proteins) was subsequently cloned in mammalian 
tissue237,250. Functionally, Cdc42 triggers the formation of the actin-based structures 
filopodia, thin and finger-like actin extensions at the front of the cell important for 
chemotaxis and motility purposes251. Like Rho which also assemblies FA for stress fibre 
association, Cdc42, as well as Rac1, stimulates the assembly of analogous multimolecular 
focal complexes. These contain proteins such as vinculin, paxillin and focal adhesion kinase 
(FAK) and associate filopodia and lamellipodia to the plasma membrane251. Actin 
polymerization of Cdc42 is performed by the Arp2/3 complex, which will nucleate new actin 
filaments and cross-link them into Y-shaped branches252. Activation of the complex is 
mediated by the Cdc42 effector Wiskott-Aldrich syndrome protein (WASP) and its 
homologous N-WASP, although other effectors can also promote actin polymerization in an 
Arp2/3-indepent route such as the formin mDia (Figure 1.5)253.  
In brain development, filopodium structures, along with lamellipodia, are essential 
components during synapsis formation and axon extensions. Mice with conditional knock-
out of Cdc42 in the brain had a reduced number of axons and are lethal when born, likely due 
to a decreased activity in its effector cofilin and consequent inhibition of filopodial 
dynamics254. In other cell types, loss of Cdc42 might be compensated by additional Rho 
GTPases that can also induce filopodia such as Rif, TCL or Wrch-1255. Besides, crosstalk 
between Cdc42 and Rac1 also influences their activities, such as the indirect lamellipodia 
formation by Rac1-dependent Cdc42 activation and partial filopodia inhibition by reduction 
of Rac1 activity251,255. 
Filopodium are involved in cell migration, whose aberrant over-activation is observed 
in pathologic conditions such as cancer256. Besides, cancer driver pathways have been 
demonstrated to be influenced by Cdc42 activity. Cdc42 also establishes cell fate 





determination by interacting with the Par6-Par3-atypical protein kinase C (aPKC) complex 
and abolition of Cdc42 causes polarity defects257. Likewise, EGFR signalling is also affected 
when Cool-1, a Cdc42-specific GEF, is abnormally phosphorylated and transduces into 




There are three different Rac isoforms, without taking into consideration the atypical 
non GDP/GTP-cycling RhoG233. Rac1 is the most highly studied Rac protein, being fairly 
ubiquitously expressed across all tissues. In contrast, Rac2 is specific to hematopoietic cells 
and Rac3 to the nervous system. Such a distinctive pattern of expression suggests large 
differences on their biological functions which will probably be not redundant. Evidence of 
the wide variety of functions carried out by Rac1 compared to Rac2 and Rac3 arose from 
genetically modified mice. Whereas whole-body Rac1-knockout mice are embryonic lethal, 
Rac2- and Rac3-knock-out mice are viable and only present cell-type specific defects259–261. 
Rac2-deficient mice showed a substantial diminution of actin content on their neutrophils, 
which impaired their motility and orientation although other functions such as superoxide 
production were compensated by the co-expression of Rac1 in these cells261. On the contrary, 
Rac3-knockout mice presented no obvious anatomic differences to their controls albeit 
subtle defects on their behaviour that improved their motor skills259.  
Subcellular compartmentalisation of Rac1 influence its activation262. When inactive, 
Rac1 is a cytosolic protein forming a GDP-bound complex with a GDI chaperone in a 1:1 
ratio263. Geranylgeranylation and prenylation modifications and a preceding polybasic region 
(PBR) to the CAAX motif are responsible for Rac1 targeting to the plasma membrane, where 
binding to GEFs will confer its active GTP-bound state. Curiously, the same PBR harbours a 
nuclear localization sequence (NLS) that allows Rac1 translocation to the nucleus264,265. Over 
30 different effectors interact with GTP-Rac1 bound protein, influencing a myriad of 
signalling pathways whose functions will be briefly summarised. 
 





1.2.1.1 Actin dynamics 
Actin polymerization driven by Rac1 leads to the formation of membrane ruffling and 
lamellipodia, essential events for cell motility266. Membrane ruffles are actin rich membrane 
protrusions that usually precede lamellipodia formation, which are flat and short actin 
filaments arranged as a dense array localised at the leading edge of a motile cell252. 
Lamellipodia-driven migration occurs when protrusions are restricted to one side of the 
plasma membrane267. Integrin participation in the focal complexes during lamellipodia 
formation induces Rac1 activation as a response of their feedback loop, which perpetuates 
Rac1 activation and makes migration more efficient268. As for filopodia, Arp2/3 complex also 
participates in lamellipodia extension but this is activated through the WAVE (WASP-family 
verprolin-homologous protein) complex, since Rac1 does not directly interact with WASP269. 
Alternatively, Rac1 can also induce lamellipodia, either by removing capping proteins at the 
barbed ends, hence allowing further polymerization at the blocked end filaments156, by 
activating mDia2 formin, or by modulating cofilin phosphorylation through its effectors p21-
activated protein kinase (PAK) and LIM kinase (LIMK) (Figure 1.5)269. Actin remodelling is 
carried out by the combination and spatiotemporal coordination of all three (Rho, Cdc42 and 
Rac1) activated GTPases. Their resultant actin structures conduct locomotion in migrating 
cells, either in normal or transformed cells270. The clearest example is the negative feedback 
regulation between RhoA and Rac1 in both their activity and location within the cells, where 
opposite positioning orchestrates synchronised cell movement (Figure 1.5)270. Their 
coordinated activity might explain why cells can migrate albeit lacking Arp2/3 or WAVE 
complexes271,272. 
Rapid cell adhesion dynamics are in close relationship with their migration process, 
given that detachment and rapid reorganization of cell-cell contacts are essential for proper 
cell integrity. Upon contact between migratory cells, the establishment of a strong cell 
adhesion involves cytoskeleton remodelling and rapid lamellipodia formation at the contact 
sites, resulting in active Rac1 accumulation273,274. Halting of cell movement and the 
commencement of adhesion also requires a steady balance in lamellipodium length. Myosin 
activity partially regulates this process by both blocking filament elongation at the back of 
the lamellipodia and organizing extracellular matrix (ECM) and cytoskeleton association275. 
Rac1, along with FA-integrin, modulates myosin activity through PAK- and PKC-dependent 
phosphorylation of myosin II276. Fluorescence resonance energy transfer (FRET) experiments 





have revealed that activated Rac1 preferentially localizes transiently at de novo cell-cell 
contact sites277. Certain plasma membrane compositions such as lipid rafts and phospholipid-
enriched zones attract GEF accumulation and therefore promotes activation of Rac1278–280. 
Continuous dynamic movement of activated Rac1 around the cell edge plus actin-myosin 
complex contractibility at cell contact sites serves as a current model for understanding Rac1 
modulation of cell adhesion281. 
Actin remodelling is also necessary for vesicular trafficking, macropinocytosis and 
phagocytosis. Intracellular uptake of bacteria, antigen presentation complexes or dead cells 
requires actin polymerization at focalised membrane regions where these particles will be 
internalised. Membrane reorganization initiates with membrane ruffling at hot spot sites and 
Rac1 activation peaks before membrane closure following vesicle (or macropinosome) 
formation282. WAVE complexes and PAK1 activation is necessary for Rac1-mediated 
macropinocytosis283. Constant Rac1 activation would impair vesicle formation so Rac1 










Figure 1.7: Actin dynamics orchestrated by Rho GTPases. Stress fibres localise at the rear 
front of the cell and regulate cell contraction and mobility. In contrast, lamellipodia and 
filopodia localise at the leading edge and the combination of these three structures induces 
forward cell movement. Filopodia is controlled by Cdc42, Rac1 promotes lamellipodia and 
membrane ruffle formation and RhoA induces stress fibres and focal adhesion. Their protein 
effectors and crosstalk during actin polymerisation and turnover are schematised in the 
figure. 





1.2.1.2 ROS production 
Following Rac1 characterization as a C3 transferase substrate236, its first functional 
description was the activation of the NADPH oxidase complex through its target p67phox285. 
NADPH reduces oxygen on superoxide molecules, which can spontaneously form hydrogen 
peroxide and eventually generate reactive oxygen species (ROS)269. Rac1-generated ROS is 
currently a well-accepted source of ROS, which contributes to a wide range of functions. 
Among the most extensively described are bacterial killing on macrophages and neutrophils 
and regulation of senescence through DNA damage286,287. Additionally, ROS production 
mediates Rho GTPases crosstalk, given that Rac1-derived ROS indirectly activates p190Rho-
GAP for Rho downregulation288. Cell survival is also affected by ROS production in a Rac1-
Tiam1-dependent manner through ERK pathway activation289. Similarly, ROS levels control 
stem cell production in a tissue-specific manner290,291 and it has been shown than in the 
intestine, generation of ROS drives abnormal stem cell proliferation outside their niche, a 
mechanism tightly associated with neoplastic processes292.  
 
1.2.1.3 Signal transduction 
Rho GTPases can regulate cellular events beyond processes related to cytoskeleton 
remodelling. In particular, Rac1 modulation of gene expression has largely been implicated 
in cell proliferation and death responses, both in homeostatic contexts and human diseases. 
The activation of at least three different MAPK pathways have been shown to be 
influenced by GTPase activation. On one side, it was initially discovered in 1995 that Rac1, 
along with Cdc42, could stimulate JNK activation293. c-Jun amino terminal kinases (JNK) are 
activated upon cellular stress and regulate the activity of the transcription factor c-Jun and 
its partner c-Fos, which upon dimerization form the transcription factor activator protein 1 
(AP1). Other subfamilies of MAPK are the p38 and ERK1/2 MAP kinases. All three follow 
distinct pathways of activation downstream of Cdc42, Ras and Rac1 activation, the latter 
performing its action though its effector Pak294–296. Signal transduction cascades driven by 
MAPKs are an essential network for cell proliferation as well as for cell survival, given that 
they can also promote apoptosis in a context-dependent manner. Hence, GTPases such as 
Rac1 have additional functions as integrators of external signals and gene expression 
transducers.  





Signalling downstream of PI3K also seems to be influenced by Rac1 activation. The 
substrate of this kinase, PIP2, was initially studied as an associated partner of Rac1 because 
of its ability to interact and promote actin polymerization297. Rac1 can activate PI3K signalling 
either by direct interaction or by indirect association of its Rho-GEFs to PIP2298. Activation of 
PI3K leads to the production of the second messenger PIP3 and the recruitment of the kinase 
Akt, which promotes survival responses such as inhibition of caspases and increased 
expression of anti-apoptotic members like Bcl2 proteins299. Thence, Rac1-PI3K interaction 
activates Akt upstream300. Likewise, Akt can also mediate activation of Rac1 through 
PI3K/AKT-dependent Tiam1 phosphorylation and activation301. An alternative method 
through which Rac1 could potentiate Akt signalling is by the mammalian target of rapamycin 
mTOR. The principal function of mTOR is to integrate catabolism and anabolism signals but 
it also targets Akt for phosphorylation, potentiating its full activity299. Recently, it has been 
demonstrated that Rac1 directly interacts with mTOR and functions as a critical mediator of 
its activity302, which could potentially suggest the coordination of both signals as a dual 
outcome of Rac1 activation303. 
Rac1 is required for cell cycle progression by stimulating G1 phase progression and DNA 
synthesis through induction of Cyclin D1304. Likewise, it might also influence cell cycle by its 
nuclear entry in G2, although the mechanism is yet unknown265. Several Rho-GTPase effectors 
have described functions contributing to mitotic entry, such as phosphoinositide-dependent 
protein kinase-1 (PDK1) and PAKs 1-3305,306. Rac1 seems to be the main PAK activator given 
its localisation at the centrosomes during G2, whereby it regulates centrosome separation 
and mitotic entry307.  
Cell survival and proliferation signals stimulated by Rac1 are also driven by induction 
of the transcriptional activity of nuclear factor κB (NF-κB). NF-κB is a ubiquitously expressed 
transcription factor (TF) composed by hetero- and homodimers of the Rel family proteins, 
which remain sequestered in the cytoplasm through binding with IκBα308. TF nuclear 
translocation and interaction with kB responsive elements triggers a wide profile of gene 
transcription, with a predominant component of immune- and proliferation-related 
responses308. Initial mechanisms through which Rac1 regulates nuclear of RelA translocation 
included inhibition of its negative regulator IκBα and Rac1-derived ROS activation309,310. Rac1-
mediated IκBα degradation is undertaken in the membrane ruffles along with the E3-ligase 
complex SCF311. It can also activate the NF-κB signalling cascade in cooperation with PI3K/Akt 





pathway, which form a signalling complex with activated Rac1 and promotes TF activation in 
response of Toll-like receptor 2 (TLR2) phosphorylation312. Recently, a novel role of Rac1 has 
been described, involving the signal transducer and activator of transcription 3 (STAT3). By 
direct binding with STAT3, Rac1 facilitates the formation of a STAT3-NF-κB complex and its 
nuclear targeting, with STAT3 potentiating NF-κB signalling313. 
The role of Rac1 in regulating the WNT signalling pathway is more controversial. A body 
of literature has widely accepted Rac1 as a nuclear translocator of β-catenin, which can 
therefore initiate the transcription of genes mediated by TCF7/LEF1 TFs314,315. Firstly, it was 
shown that Rac1 would translocate β-catenin to the nucleus through JNK2-dependent 
phosphorylation316. Additionally, Rac1 activity was suggested as an indispensable mediator 
of colon tumorigenesis for efficient β-catenin nuclear translocation in cooperation with K-
RAS mutation upon APC loss317. The latter hypothesis is controversial since tumours without 
K-RAS mutation harbour nuclear β-catenin and β-catenin functions as a canonical read-out 
of WNT signalling activation regardless of K-RAS mutational state or Rac1 activation. 
Interestingly, work from Myant et al. demonstrated nuclear accumulation of β-catenin in the 
intestine of Rac1-deficient mice, indicating that Rac1 operates downstream of canonical WNT 
activation to enhance its signal292. Likewise, Rac1 also plays an active role in the non-
canonical WNT signalling pathway, which orchestrates cell polarity through activation of 
effectors other than β-catenin-TCF/LEF318–320. 
Altogether, the broad variability of interacting effectors and GEFs regulators as its 
specific subcellular compartmentalization renders Rac1 with a plethora of roles which 
encompass a wide variety of biological processes. Elucidation of its functions by means of 
loss- and gain-of-function experiments provides clear evidence that deregulation of either its 












1.2.2 Rac1 signalling in cancer 
The first indication that Rac1 could drive cellular transformation came from early 
studies that showed Rac1 is required for K-RAS-dependent neoplasia321,322. Later on, 
validation of this data was provided in a conditional K-RAS-driven model of lung cancer323. 
The mechanisms through which Rac1 can be deregulated in cancer are fivefold. As with many 
oncogenes, it can be activated via activating mutations or by defects on its degradation 
pathway, hence increasing its expression and/or activity. Likewise, GEFs activating mutations, 
GAPs downregulation or alternatively spliced isoforms might enhance Rac1 activity.  
 
1.2.2.1 Activating mutations 
Some point mutations in RAC1 have been described in human cancers in recent years 
that correlate with poor prognosis. Melanoma has the highest occurrence of gain-of-function 
mutations in RAC1, with P29S mutation found in 4% to 9% of tumours in two large-scale 
whole-exome sequencing (WES) studies and in about 5% in the TCGA study183,324,325. RAC1P29S 
has an enhanced binding to its effectors PAK1 and MLK3, an increased migratory ERK-
dependent activity and a better induction of membrane ruffling325. Interestingly, this hotspot 
mutation confers resistance to RAF inhibitors in melanoma cells, suggesting it may be a 
potential predictive stratification biomarker for melanoma patients326. This mutation was 
also identified in head, neck and endometrial cancers, along with a newly identified RAC1A159V 
hotspot mutation. This is a paralogous mutation to that in K-RASA146T predominantly detected 
in colorectal carcinomas and shows the highest Rac1 activity in comparison to other existent 
Rac1 mutations327.  
 
1.2.2.2 Degradation defects 
Abundance of Rac1 protein increases when its degradation is impaired. Rac1 is 
targeted for ubiquitin degradation by E3 ubiquitin ligases such as HACE1 (HECT-domain and 
Ankyrin-repeat Containing E3 ubiquitin protein ligase 1). This ubiquitin ligase catalyses its 
degradation once Rac1 is aberrantly activated by point mutations or by overactivation of 
upstream growth receptors like EGFR/ERBB2328,329. Such ubiquitin ligases are usually tumour 
suppressor genes and their downregulation lead to a functional neoplastic role. 





1.2.2.3 Alterations in GEFs 
Most of the Rac1 activities described previously require Rac1 to be GTP-bound. An 
accepted paradigm of Rho GTPases in cancer is that their level of activity prevails over their 
expression level. Guanine nucleotide exchange factor were initially discovered as oncogenes, 
given their transforming potential when microinjected in mammalian cells330–332. Two 
domains classify Rho GEFs into two categories, the Dbl RhoGEFs with DH and pleckstrin 
domains or the DOCK RhoGEFs. Some of the Rac1-specific RhoGEFs that are best 
characterised with cancer-related roles belong to the Dbl group and include Vav, Tiam1 or P-
Rex333. In particular, these three RhoGEFs harbour binding regions on their sequence in order 
to be directly activated by extracellular stimuli prior their association with Rac1, like the 
activation of Ras or Src family tyrosine kinase to induce activation of Tiam1 and Vav, 
respectively333.  
Two isoforms for P-Rex exist, P-Rex1 and P-Rex2, both regulated upon PI3K/G-coupled 
receptor subunits Gβƴ activation. These have been seen overexpressed in melanoma, breast 
and prostate cancer, promoting Rac1-dependent migration and invasion334–336. P-Rex1-
deficient mice showed a metastatic-resistant phenotype in melanoma and prostate cancer 
and it mediates cancer progression in breast cancer by integrating ERBB2 receptor signals. 
Indeed, resistance to VEGFR inhibitors driven by P-Rex1-dependent activation of Rac1 was 
recently observed in prostate cancer stem cells337.  
Three different isoforms exist for Vav and all require a double phosphorylation step to 
be fully activated which is dependent on kinases like Src and Syk333. Src kinases are 
oncoproteins induced upon the activation of RTKs, linking its oncogenic role to substrates 
such as Vav. Vav proteins target all three studied RhoGTPases and the RTK-Src-Vav2-
RhoGTPase axis of activation has been demonstrated to carry cancer-related activities in 
different contexts258,338,339. This axis promotes Rac1-dependent c-myc expression upon 
platelet-derived growth factor (PDFG) stimulation339. Likewise, when Vav is activated by 
other kinases such as Jak, it is able to drive invasion through matrix metalloproteinase 2 
(MMP2) stimulation via the same axis340. Moreover, it was observed in head and neck 
squamous cell carcinoma (HNSCC) tumours that the high Rac1 activity responsible for their 
invasion was driven by EGFR-Vav2 activation341.  





Tiam1 is a Rac-selective GEF that can also indirectly activate Rac1 by functioning as a 
Ras effector342. The overexpression of TIAM1 in a large number of cancer types including 
breast, colon and prostate strongly suggest its role as oncogene343,344. Tiam1 deficiency in an 
ApcMin colon cancer mouse model decreased tumorigenesis345. Indeed, it was identified as a 
WNT/β-catenin target gene given its increased expression upon Apc loss and TCF-binding 
sites upstream of the Tiam1 promoter. In a model for Ras-induced skin tumours, reduced 
Tiam1 expression also decreased tumorigenesis and led to increased apoptosis, due to Ras-
Tiam1 association and the lack of Rac1 activation by either Tiam1 or Ras346. Hence, Tiam1-
Rac1 signalling seems relevant for both Ras- and WNT-driven tumours. Intriguingly, building 
evidence also suggests a negative role for Tiam1 in promoting invasion. For example, the few 
RAS and TIAM1 double mutant skin tumours that grew in this study developed substantially 
more invasion than TIAM1 wild type tumours346. The same scenario occurred in ApcMinTIAM-
/- mice, where invasion was enhanced compared to ApcMinTIAM+/+ control mice. In addition, 
Tiam1 expression was found to be significantly lower in advanced invasive breast 
tumours345,347. Recently, a mechanism was suggested whereby Tiam1 would function as a 
TAZ/YAP negative regulator. In the cytoplasm, Tiam1 binds to TAZ/YAP destruction complex 
and promotes their degradation. However, upon aberrant WNT signalling activity whereby 
the destruction complex is dissociated, Tiam1 translocates to the nucleus with TAZ/YAP and 
inhibits the initiation of their transcriptional activity involved in EMT, cell migration and 
invasion348. This highlights the complexity of RhoGEF functions and the need for better 
understanding of possible RhoGTP-independent roles yet to be described.  
Regarding the DOCK type of RhoGEFs, fewer studies have been conducted compared 
to their fellow partners albeit it has greatly shown a similar and valuable outcome. Expression 
of DOCK1, one of the RhoGEFs group members, significantly correlates with poor prognosis 
in the most invasive subtypes of breast cancer. Besides, conditional deletion of DOCK1 in a 
breast cancer mouse model protects mice from tumorigenesis and metastasis, indicating that 
DOCK1-Rac1 activation upon ERBB induction is necessary for tumour progression349. In a 
separate setting, Dock1 inhibition impairs both nutrient uptake and cellular invasion 
mediated by Rac1-dependent actin remodelling in the context of Ras mutation350. Further 
emphasising its important pro-tumorigenic role, a specific pharmacologically designed Dock1 
inhibitor ablated the pro-metastatic functions of Dock1350. 





Collectively, the cancer-derived functions by aberrant RhoGEFs behaviour outlines 
their requirement for cancer transformation and suggest they are a key mechanism for Rac1 
overactivation.   
1.2.2.4 Alterations in GAPs 
Following this logic, RhoGAPs, which enhance GTP hydrolysis and inactivate 
RhoGTPases, would be expected to act as tumour suppressors in cancer. Although 
downregulation of some has been demonstrated351–353, recent unbiased studies have shown 
a pro-metastatic role for RhoGAPs such as CdGAP or RacGAP1354–356. This would suggest that, 
similar to Tiam1, functions other than their binding to and inactivation of RhoGTPases might 
account for these roles.  
Therapeutic targeting of either RhoGEFs or RhoGAPs has been extensively investigated 
as an approach for some cancer treatments. Given that drug resistance has arisen for current 
RTK inhibitors mostly at the receptor level, tackling downstream cancer-hyperactivated 
pathways conjointly as an adjuvant may confer a potential benefit. Rac1 signalling is a 
promising anticancer target considering that 1) its activity is higher in neoplastic than in 
normal cells, 2) it modulates a broad range of biological process essential for cell 
transformation, 3) both upstream and downstream regulators of its activity appear to be 
druggable with promising positive outcomes. However, targeting such a ubiquitously 
expressed protein with many critical cellular outputs could also be detrimental to normal 
tissue.  
 
1.2.2.5 Alternative splicing 
The final mechanism for Rac1 overactivation is the production of a tumour-related 
alternative spliced isoform, Rac1b. Rac1b includes an additional exon in its sequence that 
causes a small but significant consequence to its conformation, leading to a virtually 
constitutive GTP-bound RhoGTPase. Since the alternative splicing process that leads to Rac1b 
formation seems enhanced in transformed cells, Rac1b may be a promising therapeutic 
target. The next section will focus on outlining its hitherto described functions, following a 
brief explanation of the RNA splicing process and other examples of malignant isoforms.  
 





1.3 Alternative splicing 
RNA splicing is a naturally occurring process whereby the exons that will make up the 
final mRNA product for protein translation are excised from the non-coding introns, 
therefore ensuring proper maturation of pre-mRNAs to mRNAs. The human body has a 
limited number of coding exons in the genome and alternative splicing (AS) acts by excluding 
or inserting additional exons, thus increasing proteome diversity. Over 130,000 alternative 
spliced isoforms can be generated from the 20,000 human protein-coding genes, with up to 
95% of all multi exon genes alternative spliced357. According to Yang and colleagues, a 
sizeable proportion of alternative spliced isoforms share less than 50% of their protein 
interactome with their canonical isoforms, hence behaving virtually as distinct proteins and 
broadening protein functionality complexity358.  
The spliceosome is a macromolecular machinery composed of small 
ribonucleoproteins (snRNPs) and numerous auxiliary proteins. It mediates intron excision 
and exon joining by catalysing two sequential transesterification reactions. It recognises and 
binds to consensus sequences in the introns at the 5’splice site, 3’splice site (SS) and branch 
site (BS). It is targeted by RNA regulatory sequences termed exonic and intronic splicing 
enhancers (ESEs and ISEs), which are bound by SR protein-containing complexes that 
assemble to promote a splice site, or exonic and intronic silencers (ESSs and ISSs), that inhibit 
splicing via recruitment of  heterogeneous nuclear ribonucleoproteins-containing complexes.  
The spliceosome conducts both splicing and AS, and the decision to whether an exon 
is or is not spliced out is mediated, in a simplistic point of view, by the functional strength of 
the splice site and by the binding of regulatory proteins at enhancer and silencer 
sequences359. Two classes of transacting RNA binding proteins (RBPs) mediate positively or 
negatively spliceosome activity, heterogeneous nuclear RNPs (hnRNPs), which bind to 
silencers, or SR (Ser-Arg) proteins, which associate to enhancers. Their function is pivotal for 
facilitating splice recognition and their tissue-specific expression and context-dependent 
expression largely influence on leading to AS events and spliceosome activity. A cooperation 
of their functions also affects splicing in an antagonistic fashion, with the outcome (inclusion 
or exclusion) dependent on their concentration360. 
There are different types of AS, the most commonly occurring being cassette exon 
inclusion. Other kinds include alternative 5’ or 3’ splice site, intron retention, mutually 





exclusive exon, exon scrambling or trans-splicing, the last two being rarely observed361. Of 
note, not all alternative spliced isoform products are functional and approximately one-third 
of premature mRNA are targeted for nonsense-mediated decay (NMD) degradation. 
Interestingly, this is also a mechanism AS uses to reduce translation of mRNA by promoting 
degradation of premature codons362. A dominant isoform transcript is produced per gene363 
but mutations in cis-acting splicing sequence, alterations in activity and protein level of 
regulatory proteins and mutations in the core splicing machinery might switch this dominant 
tendency towards less-frequent isoforms364. As the newly acquired functionality of certain 
gene might provide adaptation advantages in aberrant contexts, changes in their pattern of 
splicing is commonly associated with diseases, and cancer has been one of the best 
documented.  
 
1.3.1 Implications in cancer 
The large diversity that AS confers to the proteome can also be exploited by tumoral 
cells. For example, cellular processes altered in cancer cells, the so-called hallmarks of cancer, 
are all affected by aberrantly spliced isoforms (Figure 1.6)365. Intriguingly, some of the AS 
isoforms can have antagonist effects for example the apoptotic gene Bcl-x, whose splicing 
can produce two functionally opposite isoforms: Bcl-xS, a proapoptotic short form, or Bcl-xL, 
the antiapoptotic version366. The same scenario occurs for MCL1, another Bcl2 family protein 
that gives rise to a short pro-death isoform, MCL1S, and long antiapoptotic MCL1L form367. 
VEGFA is also a common example (Vascular endothelial growth factor A) which is normally 
secreted by endothelial cells to promote angiogenesis when oxygen is needed. Alternative 
spliced exon inclusion promotes the formation of a proangiogenic isoform over the 
antiangiogenic one, and a fine balance of their ratio dictates cells towards or against 
angiogenesis368. A non-antagonist example of AS is the tumour promoter gene CD44. This is 
a transmembrane cell adhesion molecule that translates into more than 20 distinct isoforms, 
two of them being commonly overexpressed in metastatic-related processes369. Therefore, 
mounting evidence exists of aberrant isoforms whose expression increases in transformed 
cells and serve as indicators of poor tumour prognosis.  
A high frequency of hotspot mutations in splicing factor genes is also observed in some 
malignancies, such as in U2AF1, SRSF2 or SF3B1 genes, which translate into broad 





transcriptome changes contributing to tumorigenesis370. Parallel screening shows that there 
are up to 30% more AS events in tumours compared to healthy tissue371, indicating tumoral 
cells dependency on altered RNA splicing. These differences on AS isoforms suggest tumours 
have an intrinsically more activated spliceosome, which is also a consequence of a rapid 
protein translation. Therefore, this suggests that alternative splicing is an important 

















Figure 1.8: Schematic representation of genes whose aberrant splicing affects hallmarks of 
cancer processes. Orange genes highlight those involved in more than one hallmark. Adapted 
from “Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing 
factor genes (Sveen et al, 2016)”  
 
 






Rac1b was discovered almost simultaneously by two different groups in 1999. Firstly, 
Jordan et al. noticed Rac1b for the first time when separating qRT-PCR products of Rac1 cDNA 
extracted from a set of adult and foetal intestine, skin, liver and brain tissue372. On top of 
observing the expected 600bp band for Rac1, an additional band of 720bp was detected. 
Repeating the same analysis comparing colorectal tumours and normal mucosa showed that 
this band was preferentially expressed in tumour tissues, while Rac1 band intensity was fairly 
steady across both. Further sequencing revealed that the 720bp-band was the result of an 
additional insertion of 57 nucleotides between codons 75 and 76, which translated into 19 
amino acids corresponding to a new undescribed exon, designated exon 3b (Figure 1.7A). 
Interestingly, the insertion occurs just after the switch II regions (residues 60-76), that 
controls the conformational change necessary for GTPase intrinsic activities. A few months 
later, Schnelzer et al. detected Rac1b in breast cancer and normal tissues by conducting qRT-
PCR373, confirming the discovery of a new alternative spliced isoform.  
Rac1b is specifically yielded by Rac1 alternative splicing since neither Rac2 nor Rac3 
have such exon 3b374. Despite being less expressed than Rac1, Rac1b presents higher 
activation. This activation was shown to be GEFs-dependent and it could also be negatively 
regulated by GAPs binding375. However, the additional 19 amino acids insertion prevents GDI 
binding, resulting in a steady constant activation. Further experiments concluded that Rac1b 
can be self-activated without GEFs due to a rapid nucleotide dissociation activity, and binding 
to the GEF Tiam1 or Vav2 do not enhance its activation376,377. Despite its binding to GAPs, it 
presents an impaired intrinsic GTP hydrolysis due to a highly mobile switch II, which favours 
its constant GTP-bound state (Figure 1.7B)376. 
When interrogating some of the main downstream features of activated Rac1, it was 
demonstrated that Rac1b cannot induce lamellipodia formation373,375. Moreover, it cannot 
activate the kinases PAK or JNK, but instead it can activate NFκB. Hence, it seemed like this 
additional exon insertion might confer a restricted and specific effector-binding site, which 
given its preferential tumoral expression, led to further investigation of its downstream 
signalling pathways.  
 
 












Figure 1.9: RAC1B transcript and protein activation overview. A: Schematic representation 
of the RAC1 human gene and the two transcriptional products. B: Self-activating mechanism 
of Rac1b by its rapid intrinsic nucleotide exchange activity (although it can be enhanced by 
GEF binding), impaired GTPase reaction and inability to interact with GDI.  
Figures adapted from Gonçalves et al. (2009) and Fiegen et al. (2003) respectively. 
 
1.3.2.2 Cancer-associated functions 
Given that Rac1 promotes cell adhesion and invasion, processes aberrantly activated 
during tumorigenesis, it was hypothesised that its constitutively active version would 
intensify its activity. From this regard, functional analysis of Rac1b has been assessed in 
comparison to Rac1 downstream effectors, although a partially different set of targets for 
Rac1b was already anticipated373,375. It was described that Rac1b interacts with p120ctn, 
RACK1 and SmgGDS, which are proteins related with cell-cell adhesion, motility and 
transcriptional regulation378, suggesting that Rac1b might be able to modulate cellular actin 
dynamics in a new route independent from PAK signalling. 
Initial hints for Rac1b being involved in cell transformation was observed by Singh et 
al., who noticed that Rac1b expression promoted loss of density-dependent inhibition of 
growth and acquisition of anchorage-independent growth in NIH 3T3 cells377. Moreover, 
Rac1b-expressing cells can grow under reduced growth factor and serum conditions 
compared to activated Rac1, probably because of its higher activation efficiency379,380. NF-κB 
activation is the main downstream pathway activated by Rac1b to promote cell growth. 
Mechanistically, Rac1b induces phosphorylation and membrane translocation of the NF-κB 
repressor IκBα, allowing NF-κB heterodimer to translocate to the nucleus381. In colorectal 
cancer cells, phosphorylation of IκBα is driven by Rac1b-dependent ROS production382. 
A. B. 





However, unlike Rac1 which can activate NF-κB by either releasing RelA (canonical pathway) 
or RelB (non-canonical), Rac1b can only promote the canonical route of NF-κB activation383. 
Rac1b-dependent activation of NF-κB is also relevant in papillary thyroid carcinoma, and both 
Rac1b expression and NF-κB activation associate with the presence of metastasis and poor 
survival384,385. G1/S cell cycle progression is stimulated by NF-κB-dependent and -
independent expression of Cyclin D1. Rac1b can induce Cyclin D1 expression through 
interaction with Dishevelled-3 (Dvl3) and activation of the WNT signalling pathway386. 
Consistent with a tumour promoting role, it was shown that Rac1b can enhance already high 
levels of WNT signalling in tumours in a ligand-independent manner. According to their 
model, Rac1b recruits β-Catenin and Dvl3 and facilitates their translocation to the nucleus to 
interact with the promoter regions of c-Myc and Cyclin D1387. Rac1b, like Rac1, has a polybasic 
region (PBR) in its sequence that allows its translocation to the nucleus. In contrast to the 
suggested model for Rac1 as an essential component for nuclear translocation of β-Catenin, 
this model suggests that Rac1b is not required but it rather enhances its nuclear transport. 
This is the only evidence suggesting a nuclear role for Rac1b, as its constant GTP-bound status 
likely promotes a membrane localization. Further investigations would be interesting for 
uncovering its nuclear function. In addition, Li et al. have shown that Rac1b can promote c-
Jun phosphorylation significantly more efficiently than Rac1, which then leads to cyclin D1 
expression and cell cycle progression380. Phosphorylation occurs through Rac1b-dependent 
activation of JNK2. This contradicts previous observations, given that JNK and PAK are 
presumably the two Rac1 effectors Rac1b cannot activate373,375. However, they argue that 
Rac1b can only activate JNK2 but not JNK1 or JNK3, which could explain discrepancies with 
previous results. AKT2 has also been observed to be induced by Rac1b377,380, which would 
stimulate anti-apoptotic cues by activating the anti-apoptotic protein MCL1. 
Together with cell proliferation, migration and promotion of invasion are fairly well-
accepted roles for Rac1b. EMT is commonly observed prior to cell invasion, albeit not being 
a strict requisite388. It consists of the activation of a transcriptional program (Snail, Vimentin, 
Slug, among others) for decreasing E-cadherin accumulation at the cell membrane. This 
allows morphological cellular changes for detachment from neighbouring cells and the 
surrounding extracellular matrix, hence enabling cell motility. In mouse mammary epithelial 
cells, it was observed that metalloproteinase 3 (MMP3) released from the tumour 
microenvironment, an essential protein for extracellular matrix proteins cleavage, activates 
Rac1 alternative splicing by releasing hnRNP A1 from exon 3b389. Rac1b protein then 





promotes EMT by inducing the expression of Snail and Vimentin through ROS production. 
Simultaneously, ROS causes an indirect genomic instability due to DNA oxidative damage390. 
Rac1b seemed to be necessary for MMP3-derived activities, demonstrating the first evidence 
for Rac1b tumour invasion promotion. Other than in breast cancer, MMP3 activated Rac1b-
driven invasion in human pancreatic carcinoma cells, and their expression was shown to 
correlate in PDAC human biopsies and associate with tumour grade391. A mechanism was 
suggested for MMP3-dependent EMT induction that depends on the cell substratum 
compliance. Initially, it was observed that cells undergoing EMT induced by MMP3/Rac1b 
axis needed to spread on a specific cell substrata, a requirement not observed for TGF-β-
induced EMT392. Further analysis demonstrated that in collagen-rich substrata or stiff 
substrata, like those characteristic of tumours cells, fibronectin (an ECM protein) retains 
Rac1b in the plasma membrane to form a NADP complex and produce ROS for EMT induction. 
However, soft substrata prevents Rac1b membrane localisation by laminin-rich ECM, which 
sequesters Rac1b in the cytoplasm393,394. Rac1b IHC staining of breast tumour biopsies 
provided supporting evidence for this model, showing cytoplasmic staining of Rac1b in 
normal tissue while membrane staining was detected in tumour malignant biopsies. 
In lung adenocarcinoma, EMT is observed in early adenomas in order to bypass 
oncogenic senescence and promote carcinoma formation. Interestingly, MMP3 induction of 
EMT through Rac1b expression was observed in lung adenocarcinoma cells whereby Rac1b 
would promote the expression of EMT markers such as Vimentin and decrease the expression 
of E-cadherin at the cell junctions. This will lead to EMT-bypass of senescence and 
consequently induce tumour progression395. This is an interesting observation of how the 
same stimulated process (EMT) could lead to two different phenotypes (senescence escape 
and cell invasion) but equally demonstrating the tumour progressive role of Rac1b. 
Alternatively, Esufali et al. showed that Rac1b might downregulate E-cadherin 
expression through activation of its negative regulator Slug, leading to a decrease in cell 
adhesion386. They point to the PBR of Rac1b to mediate this function, since point mutations 
in this region abrogates Slug stimulation. 
Recently, it was also suggested that Rac1b interacts with ArhGAP11A to promote 
invasion in hepatocellular carcinoma cells. Interestingly, this is a model for the 
aforementioned dual role of some RhoGAP proteins, which in certain circumstances might 
function as oncogenes. ArhGAP11A correlates with poor prognosis in hepatocellular 





carcinoma biopsies. It interacts specifically with Rac1b, but not Rac1, for mediating its pro-
tumorigenic functions which include enhanced cell growth, invasion and EMT396.  
Altogether, the available data in the literature consistently demonstrates a tumour 
promoting role for Rac1b in mediating invasion379,390,395,391,386,394,392,397,377,384,396,398,399,400,390 
(Figure 1.8A). However, a tumour suppressor role for Rac1b has also been shown by 
Ungefroren’s lab. In apparent contradiction with Mehner et al., they observed that non-
malignant pancreatic ductal adenocarcinoma (PDAC) biopsies presented higher Rac1b 
staining compared to tumour samples. Functional analysis on PDAC patient-derived cells with 
Rac1b depletion showed an enhanced TGF-β-dependent migration, which diminished when 
Rac1b was overexpressed401. Negative regulation of TGF-β was mediated by depletion of 
SMAD3 phosphorylation and its transcriptional activity, which promotes cell migration and 
EMT upon activation. As it has also been suggested by other investigators, Rac1b and Rac1 
might have antagonistic roles. However, while Nimnual et al. observed that Rac1b-driven 
Rac1 depletion led to an increase in Rho activity (due to their mutual negative regulation) 
and following promotion of invasion397, Ungefroren et al. observed a decrease in invasion 
due to Rac1b inhibition of Rac1. In their model, a ratio of Rac1/Rac1b would dictate the 
invasive behaviour of a cell. This antagonistic relationship was also demonstrated in breast 
cancer cells, whereby Rac1 would mediate invasion and migration through increasing both 
the expression of p21 and phosphorylation status of ERK1/2402. In addition to inhibiting the 
TGF-β /SMAD signalling cascade, Rac1b-mediated suppression of migration was also 
observed by inhibition of p38 and ERK1/2 MAPK phosphorylation403. Further mechanistic 
insights were recently revealed and suggest Par2 as the main Rac1b target404. Par2 is a G 
protein-coupled receptor that sustains activation of TβRI/ALK5. Initially, it was suggested that 
TGF-β-induced migration was driven by ALK5, as its expression increased upon Rac1b 
depletion and depletion of ALK5 partially attenuated the migratory phenotype405. However, 
Par2 overexpression can rescue Rac1b inhibition of TGF-β and its deletion phenocopies that 
of Rac1b. Moreover, increased ALK5 expression after Rac1b depletion was Par2-dependent, 
pointing to Par2 as the potential interacting protein with Rac1b (Figure 1.8B). 
Rac1b expression has also been associated with other oncogenic processes. For 
example, it increases upon inflammatory episodes such as colitis and can promote COX2-
dependent tumour growth in a colitis-associated cancer mice model406. Moreover, Rac1b can 
also promote the escape from oncogenic-induced senescence by suppressing the expression 





of p14, p15 and p21 similar to the oncogenic escapes induced through EMT. Interestingly, 
Rac1b expression has largely been associated with CRCs driven by mutations in BRAFV600E and 
a cooperation between Rac1b and BRAFV600E was observed to sustain cell cycle stimulation 
and apoptosis407.  
Despite of the large efforts invested over the last 20 years to depict a comprehensive 
picture of Rac1b effectors and downstream activated signalling pathways, there is a clear lack 
of functional evidence in vivo. Li et al. deleted Rac1b by CRISPR in rat normal colon mucosa 
and showed an increase in apoptosis through AKT/MCL1 pathway380. However, in their 
previous in vitro experiments, Rac1b was able to phosphorylate c-Jun while no changes in 
JNK2 or c-Jun activation was observed in their in vivo model. This indicates that an in vivo 
translation and validation of the hitherto suggested roles for Rac1b is needed. To date, only 
three different studies have used in vivo mice models to modulate Rac1b expression in 
cancer. Stallings-Mann et al. overexpressed Rac1b specifically in murine lungs. These mice 
developed fibrosis which spontaneously led to tumorigenesis in a Rac1b-dependent dose395. 
Tumours were larger in size and more invasive than controls with wild type Rac1b and 
mechanisms include the EMT-bypassed senescence explained above. Zhou et al. used a K-
ras-induced lung adenocarcinoma model to conditionally overexpressed Rac1b in the lung. 
They showed that, although Rac1b is not required for inducing K-ras-driven tumorigenesis, 
their co-expression enhanced tumorigenesis by increasing tumour number and size408. In 
contrast to the previous model, Rac1b could not promote tumorigenesis on its own, 
indicating that cooperation with other mutated cancer-related genes might be required to 
drive cell transformation. In the intestine, Kotelevets et al. showed that overexpression of 
Rac1b led to an increased proliferation through WNT signalling activation and an enhanced 
migration of intestinal epithelial cells in the small intestine409. It was insufficient to initiate 
tumorigenesis alone but overexpression of Rac1b in both the Apcmin/+ CRC model and in the 
Il10-/- colitis model led to an increased tumorigenesis in both models compared to controls. 
These observations confirm the pro-tumorigenic role for Rac1b but do not clarify the 
underlying mechanism of actions that are driven by Rac1b. Given its described malignant 
roles in tumours and its biochemical nature that confers a constant Rac1-like activated signal, 
further investigations in vivo are of urgent need to unveil its potential benefit for therapeutic 
targeting.  
 
























Figure 1.10: Downstream signalling pathways modulated by Rac1b and their cellular 
phenotypic translation. Figure A summarises the hitherto described functions of Rac1b 
related to pro-oncogenic processes, while figure B presents the suggested anti-oncogenic 











1.3.2.1 Alternative splicing regulation 
As discussed above, changes in the expression of splicing regulatory proteins can alter 
the splicing pattern of a gene. Hence, an accepted assumption for the shift from Rac1 to 
Rac1b production was the deregulation in the expression of Rac1 splicing factors, which are 
commonly overexpressed or downregulated in cancer410,411. Jordan’s lab dissected for the 
first time the molecular factors responsible for Rac1b production and found that ASF/SF2 
(SRSF1) splicing factor promotes inclusion of exon 3b, while SRp20 (SRSF3) skips it412. There 
are binding sites for both factors neighbouring exon 3b, acting as either enhancers (SRSF1) 
or silencers (SRSF3). Both factors function antagonistically and their ratio of expression leads 
to the dominant splicing event. Of note, signalling pathways upstream of these SR proteins 
indirectly modulate Rac1b splicing. They demonstrate that activation of the WNT/β-catenin 
signalling pathway, which SRSF3 is a target gene, downregulates Rac1b expression, whereas 
inhibition of the PI3K signalling pathway increases Rac1b expression through concomitant 
increase of SRSF1 at the protein and RNA level412. Protein kinases responsible for SR protein 
phosphorylation and activation include AKT2, AKT3, GSK3β and SRPK1, the latter being the 
key activator for SRSF1413. 
Another splicing factor which has been consistently demonstrated to modulate Rac1 
is hnRNP A1. Firstly, it was shown that hnRNP A1 binds to exon 3b and represses its inclusion. 
Indeed, an inverse correlation of hnRNP A1 and Rac1b was demonstrated by IHC analysis of 
breast tumour samples. It is suggested that the metalloproteinase MMP3 acts as an upstream 
regulator, releasing hnRNP A1-containing complex from the exon 3b and promoting its 
inclusion389. Another upstream signalling pathway affecting hnRNP A1 function is EGF/EGFR 
signalling. Mechanistically, EGF induces upregulation of SPSB1, an E3 ubiquitin ligase adaptor 
which targets hnRNP A1 for degradation and consequently promotes exon 3b inclusion and 
Rac1b expression, leading to EGF/EGFR-mediated cell migration398. Intriguingly, it has 
recently been demonstrated that a protein member from the hnRNP family can positively 
modulate Rac1b expression by favouring exon 3b inclusion. Xing and colleagues have shown 
that DIS3L2, an exoribonuclease with pro-tumorigenic roles in hepatocellular carcinoma cells, 
mediates hnRNP U recruitment to the exon 3b and both synergistically favour its inclusion. 
Moreover, Rac1b seems to be responsible for DIS3L2 oncogenic roles such as cell 
proliferation and tumour progression399.  





Finally, the last suggested splicing factor is ESRP1 or RBM35A. This, along with ESRP2, 
are considered tumour suppressors due to their TGF-β-dependent downregulation for 
promoting EMT. ESRP1 downregulates Rac1b expression through binding to a silencer 
sequence upstream the exon 3b400. In spite of being upregulated in tumours compared to 
normal tissue, ESRP1 is downregulated in the invasive front of the tumour, leading to Rac1b-























1.4 Animal models for CRC 
Data from literature and previous section strongly suggest Rac1b is a functional 
promoter of tumorigenesis, but it is yet undescribed whether it functions primarily as a driver 
of tumour initiation or progression. The use of 2D tumoral cell lines to modulate the 
expression of a gene has the advantage of being a rapid and straight forward method to 
conduct assays, but its poor translatability to human tissues and difficulty to control 
background mutations limits its disease relevance. Instead, mice models have been the “gold 
standard” to mimic human cancer in the lab, which can also be the source of more 
sophisticated in vitro models like 3D organoids structures. Given the little references of Rac1b 
expression modulation in other systems than 2D cells395,408,409, performing Rac1b gain and 
loss of function experiments in cancer mice models and 3D culture might considerably 
improve our current knowledge about its downstream targets.   
Despite of the current debate on the type of clonal evolution initiates tumorigenesis, 
the Fearon and Vogelstein model of stepwise sequential accumulation of mutations is taken 
as reference when designing genetic strategies to emulate tumour stages in mice models. 
Therefore, mutation or loss of the Apc gene is usually taken as the key initial event for 
adenoma formation. Homozygous loss of Apc in the murine intestinal epithelial cells derives 
to a hyperplastic tissue with highly proliferative crypts414, so heterozygous deletion is needed 
to model a long-term adenoma formation. In 1992 the first mouse model with Apc mutation 
was identified, the ApcMin model (for Multiple Intestinal Neoplasms)415,416. It has a nonsense 
mutation at the codon 850 of the murine Apc gene, which is analogous to that of FAP 
patients. Homozygosity is embryonic lethal since the mutation is autosomal dominant, and 
the model is always heterozygous for Min (ApcMin/+). When heterozygosity is lost over time, 
mice usually develop over a hundred tumours in the small intestine and rarely in the colon, 
with an average survival of 120 days417. Although being the most commonly model used for 
the last decades, drawbacks such as its specificity to the small intestine and the lack of 
invasive tumours due to a high and quick tumour burden led to the quest of more refined 
models. After different attempts of mutating the Apc gene418–420 and other genes for either 
initiating tumorigenesis421 or transforming adenomas into malignant tumours422–424, a turning 
point in animal research was the introduction of genetic modified mice with spatiotemporal 
control425,426. Through tamoxifen-inducible Cre recombinase targeted to the intestinal 
epithelium by Villin427 (small and large intestinal) or Carbonic anhydrase I (Car1)428 (colon) 





promoter, among other intestinal targetable promoters419,429–432, researchers can decide the 
timing of the experiment and limit the gene modulation to a specific tissue.  
Cre is a site-specific recombinase derived from the P1 bacteriophage that catalyses 
recombination between two loxP sites, its consensus DNA recognition sequence425. Since it 
was first discovered in 1984, there has been a huge effort to develop it as a genetic tool433,426, 
and nowadays most mouse models commonly use tissue-specific Cre recombinase for 
genome alteration. Knock-out of a certain gene is achieved by inserting the loxP sites flanking 
a critical region of the gene, which will be “floxed” following Cre expression. In the same 
manner, gene overexpression can be achieved by inserting loxP sites flanking a stop cassette 
upstream of an exogenous sequence, allowing gene expression once recombinase is 
expressed. Soon after, geneticists improved this technology by creating an inducible 
recombinase with spatiotemporal  expression control, such as the Cre-ERTM fusion protein434. 
This mutant mouse estrogen receptor (ERTM) fails to bind its physiological ligand (17β-
estradiol) but it has high affinity for the synthetic 4-hydroxytamoxifen, the active tamoxifen 
metabolite. In normal conditions, ERTM retains the fusion protein in the cytoplasm 
sequestered by Hsp90 and only after tamoxifen induction Cre-ERTM is released and induces 
recombination in the nucleus435. In addition, when the Cre recombinase (either inducible or 
constitutively expressed) is combined with a tissue specific promoter, recombination can be 
targeted and delimited to a tissue427.  
In the present project, I will make use of the murine Villin promoter to target intestinal 
epithelial cells with a tamoxifen-inducible Cre (VilCreERT2) to study Rac1b loss and gain of 
function in intestinal tissue homeostasis. Furthermore, I will combine Rac1b expression 
modulation along with Apc deletion to study its contribution in tumour formation and 
progression, and co-deletion with the tumour suppressor gene TP53 to investigate its role in 









1.5 Concluding remarks 
Colorectal cancer is the third leading cause of cancer-related death worldwide but it is 
also one of the most treatable cancers when diagnosed at early stages. Its survival has 
steadily increased over the last years, suggesting that improvements in CRC molecular 
characterisation has contributed to designing more efficient therapeutic treatments. 
However, a large proportion of patients present with invasive and metastatic disease with 
dismal prognosis and poor response to therapy. Therefore, there is an urgent need to identify 
new targets that could either serve as biomolecular indicators for anticipating pre-malignant 
tumours or as druggable candidates for therapy design. 
The intestine is a highly proliferative tissue with a rapid cell turnover, required to avoid 
potential cellular damage due to its prolonged contact with abrasive luminal content. 
Signalling pathways that maintain intestinal homeostasis are finely tuned to restrict 
proliferation to the crypt bottom/stem cell zone. Cell differentiation is promoted above this 
region, whereby specialised intestinal epithelial cells undertake their metabolic and 
defensive functions. However, imbalance in this signalling network might lead to an 
expansion of the proliferation zone and the origin of hyperplastic intestinal foci or pre-
adenomatous lesions. Key mutations that drive CRC tumorigenesis are mostly localised 
within these signalling pathways, which include the WNT, MAPK, TP53 and TGF-beta 
signalling pathways. In a neoplastic context, activating mutations in either the receptors or 
intracellular mediators of these pathways leads to a ligand-independent overactivation of 
signalling.  
Connections between receptors and intracellular cues commonly require the 
association of small GTPases, which act as molecular switches and initiate signal activation 
upon ligand-receptor binding. Hence, overactivation of these switches causes a constant 
activation of their related pathways. The best example are the Ras small GTPases, whose 
mutated isoform K-Ras is observed in 40% of all CRCs. Rho GTPases, a subfamily group within 
the Ras superfamily, is also frequently altered in cancer. However, unlike Ras, mutations in 
their activating modulators rather than in the GTPase itself is more predominant. The 
activation of one of these Rho GTPases is achieved by the production of an alternative spliced 
isoform. This isoform of the Rac1 GTPase, namely Rac1b, possess an additional exon which 
causes conformational changes that prevents its interaction with the GTPase inhibitors GDIs 





and enhances its intrinsic nucleotide exchange activity, conferring a virtually constant GTP-
bound activation state. Interestingly, Rac1b confers a growth and invasive advantage over 
the canonical Rac1 protein isoform and tumours preferentially express higher levels of Rac1b 
compared to normal tissue. Despite extensive work on describing the pro-tumorigenic roles 
of Rac1b in colon, breast, pancreas, lung and thyroid cancer cells, there is a poor 
characterisation of its function in vivo. Given that Rac1b levels are very low in normal tissue, 
it stands as a potential candidate gene to target aberrant Rac1 activity observed in many 
cancer types. Therefore, I believe it is necessary to functionally characterise Rac1b in vivo 


























1.6 Hypothesis and aims 
Hypothesis 
I hypothesise that Rac1b is a promoter of tumorigenesis and that its elevated expression in 




In order to test the hypothesis, the aims of this project were as follow: 
- Determine location of Rac1b expression in normal and tumoral mouse tissue.  
- Investigate whether Rac1b is required for intestinal homeostasis. 
- Investigate in human CRC samples whether RAC1B expression associates with poor 
clinical outcome. 
- Evaluate whether Rac1b is essential for tumour progression by modulation of its 
expression in a benign adenoma mouse model. 
- Determine whether Rac1b can promote or facilitate tumour invasion by modulating 
its expression in a more progressive CRC mouse model. 
- Investigate the downstream effectors or pathways activated by Rac1b expression in 
the intestinal epithelium. 
- If a pro-tumorigenic function is established, investigate the potential therapeutic 














Chapter 2: Material and methods 
2.1 Mouse models 
Mice were bred at the animal facilities of the University of Edinburgh and were kept in 
compliance with UK Home Office regulations. Mice were maintained in 12 hours light-dark 
cycles and had access to water and food at libitum. 
All mice were crossed with mice carrying a tamoxifen-inducible Cre recombinase gene 
under control of the Villin promoter, to target intestinal cells427. All mouse lines were inbred 
within the same colony and had a mixed background.  
 
2.1.1 Modulation of Rac1b expression 
2.1.1.1 VillinCreERT2 Rosa26lsl-Rac1b/lsl-Rac1b  
VillinCreERT2 mice were crossed with mice carrying human Rac1b cDNA knocked in to 
the Rosa26-lox-Stop-lox locus408. Upon tamoxifen induction and Cre recombination, mice 
express the ectopic Rac1b cDNA. Recombination was evaluated by human Rac1b primers. 
 
2.1.1.2 VillinCreERT2 Rac1bfl/fl 
LoxP sites were inserted on either side of exon 3b of the mouse Rac1b transcript (Rac1-
202; ENSMUST00000100489.3), at positions 143,509,597 – 143,509,653. Upon Cre 
recombination, loxP sites were excised, preventing transcription of Rac1b protein. Mice were 
generated by Douglas Strathdee and David Stevenson (Transgenic Technology lab, Beatson 
Institute, Glasgow). 
 
VillinCreERT2 Rosa26lsl-Rac1b/lsl-Rac1b (RAC1BOE) and VillinCreERT2 Rac1bfl/fl (RAC1BKO) mice 
were provided by Dr. Owen Sansom (Beatson Institute, Glasgow). For short-term assessment 
of Rac1b loss and overexpression in the murine intestine, mice were induced with two 
intraperitoneal (IP) injections of tamoxifen (120mg/kg at day 0 and 80mg/kg at day 1) and 
sacrificed 5 days after the first injection. For longer term evaluation of Rac1b overexpression, 





RAC1BOE mice were induced with two doses of tamoxifen IP and sacrificed 31 days post-
induction. C57BL/6 wild type mice were used as controls. To assess tumorigenesis, both 
mouse lines, RAC1BOE and RAC1BKO, were crossed with the following Apcfl and Apcfl TP53fl/fl 
alleles (Figure 2.1). 
Tamoxifen solution (10mg/ml) was prepared by dissolving 1g of tamoxifen (Sigma, 
#T5648) into 10ml of pre-warmed 100% ethanol at 37ºC by discontinuous vortex. When 
dissolved, 90ml of corn oil (Sigma, #C8267) was added and solution was vortexed until 
dissolved. Stocks were kept at -20ºC. 
 
2.1.2 Colorectal cancer mouse models 
2.1.2.1 VillinCreERT2 Apcfl/+ 
For specific loss of Apc, loxP sites were inserted into the introns around Apc exon 14, 
creating an Apc mutant allele (Apc580S)436. Mice were provided by Dr. Owen Sansom and were 
crossed with RAC1BOE and RAC1BKO mice to create VillinCreERT2 Apcfl/+ Rosa26lsl-Rac1b/lsl-Rac1b 
(APC RAC1BOE) or VillinCreERT2 Apcfl/+ Rac1bfl/fl (APC RAC1BKO) mice. Mice were induced with 
a single dose of tamoxifen IP (80mg/kg) and were aged for tumorigenesis evaluation (section 
2.1.1.4). VillinCreERT2 Apcfl/+ (APC) mice were used as controls. To assess the effect of acute 
Rac1b deletion in homozygous Apc-deficient cells, VillinCreERT2 Apcfl(fl Rac1bfl/fl (APC-/- 
RAC1BKO) mice were generated. These were induced with two doses of tamoxifen (120mg/kg 
at day 0 and 80mg/kg at day 1) and sacrificed 5 days following the first injection. VillinCreERT2 
Apcfl(fl (APC-/-) mice were used as controls. 
 
2.1.2.2 VillinCreERT2 Apcfl/+ TP53fl/fl 
Loss of TP53 was achieved by insertion of LoxP sites in introns 1 and 10 of the TP53 
gene. Upon Cre recombination, virtually all coding sequences (exons 2-10) were removed 
and p53 protein was not produced437. Mice were provided by Dr. Owen Sansom and were 
crossed with APC mice to create VillinCreERT2 Apcfl/+ TP53fl/fl (APC P53) mice. In turn, these 
were crossed with RAC1BOE and RAC1BKO mice and mice with the following genotypes were 
created: VillinCreERT2 Apcfl/+TP53fl/fl Rosa26lsl-Rac1b/lsl-Rac1b (APC P53 RAC1BOE) and VillinCreERT2 





Apcfl/+TP53fl/fl Rac1bfl/fl (APC P53 RAC1BKO). Tumorigenesis assessment was performed by a 
single dose of tamoxifen (80mg/kg) in APC P53, APC P53 RAC1BOE and APC P53 RAC1BKO mice 
which were aged until endpoint signs were reached (details in section 2.1.2.3). For time-point 
evaluation of tumorigenesis, APC P53 and APC P53 RAC1BOE mice were given a tamoxifen IP 
and sacrificed 31 days post-induction. Functional assessment of Rac1b overexpression on 
double Apc- and TP53-deficient cells was conducted on mice with the following genotype: 
VillinCreERT2 Apcfl/fl TP53fl/fl Rosa26lsl-Rac1b/lsl-Rac1b (APC-/- P53 RAC1BOE) and VillinCreERT2 Apcfl/fl 
TP53fl/fl (APC-/- P53). These were induced with two tamoxifen IP injections (120mg/kg at day 
0 and 80mg/kg at day 1) and terminated 4 days after induction. 
 
 
Figure 2.1: Mouse models for Rac1b expression modulation and CRC. Schematic genetic 
strategies for used genetic modified mouse models. Blue triangles represent loxP sites. Cre 
expression was achieved upon tamoxifen IP injection.  
 





2.1.2.3 Disease surveillance and tumour quantification 
After induction, mice were monitored twice a week until the end of the experiment. 
Disease progression was evaluated by the presence of rectal bleeding, weight loss, hunched 
position and pale feet, which is a sign of tumorigenesis-driven anaemia. Mice were 
terminated when these endpoints reached moderate severity. This was done in collaboration 
with Caroline Billard (ECRC, University of Edinburgh). 
A BrdU IP of 200µl (Cell proliferation label, GE, #1392253) was given to the mice 2 
hours prior to termination. Mice were sacrificed by cervical dislocation. Organs were 
harvested for evaluation of possible metastasis (spleen, pancreas, liver, lungs, lymph nodes 
and kidneys) and were fixed in 4% paraformaldehyde (PFA, VWR) for 24 hours at 4ºC. For 
tumour scoring, intestines were flushed in cold PBS, opened longitudinally on a piece of 
paper and submerged in methacarn fixative (60% Methanol, 30% Chloroform and 10% Glacial 
acetic acid). Number and size of the tumours was quantified. Tumour size was evaluated by 
measuring the surface area of tumours, and the sum of all area was considered the total 
mouse tumour burden. Alternatively, some mice within the cohort were fixed with PFA to 
allow following immunohistochemistry procedures.  
 
2.2 Tissue histology 
2.2.1 Fixation, tissue processing and sectioning 
The intestine was harvested and flushed with cold PBS. For “Swiss-roll” sections, small 
intestine (SI) was cut in three pieces of approximately 10cm each. Both SI and large intestine 
(LI) were opened longitudinally and pinned on a wax plate. For PFA fixation, the tissue was 
covered in PFA in the plate for 24h at 4ºC. Afterwards, PFA was discarded, intestines were 
rolled and immersed in 70% ethanol. For methacarn fixation, tissues were immersed in 
methacarn for 15-30 minutes, rolled up, placed in formalin and kept at RT for 24 hours. For 
transversal parcel sections, 3 pieces of 1cm each of the SI were cut, stacked on tape and fixed 
for 24h at 4ºC in formalin. Tissues were switched to 70% ethanol prior to tissue processing 
Tissue processing was automatedly conducted in the Tissue-TeK VIP Infiltration 
Processor (Sakura), which performs sequential incubation steps in ethanol (5 x 60min), xylene 
(3 x 60min) and paraffin (4 x 60min). Processed tissues were orientated and embedded in 





paraffin wax and cooled down on a cold plate for several hours. Tissues were cut into sections 
of 5 µm thickness using the microtome (Leica), mounted onto glass slides (Thermo Fisher) 
and baked in an oven at 37ºC overnight (o/n). Prior to staining, sections were deparaffinised 
and rehydrated into serial washes of xylene and graduated ethanol dilutions until water (3 x 
5min). 
 
2.2.2 Tissue staining 
2.2.2.1 Haematoxylin & Eosin (H&E) 
Deparaffinised sections immersed in water were stained in Harris haematoxylin for 
4:30 minutes and washed in running lukewarm tap water for another 5 minutes. Sections 
were differentiated in 1% acid alcohol for 5 to 7 seconds and quick washed in running tap 
water for 30 seconds. Sections were blued in saturated lithium carbonate for 7 seconds and 
washed for 5 minutes in running lukewarm tap water. Counterstain was conducted by 
immersing sections in eosin for 2:30 minutes, followed by 2-second wash in water to discard 
excess and 1min in 100% ethanol for dehydration. Sections were dehydrated in serial washes 
of ethanol (3 x 1:30min) and xylene (3 x 5min) and preserved with cover slides using DPX 
mounting medium (Sigma).  
 
 
2.2.2.2 Periodic Acid Schiff (PAS) 
Deparaffined sections hydrated in water were oxidized in 0.5% periodic acid solution 
(0.5g of Periodic acid, Sigma, dissolved on 100ml of distilled water) for 5min. Sections were 
rinsed in water, developed in Schiff reagent (Sigma) for 15min and washed for 5min in 
lukewarm running water. Counterstain was conducted by 1min immersion in Harris 
haematoxylin. Sections were washed, dehydrated as for H&E staining and mounted in DPX 
mounting medium (Sigma). 
 





2.2.2.3 Immunohistochemistry (IHC) 
Deparaffined and hydrated sections were placed in water before antigen retrieval (AR) 
process. Diluted AR solution (1:10, Citrate or EDTA buffer, Thermo Fisher) was heated up at 
99ºC in a water bath. Sections were boiled into AR buffer for 20min (for citrate buffer) or 
15min (for EDTA) and cooled down at RT for 30 min. Slides were washed and treated with 
1.5% Hydrogen peroxide (Scientific laboratory supplies) diluted in water for 15min on a 
shaker. Following a water wash, sections were circled with a hydrophobic pen (StatMark pen, 
Sigma) and washed with PBST (1X Phosphate-buffered saline, IGMM Technical services, plus 
0.1% Tween, Sigma). Slides were placed into a slide box and blocked with 5% goat serum 
(Sigma) at RT for 45minutes, depending on the antibody. Sections were covered with a small 
volume of diluted primary antibody (from 100 to 300µl per section) (Table 2.3) and incubated 
o/n at 4ºC. The day after, sections were washed with PBST (3 x 5min) and incubated with an 
HRP-polymer of conjugated mouse or rabbit secondary antibody (EnVision+ system, DAKO) 
for 1 hour at RT. Alternatively, signal was enhanced by incubating samples with Vectastain 
elite ABC-peroxidase kit (Vector laboratories), which involves 30min incubation at RT with a 
biotinylated secondary antibody followed by 30min incubation with an A+B (avidin plus 
biotinylated enzyme reagents) buffer solution. After 3 washes with PBST (5 minutes each), 
staining was developed by incubating sections with DAB substrate for 5min at RT. Sections 
were washed in PBST (3 x 5min), counterstained for 2min with haematoxylin, differentiated 
for 5 seconds with saturated lithium carbonate and washed for 5 min with running water. 
Before mounting with DPX mounting medium (Sigma), sections were dehydrated in ethanol 
and xylene.  
 
2.2.2.3.1 Nuclear β-catenin IHC 
Slight variations from the usual IHC protocol were conducted for nuclear and 
membrane staining of β-catenin. Hydrated slides were treated with a peroxidase block (4.16g 
Citric acid, 10.76g DiSodium Hydrogen Phosphatase 2 hydrate, 1g NaAz; add fresh H2O2 to 
1.5%) for 45min on a shaker. Sections were then boiled for 50min in Tris EDTA buffer (242g 
Tris, 18.6g EDTA, diluted 1:5 in distilled water) and allowed to cool down for 1 hour at RT. 
After PBST washes (3 x 5min), sections were blocked with 1% BSA (Bovine serum albumin, 
Sigma) in PBS for 30min at RT and incubated for 2 hours at RT with the primary antibody 





diluted in 1% BSA. Sections were then washed with PBST (3 x 5min) and incubated with an 
HRP-polymer of mouse conjugated secondary antibody (EnVision+ system, DAKO) for 1 hour 




BaseScope™ probe was purchased from Advanced Cell Diagnostics and was designed 
for the transcript variant 1 of Rac1 (NM_001347530.1) against the exon 3 – exon 3b junction 
(Figure 2.2), which includes the following nucleotides:             
GTTGGAGACACATGTGGTAAAGATAGACCCTCCAGGGGCAAAGACAAGCCGATTGCCGACGTGTT
C (underlined sequence refers to exon 3b).  
Paraffin blocks were sent to Colin Nixon at the Beatson Institute for Cancer Research 
(Glasgow), who conducted BaseScope™ in situ hybridization. Analyses on stained slides were 
manually performed by scoring positive dots per crypt-axis unit (normal tissue) or intestinal 
area (hyperplasic tissue). Staining with a house keeping positive control probe was used as a 
reference for RNA integrity in tissues.  
 
     
Figure 2.2: BaseScope probe for Rac1b. Schematic representation of BaseScope probe 
targeting exon 3 – exon 3b junction. Protein coding diagram downloaded from 
Ensembl.  
 





2.2.2.5 QuPath IHC quantification 
Slides were scanned using the NanoZoomer Digital slide scanner (Hamamatsu) and the 
viewer software NDP.view2 (Hamamatsu). QuPath software was downloaded 
(qupath.github.io) and scanned slides were imported to the software. The scoring area was 
delimited using the polygon tool, and cells within the area were scored by running “cell 
detection” option. For BrdU/proliferation scoring, positive cells were detected by running the 
“positive cell detection” option, selecting “nucleus: DAB OD max” option at the intensity 
threshold parameter and a threshold intensity of 0.5. Percentage of proliferation was 
calculated comparing positive cells to total cells detected within the area. For CC3/apoptosis 
scoring, positive cells were scored manually, and the percentage of apoptosis was calculated 
according to total cells detected in the area. 
When using QuPath for histoscore analyses, positive cell detection was calculated for 
different threshold intensities. Score compartment would vary according to the staining 
pattern (nucleus, cytoplasm or cell). Based on the intensity of the staining, five different 
thresholds were chosen. The lowest threshold would include cells with the weakest staining 
intensity, while the highest would detect the most positive cells. Percentage of positive cells 
within each threshold would correspond to a score of 1 to 5. For histoscore analysis of SMAD4 
IHC in tumours, threshold intensities were as follow: 0.12 (1), 0.24 (2), 0.36 (3), 0.48 (4) and 
0.6 (5).  
In contrast, area analysis (for tumour size, for example) was measured using the 
NDP.view2 software, and normal tissue BrdU/proliferation was scored manually. 
 
2.3 Molecular biology techniques 
2.3.1 RNA extraction 
2.3.1.1 Whole tissue 
When intestines were harvested, a piece of SI or LI was preserved in RNAlater (Sigma) 
and frozen at -80ºC. For extraction of RNA, a small piece of tissue (100-700µg) was dried from 
RNAlater solution and transferred to a new Eppendorf with RLT buffer (from Qiagen RNeasy 
Mini Kit) and 1% of β-mercaptoethanol (Sigma). Tissue was homogenised with stainless steel 





beads (Qiagen) using the Qiagen Tissuelyser LT (Qiagen) at 50Hz for 5min. Lysate was 
centrifuged for 3min at 10,000g. Debris-free supernatant was transferred to a new 
Eppendorf and the same volume of 70% ethanol was added. Protocol was performed 
according to Qiagen RNeasy Mini Kit instructions. RNA was eluted in 50µl of RNase-free water 
from the kit and kept at -80ºC. 
 
2.3.1.2 2D cells 
Media was removed from wells and cells were washed twice with PBS. PBS was 
aspirated and 500µl of TRIzol (Invitrogen) was added per well (for 6-well plates). Cells were 
harvested by scraping the well with a P1000 tip and lysate was collected and left for 2min at 
RT to allow cell lysis. An equal volume of 100% ethanol was added and the homogenate was 
transferred to Zymo-Spin columns (Quick-RNA Microprep kit, Zymo Research). Protocol was 
followed as manufacturer’s instructions indicated and RNA was eluted in ≥6µl of RNase-free 
water. 
2.3.1.3 Intestinal organoids 
Organoids were collected in a 15ml falcon tube by scraping with a P1000 tip and 
centrifuged at 300g for 3min. Supernatant was aspirated and 5ml of 1X PBS was added. 
Organoids were washed by pipetting up and down a few times. Cells were centrifuged again 
at 300g for 3min and this step was repeated twice. Matrigel-free pellet was resuspended in 
a lysis buffer (300µl of RTL, Qiagen, and 3µl of β-mercaptoethanol) and was left for 3min at 
RT to allow cell lysis. Homogenate was centrifuged at 10,000g for 3min and the protocol 
proceeded using the Qiagen RNeasy Mini Kit as in section 2.3.1.1. 
Once RNA was eluted, residual DNA was removed using the DNA-free DNA removal kit 
(Ambion). Final RNA concentration and quality was evaluated by the Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific), using 2µl of RNA and 2µl of the eluted water 
as blank. An UV absorption ratio of A260/A280 above 1.80 was considered optimal.  
 





2.3.2 cDNA synthesis 
Reverse transcription of RNA was conducted using the qScript cDNA SuperMix reagent 
(Quanta Bioscience). An amount of 1µg (for tissue) or 0.5µg (for cells) of RNA was combined 
with 4µg of the RT supermix, in a final volume of 20ul. PCR protocol is illustrated in Table 2.1 
and was conducted using the Peltier Thermal Cycler (PTC-225, MJ Research Inc). PCR product 
was diluted 1:10 with RNase-free water and was kept at -20ºC for further use. 
 
2.3.3 Real time PCR (qRT-PCR) 
Amplification of cDNA was conducted using the CFX Connect Real-time System (Bio-
Rad) machine. qRT-PCR primers were designed and purchased from Integrated DNA 
Technologies (IDT) (Table 2.2). A forward and reverse primer mix was diluted 1:10 in RNase-
free water and reaction was performed using the LightCycler 480 SYBR Green I Master Mix 
(Life Technologies). Reactions were conducted in a 96-well plate (Axygen) and each reaction 
mix was composed of 10µl SYBR Master mix, 5µl cDNA, 1µl primer mix and 4µl RNase-free 
water. Reactions were conducted in duplicated as technical replicates. RNase-free water was 
used as a non-template control and β-actin was used as housekeeping gene in all reactions. 








           Table 2.1: PCR protocol for cDNA and qRT-PCR programs. 
 
 












Table 2.2: Forward and reverse primer sequences used for qRT-PCR. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
Axin2 TGACTCTCCTTCCAGATCCCA TGCCCACACTAGGCTGACA 
BIM GACAGAACCGCAAGGTAATCC ACTTGTCACAACTCATGGGTG 
Ccnd1 GCGTACCCTGACACCAATCTC CTCCTCTTCGCACTTCTGCTC 
Cited1 AACCTTGGAGTGAAGGATCGC GTAGGAGAGCCTATTGGAGATGT 
C-Myc ATGCCCCTCAACGTGAACTTC CGCAACATAGGATGGAGAGCA 
Ctnnb1 ATGGAGCCGGACAGAAAAGC CTTGCCACTCAGGGAAGGA 
Defa20 TGTAGAAAAGGAGGCTGCAATAG AGAACAAAAGTCGTCCTGAGC 
E-Cadherin CAGGTCTCCTCATGGCTTTGC CTTCCGAAAAGAAGGCTGTCC 
EphB2 GCGGCTACGACGAGAACAT GGCTAAGTCAAAATCAGCCTCA 
Etv4 CGGAGGATGAAAGGCGGATAC TCTTGGAAGTGACTGAGGTCC 
Etv5 TCAGTCTGATAACTTGGTGCTTC GGCTTCCTATCGTAGGCACAA 
Fzd3 ATGGCTGTGAGCTGGATTGTC GGCACATCCTCAAGGTTATAGGT 
hRac1b CAGTAAGGGAGCTGCAGTGG GCGAAGAGTTTGTCCTCAACC 
IGFBP2 CAGACGCTACGCTGCTATCC CCCTCAGAGTGGTCGTCATCA 
Klk1 CAATGTGGGGGTATCCTGCTG GGGTATTCATATTTGACGGGTGT 
Krt20 AGTTTTCACCGAAGTCTGAGTTC GTAGCTCATTACGGCTTTGGAG 
Lef1 TGTTTATCCCATCACGGGTGG CATGGAAGTGTCGCCTGACAG 
Lgr5 GAGTCAACCCAAGCCTTAGTATCC CATGGGACAAATGCAACTGAAG 
Lyz1 GAGACCGAAGCACCGACTATG CGGTTTTGACATTGTGTTCGC 
mRac1b TGTGGTAAAGATAGACCCTCC CCCACGAGGATGATAGGAGT 
Muc2 AGGGCTCGGAACTCCAGAAA CCAGGGAATCGGTAGACATCG 
Neu3 AGCAGGAAGAACAGAGTGGG CCTCCATCAGTAGCCGTTGG 
Olfm4 GCCACTTTCCAATTTCAC GAGCCTCTTCTCATACAC 
p15 TCTGCAGCTGGATCTGGTCC TCCTGAAAGGTAGAGGGCCC 
p21 CCTGGTGATGTCCGACCTG CCATGAGCGCATCGCAATC 
Rac1 GAGACGGAGCTGTTGGTAAAA ATAGGCCCAGATTCACTGGTT 
Slc14a1 TTAAAGTAGACCGGGGTGAAAAC ACCCGTGACGTAGCCAAGTA 
SMAD4 ACACCAACAAGTAACGATGCC GCAAAGGTTTCACTTTCCCCA 
SMAD7 GGCCGGATCTCAGGCATTC TTGGGTATCTGGAGTAAGGAGG 
Tcf7 AGCTTTCTCCACTCTACGAACA AATCCAGAGAGATCGGGGGTC 
TGF-β1 CTCCCGTGGCTTCTAGTGC GCCTTAGTTTGGACAGGATCTG 
TGF-β2 CTTCGACGTGACAGACGCT GCAGGGGCAGTGTAAACTTATT 
Tiam1 GAAGCACACTTCACGCTCC CTCCAGGCCATTTTCAGCCA 
Tnfrsf19 TTCTGTGGGGGACACGATG AGAAAATTCAGCGCAGATGGAA 
Trpv6 AGGGGTTAATACTCTGCCTATGG GCACCTCACATCCTTCAAACTT 
TβRII CCGCTGCATATCGTCCTGTG AGTGGATGGATGGTCCTATTACA 
Znrf3 GGCGACTATACCACCCACAC CTTCACCACTCCTACCCAGC 
β-actin GTGACGTTGACATCCGTAAAGA GCCGGACTCATCGTACTCC 





2.3.4 RNA sequencing 
RNA quality was assessed by Stewart McKay (HGU, University of Edinburgh) on an 
Agilent 2200. Samples were considered optimal when RIN (RNA integrity number) values 
were above 8. 
An amount of 1µg of RNA was sent to GATC Biotech AG (Germany) for library 
preparation (random primary cDNA library) and Illumina RNA sequencing (a single read of 
50bp length and 30 million reads guaranteed per sample (+/-3%)). GRCm38 (Ensemble 95) 
was utilised to define coding and non-coding cDNA sequences and to build a transcriptome 
index for Kallisto, which was used to quantify the transcript abundances. Estimated counts 
were imported with Tximport and differentially expressed genes were identified using both 
Cuffdiff and DESeq. Sequencing data was analysed by Dr. Stuart Aitken (IGMM, University of 
Edinburgh). Genes with a p-value higher than 0.05 were considered for pathway analyses 
using Innate DB database (innatedb.com). 
 
2.3.5 Protein extraction and quantification 
2.3.5.2 2D cells  
From cells cultured in a 6-well plate, media was removed and wells were washed twice 
with PBS. A volume of 100µl of RIPA buffer (Sigma) supplemented with 1µl of Phosphatase 
inhibitor cocktail 3 (Sigma) and 1µl of Protease inhibitor cocktail (Sigma) was added at each 
well. Cells were scraped with a P1000 tip, collected on an Eppendorf and left on ice for 10min 
to aid cell lysis. Proteins were clarified by a 30’ vortex and a centrifugation step at 10,000g 
for 10min at 4ºC.  
 
2.3.5.3 Intestinal organoids 
Organoids in culture were collected and washed, and Matrigel was removed by 
sequential PBS washes and centrifugation steps. However, the pellet was resuspended with 
a volume of RIPA lysis buffer according to the size of the cellular pellet (from 100µl to 500µl). 
Lysate was incubated on ice for 10min and procedure followed as for 2D cells protein 
extraction. 





Protein quantification was conducted using the Pierce BCA protein assay kit (Fisher). 
Following manufacturer’s protocol, 200µl of working solution was incubated with 10µl of 
protein in a 96-well plate with a flat bottom (Greiner) and each sample was conducted in 
triplicate. After 30min of incubation at 37ºC, absorbance of the plate at 562 nm was read and 
protein concentration was calculated according to the albumin standard curve.  
2.3.6 Western blotting 
Whole protein extracts were evaluated by Western blot. Protein lysates were 
separated on 4-12% Bis-Tris protein gels from NuPage (Thermo Fisher). A mix of protein 
lysate (6µg-10µg), 4X of sample loading buffer (Thermo Fisher) and 10X of DTT (Sample 
reducing agent NuPage, Thermo Fisher) was prepared for each sample and was denatured at 
99ºC per 5min. The gel was placed in the tank filled with 1X MOPS (for large proteins) or MES 
(for small proteins) running buffer (Thermo Fisher) and proteins were loaded into the wells. 
Running was carried out at 120V at RT and, when finished, the gel was transferred to a 
methanol pre-activated nitrocellulose membrane (Fisher Scientific). Diluted 20X Transfer 
buffer (Thermo Fisher) in water and methanol was used and transfer was conducted at 4ºC 
for 1:30h at 250mAmp. Transfer efficiency was evaluated with Ponceau solution (Sigma) and 
membrane was washed with PBST 3 times prior to blocking with 5% milk/PBST (dried milk, 
Marvel) for 1 hour at RT. Alternatively, for probing phosphorylated proteins, 3% BSA/PBST 
was used for blocking. Blocked membrane was incubated with 1º antibody diluted in blocking 
solution at 4ºC o/n (Table 2.3 for antibody concentrations). After incubation, membrane was 
washed with PBST (3 x 5min) and was incubated with 2º antibody diluted in blocking solution 
for 1 hour at RT (anti-rabbit or anti-mouse IgG, HRP-linked, Cell Signalling). Following 3 more 
washes with PBST, signal was detected by chemiluminescence using ECL Plus substrate 
(Thermo Scientific) for 5 min and membranes were develop with ECL hyperfilm (Amersham) 
at the darkroom using the Medical Film Processor SRX-101A (Konica Minolta).  
To strip and for further probing with other antibodies, membrane was incubated for 
15min at RT with a Stripping solution (1:10 dilution, Millipore).  
Densitometry of Western blot bands was assessed using ImageJ 
(https://imagej.nih.gov/ij/download.html). 






Table 2.3: List of antibodies used for IHC and WB. Incubation time were o/n unless stated. 
AR Proteinase K: 20X Proteinase K (Sigma) dissolved 1:20 in TE buffer, incubated for 5min at 
37ºC. 
 
2.3.7 Protein interaction study by BioID 
2.3.7.1 Cloning the BirA* enzyme into a lentiviral vector 
Myc-BioID2-MCS plasmid was purchased from Addgene (#74223), containing the BirA 
with a myc tag on the C-terminal. Bacterial stab was purified by Miniprep (Qiagen) following 
manufacturer’s instructions. Myc-BioID2 sequence was introduced into the pLJM1-EGFP 
(#19319, Addgene) lentiviral vector by digesting 5µg of both plasmids with NheI-HF (NEB, 
#R3131) and EcoRI-HF (NEB, #R3101S) restriction enzymes (RE). CutSmart (NEB) was used as 
the digestion buffer and digestion protocol followed manufacturer’s instructions. Digestion 
was separated on 1% agarose gel (3g agarose dissolved in 300ml 1X TAE buffer) ran at 120V 
at RT.  
Bands appeared at 775bp for Myc-BioID2 and 7315bp for pLJM1 vector. These were 
cut out of the gel using the Zymoclean Gel DNA recovery kit (Zymo Research) and DNA was 
quantified by Nanodrop. Ligation was performed using the T4 ligase kit (Promega) o/n. 
Ligation was transformed into One Shot TOP10 bacteria (Thermo Fisher) by heat shock, 





followed by 1-hour incubation at 37ºC with SOC media (provided with bacteria) and plated 
in Ampicillin (AMP, IGMM Technical services) resistant plates o/n at 37ºC. Efficiently 
transformed colonies were picked and grew on 2ml L-Broth media (IGMM Technical services) 
supplemented with Penicillin-Streptomycin (PEN/STREP, IGMM Technical services) and AMP 
for following Miniprep.  
 
2.3.7.2 Amplification of Rac1 and Rac1b by PCR 
cDNA synthesised from normal murine SI was used to amplify Rac1 DNA. On the 
contrary, Rac1b DNA was purchased from GeneScript (#OHu22224). Primers were designed 
to insert EcoRI sequence at the C-terminal and SacII sequence (NEB, #R0175S) at the N-
terminal. Primer sequences and PCR protocol were as follows: 
- RAC1/RAC1B F (5’-3’): TTTTTGAATTCCAGGCCATCAAGTGTGTG 





Table 2.4: PCR protocol for Rac1 and Rac1b amplification. 
 
2.3.7.3 Cloning of Rac1/Rac1b into the pLJM1-myc-BioID2 vector 
Rac1 and Rac1b sequences were independently inserted into the lentiviral vector by 
using the pGEM-T Easy Vector Systems (Promega). This system required of an A-tailing 




Table 2.5: A-tailing protocol. 
 





The reaction was ligated into the pGEM-T vector following manufacturer’s 
instructions. Ligation was transformed as detailed in section 2.3.7.1 and transformation was 
plated in X-gal/IPTG plates (reagents and protocol from Goldbio, Blue White Screening using 
X-Gal and IPTG), necessary to discriminate between positive (white) and negative (blue) 
transformed colonies. White colonies were grown for Miniprep extraction and insertion was 
verified by digesting plasmid with EcoRI and SacII RE and running product into a 1% agarose 
gel. Detected bands were extracted using the Zymoclean Gel DNA Recovery kit and DNA was 
sequenced by Jeffrey Joseph (Technical Services, MRC, University of Edinburgh).  
pLJM1-myc-BioID2 vector was digested with EcoRI and SacII RE and was purified after 
running on an agarose gel. Digested vector was ligated with pGEM-T inserts whose sequences 
were verified. Ligations were transformed into TOP10 bacteria and colonies grown, then 
purified by Miniprep. These were sent for sequencing and plasmids with verified sequences 
were amplified by Maxiprep (Qiagen). A vector with no insert was amplified by Maxiprep to 









Figure 2.3: BioID plasmids. Schematic representation of the resultant cloned plasmids. A: 
Control for BioID experiment, with only the myc-BirA* sequence cloned. B: Either Rac1 or 









2.3.7.4 Streptavidin-biotin pull-down for MS 
Upon biotin treatment, transfected cells were collected for protein extraction. A 
volume of 500µl of RIPA buffer supplemented with phosphatase and protease inhibitors was 
added per 10cm2 dish. Cells were scraped and transferred to a 1.5ml Eppendorf tube. 
Following 15min of lysis incubation on ice, cells were vortexed for 30’’ and clarified at 
maximum speed for 10min at 4ºC. In the meantime, 15µl of Streptavidin Sepharose matrix 
(GE Healthcare, #17-5113-01) were neutralised on 1ml of RIPA buffer by gently pipetting, and 
centrifuged for 2min at 1,000g. RIPA supernatant was removed and clarified proteins were 
added to the beads. These were mixed without pipetting and incubated on a rotator at 4ºC 
for 6 hours.  
After incubation, the mix was spun down at 1,000g for 5min. Without altering the 
beads pellet, supernatant was removed and 1ml of wash buffer (50mM TrisCl, 8M Urea, pH 
7.4) was gently added and mixed by inversion. The tube was placed on a rotator for 8min at 
RT and centrifuged for 2min at RT. This step was repeated three times, the last wash being 
with urea-free wash buffer. Beads were kept at -20ºC without supernatant to send for MS 
analysis. MS experiment and analysis of the data was performed by Dr Alexander von 
Kriegsheim (Mass Spectrometry Facility Manager, IGMM, University of Edinburgh). 
Interactome analyses from the resultant protein hits was conducted using the 
NetworkAnalyst web-based platform (https://www.networkanalyst.ca). 
For validation of BioID hits, pull-down beads were resuspended with 55µl of RIPA 
buffer supplemented with 5.5µl of 10X DTT. Lysate input was used as a positive control. 
Protein lysates were run on a Western blot as detailed in section 2.3.6. 
 
2.4 2D cell culture 
2.4.1 Cell line model 
The mouse rectal carcinoma cell line CMT93 was used for 2D cell culture experiments. 
Cell line was previously characterised by Kitamura et al438 (Table 2.6). 
 
Table 2.6: Mutational profile CMT93 cell line. Adapted from Kitamura et al.  
 





2.4.2 Routine cell culture maintenance 
Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) 
supplemented with 10% foetal calf serum (FCS, IGMM Technical services) and 1% penicillin 
and streptomycin (Life technologies) and cultured in T25 or T75 (25cm2 or 75cm2) flasks 
(Corning) at 37ºC in a 5% CO2 incubator (Heracell 150i, Thermo Fisher). Manipulation of cells 
was carried out under a laminar flow cabinet. To passage, cells were washed with PBS and a 
volume of 0.25% Trypsin-EDTA (Gibco) was added to detached cells from flask. When all were 
detached, DMEM was added to neutralise Trypsin. Cells were recollected into a falcon tube 
and were centrifuged for 5min at 300g. Cells were diluted 1:5 to 1:10, depending on the 
experimental plan.  
To seed a precise number of cells, Countess™ cell counter was used (Thermo Fisher). 
Following the centrifuge step, pellet was resuspended with 5ml of DMEM. In a new 
Eppendorf, 10µl of trypan blue (Thermo Fisher) was merged with 10µl of cells and the mix 
was inserted into a disposable Countess chamber slide. The slide was introduced into the 
instrument and counting was automatedly conducted.  
To maintain cell stock, cells were frozen at a concentration of 3.5-5milions cells/ml 
diluted in 10% DMSO (Sigma). Aliquots were frozen in an isopropanol freezing chamber 
(MrFrosty, Thermo Fisher) at -80ºC prior transfer to N2. Cells were recovered by thawing for 
1-2min in a 37ºC water bath.  
 
2.4.3 Plasmid transfection 
One day before transfection, cells were seeded in a 6-well plate at a density of 3 x 105 
cells/well. 4µg of DNA plasmid per well was diluted in 250µl of Opti-MEM (Gibco). In a 
separate tube, 25µl of Lipofectamine 2000 was gently mixed with 150µl of Opti-MEM, and 
left at RT for 5min. The DNA-containing tube and Lipofectamine-containing tube were mix 
and incubated at RT for 20min. Cell media was replaced with 2ml fresh DMEM and 500µl of 
transfection mix media. Cells were incubated at 37º and transfection was evaluated 48 hours 
later.  
 





2.4.4 Biotin treatment for MS analysis 
To start, a total of ~3 x 106 cells were seeded on two 10cm2 dish (Thermo Fisher). The 
following day, transfection was carried out as detailed in section 2.4.3, using 24µg of DNA 
and 60µg of Lipofectamine 2000 per dish. 40 hours after transfection, transfection media was 
replaced by 10ml with 50µM of Biotin (Sigma; from 1mM stock, 0.0122g Biotin dissolved in 
50ml DMEM). Cells were collected 20 hours later for protein extraction (section 2.3.5.2). 
 
2.4.5 Depletion of Rac1b with morpholino 
An antisense morpholino to target exon 3b exon skipping was especially designed by 
Dr Linda Popplewell and Prof George Dickson (Royal Holloway, London) and was purchased 
from GeneTools (USA). 
To deplete Rac1b cells were seeded for 2 days with 5µl/ml of Rac1b Morpholino (Rac1b 
PMO) or non-targeted morpholino (NT, control) in the media (Figure 2.4). After two days, 
cells were split and counted with an automated cell counter. In a 6-well plate, 2.5 x 105 cells 
were seeded per well with 2.5µl of Rac1b PMO or NT for one day. Depletion was determined 







Figure 2.4: Schematic representation of morpholino-mediated Rac1b knockdown. The 
morpholino (PMO) promotes exon skipping by binding to the exonic splice enhancer 
sequence in exon 3b. 
 





2.4.6 EGF stimulation 
On the day prior to experiment, 2.5 x 105 cells/well were seeded in a 6-well plate. The 
day after, cells were serum starved for 4 hours before EGF was added to the media (except 
the non-starved control cells). A media mix solution was prepared with 20ng/ml of EGF 
(Invitrogen). After starvation, cell media was replaced by 2ml of EGF-containing media. Plates 
were put back into the incubator and cells were collected for protein extraction after 5, 10, 
15 and 30min. Two EGF non-treated wells were used for treatment control and to validate 
Rac1b depletion by qRT-PCR.  
 
2.5 3D Organoid culture 
2.5.1 Small intestine epithelial isolation and culture 
Small intestine was harvested and flushed thoroughly with cold PBS. The tissue was 
opened longitudinally and villi were scraped off with a coverslip. Under the hood, small 
pieces of tissue (~5mm) were cut and transferred to a 50ml falcon tube. Tissue was washed 
with 10ml of cold PBS up to 5 times, allowing the pieces to settle down and discarding the 
supernatant with debris. A volume of 25ml of 2mM EDTA (IGMM Technical services) in PBS 
was added to the intestinal pieces, and the falcon was incubated at 4ºC with agitation. This 
step allows the crypts to separate from surrounding tissue. After 30min, EDTA was aspirated 
and pieces were gently washed from the EDTA with 10ml of PBS. Supernatant was discarded 
and 10ml of cold PBS was added to the pieces. Tissue was thoroughly pipetted up and down 
about 10 times to loosen intestinal cells. Supernatant was separated into a different 15ml 
falcon tube and this step was repeated three more times. A total of 4 supernatants were 
collected, namely epithelial fractions. 10µl of each fraction was used to evaluate their cellular 
content at the microscope. The last fractions are higher enriched in crypt/stem cells 
compared to the first collected fractions, and these were the ones usually used to plate. 
Chosen fractions were combined in a 50ml falcon tube and filled up with supplemented 
Advanced DMEM/F-12 media (ADF, Gibco) (Table 2.7)  to centrifuge for 3min at 300g. 
Supernatant was discarded and the pellet was passed through a 70µm cell strainer (Scientific 
laboratory supplies) with 10ml of media to obtain isolated crypts. Crypts were spun in a 15ml 
falcon tube at 700g for 10min. Pellet was carefully resuspended with Matrigel (Corning) and 





a volume of 20µl was plated in a pre-warmed 24-well plate. Crypts were incubated at 37ºC 
for 5-10min to allow Matrigel solidification. 500µl of pre-warmed growth media was added 
per well. Details of media and growth factors are illustrated in Table 2.7.  
 
2.5.1.1 Epithelial fractionations  
To evaluate the expression of Rac1b across the crypt-villus axis, fractions obtained 
from intestine epithelial cells isolation were used. Wild type or RAC1bOE mice acutely induced 
with tamoxifen for 5 days were used for the experiment. SI was harvested and epithelial 
fractions were obtained as detailed in the previous section. Collected fractionations were 
separately spun down at 300g for 10min. The pellet was washed once with cold PBS and cells 
were spun at 300g for 5min. RNA was extracted from epithelial cells as detailed in section 
2.3.1.3. 
 
2.5.2 Tumour adenoma isolation 
Harvested adenoma from mice was cut in small pieces in a petri dish and transferred 
to a 15ml falcon tube with ADF+. After washing the tumour twice with ADF+, tumour was 
incubated with 2ml of digestion media (Table 2.7) for 60-90min at 37ºC. While incubated, 
tumour was pipetted vigorously every 15min to facilitate cell dissociation. When digestion 
was completed, tumour cells were passed through a 70µm cell strainer and 100µl of 1% BSA 
was added to stop digestion. Cells were spun down at 600g for 3min and the pellet was 
washed twice with ADF. Final pellet was resuspended in an appropriate volume of Matrigel 
(up to 500µl for a 24-well plate) and plated in a pre-warmed plate.  
 
2.5.3 Routine organoid culture maintenance  
Organoid media was renewed every 3 to 4 days. When organoids reached confluency, 
these were split, usually up to 7 days. Organoids were mechanically passaged by scraping the 
wells with a 5ml pipette to disintegrate the Matrigel drop. Media was recollected and spun 
at 300g for 3 min. Supernatant was discarded and pellet was washed with 5ml of ADF+, 
pipetting up and down vigorously several times. This step was repeated twice until Matrigel 





was dissociated from the cellular pellet. To physically break the crypts, the pellet was 
resuspended using a P200 with 200µl of ADF+ and centrifuged at 600g for 3min. Supernatant 
was aspirated and the pellet resuspended with Matrigel in a pre-warmed 24-well plate. 
Growth media was added when Matrigel was solidified in the incubator.  
To freeze an organoid cell line, cells were dissociated from Matrigel and incubated for 
15min at 37ºC with the freezing media. After incubation, 100µl of DMSO were gently added 
and cells were transferred to a freezing vial. Isopropanol freezing step is required prior to N2 
storage.  
To thaw an organoid cell line, frozen vial was incubated for 30 seconds at 37ºC in the 
water bath. Aliquot was mixed with 9ml ADF+ and two washes with ADF+ were performed. 
Cells were broken with a P200 and embedded in Matrigel as usual. Importantly, Y-27632 was 









 Table 2.7: Organoid media conditions and supplemented growth factors. 
 
2.5.4 Clonogenicity assay 
This assay measures the ability of a tumoral cell to initiate a clone. APC P53 and APC 
P53 RAC1bOE tumour organoids were washed and dissociated from Matrigel as usual (section 
2.5.3). Crypt cells were chemically digested into single cells using 500-700µl of StemPro 
Accutase solution (Life technologies) for 10min at 37ºC. Digestion was stopped with ADF+ 





and cells were passed through a 40µm cell strainer (Scientific laboratories supplies). Cells 
were centrifuged at 600g for 5min and resuspended with 500µl of PBS supplemented with 
5% of FCS. For an accurate count of single cells, a total number of 30,000 living and single 
cells were sorted through the flow cytometer (performed by Elisabeth Freyer, MRC, 
University of Edinburgh). These were centrifuged at 600g for 5min and resuspended in 150µl 
of Matrigel. Drops of 5µl Matrigel containing 1,000 single cells were plated in a 24-well plate. 
Growth media was added as usual and formed clones were scored 4 days after.  
Clonogenicity assay of APC and APC RAC1bKO tumour organoids was performed by Dr 
Patrizia Cammareri. Single cells were scored using the Countess machine. 
 
2.5.5 EGFR inhibition with PD153035 treatment 
APC and APC RAC1bKO organoids were split as fragments at a density of 100 
fragments/µl of Matrigel, distributed in drops of 15µl each. Cell fragments were achieved by 
gently breaking crypt cells with the P1000 instead of the P200, avoiding dissociation as single 
cells. After 24 hours, media was replaced by treatment media. Two different experimental 
conditions existed: control (1% DMSO) or EGFR inhibitor group (1µM PD153035, Sigma, cat# 
SML0564). DMSO or inhibitor were diluted in normal organoid growth media.  
After 20 hours of treatment, pictures were taken for organoid area measurement, 
assessed with ImageJ. Furthermore, cell viability assay was conducted using Resazurin. 
Resazurin (R&D systems) was added to the media at 10% and cells were incubated for 7 
hours. Fluorescence was read at 560/590nm emission wavelength using Victor Multilabel 
Plate Reader (Perkin Elmer).  
In parallel, assay measuring organoid cell growth with or without EGF supplemented 










2.5.6 Acute and time course induction with TGF-β treatment 
APC-/- P53 and APC-/- P53 RAC1bOE organoids were digested into fragments and plated 
at a confluency of 100 fragments/µl of Matrigel (as in section 2.5.5). After 3 days when 
organoids have reached confluency, media was replaced by growth media supplemented 
with 5ng/ml of TGF-β1 ligand (Peprotech, cat# 100-21-10) or nothing as control. Organoids 
were collected after 2 hours for analysis of early response TGF-β target genes and RNA or 
protein was extracted (see sections 2.3.1.3 or 2.3.5.3 for details). For time point analysis, 
organoids were collected after 2, 4, 6 and 24 hours of TGF-β treatment and protein was 
extracted (section 2.3.5.3). 
 
2.5.7 TGF-β-induced cell death 
Around 40 fragments per 4µl drop of Matrigel were plated from APC-/- P53 and APC-/- 
P53 RAC1bOE organoids. The number of clones formed was scored after 48 hours and the 
growth media was replaced with TGF-β1-supplemented growth media. A titration of TGF-β1 
doses was used to evaluate cell death: 0, 0.3ng/ml, 1ng/ml, 3ng/ml, 10ng/ml and 30ng/ml. 
Dead organoids were scored following 24 hours of treatment, using the work from Grabinger 
et al. as a reference for the morphology of dead organoids439. Percentage of cell death was 
calculated individually per well compared to the initial number of organoids. 
Furthermore, cell death was measured using the CellEvent™ Caspase-3/7 Green 
Detection Reagent (Invitrogen). After 24 hours that organoids were split as fragments, 1000X 
of reagent was added to the media, which would release fluorescent light upon reagent 
substrate cleavage by caspase-3 and -7 activation. Both types of images, brightfield and 
fluorescent, were taken following 24 hours of treatment. Quantification was carried out on 
ImageJ, whereby brightfield pictures were used as a reference for organoid ROIs (region of 
interest) to overlay with fluorescent images and to calculate the percentage of green pixels 
per organoid. Validation of this assay was conducted by simultaneous scoring of cell death 
according to organoid morphology.  





2.6 TCGA dataset analysis 
Synapse is a database system to allow public access to the data generated by the TCGA 
program, as well as by the Colorectal Cancer Subtyping Consortium (CRCSC).  
Isoform data from TCGA COAD tumours were downloaded from the TCGA Synapse 
group (synapse accession: doi:10.7303/syn300013)440 and “IlluminaHiSeq_RNASeqV2” study. 
Expression of RAC1 (uc003spx.3) and RAC1B (uc003spw.3) was compared in tumours and in 
matched normal tissue.  
PSI data was downloaded from the TCGASpliceSeq web-based platform441. Data for 
RAC1 PSI was downloaded per each tumour type. Types which had normal tissue expression 
were compared with tumour expression. Moreover, COAD tumours were subdivided 
according to their RAC1 PSI: 
- RAC1Bhigh: if PSI value > 0.2 above the average PSI of normal tissue 
- RAC1Blow: if PSI value < average PSI of normal tissue 
Clinical data from TCGA COAD tumours was extracted from the CBioPortal website, 
which included survival, lymphovascular invasion and metastasis data. TCGA tumour codes 
were overlapped with those from the TCGASpliceSeq and survival and invasion data were 
classified according to RAC1Bhigh or RAC1Blow groups.  
Pathway analysis was also facilitated by the CBioPortal website, whereby TCGA 
tumours can be analysed according to the presence or absence of mutations in a particular 
gene.  
RSEM-calculated (RNA-Seq by Expectation Maximization) reads of COAD tumours  
were downloaded from the analysis performed by Wang et al442. Based on the CMS gene 
signatures (provided to the laboratory), RSEM of TCGA tumours were distributed according 
to the CMS gene profile. PSI values were associated to their corresponding TCGA code and 
both, PSI and RSEM values were correlated by a Pearson’s test. Moreover, CMS groups were 
compared each other according to RAC1 PSI.  
Expression of particular genes (such as LRG5 or AXIN2) was calculated from the RSEM 
data set overlapped with RAC1 PSI values.  





For CMS survival analyses, TCGA codes with CMS and RAC1 PSI information were 
compared to the survival information downloaded from the CBioPortal clinical data. 
Tumour stage data was acquired from the clinical data published by the CRCSC synapse 
group (accession: doi: 10.7303/syn2623706), whose TCGA codes were overlapped with the 
corresponding RAC1 PSI values. Moreover, MSI status and BRAF mutations were also 
facilitated by this dataset.  
Finally, RPPA data was downloaded from The Cancer Proteome Atlas 
(https://tcpaportal.org/tcpa/download.html). Protein expression values were correlated 
with RAC1 PSI by Pearson’s correlation.  
 




















2.8 Statistical analysis 
GraphPad Prism version v7.0 software was used for all statistical analyses. Data was 
analysed as follows: 
- Comparison between two groups was assessed by Student’s T-test, 2-tailed, 
parametric and unpaired. If groups did not follow normality, a non-parametric 
Mann-Whitney test was conducted instead.  
- Percentage of survival was analysed by a Log-rank (Mantel-Cox) test. 
- Correlation between two data sets was evaluated by 2-tailed Pearson 
correlation, with a 95% of confidence interval.  
- Association between two categories was assessed by two-sided Fisher’s test 
P values < 0.05 were considered statistically significant. Levels of significance are 
labelled as follows: * = p < 0.05; ** = p < 0.001; *** = p < 0.001; **** p ≤ 0.0001. Not 
















Chapter 3: Characterization of Rac1b expression 
3.1 Localization of Rac1b in the mouse intestine 
Little is known about where Rac1b is localized within a tissue. To date, most 
investigations of Rac1b expression have been made in 2D cell lines, so its subcellular 
localization is better defined than its tissue distribution. Given that it is a small GTPase 
protein, and its best characterised for its GTP bound state, it is expected to be membrane 
bound as Rac1 is in its active version443. Early studies investigating Rac1b function showed 
that it is predominantly localised at the membrane, where is functionally active375. For 
instance, Lee et al., demonstrated that Rac1b-dependent ROS production only occurs when 
Rac1b is retained in the membrane with fibronectin393,394. IHC staining for Rac1b in breast 
cancer biopsies validated a membrane localisation of Rac1b in the most malignant tumours, 
which potentially would also present ROS-driven EMT activation. Other investigators have 
also shown immunohistochemical analysis from human cancer tissue395,400 and all of them 
have used the unique commercial Rac1b antibody available except Li et al., who generated 
their own380. Indeed, they were pioneers in publishing an in vivo investigation deleting Rac1b. 
Initially, they studied Rac1b function in vitro using transduced colonic cells with lentivirus 
overexpressing either Rac1 or Rac1b and saw that, while Rac1 was mainly localized in the 
nucleus or the cytoplasm, Rac1b had a membrane and cytoplasmatic localization380. Then, 
they knocked out Rac1b using CRIPSR, only affecting the exon 3b and without altering Rac1 
expression. They showed by immunohistochemistry that, in normal conditions, Rac1b was 
expressed in the colonic epithelium. This is validated by their knock-out rats, which are 
completely negative for Rac1b staining, although the low-resolution images used in the paper 
make a definite conclusion in tissue location difficult. Regarding murine models, to date there 
is no in vivo data describing Rac1b localization in either normal tissue or tumours. Recently, 
Chastre et al. presented their in vivo work using a Villin promoter and the Cre recombinase 
system to overexpress Rac1b in an ApcMin/+ mice model409, but they only characterized Rac1b 









3.1.1 Unespecific signal with Rac1b antibody 
The aim of this project is to investigate the function of Rac1b in both normal and 
tumour intestine tissue by modulating its expression in mouse models. Therefore, it is 
important to characterise its tissue location for a better functional description. To this end, I 
harvested intestinal tissue from wild type (WT) mice and fixed in PFA for paraffin wax 
embedding and microtome sectioning. Since I also have available mice that either 
overexpress a copy of Rac1b in the Rosa26 locus (RAC1BOE) or that have deleted the exon 3b 
(RAC1BKO) specifically in the intestine (more detail of these models explained further in this 
chapter), intestines from these mice were also harvested as positive and negative controls, 
respectively. As mentioned above, there is only a commercial Rac1b antibody available from 
Millipore which I used for immunohistochemistry (IHC). After several IHC protocol 
optimizations, I observed an interesting pattern of staining in the WT mice, with a punctuated 
cytoplasmatic staining in the crypts, which looked very alike the normal breast biopsies from 
Lee et al. paper393, and a membrane staining as it goes up the villus axis (Figure 1A). However, 
performing the same IHC protocol in the control sections showed an identical pattern and 
intensity of staining (Figure 1B and C), indicating that the antibody is not binding specifically 
to Rac1b antigen. Of note, RAC1BOE mice overexpress a human Rac1b cDNA, implying that 
the antibody recognises neither mouse nor human Rac1b. Thence, I was unable to validate 
this antibody for IHC and, from this perspective, it potentially calls into question the data 
presented in the literature using it, especially the studies which have used this antibody to 


































Figure 3.1: Rac1b immunohistochemistry of the murine intestine. Images for tissue 
staining with Rac1b antibody in WT (A), RAC1BOE (B) and RAC1BKO (C) mice. 
Magnification at 20x. 
A. 
B. C. 





3.1.2 Intestinal epithelial fractionation for Rac1b characterization 
Hence, I sought an alternative method to study Rac1b localization in the small intestine 
in vivo but at the RNA level. To do so, I made use of an intestinal epithelial extraction protocol 
to fractionate the epithelium into different grades of crypt enrichment, subsequent 
extraction of RNA from each fraction and then, cDNA synthesis for qRT-PCR analysis. In brief, 
extraction of intestinal epithelial cells consists on the scraping of the inner part of the 
intestine to get rid of the villus and thorough sequential washes of PBS:EDTA to collect 
released intestinal epithelial cells, with each wash corresponding to a fraction more enriched 
for cells closer to the crypt base. An outline of each fraction is schematised in figure 2A: the 
last fraction extracted (3) represents the most crypt-enriched part of the intestine, 
presumably containing the stem cells, while the villus would be highly enriched with 
intestinal differentiation markers. As a characterization of the fractions, I investigated the 
expression of EphB2 and Krt20, a crypt and a differentiation marker respectively444. As can 
be seen in figure 2C, their expression changes reciprocally as fractions become more crypt-
enriched, with EphB2 being more highly expressed in fraction 3 and Krt20 significantly 
decreased at the last fraction. For a further validation, I also looked at the expression of stem 
cell markers such as Lgr5131 and Scl14a1445, which are almost uniquely expressed in fraction 
2 and 3, and at the expression of proliferation markers like c-Myc446 and Tiam1345, which have 
an increased gradient of expression towards the last fractions but not exclusively (Figure 2B 
and D). Once fractions were validated to be representative of a crypt-villus axis, I looked at 
the expression of Rac1 and Rac1b. Rac1 presents a fairly flat pattern of expression across the 
different fractions, only being slightly increased in fraction 3 (Figure 2E). This is consistent 
with previous studies demonstrating control of Rac1 activity via the expression of regulatory 
genes447. Indeed, as seen in the previous figure, Tiam1, a Rac1-GEF, has an increased 
gradation of expression towards the most crypt-enriched fractions, presumably maintaining 
a high crypt Rac1 activity as has been previously demonstrated by Myant and collegues292. In 
contrast, Rac1b expression significantly increases in each fraction, reaching its highest 
expression at fraction 3 (Figure 2F). However, there is a considerable amount of Rac1b 
transcript in the other fractions, so Rac1b cannot be considered as a stem cell marker. 
Instead, it behaves more like c-Myc or Tiam1, increasing gradually from the villus down to 
the crypts. Therefore, these data suggest that Rac1b transcript is expressed with elevated 
expression in the proliferative crypts 

























Figure 3.2: Intestinal fractionation experiment characterises a crypt-base location of Rac1b. 
A: Schematic representation of each epithelial extraction (EE) fraction. B, C and D: Validation 
of the epithelial fractions by the expression of differentiated (Krt20), crypt-base (EphB2), 
proliferative (c-myc and Tiam1) and stem cell markers (Lgr5 and Slc14a1). E: Expression of 
Rac1 is consistent across fractions. F: Rac1b is higher expressed at the intestinal proliferative 
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3.1.3 Designing a BaseScope probe for exon 3b 
Even though this fractionation experiment provided important information about 
Rac1b location and potential role, I wanted to visualise Rac1b expression in the context of 
whole tissue. To this end, I used an RNA in situ hybridization method named BaseScope, 
specifically designed to discern between closely related isoforms. This technique, as 
RNAscope, consists of a probe that specifically hybridises to a targeted RNA and provides a 
signal that will be amplified by a series of reagents. The advantage BaseScope offers among 
RNAscope is that it can detect short RNA sequences, difficult RNA targets or, as in the current 
interest, detection of exon junctions, being ideal to differentiate between splice isoforms. 
We designed a probe that specifically bound the exon 3-3b junction, which corresponds to 
the end of the exon 3 and the beginning of the following exon (Figure 2.2). Therefore, this 
probe would only release signal when it hybridises to Rac1b-exon3b containing isoform and 
not Rac1.  We stained wild type mice small intestine (SI) and large intestine (LI) sections and 
RAC1BKO as a negative control with the designed probe. Signal is observed as small pink dots 
every time the probe detects a Rac1b transcript molecule. As shown in figure 3.3A, an 
average of 2-3 dots per crypt are detected in the SI and it is significantly more abundant in 
the LI than in the SI (Figure 3.3D). Sections were also stained with the PPIB (positive) and 
DAPB (negative) probes for RNA quality control of the tissue (Appendix 1). Importantly, 
BaseScope staining also reveals a crypt preferential Rac1b localization, with significantly 
more transcript-dots in the crypts compared to the villus, reaffirming the crypt position of 
Rac1b seen with the fractionation experiment. Moreover, the RAC1BKO negative control 
presents virtually no staining at all, validating both the technique and my KO model. 
Mutations in the tumour suppressor gene Adenomatous polyposis coli (Apc) is a key 
event in the vast majority of sporadic human CRC and the main characteristic for the low 
frequency hereditary Familial Adenomatous Polyposis (FAP) syndrome50. Mouse models for 
in vivo ageing modelling of CRC usually harbour heterozygous mutations in the Apc gene, 
which do not present a phenotype until the remaining copy of Apc is lost. On the contrary, 
mice with homozygous deletion of Apc cannot be used for long-term experiments, since the 
complete loss of Apc causes a rapid nuclear translocation of β-catenin, activation of the WNT 
signalling pathway, misslocalization of Paneth and stem cells and a consequent intestinal 
hyperproliferation after 5 days of tamoxifen induction414. However, this phenotype 
corresponds to early CRC lesions and it has become a suitable model to study acute 





activations of the WNT pathway along with other mutations in a cell population relatively 
homogenous without compensatory mechanisms. Therefore, I sought to determine whether 
Rac1b transcript localization would be altered immediately after Apc loss. By using a 
tamoxifen inducible Cre recombinase that targets specifically intestinal and colonic cells by a 
Villin promoter (VilCreERT2), the Apc gene was targeted for deletion.  Mice with homozygous 
Apc deletion (VilCreERT2Apcfl/flRac1b+/+, from now on APC-/-) and their Rac1b controls 
(VilCreERT2Apcfl/flRac1bfl/fl, hereafter named APC-/- RAC1BKO) were induced for 5 days and 
tissue was fixed and sectioned for BaseScope staining. Intriguingly, Rac1b+ve signal 
dramatically increased compared to wild type mice (Figure 3.3F). In the SI, it still maintained 
its preferential crypt position, but it was not as delimited as before due to abnormal intestinal 
proliferation and crypts hyperplasia (Figure 3.3E). This result is confirmed by qRT-PCR, where 
Rac1b expression is significantly increased in Apc deficient tissue compared to WT (Figure 
3.3G). In conclusion, BaseScope staining demonstrates Rac1b to be mainly localised in the 
crypts, that it is more abundant in the LI compared to the SI and that its expression increases 
























































































































































Figure 3.3: Visualisation of Rac1b transcript in the murine intestine by BaseScope. A: an 
average of 2 to 3 dots are detected in the SI (i) and LI (ii) of WT mice, while its expression 
significantly raises upon Apc deletion (vi and vii). Probe specificity is validated by staining of 
Rac1b-deficient mice (iii and iv for SI and LI of WT mice respectively; viii and ix for SI and LI of 
APC-/- mice respectively). Arrows mark an example of a dot in each positive image. B and C 
show an overview of the SI in WT and APC-/- mice, respectively. Amplification of crypt and 
villus regions are illustrated below; circles highlight positive signal (pink dots).  
Probe scores in WT (D) and APC-/- (E) tissue, comparing crypt vs villus and SI vs LI. F: total 
number of probes scores in WT and APC-/- tissue. G: qRT-PCR for Rac1b in WT and APC-/-, 
validating the increased expression in Apc-deficient tissue observed by BaseScope. 
T-test: *= p≤0.05, **= p≤0.01, ***= p≤0.001, ****= p≤0.0001. N = 3 vs 3. 




























































































Colorectal cancer is one of the diseases Rac1b has been most investigated in, together 
with breast and lung cancer. However, most of the studies focused their effort on its 
functional characterization, leaving a gap in other aspects of its characterization such as 
cellular and tissue localization. Besides, since it has been mainly studied in 2D cell lines, there 
is a lack of in vivo characterization and validation of the current knowledge. In this section I 
aimed to depict Rac1b localization in mice intestine using wild type and genetic modified 
mouse models with either Rac1b overexpression or deletion. I initially tested a commercial 
Rac1b antibody in the murine intestine of WT mice. After several IHC optimization and using 
as reference the positive (RAC1bOE) and negative (RAC1bKO) mice controls, I was unable to 
validate its specificity so I sought an alternative methodology to study its intestinal 
expression. Using a fractionation experiment and BaseScope staining, we found that Rac1b 
is mainly expressed in the crypt zone. It presents a low expression in normal conditions, 
which is more abundant in the LI than in the SI, and expression significantly increases after 















3.2 RAC1B expression in human CRC 
3.2.1 RAC1B as a tumour-related isoform 
Rac1b was first discovered in tumoral 2D cells372,448 and since then it had been 
attributed a tumour promoter role. However, further investigations are needed to confer a 
more direct human relevance in cancer. In the last couple of decades, advances in genome 
sequencing techniques and bioinformatic analysis have made it possible to explore at an in-
silico scale diseases such as cancer, and facilitate the discovery of both tumour suppressor 
and oncogenes by differentially expressed genes (DEGs) between tumoral and normal tissue. 
One of the key tools for cancer researchers from the bioinformatic point of view was the 
realisation of The Cancer Genome Atlas (TCGA). Data generated from the TCGA is stored in 
Sage Bionetworks’ Synapse database and is available for public download. For my project, I 
made use of this source to extract isoform expression data for both Rac1 and Rac1b in 
colorectal cancer (COAD). By downloading the data from Synapse and splitting normal and 
tumour samples I saw that the estimated counts for Uc003spx (Rac1 isoform) were 
significantly lower in tumours compared to normal tissue (Figure 3.4A, p=0.0005). On the 
contrary, Uc003spw (Rac1b isoform) is strongly significantly elevated in tumours (Figure 3.4B, 
p<0.0001). Given that Rac1 signalling is required and activated during CRC tumorigenesis292 
but its expression diminishes in tumours (Figure 3.4A), it highly implies alternative methods 
for pathway activation, such as the observed increase in the Rac1b isoform.   
Aside from the raw data downloaded from Synapse, other groups have made efforts 
to create comprehensive and user friendly web platforms to help with the general analysis 
of a specific target gene or cancer type, such as cBioPortal449,450 or Xena451. Given that Rac1b 
is an alternative splice isoform, other web bioinformatic platforms able to discern between 
similar isoforms are needed. Ryan et al. created a platform specifically designed for the study 
of alternative spliced genes in cancer using the TCGA database, named TCGA SpliceSeq441. 
They previously designed SpliceSeq, a Java application that allows RNAseq transcript 
expression visualization through splice graphs and further functional prediction by protein 
sequence translation452. The TCGA isoform expression data was run through SpliceSeq to 
obtain a complete and comparative alternative splice analysis of specific genes across 
different tumour types which is stored in a public web-based interactive database, the TCGA 
SpliceSeq. A gene of interest or the top genes with most significant splicing events can be 





selected for one or more tumour types and among the different results of the search, appears 
a splice graph and the Uniprot sequence, a short description, the type/s of splicing event/s 
and a Percent Spliced In (PSI) graph comparing tumour vs normal tissue. The PSI measures 
the number of transcript reads that contain an exon and is a value used for quantifying 
splicing events361. Indeed, in the paper presenting the TCGA SpliceSeq, Rac1 was used as a 
queried gene example to explore its splicing events and showed that the isoform with exon 
4 inclusion (Rac1b) has higher PSI in tumours compared to normal tissue. Prompted by this 
result, I used the TCGA SpliceSeq website to download the PSIs values of Rac1 for each 
tumour type that contained matching normal tissue data and conducted statistical analysis. 
As shown in figure 3.4D, cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), lung 
adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma 
(READ), stomach adenocarcinoma (STAD) and thyroid carcinoma (THCA) presented 
significantly increased levels of Rac1 PSI in tumours compared to normal tissue. On the 
contrary, glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), 
kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) 
showed the opposite trend, with Rac1b underrepresented in tumours according to its PSI. 
For a more general concern, it would be interesting to study similarities/shared properties 
between these two groups of tumour types (increased vs decreased Rac1 PSI). Several 
studies have been made using TCGA data to cluster different cancers according to its 
mutations, as the one published by Kandoth et al. in 2013. In their work, albeit they only 
analysed 12 tumour types, it can be seen that COAD/READ, LUAD and LUSC have the highest 
percentage of significantly mutated genes in WNT/β-catenin, MAPK and TGF-β signalling 
compared to GBM, HNSC and KIRC, which have the lowest83. Even though this could lead to 
an intriguing literature and TCGA bioinformatic research, it was not the aim of the current 
project and I kept focus on the main finding from the TCGA SpliceSeq analysis: COAD was one 




















































































































Figure 3.4: Expression of RAC1B increases in human cancers. A and B: RSEM counts for 
Uc003spc/Rac1 (A) and Uc003spw/Rac1b (B) isoforms comparing colorectal tumours and 
matching normal tissue. C: PSI values for Rac1 exon inclusion (RAC1B) in COAD TCGA dataset 
for normal tissue and tumour. D: PSI values for Rac1b across 20 different tumour types 
comparing normal tissue and tumour.  
Mann-Whitney test: *= p≤0.05, **= p≤0.01, ***= p≤0.001, ****= p≤0.0001, n.s. = not 
significant, p>0.05. 
PSI: Percent Spliced In, BLCA: bladder urothelial carcinoma, BRCA: breast invasive carcinoma, 
CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL: 
cholangiocarcinoma, COAD: colon adenocarcinoma, ESCA: oesophageal carcinoma, GBM: 
glioblastoma multiforme, HNSC: head and neck squamous cell carcinoma, KIHC: kidney 
chromophobe, KIRC: kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell 
carcinoma, LIHC: liver hepatocellular carcinoma, LUAD: lung adenocarcinoma, LUSC: lung 
squamous cell carcinoma, PAAD: pancreatic adenocarcinoma, PRAD: prostate 
adenocarcinoma, READ: rectum adenocarcinoma, STAD: stomach adenocarcinoma, THCA: 
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Individual RAC1B PSI values with TCGA tumour identifiers were downloaded and 
overlapped with TCGA clinical data, such as patient survival or tumour stage. First, I classified 
tumours as high or low for Rac1 PSI using thresholds taken from Kahles et al.371. Using a more 
stringent threshold a Rac1b high group (RAC1Bhigh) was designated if the PSI value was higher 
than 0.2 delta PSI of normal tissue. Contrariwise a Rac1b low group (RAC1Blow) was 
designated when the PSI value was lower than the average of normal tissue PSI, leaving a 
group of Rac1b intermediate expression group (RAC1Bint) (Figure 3.5C). Overall survival (time 
between disease diagnosis and patient alive status) and the disease-free survival (time 
between treatment and signs of disease) was analysed. I compared both between RAC1Bhigh 
and RAC1Bint+low (all tumours that are not classified as high) groups by overlapping TCGA 
codes. Interestingly, patients with RAC1Bhigh tumours have a significantly poorer overall 
survival and disease-free survival compared to patients with RAC1Bint+low tumours (Figure 
3.5A and B; p=0.0247 and p≤0.0001 respectively). Therefore, high RAC1B levels in CRC 
correlate with worse survival prognosis.  
Seeing that Rac1b might confer an advantage to tumours compared to non-tumoral 
tissue, I wondered whether RAC1B expression correlates with advanced tumour stages. 
Clinical data downloaded from CbioPortal using COAD TCGA study data set provided 
information about tumour stage and its invasion into the lymphovascular system. 
Interestingly, tumours with the highest PSI value for RAC1B were enriched for invasive stages 
(III and IV) compared to non-invasive (p=0.0029, figure 3.5E). The same analysis was carried 
out using the isoform data from figure 3.4A and B and overlapping with CbioPortal TCGA 
codes, showing that only RAC1B isoform but not RAC1 correlated with stages III and IV 
(p=0.0283, Figure 3.5E). Consequently, tumours with high RAC1B were more likely to present 
with invasion into the lymphovascular system (p=0.004, Figure 3.5F) and metastasis 
(p=0.0008, Figure 3.5G). Altogether, these analyses indicate that Rac1b is preferentially 
expressed in tumours compared to normal tissue, and correlates with malignant behaviour, 
driving invasion into blood vessels and the lymphatic system and progression to metastatic 



























Figure 3.5: Expression of RAC1B in CRC correlates with poor prognosis and tumour invasion. 
A and B: Kaplan-Meier plots for overall survival (A) and disease-free survival (B) for COAD 
patients from TCGA dataset (Log-rank test). C: Distribution of COAD TCGA normal tissue and 
tumours based on RAC1B PSI values. D: RSEM counts for RAC1 and RAC1B isoforms 
comparing expression in early (I&II) or late (III & IV) stages. E, F and G: Evaluation of tumour 
stages (E), presence or absence of lymphovascular invasion (F) and metastatic disease (G) 
according to RAC1B PSI values.  
M0: no distant metastasis, M1: metastasis. HR: Hazard Ratio, CI: Confidence Interval. 
Mann-Whitney test: *= p≤0.05, **= p≤0.01, ***= p≤0.001, ****= p≤0.0001, n.s. = not 
significant, p>0.05. 
 











































































































































































3.2.2 CMS tumour stratification and correlations based on RAC1B expression 
The TCGA data has facilitated the molecular stratification of the majority of tumour 
types analysed197,198. Accurate tumour classifications allow more precise information for 
clinical decision making. Compared to previous CRC classification merely based on their MSS 
status (either MSI or MSS), recent joint efforts from the CRC subtyping Consortium group 
(CRCSC) identified four RNA-based groups dubbed the CMSs subtypes185. Briefly, the CMS 
include the immune-related CMS1, the canonical WNT/β-catenin-activated CMS2, the 
metabolic rearranged CMS3 and the mesenchymal/TGF-β enriched CMS4. Since they were 
published and accepted as a “gold standard” classification method in CRC, assigning a CMS 
label to a certain tumour becomes of an indubitable need, especially when it comes to 
treatment and survival likelihood prediction for the patient. After revealing the worse 
prognosis for patients with high RAC1B levels (Figure 3.5), I sought to determine whether 
there was a correlation between these tumours and any of the CMS subtypes. To do so, I 
downloaded the RSEM expected counts data from the TCGA RNAseq analysis within the 
COAD data set442 and extracted expression data of the genes that classify the different CMS 
subtypes and correlated their expression to RAC1B PSI values (list of CMS genes provided 
from a colleague to the lab). As illustrated in Figure 3.6A, few genes that classify CMS3 and 
CMS4 correlated with RAC1B PSI. However, CMS1 and CMS2 showed interesting correlations 
with RAC1B expression. In the case of CMS1, the majority of genes that classify this subtype 
negatively correlated with RAC1B expression (66% of the signature genes significantly 
negative correlated (blue zone)). In contrast, almost 53% of the genes that classify CMS2 had 
a positive correlation with RAC1B (red zone). Given that the CRCSC uploaded in Synapse the 
clinical data from the TCGA data set they used, and each tumour is labelled with the CMS 
type that was assigned, I could also demonstrate these correlations by overlapping these 
TCGA codes with the TCGA RAC1B PSI codes and plot RAC1B PSI values according to each 
subtype, demonstrating the increased RAC1B expression in CMS2 tumours and reduced 
expression in CMS1 tumours (Figure 3.6B). Moreover, and as mentioned previously, there 
are certain characteristics that define each CMSs type, like the TGF-β signature in the CMS4 
or the WNT pathway activation in the CMS2. In order to fully support the observed 
correlations, I sought whether these characteristics were also in line with Rac1-exon 3b 
insertion. Increased expression of the targeted genes of a signalling pathway is generally 
accepted as a read out for pathway activation. LGR5, AXIN2, ASCL2 and TCF7 are canonical 
target genes of the WNT/β-Catenin signalling pathway and their RSEM values are all highly 





significantly increased in the RAC1Bhigh compared to the RAC1Blow, validating the positive 
correlation with the CMS2 in tumours with higher Rac1b expression (Figure 3.7A). On the 
contrary, CMS1 is defined for its high percentage of MSI tumours and BRAF mutation. The 
same analysis revealed reduced expressing of RAC1B in tumours positive for MSI and/or B-
RAF mutation, as hypothesised by the negative correlation with CMS1 (Figure 3.7B). This data 
was also validated using the TSVdb software, another TCGA web-based platform specialised 
in alternative spliced isoform analysis453 (Figure 3.7C). 
Another useful parameter one could extract from the clinical data provided by the 
CRCSC was the disease-free survival per each tumour labelled with a CMS type. As an 
additional validation of the CMSs prognosis presented in the paper, survival data for each 
subtype is plotted in figure 3.8A. CMS4 has the worst relapse-free survival among the four 
subtypes and CMS2 one of the best prognosis, along with CMS3. Interestingly, I saw in the 
previous analysis that high levels of RAC1B predispose patients to a worse overall survival 
and disease-free survival (Figure 3.5). This is in apparent contradiction to my finding that 
RAC1B levels in tumours correlate with the relatively good prognosis CMS2 subtype (Figure 
3.8B). To further investigate this, I analysed disease-free survival in patients with CMS2 
tumours according to RAC1B expression (keeping the same RAC1Bhigh/RAC1Blow+int grouping 
methodology as before). Interestingly, patients from the CMS2 group with high RAC1B 
expression had very poor prognosis, with a similar survival outcome as patients with CMS4’ 
tumours. Therefore, this apparent contradiction is resolved if tumours within the CMS2 
subtype are secondarily categorised according to RAC1B levels, demonstrating that patients 
with the worst survival were potentially driven by high RAC1B expression. Altogether, these 
results would suggest that RAC1B expression is higher in the WNT activated CMS2 subtype 
and characterizing RAC1B levels within a tumour might help to define survival prognosis. 
Besides, defining its strong correlation with CMS2 and antagonism with CMS1 may also shed 






























Figure 3.6: Expression of RAC1B correlates with CMS1 and CMS2 subtypes. A: Pearson’s 
graphs correlating RAC1B PSI and genes defining CMS1, CMS2, CMS3 and CMS4 expression 
signature. Blue zone: significant negatively correlated genes, red zone: significant positively 
correlated genes, grey zone: not significant correlation. B: RAC1B PSI values classified 
comparing one CMS subtype vs the other subtypes.  





































































































































































Figure 3.7: Featuring traits of CMS1 and CMS2 correlate with RAC1B expression. A: RSEM 
counts of the WNT/β-catenin target genes LGR5, ASCL2, AXIN2 and TCF7 comparing RAC1Blow 
and RAC1Bhigh groups. B: Microsatellite status and presence of B-RAF mutation plotted 
according to RAC1B PSI values. C: Microsatellite status of COAD TCGA tumours extracted 
from the TSVdb platform. Arrow marks information for RAC1B isoform, and this data is 
plotted in the adjacent graph.  



















































































































































































Figure 3.8: Expression of RAC1B subclassifies CMS2 survival outcome. A: Kaplan-Meier plot 
for disease-free survival of the CMS subtypes. B: CMS2 survival is plotted based on RAC1Blow 
and RAC1Bhigh tumours. CMS4 is illustrated as a comparative survival curve. Log-rank test 
comparing CMS2 RAC1Blow and CMS2 RAC1Bhigh survival curves. HR: Hazard Ratio, CI: 
Confidence Interval.  
 
















































p =  0.0102





3.2.3 RAC1B PSI correlates with genetic alterations in cancer-driver genes 
Analysing the B-RAF mutational status in relation to RAC1B overexpression paved the 
way to carry a similar search for other relevant oncogenes/tumour suppressor genes in CRC 
according to RAC1B PSI. Clinical data from TCGA only provides information about B-RAF and 
K-RAS mutations, but CBioPortal allows for the search of a manually entered list of genes 
within a data set (TCGA COAD) and informs about the kind of mutation it has taken place. A 
set of thirteen genes representative of the most commonly mutated cancer pathways were 
selected and RAC1B PSI was plotted relative to presence of absence of alteration in them 
(Figure 3.9B). Since the number of samples in this data set is larger, the reduced RAC1B 
expression previously observed in B-RAF mutated tumours is now more evident, with a 
stronger statistical power than before (Figure 3.9A). Other signalling pathways that when 
mutated exhibit lower RAC1B expression are the PI3K (by PIK3CA and PTEN genes) and the 
TGF-β signalling pathway (by SMAD4 and SMAD2), which might support results evidenced in 
the following chapters. Notably, tumours where the APC gene is mutated express 
significantly higher levels of RAC1B, reinforcing Rac1b-related WNT signalling roles. RAC1B 
expression was also higher in tumours that carry TP53 or K-RAS mutations but the functional 
relevance of such associations is unknown. Given the fact that these genes are amongst the 
most mutated genes in CRC, their mutational correlation with RAC1B support the rationale 
for further experiments to determine the relevance of these findings. Overall, the mutational 
analysis indicates RAC1B expression is highest in APC mutant tumours and lowest in tumours 

































Figure 3.9: Mutational status of cancer-driver genes according to RAC1B expression. A: 
Individually plotted mutational data for APC, SMAD4, B-RAF and K-RAS. B: Array of twelve 
highly mutated genes in CRC, presented according their mutation status (WT or mutated) in 
relation to RAC1B PSI. Percentages indicate their incidence of mutation in CRC.  








































































































































































3.2.4 RPPA identifies cellular processes associated with RAC1B expression 
To conclude the in-silico study of Rac1b in cancer, I explored a different type of data 
also published by the TCGA. Reverse Phase Protein Array (RPPA) is a technique that allows 
efficient and high-throughput protein expression quantification by the binding of high-quality 
antibodies to a dot-blot membrane. Unlike RNA- or DNA-based assays, RPPA can detect 
pathway activation via post-translational modifications such as phosphorylation or protein 
cleavage. Based on the proteomic dataset provided by The Cancer Proteome Atlas (TCPA) 
web portal454,455, level 4 data was downloaded from the TCGA COAD dataset. These data 
consisted of a list of protein names per each TCGA tumour, including phosphorylated or 
cleaved proteins, that were quantified using a “supercurve fitting” methodology, developed 
as well at the MD Anderson Cancer Centre. After overlaying TCGA codes with the codes from 
the Rac1 PSI list, a Pearson’s correlation test was run per all proteins. Out of 223, seventeen 
positive and twenty-one negative significantly correlated proteins resulted from the test, 
names of which are highlighted in Figure 3.10. There were some interesting targets, as the 
positive correlation with c-myc, SRSF1 (Rac1b’s postulated positive regulator), INPP4B 
(phosphatase within the phosphatidylinositol pathway) and activation of YAP. On the 
contrary, within the negative correlated list there were a number of caspases (Caspase-3, -8 
and cleaved-caspase-7) and cell check-point proteins (as activated Chk1) that would suggest 
a potential avoidance to cell-death programs. Finally, the most negative correlated protein is 
Prex1, a Rac1 guanine nucleotide exchange factor (GEF), which may indicate that high levels 
of Rac1b in tumours are not redundant with other mechanisms of Rac1 signalling activation. 
Therefore, analysing an additional TCGA dataset as RPPA has reinforced previous 
observations like the WNT signalling pathway correlation (c-myc) and downregulation of PI3K 
pathway, and suggested new processes to be evaluated like the Hippo-YAP signalling 





























Figure 3.10: Heatmap correlation of TCGA RPPA and RAC1B PSI. Protein names refer to the 


























































The TCGA program has become of a great value to estimate the significance of a certain 
gene in cancer, to prognosticate the relationship with its expression and patient survival and 
to correlate with other genes or signalling pathways. As data sets were being compiled, many 
studies have been published gathering different cancer types together to analyse a cellular 
process456,457, as well as to elucidate unknown cancer driver genes458 or to predict the efficacy 
of a therapeutic agent459. Due to its ease of availability, it is the main dataset source for 
assessing human relevance of experimental findings and many projects have benefited from 
it. Utilising this dataset I find that RAC1B has an increased expression in tumours compared 
to normal tissue and that RAC1 presented the antagonist result (Figure 3.4), highly suggesting 
Rac1b as a mechanism to maintain high Rac1 signalling in cancer. I then carried out a pan-
cancer analysis by making use of the TCGA SpliceSeq web platform data. I showed that in 
seven out of twenty different cancer types, there was a significant increase of RAC1B 
expression in tumours compared to matching normal tissue (Figure 3.4D) and that COAD was 
among these seven. Dividing the COAD tumours according to its RAC1B expression (low or 
high) (Figure 3.5) showed a survival difference depending on RAC1B expression, since 
tumours within the high group have a worse overall survival and a disease-free survival 
compared to RAC1Blow. Accordingly, high RAC1B expression correlated with late stage disease 
(III and IV). These tumours were more aggressive given that they were more prone to invade 
the lymphatic system and blood and presented more metastasis compared to low RAC1B 
tumours. When trying to classify RAC1B+ve tumours to one of the fours CMS subtypes, I found 
a negative correlation with the CMS1 subtype and a positive correlation with the WNT high 
CMS2 subtype (Figure 3.6). Remarkably, the CMS2 is the one with the best survival prognosis 
but this is driven by the tumours with low RAC1B expression, given that CMS2- RAC1Bhigh 
presented a worse survival curve, similar to that of CMS4 (Figure 3.8). Mutational analysis of 
the top cancer-driver genes in CRC revealed some interesting correlations with RAC1B 
expression, such as the positive correlation with APC, TP53 and KRAS, top three mutated 
genes in CRC, and the negative correlation with genes involved in the TGF-β and PI3K 
signalling pathways (Figure 3.9). Some of these were further supported by the RPPA analysis, 
which also suggested new cellular processes up to date not linked like cell death resistance 
or Hippo-YAP signalling (Figure 3.10). However, correlating RNA-base data (RNAseq) with 
Protein-based data (RPPA) might derive to some missassociation and further functional 





validation is required before making any assumptions. Altogether, this study has reinforced 
the need to further investigate the function of Rac1b in cancer. 
 
3.3 Studying Rac1b oncogenic function in vivo  
Mouse models were the chosen method to study Rac1b cancer-related roles in vivo. In 
human tumours, I observed that RAC1B expression is increased in tumours that invade and 
metastasise. In order to validate that cancer murine models could emulate a similar situation, 
the expression of Rac1b was analysed in a set of CRC mice models, ranging from benign 
(homozygous deletion of Apc, APC) to the most invasive (Apc deletion along with 
homozygous deletion of PTEN and overexpression of c-Myc, APC PTEN CMYC). A preliminary 
analysis by qRT-PCR showed that intestine from mice that had lost both copies of Apc had 
significant more expression of Rac1b compared to Apc wild type mice (Figure 3.11). 
Moreover, this expression increased as mice acquired additional mutations like TP53, PTEN 
or a combination of PTEN and c-Myc mutations, which mimics a metastatic model. This 
suggests that upon oncogenic mutations, the murine intestine also increases Rac1b 
expression. Besides, Rac1b may be involved in driving the malignant phenotype of these 
models and the modulation of its expression could derive interesting yet unknown functions 
of Rac1b. Following the literature and my own TCGA research about Rac1b, I have postulated 
two different (and not mutually exclusive) hypotheses for its function in CRC. On one side, 
since its expression significantly increases immediately after Apc loss (Figure 3.3) and it seems 
to correlate with a WNT phenotype in tumours (Figure 3.7) I hypothesise that it facilitates 
Apc loss driven tumour initiation. On the other side, I have also observed that patients with 
tumours with high RAC1B expression have poor survival and are more prone to disease 
progression (Figure 3.5). Therefore, I hypothesise that Rac1b is also involved in driving 
tumour invasion. In order to answer whether Rac1b is either required or a promoter of these 
aforementioned processes, I used CRC animal models with the Villin Cre tamoxifen-inducible 
system to emulate different disease stages, modulate Rac1b expression and determine the 
phenotypic outcome. For Rac1b overexpression I utilised the previously described model 
developed by Zhou et al., which consist of an inducible human Rac1b cDNA knocked into the 
Rosa26 locus (termed Rosa26-LSL-Rac1b). For loss of function experiments, knockout of the 
exon 3b was achieved by the insertion of loxP sites flanking the exon 3b (Rac1bfl/fl). These 





mice were generated by Douglas Strathdee and their phenotypic outcome has not been 
described yet. Both mice were crossed with VillinCreERT2 mice, permitting tamoxifen inducible 
expression408 (Figure 2.1). 
 
3.3.1 Modelling early adenomas 
Adenoma formation can be modelled by loss of one copy of the Apc gene. The model 
chosen was the VilCreERT2Apcfl/+ (hereafter referred as APC)427,447. After tamoxifen induction, 
the Cre efficiently recombines along the intestine but Apc heterozygosis does not translate 
into an external phenotype. Stochastic loss of the remaining Apc copy allows tumour 
formation in the SI and LI. As of 100 days, mice start to present pale feet which is a sign of 
anaemia due to tumour burden. Some of them might present prolapses as a consequence of 
tumour formation in the distal colon and when the overall performance of the animal and 
anaemia have reached their endpoint threshold, mice are sacrificed with an average survival 
of 180 days. Tumours developed are mostly from the small intestine, ranging from 42 to 88 
tumours and invasive tumours are rare460. To study the role of Rac1b gain and loss of function 
in tumour initiation, Apcfl/fl mice were crossed with VilCreERT2Rosa26lsl-Rac1b/lsl-Rac1b (APC 
Rac1bOE) and VilCreERT2Rac1bfl/fl (APC Rac1bKO), respectively (Figure 2.1). Results from both 
cohorts correspond to chapter 4.  
 
3.3.2 Modelling invasive adenocarcinoma 
In order to generate an invasive CRC mice model, the APC model can be combined with 
other oncogenic mutations. A large number of models have been described424,461,462 and for 
the present project, I will use a model that targets TP53 for deletion along with heterozygous 
Apc deletion. Thanks to the O. Sansom lab, a VilCreERT2Apcfl/+TP53fl/fl model is available. Its 
phenotype has not been described before but unpublished data from his lab observed a high 
frequency of invasive tumours and a reduction of survival compared to wild type TP53 allele, 
which gives as a window to exacerbate or ameliorate the phenotype by Rac1b gain or loss of 
function.  
Following the same methodology as with the APC cohort, TP53 mutant mice were 
crossed with Rac1bOE and Rac1bKO mice (Figure 2.1). Using these models, my goal was to 





determine whether the invasive tumour phenotype observed in these mice is altered by 
deletion or overexpression of Rac1b. Results from these cohorts are presented in detail in 
chapter 5. Depending on the outcome I will be able to determine whether Rac1b promotes 











Figure 3.11: CRC mouse models emulate Rac1b expression pattern observed in human 
cancer. qRT-PCR for Rac1b in WT mice and mice with mutations in the following alleles: 
APCfl/fl, APCfl/fl TP53fl/fl, APCfl/fl PTENfl/fl, APCfl/fl PTENfl/fl c-Mycmut. T-test for significance: ns = not 










































To initially characterise Rac1b expression in vivo it was necessary to describe its 
intestinal localisation. An initial handicap found in the project was the inability of the Rac1b 
antibody to specifically recognise neither murine or human Rac1b protein. However, that 
problem was overcome by studying its expression at the RNA level. Both fractionation 
experiments and BaseScope staining demonstrated a preferential crypt location of Rac1b 
which significantly increased upon homozygous deletion of Apc. Unfortunately, I could not 
validate its subcellular location. Rac1b, as well as Rac1, have a PBR region in its sequence 
which harbour a nuclear localisation signal (NLS), pointing to a possible role in the nucleus. 
Nuclear function of Rac1 has extensively been reported, while only Bapat and colleagues 
observed Rac1b nuclear location, acting as a cofactor to translocate β-catenin and Dvl3387. 
Even though its membrane localisation is fairly accepted, further investigation within cellular 
compartments could render interesting insights. Nevertheless, these novel RNA-based 
studies provided and validated some previous hypotheses. On one side, its crypt-enriched 
position suggests that it might be involved somehow in maintaining proliferation at the crypt 
zone, either directly or by modulating crypt-enriched signalling pathways. On the other side, 
its overexpression upon Apc deletion validates the association of Rac1b expression with 
tumours. On top, it might also suggest a link with the WNT signalling pathway, given that Apc 
is its core negative regulator. Indeed, TCGA data analyses revealed a strong association 
between tumours expressing RAC1B and the CMS2, which is the canonical/WNT activated 
subgroup.  
Analysis of TCGA data revealed a significantly poorer prognosis in patients with 
tumours expressing high levels of RAC1B, reflected in both disease-free survival and overall 
survival. Moreover, high levels of RAC1B is associated with a malignant phenotype. 
Intriguingly, this contradicts its high expression in CMS2 tumours, as CMS2 is one of the 
subtypes with best prognosis. However, RAC1B expression enabled a second subclassification 
within the CMS2: tumours with low RAC1B expression had good prognosis and tumours with 
high RAC1B expression had poor prognosis. Indeed, the latter had as poor survival as the 
CMS4. This indicates that, in spite of belonging to a canonical subgroup with a rather 
treatable cancer, Rac1b might be responsible for the dismal response of some of them. 
Consistent with this, a former CRC stratification by Sadanandam and colleagues identified a 
subgroup within a group analogue to CMS2 (the trans-amplifying subtype) which presented 





a cetuximab-resistant phenotype (and EGFRi) and a poor prognosis202. Altogether, this might 
indicate that RAC1B expression can stratify CMS2 tumours according to their survival 
outcome and may function as a biomarker to anticipate treatment response.  
Interestingly, another strong association with the CMS was the negative correlation 
with CMS1. To date, RAC1B expression was believed to associate with BRAFV600E mutated 
CRCs and accordingly, with tumours originated through the serrated pathway407. However, 
TCGA data revealed exactly the opposite, as it is also supported by its negative correlation 
with MSI status. Even though BRAFV600E mutation and RAC1B overexpression might cooperate 
to promote cell growth in an artificial setting, such as when RAC1B is ectopically 
overexpressed in CRC cell lines, TCGA data indicate that they do not associate in human 
tumours. Besides, given the significant correlation with APC mutations and RAC1B 
expression, BRAF negative correlation is somehow expected due to their mutational 
exclusivity.  
The observation that Rac1b expression also increases in CRC mouse models as the 
model become more aggressive points to a potential approach for determining Rac1b 
function using a model that emulates what is seen in human tumours. Hence, my TCGA 
analyses have served as an initial basis to reinforce the Rac1b pro-tumorigenic role in CRC. It 
has identified two main functionally relevant traits: association with CRC progression and 
correlation with WNT/β-catenin-activated tumours. These findings are the basis for the 
















Chapter 4: Rac1b function in adenoma tumour initiation 
Mutations or loss in the Apc gene are considered a key initiating event in human CRC 
and a starting point for most mouse models. As a negative regulator, it is a core element 
within the WNT/β-catenin signalling pathway and overactivation of the pathway is a hallmark 
in CRC initiation. My previous TCGA analyses have shown a strong positive correlation 
between Rac1b, WNT-activated target genes (Figure 3.7) and Apc mutations (Figure 3.9). In 
addition, homozygous deletion of Apc in the murine intestine gives rise to an elevated 
expression of Rac1b (Figure 3.3), suggesting their inter-connection. Bearing all this in mind, 
the present chapter aims to describe the phenotypes observed following Rac1b gain and loss 
of function in an Apc-dependent mouse tumour model. Alongside, modulation of Rac1b 
expression will also be evaluated in normal tissue to study its potential role during regulation 
of homeostasis. 
 
4.1 Rac1b expression is not required to maintain intestine homeostasis  
In physiological conditions, normal intestine expresses low levels of Rac1b. I wanted 
to test whether this expression was necessary for normal functioning of the tissue and 
whether abrogation of Rac1b could cause any phenotypic effect. I used a mouse model where 
Rac1 exon 3b is flanked by loxP sites permitting specific deletion of Rac1b without altering 
Rac1 expression. These mice were crossed with VilCreERT2 line generating cohort of 
VilCreERT2Rac1b+/+ (WT) and VilCreERT2Rac1bfl/fl (RAC1BKO) mice. Following tamoxifen 
induction and Cre expression, lox-exon3b-lox is excised and the remaining transcript only 
produces Rac1 protein (Figure 2.1). The effect of Rac1b deletion in the murine intestine was 
investigated by short term tamoxifen induction in WT and RAC1BKO mice. As described in the 
previous section, the LI expresses higher levels of Rac1b than the SI. Consequently, Rac1b 
knockout in the SI is hardly distinguishable by qRT-PCR, while the colon presents a significant 
deletion of Rac1b with about 3-fold decrease (Figure 4.1A). Although I cannot corroborate 
the knockout in the SI by qRT-PCR, I described in the previous section how expression of 
Rac1b is virtually undetectable after acute tamoxifen induction by means of BaseScope 
(Figure 3.3), validating the Cre knockout system in both SI and LI. I then focused in the SI to 
study the stem cell population and the WNT signalling pathway by qRT-PCR and Paneth and 





goblet cells by IHC in order to evaluate homeostatic changes made by Rac1b deletion. Figures 
4.1B and C illustrate a characterization of all cell populations and WNT activity which is nearly 
equal in both groups, and consequently, there is no change in proliferation upon Rac1b 
deletion. Thence, abolition of Rac1b expression in normal intestine does not cause a 





















Figure 4.1: Deletion of Rac1b in the normal murine intestine. A: Validation of Rac1b 
depletion by qRT-PCR from SI and LI tissue. B: Analysis of stem cell markers (Lgr5, Slc14a1 
and Olfm4) and WNT/β-catenin target genes (Axin2, Lef1, Tcf7 and Tiam1) RNA expression in 
SI tissue. C: Evaluation of cell proliferation (Brdu), Paneth (Lyzosyme) and goblet cells (PAS) 
by staining of the SI. Adjacent graph presents the proliferation score for at least 50 half crypts 

























































































4.2 Deletion of Rac1b extends mice survival through two potential mechanisms 
4.2.1 Ageing cohort with Rac1b-deficient mice 
To our knowledge, there is no in vivo evidence to demonstrate whether Rac1b could 
delimit or be required to drive cell transformation and tumour formation by loss of function. 
Hence, we decided to test in vivo, for the first time, how deletion of Rac1b but not Rac1 could 
affect early stages of tumour development. Taking Apc as the tumour initiating event, 
VilCreERT2Apcfl/+ mice were crossed to the Rac1b floxed miced to generate cohorts of 
VilCreERT2 Apcfl/+Rac1b+/+ (APC) or VilCreERT2 Apcfl/+Rac1bfl/fl (APC RAC1BKO) mice (Figure 2.1). 
Once they were over 8 weeks old or reached 20 grams, mice were injected with one dose of 
80mg/kg of tamoxifen and aged until they became symptomatic of disease. In collaboration 
with Caroline Billard, mice were closely monitored twice a week and changes in their weight 
or their performance were annotated. Pale feet, a sign of anaemia due to tumour burden, 
were noticeable after 100 days of induction and termination was required approximately two 
weeks after. As shown in figure 4.2A, APC RAC1BKO mice presented with significantly 
increased survival compared to controls, with a median survival of 170 days compared to 138 
respectively (p=0.0395). The prolonged survival of APC RAC1BKO mice is due to a reduction in 
tumorigenesis, since they developed significantly fewer tumours than the APC group (41 vs 
25 tumours for APC and APC RAC1BKO respectively, p=0.0058, figure 4.2C). Importantly, the 
lack of differences in tumour burden states that all mice were terminated at the same clinical 
endpoint criteria (Figure 4.2D). In this model, tumorigenesis is predominantly localised to the 
SI; the reduction in tumour number occurred in the most proximal regions of the intestine 
(duodenum and jejunum) (p=0,00023 and p=0.0026 respectively, Figure 4.2E). Therefore, this 
data demonstrates that deletion of Rac1b in the murine intestine significantly reduces 
tumour formation and prolongs survival.  
I have previously confirmed that the model efficiently deletes Rac1b expression 
without altering Rac1 (Figure 4.1). However, I did not test a long-term deletion in an Apc 
deficient context. In order to validate that suppression of Rac1b is maintained in the tumours 
and to establish the relationship between decreased tumorigenesis and Rac1b knockout, 
RNA from SI normal tissue and tumour from APC and APC RAC1BKO mice was extracted and 
analysed by qRT-PCR.  As expected, Rac1 expression is unaltered in the APC RAC1BKO group 
and it also remains constant after losing Apc (Figure 4.2F). Of note, it does slightly but 





significantly increase in the tumours without Rac1b, suggesting a potential compensatory 
effect (average 0.037 vs 0.042 log2ΔCT respectively, p=0.013). Rac1b expression is increased 
4.5-fold in APC tumours compared to normal tissue (p=0.0044, Figure 4.2G). It is successfully 
deleted in the normal SI of APC RAC1BKO mice compared to SI APC (p=0.0093) but 
interestingly, there are two outcomes in tumours from the APC RAC1BKO mice. While 6 out 
of the 11 tumours analysed have efficiently deleted Rac1b, 5 of them still express Rac1b at 
comparable levels to APC mice. This might suggest a positive selective pressure maintaining 
Rac1b expression for efficient tumorigenesis. 
Therefore, these results validate the previous observations with short-term 
experiments: Rac1b expression is increased upon WNT signalling activation. They also 
demonstrate for the first time a functional requirement for Rac1b during the formation of 








































Figure 4.2: Deletion of Rac1b improves mouse survival and reduces intestinal 
tumorigenesis. A: Kaplan-Meier survival plot for APC and APC RAC1BKO cohort mice (Log-rank 
test). B: Representative pictures of APC and APC RAC1BKO intestines fixed on methacarn 
during dissection. Arrows mark developed tumours on the first 15 cm of the SI. C, D and E 
presents quantification of intestinal tumorigenesis, scored during dissection. C: Number of 
tumours developed per mouse (Mann-Whitney test, **= p≤0.001). D: Sum of diameters of 
developed tumours in each mouse. E: Tumour number presented according to the region 
where they originated. F: Expression of Rac1 in both SI tumour and matched normal tissue 
for each genotype by qRT-PCR. G: RNA expression of Rac1b presented as individual values in 
both SI tumour and matched normal tissue. Arrows highlight samples that maintained Rac1b 
expression. Mice in the cohort (n): APC = 19, APC RAC1BKO = 15. T-test: *= p≤0.05, **= p≤0.01, 
***= p≤0.001, n.s. = not significant, p>0.05. N(qRT-PCR) 6 vs 6. Cohort conducted alongside 
Caroline Billard. 
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4.2.2 Histological study of the tumour phenotype 
To understand mechanistically how Rac1b abolition impaired tumorigenesis and 
favoured mice survival, a histological characterization of the tumours was conducted. 
Immunohistochemical (IHC) analysis using markers for Goblet cells (Muc2) and Paneth cells 
(Lyz1) showed no differences in these cell populations, as neither did their corresponding 
qRT-PCR (Figure 4.3A and B). Besides, nuclear β-catenin IHC was used to validate high WNT 
activation within the tumours, which showed no differences between genotypes (Figure 
4.3C). We then interrogated whether there were differences in tumoral cell death or 
proliferation. Apoptosis was analysed using cleaved-caspase 3 IHC and both APC and APC 
RAC1BKO tumours had similar apoptotic rates (Figure 4.3A). However, when cell proliferation 
was scored by BrdU incorporation, Rac1b-deleted tumours had a significant reduction in 
BrdU+ cells compared to APC tumours (33.55% and 24.39% of proliferation for APC and APC 
RAC1BKO respectively, p=0.0031, Figure 4.3D). Notably, some of the tumours scored within 
the APC RAC1BKO group still express Rac1b, indicating that the reduced proliferation in these 
mice could be more dramatic if only Rac1b-deficient tumours were scored. Therefore, 
deletion of Rac1b in Apc-deficient tumours impairs cell proliferation, which likely translates 














































































































































Figure 4.3: Rac1b deletion reduces tumour proliferation. A: Histological analyses of cohort 
tumours. First images offer an overview of SI Swiss-roll. Tumours in the section are 
highlighted with arrows and tumours within the rectangle are amplified underneath, both 
H&E stained. Images below show staining of Paneth cells (Lysozyme), goblet cells (Mucin 2) 
and cleaved caspase 3 (CC3). Average percentage of positive cells within a tumour is plotted 
underneath. Scores conducted with QuPath. B: qRT-PCR for Paneth (Defa20 and Lyz1) and 
goblet cells (Muc2) from tumour RNA. C: Nuclear β-catenin IHC of tumours at 10X and 40X. 
D: BrdU staining at 10X and 20X. Proliferation scoring was conducted with QuPath and it is 
plotted in the graph. Analyses performed alongside Caroline Billard and Kevin Myant.  
T-test: **= p≤0.01, n.s. = not significant, p>0.05. N(qRT-PCR) = 3 vs 3; N(CC3, Lyz) = 7 vs 4; 


























4.2.3 The WNT signalling pathway is modulated by Rac1b 
 
4.2.3.1 RNAseq analysis 
Many signalling pathways could be implicated in the decreased cell proliferation 
observed. In order to explore from an unbiased perspective the altered genes following 
Rac1b downregulation, an RNA-seq comparing 4 APC and 4 APC RAC1BKO tumours (with 
validated Rac1b deletion) was conducted. 558 differentially expressed mRNAs were 
identified (fold change>1.5, q value<0.05), of which 294 were significantly overexpressed and 
264 were significantly downregulated (list of genes and FastQC details on Appendix 2.1 and 
2.2, respectively). Gene ontology enrichment analysis of the identified data set demonstrated 
that immune regulatory processes such as immune and innate immune response, peptide 
antigen binding or antigen processing and presentation were among the top 
overrepresented pathways (Figure 4.4A). Interestingly, regulation of the canonical WNT 
signalling pathway was the most downregulated pathway in Rac1b-deficient mice, along with 
cell surface, protein import, cell proliferation in the midbrain and WNT-protein binding 
(Figure 4.4A and B). Further gene set enrichment analysis (GSEA) querying for WNT/β-catenin 
and APC target genes as well as for Lgr5+/stem cells expression profile revealed a strong 
significant negative association with genes downregulated in our RNAseq data set (Figure 
4.4C) (Appendix 3). For validation of our data set, qRT-PCR for WNT-related target genes was 
carried out on tumour samples from APC and APC RAC1BKO mice, as well as on normal small 
intestine tissue from wild type mice (WT and RAC1BKO). As it is shown in figure 4.4D, deletion 
of Rac1b in tumour samples let to a significant downregulation in our queried genes, while 
expression in matched normal tissue was not different between genotypes. Altogether, this 
points to the attenuation of WNT signalling activity as a possible mediator through which 
Rac1b deletion reduces tumour proliferation. 
 
4.2.3.2 Acute tamoxifen induction reaffirms WNT-driven phenotype 
To confirm the requirement of Rac1b for efficient WNT signalling following Apc loss, I 
analysed target gene expression in the SI of mice following acute Apc deletion. qRT-PCR from 
the SI of VilCreERT2 Apcfl/fl (APC-/-) and VilCreERT2 Apcfl/fl Rac1bfl/fl (APC-/- RAC1BKO) mice five 
days post induction showed a significant downregulation of a subset of WNT-targeted genes 





such as Tiam1, Axin2 or Lef1 (Figure 4.4E), indicating that WNT signalling pathway activation 
immediately following Apc loss is mediated by Rac1b expression. Moreover, epithelial 
intestinal cells from these mice were extracted and cultured as 3D organoids for conducting 
a clonogenicity assay. Briefly, epithelial extraction protocol (material and methods chapter) 
was conducted and crypt-enriched cells from last fraction were digested with Accutase® and 
embedded as single cells in Matrigel®. The number of organoids formed was scored after 
four days of plating. As is shown in figure 4.4F, APC-/- RAC1BKO organoids have a worse 
clonogenic capacity compared to Rac1b-expressing organoids (p=0.028), suggesting that 












































































































Figure 4.4: Identification of a WNT signature upon Rac1b deletion. Differentially expressed 
genes between APC and APC RAC1BKO tumours identified by RNAseq were analysed through 
InnateDB database. Figure A presents the top ten pathways upregulated and downregulated 
in APC RAC1BKO. B: Heatmap to illustrate the expression of WNT-related RNAseq target genes 
among tumour replicates. C: Gene set enrichment analysis (GSEA) of the RNAseq data set, 
utilising four different WNT-related gene sets. Genes are ranked based on their differential 
expression between the two cohorts. Black bars represent the ranked gene position, 
indicating a strong downregulation in all gene sets analysed. D: Validation of the WNT 
signature by qRT-PCR comparing tumours and matching normal tissue, the latter showing no 
statistical differences. E: qRT-PCR for WNT target genes on short-term APC-/- induced mice, 
presenting the same phenotype as endpoint tumours. F: Clonogenicity assay of APC-/- and 
APC-/- RAC1BKO organoids. Number of clones formed after 4 days is plotted in the graph. 
T-test: *= p≤0.05, **= p≤0.01, ***= p≤0.001, ****= p≤0.0001, n.s. = not significant, p>0.05. 
Experiments performed in collaboration with Kevin Myant and Patrizia Cammareri. N = 4 vs 


































































4.2.4 BioID protein interaction study reveals unknown Rac1b-interacting partners 
A large number of genes involved in the WNT signalling pathway are downregulated in 
tumours lacking Rac1b and Gene Set Enrichment Analysis (GSEA) using WNT- and Apc-related 
gene lists demonstrates a strong negative correlation between this pathway and Rac1b-
deficient tumours. Taking these data together with the results from the TCGA analysis (which 
revealed a positive correlation with Rac1b and CMS2 tumour subtype, the canonical WNT-
activated subtype), there is a strong indication that Rac1b might enhance WNT activation 
following Apc loss. However, it is unknown how this regulation could be mediated. In order 
to gain insights into Rac1b downstream targets and its implication in other signalling 
pathways, a protein-protein interaction (PPI) experiment was conducted using BioID.  
 
4.2.4.1 BioID experiment layout 
BioID is a proximity-dependent biotin identification approach to uncover interacting 
partners of a given protein463. It relies on the fusion of a promiscuous mutated enzyme called 
BirA*, to a bait protein or protein of interest. Originally, BirA is a prokaryotic biotin ligase 
isolated from Escherichia coli. Due to its mutation, BirA* will biotinylate without specificity 
any interacting and vicinal proteins within a labelling radius of   ̃20nm upon exogenous biotin 
addition464. After biotin exposure, biotinylated proteins are pulled-down via streptavidin 
affinity and identified by Mass Spectrometry (MS) (Figure 4.5A). Compared to conventional 
methods to study PPIs such as affinity purification, yeast two-hybrid (Y2H) or fluorescence 
resonance emission transfer (FRET), BioID is an advantageous system to detect weak and 
transient interactions and study PPIs on their natural cellular environment avoiding solubility 
problems.  
I made use of the BioID2 system to investigate Rac1b interacting partners, aiming to 
outline the mechanism through which it regulates the WNT signalling pathway and other as 
yet unknown downstream pathways. In addition, Rac1-containing BioID vectors were also 
generated in order to compare both interactomes and to establish specific Rac1b targets.  
 





4.2.4.2 Rac1b and Rac1 cloning strategy 
I used a BioID2 plasmid from Addgene® with Myc as a cellular tag in the N-terminus 
and cloning sites in the C-terminus for our protein (myc-BioID2-bait). Regarding the proteins 
of interest, Rac1b was purchased as a mouse cDNA from GeneScript® and amplified by PCR. 
In contrast, given that Rac1 is highly and ubiquitously expressed in all tissues, its sequence 
was extracted by PCR from a piece of SI normal tissue. Since I aimed to eventually use this 
technique in organoids, which would only allow lentivirus transfection, I cloned the fused 
myc-BioID-Rac1b and myc-BioID-Rac1 vectors into a lentiviral vector (pLJM1-EGFP from 
Addgene®) to ultimately generate viruses (Figure 2.3). Cloning of a free-bait myc-BioID vector 
into the lentiviral vector was used as a BirA* control and an empty lentiviral vector (only 
pLJM1-EGFP) was used as a transfection control. 
 
4.2.4.3 Optimization of BioID technique in CMT93 cell line 
Once cloning was successful and sequences validated, pLJM1 vector with myc-BioID2-
Rac1b (from now on, BirA-Rac1b), myc-BioID2-Rac1 (hereafter BirA-Rac1) and the control 
myc-BioID2 (BirA) were transiently transfected into mouse rectal carcinoma cells, the CMT93 
cell line, by Lipofectamine® 2000 transfection reagent to verify correct protein expression 
and BirA biotinylation ability. Following Roux et al. protocol465, 50µM of Biotin was added to 
the cell media when cells reached their transfection peak after about 40 hours. Although they 
recommended 24h of biotin treatment, I wanted to see whether biotinylation could be 
detected after shorter periods of time, which might then diminish potential contaminating 
protein background during MS. Cells were collected for RNA and proteins were extracted 
after 6 and 19 hours of treatment and both qRT-PCR and Western blot (WB) were conducted. 
As shown in figure 4.5B, there was a robust overexpression of mouse Rac1 and Rac1b in Bir-
Rac1 and Bir-Rac1b vectors respectively. Additionally, Western blots were used to evaluate 
protein biotinylation by Streptavidin-HRP antibody and protein bait overexpression by anti-
myc-tag (9B11) antibody. As shown in figure 4.5D, biotinylation is already detectable after 6 
hours only in the BirA-containing vectors and streptavidin bands were increased and more 
defined after 19 hours of biotin treatment. As expected, BirA has a higher streptavidin signal 
due to its unspecific protein affinity. The size of the myc-tag band will depend on the total 
size of the fusion protein. For the control vector (BirA) will be the sum of the myc-tag (about 





8kDa) plus the BioID2 (23kDa), so a band at about 31kDa will be expected. However, for Rac1 
will be 50kDa (19kDa Rac1) and about 53kDa for Rac1b. Figure 4.5C presents the WB films 
showing the expected size bands, indicating that protein overexpression and translation has 
been correct. The weak upper band in the BirA lane might probably be unspecific binding due 
to high antibody concentration, since subsequent WBs using a more diluted antibody 
concentration do not present this double band (data not shown). Therefore, both vectors 
















Figure 4.5: Set up of BioID experiment in the CMT93 cell line. A: Layout of the BioiD 
experiment using BirA*+Rac1 or BirA*+Rac1b plasmids and the non-fused BirA* plasmid as 
an experimental control. B and C: Validation of Rac1b and Rac1 overexpression by qRT-PCR 
(B) and WB probing for the myc-tag (C). D: Streptavidin WB to identify biotinylated proteins, 















































































































4.2.4.4 Mass Spectrometry analysis 
Upon vector expression and biotinylation validation in the cell lines, I proceeded to the 
second phase of the BioID experiment. 20 hours of biotin treatment was established as the 
ideal length of time for detecting enough biotinylated proteins without background excess. 
Cells were collected and proteins were extracted in RIPA buffer supplemented with 
phosphatase and protease inhibitors. A small amount of lysate was used to validate 
biotinylation and the remaining was used for streptavidin pull-down. Due to the high affinity 
between streptavidin and biotin, biotinylated proteins were efficiently separated from non-
biotinylated by streptavidin beads immersed in an agarose resin. Briefly, protein lysate was 
incubated in a rotator with a small amount of agarose for 6 hours at 4ºC. The reason for using 
an agarose-containing beads instead of magnetic beads was mainly to avoid interference 
with MS analysis465, as well as being easier to handle. Following incubation, washing of the 
beads from unbound biotinylation-free proteins was achieved through centrifugations and 
sequential pellet washes. The final pellet was then sent to the MS facility (IGMM) for protein 
identification.  
A list of 60 proteins specific for either Bir-Rac1 or Bir-Rac1b came up from the MS 
analysis (Figure 4.6A, Table 4.1 and Appendix 4). The first main conclusion from the 
experiment was that both Rac1 and Rac1b share the vast majority of their interacting 
partners, since only two proteins are specific for Rac1 (Stxbp6 and Sms) and 8 for Rac1b 
(Itga3, Rap1gds1, Fam171a1, Wasf2, Flrt3, Pak4, Ttll3 and Ccdc127). In order to visualise the 
PPI networks Rac1 and Rac1b proteins were involved in, a meta-analysis of the listed proteins 
was performed using the NetworkAnalyst web-based platform466,467 and the IMEx 
interactome database (Figure 4.6C). Seven protein subnetworks resulted from the analysis, 
with Rac1 as the core protein in the larger and main subnetwork and validating the 
interactome as Rac1/Rac1b-mediated. Bearing in mind the membrane cellular localisation of 
Rac1 (and for Rac1b as suggested and discussed in chapter 3), it functions as a further 
validation of the fact that most of the interacting proteins have a membrane localisation 
(either receptors or transporters) (Table 4.1) and both membrane and cytoskeleton 
processes are among the top most significantly represented pathways (Figure 4.6B). 
Disappointingly, there were no direct core proteins from the WNT signalling pathway in the 
list, although some of the candidates could be indirectly related such as Cyclin-Y468 or 
Prominin1469. Intriguingly, the major subnetworks were represented by the core proteins 





Ephrin-B2, Erbb2, EGFR and IGF1R, all four implicated in major cancer-related processes such 
as ephrin470, ERBB family receptors471,472 and insulin growth factor473 signalling pathways. 
These pathways are associated with cell growth processes, they are of huge interest in CRC 
and their yet undescribed connection with Rac1b confers an additional significance to these 
findings. 
 The ERBB family of receptors were the subnetwork of interacting proteins that most 
attracted our attention. Two of these receptors, Erbb2 and EGFR, were identified as proteins 
that both Rac1 and Rac1b interact with, as well as other EGFR-related signalling components 
such as Yes1474, Asap1475,476 or Ptprj477. Moreover, crosstalk between EGFR and WNT pathway 
have been previously suggested478,479. For this reason, I decided to pursue the potential 
crosstalk between EGFR and Rac1b signalling. Initially, I tested whether EGFR was a specific 
Rac1b-biotinylated protein. The BioID experiment was repeated in BirA- and BirA-Rac1b-
transfected cells by biotin treatment and streptavidin-dependent pull-down, and a Western 
blot was conducted against streptavidin-HRP and EGFR antibody. As it is shown in figure 4.6D, 
only the product from the pull-down is positive for streptavidin, validating the biotinylation. 
However, EGFR is exclusively seen in the Bir-Rac1b lane, demonstrating that EGFR and Rac1b 
are either interactors or neighbouring proteins.  
Overall, BioID has demonstrated to be a useful and informative tool to investigate the 
interactome of a certain protein. The experiment with Rac1 and Rac1b as bait proteins 
showed a concise list of interacting proteins which will lead to a new perspective into their 


































Figure 4.6: Members of the EGFR signalling pathway interact with Rac1b. A: 60 different 
proteins were identified as interactors of Rac1 and Rac1b, 50 of which were overlapped and 
10 were specific for each one. B: Enriched signalling pathways in the BioID gene list, analysed 
by InnateDB. C: Main subnetwork identified for Rac1b interacting proteins, analysed by 
NetworkAnalyst. This include core members of oncogenic signalling pathways such as EGFR, 
Ephrin and Yes. D: Validation of EGFR as a Rac1b interacting protein by biotin-streptavidin-
based pull-down. FCGR: Fcgamma receptor. MS analysis conducted by Alexandre von 
Kriegsheim. N= 3 vs 3 vs 3. 
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Table 4.1: List of BioID interacting proteins for Rac1/Rac1b. Highlighted rows correspond to 
proteins either specific for Rac1 (blue) or Rac1b (yellow). 





4.2.5 Functional study of Rac1b-EGFR signalling pathway crosstalk 
4.2.5.1 ERBB family receptors 
Four different types of receptor tyrosine kinase (RTK) compose the ERBB or the 
Epidermal Growth Factors Receptor (EGFR) family: Erbb1 or EGFR, ErbB2 (or HER2), ErbB3 
and ErbB4. In a ligand-free state, receptors are found inactive as monomers and they require 
homo- or heterodimerization for phosphorylation of tyrosine residues in the cytoplasmatic 
receptor tail480. Ligand binding to the receptor causes a conformational change that allows 
dimerization prior to receptor activation481. EGFR and ErbB4 are fully functional as homo- or 
heterodimers. In contrast, ErbB3 lacks intrinsic tyrosine kinase activity, albeit it still can 
transduce downstream signals through heterodimerization with the other ErbB receptors482. 
All of them can bind to a wide range of EGF-family of ligands except for ErbB2, which has only 
a fixed monomer constitution ready to form heterodimers with the other receptors. 
Although it has no ligand specificity, ErbB2 is the preferred receptor for heterodimer 
formation483 and high concentrations of ErbB2 have been found in the cell membrane of 
many tumours, leading to increased EGFR signal activation.  
Phosphorylated residues in the carboxy-terminal domain activate docking sites for 
recruiting proteins that will initiate intracellular signalling pathways484.  Aberrant activation 
of ErbB receptors have been found in a large variety of human tumours. EGFR is the most 
mutated ErbB receptor family in epithelial cancers, usually by gene amplification or 
extracellular domain deletion485. It is followed by ErbB2, most commonly mutated in breast 
cancer486. Consequently, targeting the EGFR signalling pathway either by monoclonal 
antibodies or small-molecule inhibitors is currently a major therapeutic strategy487. 
Unfortunately, their secondary effects, low percentage of efficiency or acquired resistances 
demand more finely developed drugs or complementary treatments to improve the outcome 
of EGFR-driven tumours.  
 
4.2.5.2 Kinetics of CMT93 cells following EGF stimulation  
Regulation of EGFR signalling is mainly achieved by receptor recycling through the 
endosomes or lysosome targeting by ubiquitylation signals482. Once EGFR binds to EGF, its 
main ligand, the number of receptors in the cell surface diminishes and therefore, EGF is in 
turn its major negative feedback too. Even so, EGF-EGFR dimers are still active and continue 





signalling after endosome internalization488. The EGFR signalling dynamic can be monitored 
depending on the EGFR peak of phosphorylation and downstream pathways activation. 
However, its kinetics will vary depending on the cellular context. Since I decided to use the 
CMT93 cell line to interrogate whether Rac1b is functionally required for EGFR downstream 
signalling, an initial characterization of EGF-stimulated EGFR activation in this cell line was 
needed.  
EGF concentration is another factor to consider during in vitro cell stimulation488. 
Therefore, two different EGF concentrations were supplemented in the media following 4 
hours of serum starvation. Upon EGF addition, cells were collected after 5, 10, 15 and 30 
minutes and proteins were extracted for WB analysis. As it shown in figure 4.7A, EGFR 
phosphorylation peaked at 5 minutes and then the signal gradually decreased. MAPK and 
AKT pathways were checked as downstream activation read outs and both had the same 
pattern of activation like EGFR, with p-AKT and p-ERK1/2 reaching their maximum of 
activation at 5 minutes. Both EGF concentrations led to the same signal dynamic but 20ng/ml 
was much stronger and then more likely to detect differences if reduced, so this was the 
preferred concentration for the experiment. 
 
4.2.5.3 Exon-3b targeted morpholino efficiently knock-outs Rac1b in CMT93 cells 
The use of a targeted morpholino to Rac1 exon 3b was chosen as a strategy to 
knockdown Rac1b in the CMT93 cells. Antisense morpholino induce exon skipping by binding 
to exon splice enhancers and disrupting binding of splicing factors. There is evidence of 
promising therapeutic results with exon skipping morpholinos in diseases such as Duchenne 
muscular dystrophy and Spinal muscular atrophy489,490. For Rac1b, a specific morpholino was 
designed to bind to the exon 3b splice enhancer site thus blocking exon 3b inclusion. 
Morpholino knockdown efficacy was then tested in CMT93 cells. Cells were treated with 
5µl/ml of either non-targeted (control or NT PMO) or targeted morpholino (Rac1b PMO) for 
2 days and then lysed for RNA extraction. qRT-PCR analysis of three replicate experiments 
shows an approximate 95% of reduction in Rac1b transcript compared to NT PM (p=0.0095, 
Figure 4.7B). Importantly, Rac1 transcript remained intact, indicating the morpholino’s 
efficiency at only targeting the splicing event and not total transcript. Therefore, pre-





treatment of morpholino prior to the experiment is an efficient method to transiently knock 
down Rac1b expression in 2D cells.  
 
4.2.5.4 Rac1b deletion impairs EGFR phosphorylation and downstream signalling activation 
CMT93 cells were pre-treated with either NT PMO or Rac1b PMO for two days and 
then treated with 20ng/ml of EGF after serum starvation. Protein collection times were at 5, 
10, 15 and 30 minutes and untreated EGF cells with 10% of serum or following serum 
starvation were used as controls.  Interestingly, Rac1b-deleted cells presented a marked 
reduction in the phosphorylated status of EGFR, implying lower levels of activation (Figure 
4.7C). This difference in p-EGFR was most evident at 10 minutes, and notably, Rac1b PMO 
treated cells never reached a level of phosphorylation as high as the NT PMO. Technical 
replicates of the experiment showed the same results and densitometry quantification of p-
EGFR bands relative to their EGFR expression demonstrated a significant reduction in EGFR 
activation at 10 minutes (p=0.035).  
Whether decreased EGFR phosphorylation translated into lower downstream EGFR 
pathway activation was assessed by ERK1/2 and AKT phosphorylation. As it is illustrated in 
figure 4.7D and E, both proteins were less phosphorylated in Rac1b PMO treated cells 
compared to controls. In this case, pathway activation levels were steady at all time points 
and so the reduction in phosphorylation observed in Rac1b-deficient cells was also equally 
diminished at the measured times.  
Given that 10 minutes treatment with EGF displayed the most different time point of 
EGFR phosphorylation between cell conditions, concurrent replicates were performed in 
serum starved cells with EGF treatment for 10 minutes. Accordingly, Rac1b PMO treated cells 
presented a decreased activation in p-EGFR as well as in p-ERK1/2 and p-AKT, as evidenced 
by a 2-fold reduction in all phospho-proteins by densitometry analyses (Figure 4.7F).  
These results strongly suggest that Rac1b modulates EGFR receptor and signalling 
activation. Intriguingly, the clearest difference in phosphorylation levels is after 10 minutes 
of EGF stimulation. At this time point, EGF-EGFR dimers are being internalised at the early 
endosome, suggesting that Rac1b might participate during EGFR recycling and therefore, it 
could alter the exposure and signal transmission time of the receptor-ligand dimer.  





















Figure 4.7: Deletion of Rac1b impairs EGFR phosphorylation and downstream signalling 
activation. A: Response of CMT93 cell line to EGF stimulation at two different doses, 
evaluated by EGFR, AKT and ERK phosphorylation. 20ng/ml was the chosen concentration to 
test EGFR signalling modulation in this cells. B: Validation of efficient Rac1b depletion by 
morpholino treatment on the CMT93 cells. qRT-PCR presents its downregulation, while Rac1 
expression remains intact. C-E: Rac1b-depleted (Rac1b PMO) and control (NT) cells following 
morpholino pre-treatment were subjected to EGF stimulation for 5, 10, 15 and 30min. 
Signalling activation was evaluated by EGFR (C), ERK1/2 (D) and AKT (E) phosphorylation. This 
experiment was conducted in triplicate. Band densitometries for p-EGFR are plotted in the 
adjacent graph, whose values are relative to non-phosphorylated EGFR. F: PMO and NT pre-
treated cells were stimulated with EGF during 10 min. Four simultaneous technical replicates 
were conducted and EGFR downstream signalling was evaluated. EGFR, ERK and AKT 
phosphorylated proteins are quantified relative to their no phosphorylated expression.  
T-test: *= p≤0.05, **= p≤0.01, ***= p≤0.001, n.s. = not significant, p>0.05. N (test) = 1 vs 1. N 
(time course) = 3 vs 3. N (replicate 10min) = 4 vs 4.  
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4.2.5.5 Organoids from VilCreERT2Apcfl/flRac1bfl/fl mice present an EGF-sensitivity phenotype 
 
4.2.5.5.1 Impaired cell growth with EGF withdrawal 
Growing intestinal cells as organoids requires recapitulation in culture of the conditions 
that maintain the stem cell niche in vivo. Murine epithelial cells from the small intestine are 
probably the easiest to grow, since only three growth factors are needed to retain high 
activity of WNT and EGFR signalling and to inhibit BMPs: R-spondin-1, EGF and Noggin491. In 
the scenario of tumours or intestinal epithelial cells derived from acute hyperplasic tissues 
whose WNT signal is already hyperactivated, R-spondin-1 is unnecessary. However, EGF is 
essential for stem cells’ normal maintenance and proliferation151, whereas Noggin is 
dispensable for their expansion but needed for long-term culture491.  
We previously observed that organoids derived from Apc and Rac1b deficient mice 
have decreased clonogenic capacity compared to mice with wild type Rac1b expression 
(Figure 4.4F). Bearing in mind the EGFR modulation observed in CMT93 cells by Rac1b, we 
wondered whether these organoids would suffer differently upon EGF withdrawal. APC and 
APC RAC1BKO organoids were split and an equal number of fragments were cultured for each 
group. Culture media was supplemented with either Noggin and EGF (+EGF) or just with 
Noggin (-EGF) and organoid size was evaluated. After four days, there was no difference in 
the size of organoids when EGF is present in growth media. However, when EGF was 
withdrawn, Rac1b-deficient organoids were significantly affected. More apoptotic organoids 
were observed in APC RAC1BKO organoids without EGF and their size was significantly smaller 
than APC organoids (101,989 vs 57,503µm3, p=0.0155, Figure 4.8A). Moreover, lysozyme WB 
from these organoids indicates that there was not an increase in the Paneth cell population 
to compensate for the lack of EGF (Figure 4.8C). This result indicates that organoids with 
Rac1b deletion have lower basal levels of EGF signalling than APC organoids and therefore, 
their survival might be compromised if EGF is no longer supplemented.   
 
4.2.5.5.2 Increased sensitivity to EGFR inhibitor treatment 
EGFR tyrosine kinase inhibitors (TKIs) treatment is a targeted therapy which is 
preferentially used in non-small-cell lung cancer (NSCLC), since a subset of these tumours 
harbour EGFR kinase domain mutations492. However, other cancer subtypes with high EGFR 





pathway activation also benefit from this therapy such as cholangiocarcinoma493, breast494 
and colorectal cancer495,496. Although efficient, a shared problem of this treatment is the 
development of resistance, which leads to surviving tumoral cells, tumour recurrence and 
death within 1- or 2-years497. The response of non-canonical pathways downstream EGFR 
activation to EGFRi have been explored as a possible tumour vulnerability, whereby their 
concomitant targeting would more efficiently lead to drug-sensitivity in tumour cells. A 
postulated one is the Rac1 signalling pathway, which is activated following EGFR 
phosphorylation and contributes to cell proliferation and migration signals via MAPK and c-
Jun cascades498,499. In erlotinib-resistant gliobastoma cells, Rac1 expression was shown to be 
associated with erlotinib sensitivity500 and double treatment with erlotinib and Rac1 inhibitor 
(NSC23766) proved to act synergistically and efficiently enhanced their anti-neoplastic 
effects in vitro and in vivo in a xenograft mouse model501. A similar effect was observed in 
NSCLC-resistant cells, where NSC23766 and gefitinib combination reduced cell migration and 
growth502. Indeed, a recent work from Marcar and colleagues has demonstrated the effect 
of a Rac1-related drug against a large spectrum of TKI-resistant lung tumoral cells503. They 
showed that unlike TKI-sensitive cells, resistant cells produce more amounts of Rac1-derived 
ROS species, which makes them more dependent of a poly (ADP-ribose) polymerase 1 (PARP-
1), indispensable to catalyse Rac1 and delimit their ROS cytotoxicity. This is a promising 
strategy of synthetic lethality against resistant tumours and PARP inhibitors are now under 
initial phases of a clinical trial. However, none of these studies have explored the possibility 
of Rac1b being involved in EGFR-triggered Rac1 activation. Given that Rac1b is its 
constitutively active tumoral isoform and bearing in mind the mounting evidence of EGFR-
Rac1 signalling combination, I decided to investigate whether the tumour-like organoids 
derived from APC and APC RAC1BKO short-term induced mice would respond differently to 
EGFRi treatment.  
APC and APC RAC1BKO organoids were treated with 1µM of an EGFR small molecule 
inhibitor (PD153035, Sigma®)504 or its vehicle control (DMSO). After 20 hours, pictures were 
taken for organoid size measurement and resazurin was added in the media for 7 hours as a 
cell viability assay. As can be seen in Figure 4.8B, APC RAC1BKO organoids treated with 
PD153015 performed noticeably worse compared to APC controls, since most of the 
organoids were dead or shrunk. While both genotypes remained the same when treated with 
DMSO, area analysis revealed that Rac1b-deficient organoids were 2-fold smaller in size upon 
EGFRi treatment, with almost no effect in control APC organoids (p=0.0037). Resazurin 





absorbance measurements showed that cell growth was affected in both genotypes but APC 
RAC1BKO organoids had a significantly worse viability compared to APC-treated organoids 
(p=0.048). 
Altogether, these results demonstrate that deletion of Rac1b in adenoma-like 
organoids with high WNT activation are more sensitive to EGFR inhibition and suggest 
reduction of both signalling pathways as an attractive therapeutic strategy in high WNT 
activated CRC tumours. 
 
4.4.3.1 EGFR signalling pathway activation is decreased in Rac1b-deficient mice 
The ageing cohort presented a marked WNT-driven phenotype, evaluated by RNAseq 
analysis and qRT-PCR validation which might be responsible for both the downregulated cell 
proliferation within the tumours and the consequent decrease in tumorigenesis and 
extended survival in Rac1b-deficient mice. However, interactome analysis pointed to an 
additional yet unexplored signalling network led by the ERBB tyrosine receptors family. In 
vitro 2D and 3D analysis revealed a modulation of EGFR signalling by Rac1b expression, 
translating into a worse cell growth and an increased sensitivity to TKI treatment. Whether 
the same regulation occurs in vivo and contributes to tumour formation remains to be 
elucidated.  
To this end, tumour and matching normal tissue samples from the ageing cohort were 
subjected to transcriptome analysis of the EGFR pathway through qRT-PCR analysis. Etv4 and 
Etv5, two transcriptional target genes of the ERK pathway, were highly significantly 
downregulated in Rac1b-knock-out tumours compared to APC (p=0.0005 and p=0.0007 
respectively, Figure 4.8D). Besides, Etv4 already came up as one of the most downregulated 
genes in the RNAseq, validating its depletion upon Rac1b deletion. 
Altogether, this result indicates that, in addition to the WNT signalling, deletion of 
Rac1b causes a decrease in EGFR signalling and both pathways might be responsible for the 
reduced tumorigenesis seen in this model.  
 
 
























Figure 4.8: Ex-vivo and in vivo modulation of EGFR signalling by Rac1b expression. A: APC 
and APC RAC1BKO tumour organoids pictures with or without EGF-supplemented growth 
media. B: Pictures of tumour organoids upon EGFRi (PD135035) treatment. Size of the 
organoids for both experiments (A and B) was scored manually with ImageJ. Cell viability for 
PD135035 treatment was assessed with Resazurin. C: WB presenting lysozyme expression of 
tumour organoids. D: qRT-PCR of tumour and matching normal tissue from cohort mice for 
Etv4 and Etv5 expression. Experiments were conducted alongside Kevin Myant. 
T-test: *= p≤0.05, **= p≤0.01, ***= p≤0.001, n.s. = not significant, p>0.05. N (organoids) = 3 


















































































































Since it was discovered in 1999, Rac1b has largely been described as a tumour-related 
isoform385,391,395,505,506. As important as it is to fully investigate its tumorigenic role, a 
comprehensive study of its function in physiological conditions is also necessary. My analyses 
indicate that Rac1b is not essential for normal intestine homeostasis as its deletion did not 
translate into any physiological change (Figure 4.1). This is not entirely surprising, given its 
low levels of expression. However, it adds extra value to the suggested tumour specificity for 
Rac1b and provides evidence for a lack of potential secondary effect in normal tissue upon 
artificial deletion. Furthermore, in this section I have presented how Rac1b contributes to 
tumour formation in a mouse adenoma model and investigated which signalling pathways 
were modulated and constitute its mechanisms of action. By unbiased transcriptomic and 
proteomic analyses, two major signalling networks with broad implications in cancer-related 
pathways were found to be altered upon Rac1b deficiency, and their modulation was studied 
by means of functional in vitro techniques.   
In vivo deletion of Rac1b in cancer animal models has not been reported yet and given 
the building evidence of cancer-associated functions for Rac1b, an urgent need to conduct in 
vivo loss of function experiments in tumour models was apparent. Interestingly, Rac1b-
deficient mice had an extended survival due to a decreased tumorigenesis, which was mainly 
developed in the most proximal parts of the intestine (Figure 4.2).  
Phenotypically, none of the cell populations previously observed to differ upon 
modulation of Rac1b expression were different between genotypes409 but interestingly, APC 
RAC1BKO tumours had a diminished proliferation rate (Figure 4.3). RNAseq analysis from 
these tumours and additional qRT-PCR from acutely induced mice revealed the WNT 
signalling pathway to be significantly downregulated in Rac1b-deficient tumours (Figure 4.4). 
This correlates well with the reduction in proliferation since WNT is the major signalling 
pathway orchestrating proliferation and cell division processes in the intestine142. Moreover, 
a clonogenicity assay of intestinal epithelial cells derived from acutely induced Apc knockout 
mice presented a reduction in their clonogenic capacity, an in vitro phenotype analogue to 
that of reduced proliferation in tumours and reduced stem function. It needs to be 
mentioned that nuclear β-catenin, which is the main histological read out for WNT activation, 
is not decreased in APC RAC1BKO, even though our transcriptome analysis shows that WNT-
targeted genes are downregulated. This also indicates that Rac1b mediated regulation of the 





WNT pathway is likely downstream of β-catenin nuclear localization, in agreement with the 
phenotype observed following Rac1 deletion292. 
 A correlation of WNT signalling activity and high Rac1b levels was also observed in my 
TCGA analysis from the previous chapter, where human colonic tumours with high Rac1b 
expression positively correlated with both the CMS2 subtype (the canonical WNT-activated 
subtype) and with WNT-targeted genes such as Lgr5, Axin2, Tcf7 and Lef1 (Figure 3.7). The 
fact that our own RNAseq data and GSEA analysis overlapped with the results observed in a 
large set of human tumours strongly supports the hypothesis that Rac1b is a functional 
mediator of WNT signalling. This is not completely unexpected, since Esufali et al. previously 
suggested a model, albeit controversial, whereby Rac1 and Rac1b activate WNT signalling 
through nuclear targeting of β-catenin507. Later on, they presented an upstream Dishevelled-
3-dependent (Dvl-3) mechanism through which Rac1b would enhance β-catenin/Tcf-
mediated transcription in the nucleus which in turn is WNT3A ligand independent387,505. 
However, additional evidence and the present observation that Rac1b likely acts 
downstream β-catenin signalling suggests certain discrepancies about Rac1 and Rac1b being 
necessary for its nuclear localization292.  
Considering the Rac1b-driven WNT signalling modulation, I was encouraged to 
investigate its mechanism of action by a PPI assay using BioID. Ensuing Mass Spectrometry 
analysis resulted in a concise list of interacting or neighbouring proteins, 60 in total, 50 of 
which were shared between Rac1 and Rac1b (Figure 4.6). This large overlap in their 
interactomes suggests that Rac1 and Rac1b might likely share most of their effectors, thereby 
Rac1b would enhance Rac1 activity rather than activate specific downstream signalling. Most 
of them were membrane proteins such as receptors (IGFR, EGFR, Cxadr and Gpr39), 
transporters (Slc12a7, Tmem237 and Slc29a1) or cell adhesion proteins (Ocln, Flot2 and 
Jam2), acting as evidence for Rac1/Rac1b preferential membrane localization. Protein meta-
analysis revealed three branches of subnetworks that come out from Rac1 protein (Figure 
11B). One is linked with Rho GTPases-related proteins with Cdc42 effector protein 1 
(Cdc42ep1) as the core of the subnetwork. Another one is associated with Rac1 effector 
proteins involved in membrane ruffling and lamellipodia formation (Baiap2 and Wasf2)508,509 
and endocytosis (Asap1 and Uaca)510,511. Finally, the last branch connects to the major set of 
subnetworks, the majority of which are cell receptors related with cell growth processes and 
involved in pathways deregulated during cancer, such as the ErbB family of receptors (EGFR, 





ERBB) and Insulin growth factor 1 receptor (IGF1R). A few proteins of the list could have a 
direct implication with the WNT signalling pathway, such as Prominin1 (CD133), which is 
considered an intestinal stem cell marker and a WNT regulator469,512, and Cyclin-Y, which 
phosphorylates Lrp6 and induces activation of WNT/β-catenin pathway in a cell cycle-
dependent manner468. I initially tried to study CMT93-morpholino treated cells response to 
the WNT ligand WNT3a, since theoretically, they have no mutations in the WNT pathway438. 
However, stimulated and non-stimulated cells responded equally to WNT3a treatment, 
evaluated by β-catenin WB and WNT-targeted genes qRT-PCR (data not shown), implying 
mutations somewhere in the pathway and requiring a different cell model to functionally 
investigate WNT modulation by Rac1b. An indirect relationship with the WNT pathway could 
also occur through other signalling pathways, such as EGFR513,514. Two out of four receptors 
from the ErbB family came up in the MS analysis, including other proteins that have already 
been proven to be related with EGFR signalling (such as Yes1, Asap1 and Prprj). A recent study 
by Wang et al. provided evidence for an EGF-Rac1b axis, since EGF would induce both 
ubiquitylation of the negative Rac1b-splicing regulator hnRNPA1 and activation of the 
SRPK1/2 and, consequently, increasing Rac1b expression398. In agreement with my data, this 
indicates a possible feedback regulatory loop between EGFR and Rac1b. However, a potential 
EGFR-modulation by Rac1b has not been described nor has any mechanism of action.  With 
this rationale, the CMT93 cell line was used with an exon-3b targeting or control antisense 
morpholino to explore if Rac1b interaction with EGFR-related proteins translates into a 
functional phenotype.  
Interestingly, EGF treatment to CMT93 cells showed a different activation of the 
pathway depending on Rac1b expression. Monitoring EGFR activation demonstrated that, 
after 10 minutes of EGF supplementation in the media, there was the largest difference 
between cell conditions in all evaluated proteins. It is believed that at this time point, EGFR-
EGF dimers will be in the early endosomes sorting to multivesicular bodies (MVB) or late 
endosomes515, suggesting that a depletion of Rac1b could have caused alterations in the 
endocytic route.  
Prior to constructing any hypothetical model, we wanted to validate our findings in 
additional models that more closely reassemble human conditions491. To this end, organoids 
derived from tamoxifen-induced mice with double homozygous deletion in both Apc and 
Rac1b and their Apc knockout controls were plated and growth was evaluated under EGF-





deficient conditions. EGF is an essential growth factor in organoid culture for maintenance 
and proliferation of stem cells151 and withdrawing it from the media would subject the 
organoids to extra stress. However, Paneth cells in the intestinal crypts are capable of 
producing EGF136 and they could partially and temporally overcome the lack of EGF. Organoid 
size measurement following EGF starvation treatment revealed that only Rac1b-deficient 
organoids had an impaired growth, since they were visibly more affected and phenotypically, 
their size was reduced (Figure 4.8A). Western blot of these organoids showed that they did 
not have fewer Paneth cells, as previous analysis from ageing tumour cohort (Figure 4.8C) 
and normal tissue depleted for Rac1b has already revealed (Figure 4.1). Therefore, less 
intrinsic production of EGF due to a decreased Paneth cell population does not account for 
the EGF increased sensitivity in APC RAC1BKO organoids and, more likely, a diminished 
activation of the EGFR signalling pathway as observed in the CMT93 cells might be 
responsible for their dependency.  
I did not have time to fully interrogate EGFR signalling output in the ageing tumour 
cohort, but initial analysis showed the expression of ERK-targeted genes Etv4 and Etv5 was 
downregulated in Rac1b deficient tumours (Figure 4.8D). This suggests that Rac1b expression 
is also important for EGFR signalling in vivo and it acts predominantly in tumour cells, making 
it a potential therapeutic target.  
Upon EGFR ligand binding and activation, a broad spectrum of signalling pathways are 
activated downstream and contribute to their malignant phenotype in tumour cells. Among 
them is the Rac1 signalling pathway, whose activation has already been investigated as a 
synergetic mechanism whereby EGFRi-treated tumours could be more efficiently 
eradicated500–503. Resistance to EGFRi is a growing problem, since a rising high percentage of 
tumours with elevated EGFR signalling, which initially have a good response to TKI drugs, will 
eventually develop resistance. An emerging therapeutic strategy is the combination of drugs 
which act at different levels the tumour is dependent on and weaken it before resistances 
are acquired. Given our results from CMT93 and tumour organoids, we hypothesised that 
efficiency of EGFRi could be increased if Rac1b expression is simultaneously deleted. To 
address this issue, APC and APC RAC1BKO organoids were treated with the EGFRi PD153035 
and cell size and viability was evaluated. Apc wild type organoids remained unaltered by the 
inhibitor, which is the optimal outcome for any cancer-targeting treatment. Interestingly, 
only Rac1b-depleted organoids were sensitive to the inhibitor (Figure 4.8C), demonstrating 





that coupled deletion of Rac1b to an EGFRi could potentially enhance its outcome without 
affecting non-tumour cells.  
Altogether, these were promising and novel results for Rac1b-related roles, and due 
to limited time, further description on its mechanisms of action could not be conducted. 
Observation of these data plus the data obtained from our RNAseq and MS analysis 
prompted us to postulate a hypothesis of how Rac1b could be interfering during EGFR 
signalling. As mentioned previously, the second branch of the subnetwork was related with 
membrane cellular processes, which are the canonical roles for Rho small GTPases and Rac1 
in regulating the organization of the cytoskeleton, such as membrane ruffles, filopodia and 
lamellipodia. Rac1 modulates these processes by stimulating actin polymerization at the 
plasma membrane, whose dynamics have also been recognized to be important for 
membrane trafficking and endocytosis516. 
Endocytosis is the uptake mechanism of molecules from the surface and subsequent 
intracellular sorting for either degradation through multivesicular bodies (MVB) and 
lysosomes or recycling back to the plasma membrane. Upon ligand binding to membrane 
receptors, endocytosis has a prevalent role as a regulator and pathway attenuator of the 
signalling triggered by activated receptor tyrosine kinases (RTK)517 and EGFR internalization 
serves as a working model for other RTK endocytosis.  Briefly, upon EGFR dimerization and 
activation of phosphorylated binding sites, adaptor protein Grb2 and ubiquitin ligase Cbl are 
recruited, along other proteins, and start mono or polyubiquitylation of the receptor dimer. 
Although not necessary for receptor internalization518, ubiquitin cues are recognized by 
ubiquitin binding proteins of the clathrin-coated pits which excise vesicle from the plasma 
membrane to an early endosome. Clathrin-independent endocytosis (CIE) have also been 
reported for EGFR internalization519, although it is a slower mechanism and apparently only 
relevant during high EGF concentrations conditions, when clahtrin-dependent endocytosis 
(CME) might be saturated. At the endosomes, ubiquitylation can be recognized by the 
endosomal sorting complex required for transport (ESCRT) machinery which will target 
receptor dimer to lysosomes for degradation. Alternatively, deubiquitylating enzymes (DUBs) 
from the endosome plus other mechanisms can direct receptors to the recycling route and 
avoid degradation. In cancer, impaired endocytosis and imbalanced receptor recycling is 
considered an oncogenic signal, since altered dynamics in the endocytic traffic are associated 
with prolonged activation of tumorigenic signalling pathways520. 





In normal situations, EGF-bound EGFR is found at the early endosomes 2 to 5 minutes 
upon ligand binding and it is not until 15 to 20 minutes later when they translocate to the 
MVB and are sorted to the lysosomal pathway. In the CMT93 experiment wherein EGFR 
phosphorylation was decreased in Rac1b-deficient cells, the maximum difference was seen 
at 10 minutes after stimulation. At this point, receptors could still be recycled back to the 
membrane and it would suggest that Rac1b might somehow interfere in this step. A literature 
search of some of the candidate Rac1b-interacting proteins from the BioID experiment 
indicates that they have already been described to play a role during EGFR internalization or 
signalling, and their aberrant function assigns them as cancer drivers (Table 4.2 for an 
overview). On one hand there is Flotilin-1, which initially was shown to be essential for 
receptor dimerization521 but recently has also been described to be involved in ESCRT internal 
movement and EGFR degradation522. On the other hand there is Ptprj or DEP1, a protein 
tyrosine phosphatase considered a tumour suppressor gene since it deactivates 
phosphorylated RTKs and it was found to inhibit EGFR signalling by physical interaction477. In 
addition, there is also Wiscott-Aldrich syndrome protein family member 2 (Wasf2 or WAVE2), 
which belongs to a complex in charge of mediating vesicle membrane fission, and recently, 
shown to take part in endosomal recycle to the plasma membrane through Arp2/3 complex 
activation523–525. Indeed, Rac1 has already been shown to indirectly activate WAVE proteins 
and to participate during vesicle movement by inducing actin polymerization516. This indirect 
activation is conducted by a protein which is also present in my MS list, the Baiap2 or ISRp53 
protein526. Finally, another interesting candidate is Asap1. Asap1 is an Arf GAP protein that 
induces hydrolysis of the ADP-ribosylation factor (Arf) proteins, which recruit coat proteins 
and regulate vesicular transport527. Importantly, it has a BAR domain, as IRSp53 does508, 
through which it mediates membrane bending and accelerates EGFR recycling528. The 
literature associates ASAP1 expression with tumour invasion and metastasis in a spectrum of 
tumour types529–531 and poor human CRC survival532. Aside from modifying endosome 
recycling through its BAR domain533, other mechanisms of action have been described. Asap1 
is an effector of Arf6, whose activity promotes invasion530,534. Furthermore, Asap1 is also an 
effector of the adaptor protein CIN85 which, through its SH3 domain, binds to the ubiquitin 
ligase Cbl and decreases EGFR ubiquitination, increasing in turn its recycle pathway510,531. 
Interestingly, both mechanisms are equally appealing for the endocytosis related Rac1b 
hypothesis. Regarding CIN85, a GEF protein has recently been described which is a Cdc42 
effector, Cool-1, whose overactivation in tumours displaces Cbl in an equal manner as CIN85 





and consequently increases EGFR signalling258, reaffirming CIN85-ASAP1 function in 
potentiating EGFR activation. However, a direct relationship between Arf6 and Rac1b 
regulating endocytic recycle in neurons has already been shown, where membrane 
trafficking and lamellipodia plays an essential role for neurons growth535. Altogether, this 
literature overview argues for a mechanism of action whereby Rac1b could modify EGFR 
signalling through regulating endosomal trafficking and likely, shifting its internalization to 





































































































































































































Nevertheless, I initially observed a strong WNT-related phenotype in the ageing cohort 
and its RNAseq analysis, and the Rac1b-WNT signalling association is further validated with 
the TCGA data. WNT and EGFR (or its downstream effector, Ras) signalling are major 
pathways maintaining tissue homeostasis and their aberrant activation have been detected 
in almost all cancer types450,536. Although their signalling mechanisms have been a topic of 
interest for decades and we currently have a large understanding of their function, their 
interconnection and crosstalk is more poorly understood. The synergistic potential of 
activated K-Ras and WNT signalling pathways has been observed in mouse models, leading 
to invasive tumours537,538, but the underlying mechanism is not yet defined. A link was 
suggested through Axin1-mediated phosphorylation of H-Ras, whereby GSK3β 
phosphorylation is essential for H-Ras binding to the ubiquitin β-TrCP and targeting its 
degradation478. This indicates that both β-catenin and H-Ras utilise the same mechanism for 
protein degradation, and aberrant WNT activation due to loss of the β-catenin destruction 
complex enhances H-Ras stabilisation too. In liver cells, Tan and colleagues demonstrated 
that EGFR is a direct target gene of β-catenin539. Likewise, EGF can also induce nuclear 
translocation of β-catenin and enhance TCF/LEF1 driven transcription through increased E-
cadherin caveolar-mediated endocytosis and/or α- and β-catenin complex 
disruption514,540,541. Destabilization of β-catenin complex in the membrane through E-
cadherin downregulation and cell-cell adhesion alteration is suited to my model, since Rac1b-
dependent E-cadherin decrease has been previously suggested505 and an involvement of 
Rac1b maintaining cell membrane structure is by now fairly plausible. However, during my 
PhD project, results regarding Rac1b-E-cadherin regulation have not been conclusive and 
from that point of view, I cannot either discard or support this hypothesis. Both pathways 
could also be linked through their shared target gene c-Myc144,542, whose expression shown 
a downregulation trend in the murine intestine with Rac1b depletion (Figure 4.4). Moreover, 
a recent investigation in haematopoietic stem cells has shown that EGFR functions as a co-
factor for WNT9a-driven signalling479. They demonstrate that upon ligand binding, EGFR 
phosphorylates the receptor Fzd9b and this is essential for signal activation, hence 
demonstrating a functional link between these two pathways. Of note, the mouse model I 
used had Apc deletion as a tumour initiating event. Although expression of Rac1b correlates 
with Apc mutations in human tumours (Figure 3.9) and more probably, Rac1b-driven WNT 
regulation would be observed likewise in other mutational landscape, it would be interesting 
to test this phenotype in an additional WNT-independent CRC mouse model.  





Dual inhibition of both pathways has recently been suggested as a necessary 
mechanism to efficiently treat all tumour populations, including CSC. Contrary to the current 
assumption for WNT and EGFR/Ras pathway acting synergistically, a recent study from Zan 
and colleagues have demonstrated that the use of MEK inhibitors (MEKi) can activate the 
WNT pathway. This activation occurs through Axin1 downregulation, which induced tumour 
‘stemness’ and could increase chances of relapse171. MEKi are commonly used to overcome 
resistance to EGFRi inhibitors, acting downstream of the receptor and oncogenic RAS or RAF. 
However, the side effect of increasing WNT signalling leads to an increase in stem cell gene 
signature in the tumour, suggesting a cell dedifferentiation reprogramming that would fuel 
the tumour with highly proliferative cells and induce treatment relapse. Interestingly, EGFRi 
inhibitors do not cause this effect, likely because they are not as potent in inhibiting Ras 
signalling as MEKi. While Zan et al. suggested a co-treatment with MEKi and WNTi, these 
results indicate that dual inhibition of EGFR and Rac1b is potentially equally efficient in 
sensitising tumours cells. Moreover, EGFRi and Rac1b inhibitor would downregulate the WNT 
pathway instead of activating it, preventing an unexpected side effect. 
One of the points remaining that needs to be addressed is the effect of Rac1b in cells 
harbouring K-Ras mutations. K-RAS mutational status is one of the few parameters taken into 
accounting for clinical decision-making, as patients with K-Ras mutation cannot benefit from 
EGFR monoclonal antibodies. Given the finding of Rac1b as a modulator of EGFR signalling, it 
would be of major relevance to test whether its inhibition could sensitise K-RASmut tumours 
to EGFRi treatment. In the TCGA analyses from the previous chapter, I observed that RAC1B 
expression significantly correlated with K-RAS mutation in tumours. This might indicate a 
certain cooperation and/or requirement for Rac1b in tumours presenting K-RASmut. CRCs with 
mutations in K-RAS accounts for 40% of all tumours. Therefore, investigating whether Rac1b 
inhibition sensitises K-RASmut cancers could translate into a large impact. 
In summary, the work from this section has described how depletion of Rac1b could 
inhibit two important pathways in intestine homeostasis, the WNT and EGFR signalling 
pathway, and translate into a less tumorigenic phenotype. Moreover, I have postulated a 
hypothesis whereby Rac1b could be regulating EGFR signalling through its participation in 
endocytic recycling routes. Although WNT and EGFR crosstalk is still unclear, I have shown 
that deletion of Rac1b in combination with EGFR inhibition might be a potential therapeutic 





strategy, and the concomitant WNT inhibition may play a role in enhancing its treatment 
efficiency. 
 
4.2.7 Future work 
The results obtained from this work and the hypothesis built around them left some 
unanswered questions. One of the next experiments planned was to test Rac1b-dependent 
sensitivity on human colorectal cancer organoids, a more reliable and advanced model for 
clinic translation. These experiments were performed by other members of the laboratory 
and led to some interesting results. As mouse and human Rac1 exon 3b differs in 6 
nucleotides, a new morpholino for human RAC1B was designed. Two types of human 
organoids cell lines were used, one derived from a benign polyp and another from an invasive 
carcinoma. When Rac1b was depleted by addition of morpholino in the media, only the polyp 
showed a significant reduced clonogenic capacity while the invasive organoid line did not 
present differences. However, when morpholino was administered co-treated with the EGFRi 
PD153035, both cells lines showed a significant decrease in proliferation compared to 
controls. This validates our previous findings and highly suggest that dual inhibition of Rac1b 
and EGFRi, rather than their single treatment, could potentially be an efficient therapy for 
advanced adenocarcinomas.  
Following this, other experiments are necessary to complete a comprehensive 
characterisation of EGFR-Rac1b interaction. Firstly, it would be interesting to test Rac1b-
dependent EGFR modulation in organoids derived from patients with K-RAS mutation or with 
acquired resistance to EGFR inhibitors. At the same time, I would like to test the endocytic 
recycle-related hypothesis. Initially, it should be validated if Rac1b has a physical interaction 
with some of the most interesting targets such as Asap1, Flotilin-1 or Ptprj. If confirmed, loss 
and gain of function experiments should be conducted to determine if they phenocopy Rac1b 
depletion. Additionally, there are several techniques to monitor EGF-EGFR internalization 
dynamics as for example, adding FITC tagged into the media and track GFP movement and 
localization on cells. I briefly tried this before finishing the project but the technique was not 
optimised and the results were not reliable. A combination of all these experiments should 
provide confident data to confirm or discard my hypothesis that Rac1b functions in 
membrane trafficking. 





Aside from EGFR, there were other interesting interacting candidates such IGFR or 
Cyclin-Y, whose functions could also be important for Rac1b function. Experiments analysing 
their interaction in CMT93 and other cell lines and the phenotypes driven by their loss or gain 
of function would be valuable when describing Rac1b function and gaining a complete 
understanding of the Rac1b interacting landscape. 
Finally, it would be intriguing to conduct further experiments to try to gain a better 
understanding of the potential WNT and EGFR signalling crosstalk mediated by Rac1b.  
Completion of these experiments would then provide important data for the Rac1b 
requirement during early tumour development in addition to a better understanding of its 



















4.3 Acute ectopic overexpression of Rac1b in the murine intestine does not alter 
homeostasis 
Rac1b overexpression is achieved by the insertion of a human cDNA copy of Rac1b 
(hRac1b) in the Rosa26 locus after a stop cassette flanked by loxP sites408. I crossed these 
mice to the VilCreERT2 model to generate cohorts of VilCreERT2Rosa26+/+ (WT) and 
VilCreERT2Rosa26lsl-Rac1b/lsl-Rac1b (RAC1BOE) mice. Upon Cre expression, the lox-stop-lox 
sequence is excised and hRac1b is expressed (Figure 2.1). WT and RAC1BOE mice were induced 
with tamoxifen and analysed 5 days later to investigate the effects generated by high levels 
of Rac1b in the intestine. Initially, induction was validated by qRT-PCR from SI tissue, showing 
a strong overexpression of hRac1b accomplished after 5 days, without altering either mRac1b 
or Rac1 expression (Figure 4.9A). 
Acknowledging that Rac1b has a preferential crypt location could suggest an intestinal 
stem cell-related role for Rac1b, with potential functions as diverse as control of 
proliferation, stem cell maintenance and renewal and/or intestinal cell lineage regulation, 
among others. Using qRT-PCR I analysed the expression of a set of stem cell marker genes in 
the SI. Lgr5 was slightly but significantly increased in the RAC1BOE group, but neither Slc14a1 
nor Olfm4 were changed (Figure 4.9C). Besides, measuring cell proliferation in the crypts by 
BrdU incorporation did not show any differences among groups (Figure 4.9B), indicating that 
cell growth is not altered by Rac1b overexpression, and that the small increase in Lgr5 does 
not account for any gross phenotypic change. Furthermore, analyses of Paneth cells by 
lysozyme IHC and goblet cells by both Periodic Acid Schiff (PAS) did not present any significant 
differences, implying that these cell populations remained at their normal state following 
Rac1b overexpression. 
Intestinal homeostasis is controlled in part by regulation of the WNT signalling 
pathway. Therefore, I determined whether Rac1b overexpression could impact its normal 
function by analysing expression of a selection of WNT target genes in the murine intestine. 
As it is shown in figure 4.9C, none of them (Axin2, Lef1, Tcf7 and Tiam1) are changed in the 
RAC1BOE group, pointing to normal levels of activity of the WNT signalling pathway. I 
repeated the fractionation experiment explained in the previous section with RAC1BOE mice 
and saw the same pattern of expression in all tested genes (Figure 4.9D). Therefore, I 
conclude that short term overexpression of Rac1b in wild type mice does not cause any gross 
changes to intestinal function.  























Figure 4.9: Overexpression of Rac1b in the normal intestine. A: qRT-PCR from SI tissue, 
showing that ectopic Rac1b is efficiently overexpressed without affecting endogenous Rac1b 
and Rac1 expression. B: BrdU (proliferation), Lyzosyme (Paneth cells) and PAS (goblet cells) 
staining in the normal SI tissue. Proliferation score is plotted underneath, through manual 
score of at least 50 half crypts per mouse. C: qRT-PCR of normal SI tissue for stem cells 
markers (Lgr5, Slc14a1, Olfm4) and WNT/β-catenin target genes (Axin2, Lef1, Tcf7, Tiam1). 
D: qRT-PCR from fractionation experiment comparing the expression of stem cells (Lgr5 and 
Slc14a1) and proliferation markers (Tiam1, c-Myc) in WT and RAC1BOE tissue. 
T-test: *= p≤0.05, ****= p≤0.0001, n.s. = not significant, p>0.05. N (qRT-PCR) = 3 vs 3. N 


















































































































































































































4.4 Overexpression of Rac1b increases colonic tumorigenesis 
4.4.1 Ageing cohort with Rac1b-overexpressing mice 
I have previously shown that Rac1b expression significantly increases in tumours 
compared to normal tissue, and this increase is higher in more advanced tumours from 
complex genetic models carrying multiple oncogenic mutations (Figure 3.11). Therefore, I 
sought to determine whether an ectopic overexpression of Rac1b in an adenoma could lead 
to a more aggressive carcinoma that might grow faster or even invade. Using the 
VilCreERT2Apc+/- and Rosa26Rac1b/Rac1b system, I studied two groups of mice: control 
VilCreERT2Apc+/- Rosa26+/+ (hereafter APC or wild type) and VilCreERT2Apc+/-Rosa26Rac1b/Rac1b 
(hereafter APC RAC1BOE). Mice were tamoxifen induced and aged until they become 
apparent of disease (assessed by weight loss, feet paleness or presence of prolapses). 
As it is shown in Figure 4.10A, intestinal overexpression of Rac1b did not cause a 
survival difference compared to the APC group (215.5 and 192 days for APC and APC RAC1BOE 
group). Accordingly, both genotypes developed the same number of tumours (18 and 22 
tumours), indicating that higher levels of Rac1b did not enhance tumorigenesis and 
consequently, both groups presented the same survival. However, tumour analysis according 
to intestinal region revealed a significant difference in the number of colonic tumours. Mice 
with Rac1b overexpression developed twice as many tumours as the APC group (3 vs 6.7 
tumours on average, p=0.0089, Figure 4.10A) which were also significantly larger (70.92mm3 
vs 141.2mm3 respectively, p=0.0036, Figure 4.19C). Altogether, this suggest that Rac1b 
overexpression might promote tumorigenesis in the colon.  
In order to validate this colonic phenotype, I repeated the same ageing cohort again 
but with smaller groups (n=8 and 6 for APC and APC RAC1BOE, respectively). Interestingly, 
they performed the same as the previous cohort did: there were not differences either in 
survival or in overall tumour number, but APC RAC1BOE mice presented a significant increase 
in colonic tumour number (10 vs 15 tumours respectively, p=0.045, Figure 4.10B). Thus, 
overexpression of Rac1b in the intestine of mice upon Apc deletion facilitates tumorigenesis 
in a tissue-limited manner, leading to increased colonic tumour formation without altering 
overall survival.  
 

























Figure 4.10: Rac1b overexpression promotes colonic tumorigenesis. A: Data from the first 
ageing cohort induced mice, presenting Kaplain-Meier survival plot (Long-rank test) and 
tumour number based on intestinal tumour origin. Mice in the cohort (n): APC = 19, APC 
RAC1BOE = 15. B: Same as (A) but data correspond to the second ageing cohort. Mice in the 
cohort (n): APC = 8, APC RAC1BOE = 6. C: Tumour number and burden data merged from both 
cohorts. D: Swiss-roll overview of colons from cohort mice. Arrows mark tumours in the 
section.  
T-test: *= p≤0.05, **= p≤0.01, n.s. = not significant, p>0.05. 









































































































































4.4.2 Rac1b-driven colonic tumorigenesis does not appear to be mediated by WNT or EGFR 
signalling 
In the previous section, I observed that deletion of Rac1b led to a decreased 
tumorigenesis and a reduction in proliferation of Rac1b-deficient tumours. Given that Rac1b 
overexpression consistently enhances tumorigenesis in the LI, both SI and colonic tumours 
were assessed for proliferative changes. Interestingly, while SI tumours present the same 
proliferative rate in both groups, APC RAC1BOE colonic tumours displayed a slight but 
significant increase in proliferation (p=0.0426, Figure 4.11A). This indicates that Rac1b 
promotes colonic tumorigeneses through a specific increase in cell proliferation restricted to 
the LI. 
As Rac1b appears to modulate WNT and EGFR signalling to promote tumorigenesis, 
assessment of these two pathways was conducted by qRT-PCR. Especially, I wanted to 
determine if a differential level of activation between SI and LI might explain the confined 
tumour promotion phenotype. RNA from SI and LI tumours and matching normal samples 
was extracted and cDNA was synthetized to conduct qRT-PCR analysis. Initially, I confirmed 
overexpression of hRac1b, which, as expected, is only expressed in samples from the APC 
RAC1BOE group (Figure 4.11B and C). Subsequently, WNT target genes were evaluated. Even 
though the expression of all of them increased in SI and LI tumour samples, there were no 
differences between groups (Figure 4.11B and C). Etv4 and Etv5 were used as transcriptional 
markers for ERK1/2 activation, but none of the groups showed significant differences. 
Overall, this indicates that neither WNT or EGFR signalling are responsible for Rac1b-driven 

































Figure 4.11: Rac1b promotes colonic tumour proliferation independently of WNT and EGFR 
signalling activation. A: Representative pictures of colonic tumours stained for BrdU IHC. 
Proliferation score was carried out by QuPath and percentage of proliferation is plotted in 
the adjacent graph. B and C: Validation of Rac1b overexpression and evaluation of the 
expression of WNT/β-catenin (Axin2, Tiam1, Lef1, Tcf7 and c-Myc) and ERK1/2 transcriptional 
targets (Etv4 and Etv5) by qRT-PCR from SI (B) and LI (C) tumours and matched normal tissue. 


















































































































































B. Small intestine 



































4.4.3 Functional investigation of Rac1b in a time-point model 
A caveat of studying samples from long experiments might be that, at their endpoint 
(about 200 days), Rac1b-driven processes that could point to a hint of its function might be 
masked by other co-occurring and additional genetic alterations acquired over time. Since I 
did not find major differences in the forecasted altered pathways, I sought an alternative 
approach to investigate this colonic-related phenotype. Even though acute overexpression 
of Rac1b did not translate into major homeostatic differences, it may be possible that, after 
a longer period of time, but prior to tumour initiation, activated pathways downstream of 
Rac1b could be observed.  To this end, mice either wild type for Rac1b (WT) or overexpressing 
two copies of hRac1b (RAC1BOE) were induced and terminated after 31 days (namely day-31 
experiment). Unlike short-term experiments carried over 5 days, which can harbour 
collateral effects due to tamoxifen-dependent stem cell population depletion543 or can miss 
slow-developing changes, I reasoned that any potential difference observed would 
exclusively be causative of Rac1b overexpression.  
An initial characterization of the large intestines was conducted by both histology and 
qRT-PCR. As it is illustrated in figure 4.12A, there was no difference in their goblet cells -
measured by PAS staining- nor in their inflammation status, evaluated by CD3 (T-cell 
lymphocytes marker) and F4/80 (macrophages marker) IHC. Moreover, qRT-PCR analysis of 
stem cells, WNT and ERK1/2 target genes showed no differences between groups (Figure 
4.12C). Regarding proliferation, half crypts from the distal colon were scored and presented 
the same proliferative rate (Figure 4.12B). Therefore, this indicates that general intestinal 
































Figure 4.12: Short-term overexpression of Rac1b does not induce major changes in the 
murine colon. A: H&E, PAS (Goblet cells) F4/80 (macropaghes) and CD3 (T-cell lymphocytes) 
IHC from WT and RAC1BOE colonic tissue. B: BrdU staining and proliferation score of from at 
least 50 half LI crypts. C: Evaluation of stem cell markers (Lgr5, Slc14a1), ERK1/2 (Etv4 and 
Etv5) and WNT/β-catenin target genes (Axin2, Lef1, Tcf, c-Myc and Ccdn1) in colonic tissue 
from WT and RAC1BOE mice by qRT-PCR. 
T-test: n.s. = not significant, p>0.05. N = 3 vs 3.  
 
 





























































4.4.3.1 Molecular evaluation of the day-31 model 
Each intestinal region harbours many anatomical and functionally different traits. For 
instance, since nutrition absorption is done in the small intestine while the large intestine is 
in charge of water absorption and fermentation, villi structures are only found in the small 
intestine as a method to increase its surface area. Likewise, there is a large heterogeneity of 
commensal microbes (microbiome) depending on the intestinal region they reside, partially 
maintained by the asymmetrical Paneth cells distribution (restricted to the SI) or by distinct 
anti-microbial peptides the Enterocytes release along the intestine544. Different anatomy also 
translates into gradients of pathway activation and sensitivity to some diseases, such as 
inflammatory bowel disease (IBD) or cancer, which in humans is more frequent to develop in 
the large intestine than in the small intestine. Given the phenotype observed in the ageing 
cohort with Rac1b overexpression, an understanding of its differential function according to 
the intestinal region could be relevant in some colon-dependent human diseases. Taking 
advantage of the homogenous samples from the day 31-experiment, I proceed to investigate 
two clinically relevant cellular processes in relation to Rac1b overexpression: cell-adhesion 
and the TGFβ signalling pathway. 
 
E-cadherin is a cell-cell adhesion molecule localised at the adherens junction region of 
epithelial cells545. Apart from being essential to organise proper cell contact, E-cadherin is 
also necessary for maintaining a ratio of E-cadherin:β-catenin complexes in the membrane. 
Therefore, loss of E-cadherin promotes cell detachment and invasion but, at the same time, 
it also leads to the release of β-catenin from the membrane and allow its translocation to the 
nucleus for initiating transcription of WNT target genes546. Work from Huels et al. showed 
that the murine LI expresses more E-cadherin compared to the SI, making the colon a more 
resistant region of the intestine in initiating tumour transformation. This helps explain why 
in most of the CRC mouse models, tumorigenesis more often occurs in the SI than in the LI, 
making it a more challenging translational model for studying human CRC. Given the 
suggested role for Rac1b in decreasing E-cadherin expression, I tested whether E-cadherin 
levels were altered upon Rac1b overexpression in the day-31 model. Initially, I performed 
qRT-PCR for E-cadherin in both SI and LI of WT and RAC1BOE samples. As it is shown in figure 
4.13A, the RAC1BOE group has a 2-fold reduction in E-cadherin transcript compared to wild 
type mice specifically in the colon, whereas the SI has equally lower levels of E-cadherin 





(p=0.0058). With the purpose of validating this result, I also looked at the protein level of E-
cadherin by IHC. However, all six mice showed a quite similar pattern and intensity of staining 
(Figure 4.13B). IHC is not the most suitable technique to evaluate quantitative changes, but 
this indicates that, if any, Rac1b does not cause major protein changes in E-cadherin although 
the reduction in mRNA transcript warrants further validation.  
 
Another signalling pathway with differential activation between small and large 
intestine is the TGF-β signalling pathway. This is a superfamily of proteins and receptors that 
are involved in many cellular processes such as cell proliferation and cell death, invasion and 
differentiation. Upon ligand binding and receptor activation, the canonical TGF-β signalling 
activates two different SMAD signalling cues that converge to associate with co-SMAD4 for 
nuclear translocation. SMAD4 is an essential cofactor for translating TGF-β signalling to the 
nucleus, and compelling evidence in the literature have shown the loss of SMAD4 to be an 
important event during CRC development. Interestingly, a work from Means et al. has 
demonstrated that loss of SMAD4 in cooperation with an acute inflammation driven by 
Dextran sodium sulphate (DSS) was sufficient to initiate carcinogenesis in the colon of treated 
mice, emulating human colitis-associated carcinoma547. This finding, along with other similar 
publications548,549, suggests that TGFβ might exert its tumour suppressor effect more 
efficiently in the large intestine compared to the small intestine. Given the suggested role for 
Rac1b in modulating TGF-β signalling, I decided to assess the activity of the pathway in my 
samples.  Following a similar strategy as used to evaluate the potential Rac1b effect on E-
cadherin levels, I looked at the status of the TGF-β pathway in the day-31 samples by qRT-
PCR. Possible mechanisms Rac1b might use to inhibit the pathway could be downregulation 
of either SMAD4 or TGF-β receptors. Comparing RNA extracted of colonic tissue from WT and 
RAC1BOE mice, I saw a small but highly significant decrease in SMAD4 transcript in RAC1BOE 
compared to WT, and no difference in TGF-β receptor 2 (TβR2) (Figure 4.13C). Bim, a TGF-β 
target gene I have looked previously in other studies and has shown to have a promising link 
with Rac1b (further described in Chapter 5), is also downregulated at a similar fold change in 
the RAC1BOE group, albeit not being significant. These results would initially point to a 
potential alteration of the pathway and suggest that Rac1b might reduce TGF-β activity in 
order to prevent its inhibition of proliferation. 
 






















Figure 4.13: Potential downregulation of E-cadherin and SMAD4 levels in the colon of 
RAC1B overexpressing mice. A: Assessment of E-cadherin expression in SI and LI tissue from 
WT and RAC1BOE mice by qRT-PCR. B: E-cadherin IHC of colonic tissue. C: Colonic expression 
of SMAD4, TβR2 and Bim measured by qRT-PCR. 
































































In this section, I have provided information about the effects of ectopic overexpression 
in the murine intestine in both physiological and neoplastic conditions. On one side, I have 
demonstrated that overexpression of Rac1b does not translate into phenotypic differences 
in the intestine, neither after an acute induction for 5 days nor after 31 days of induction. 
This is contrary to the observations made by Kotelevets et al. who show, with the same 
model, that Rac1b overexpression causes increased proliferation, enhanced activation of the 
WNT signalling pathway and an expansion of Paneth cells409. However, their experimental 
mice were aged for 18 months, which is a substantially different experimental condition to 
my experiments and could lead to such discrepancies. 
 In order to assess whether Rac1b might potentiate the tumorigenic potential of the 
APC model, VillinCREERT2Apcfl/- mice were crossed with Rac1b overexpressing mice and were 
aged until symptomatic of disease for evaluating tumour number and survival differences. 
However, Rac1b overexpression did not reduce mice survival as it did not increase overall 
intestinal tumorigenesis. Intriguingly, it did increase colonic tumorigenesis reflected in both 
tumour number and size. This was consistently reproduced in two independent cohorts 
conducted at separate periods, validating these results. Interestingly, the increase in colonic 
tumours was not due to a shift from SI to LI tumorigenesis, since tumour number in the SI 
was unchanged. Survival changes in mouse CRC are predominantly driven by increased 
tumorigenesis in the SI, which explains the lack of differences in this model. Although mouse 
survival was not reduced, enhanced colonic tumorigenesis might imply that Rac1b 
cooperates with large intestinal traits not found in the small intestine and uncovering this 
mechanism could shed some light into processes important for colon-related diseases such 
as IBD or colitis-associated cancer (CAC). 
Our first hypothesis was that this cohort resembled the opposite phenotype as seen in 
the Rac1b-knock-out cohort, but attenuated and restricted to the colon. Interestingly, cell 
growth analyses revealed that LI tumours, but not SI, had a slight but significant increase in 
proliferation. However, when WNT and EGFR signalling pathways were evaluated by qRT-
PCR, neither of the samples presented any difference. Therefore, the current phenotype does 
not feature the opposite signalling outputs observed in the Rac1b-deficient mice, and new 
pathways should be investigated to understand its phenotype. 





Given that I was analysing endpoint tumours, I was concerned that additional 
mutations acquired as a consequence of tumour formation could be covering and/or masking 
changes led by Rac1b. In order to circumvent these problems, a tumour-free cohort with or 
without Rac1b overexpression induced for 31 days was carried out. An initial histological 
characterization did not demonstrate major significant changes in any of the cell populations 
investigated. Next, I evaluated two molecular processes that have been already suggested to 
have both, a relation with Rac1b and a different output between SI and LI505,550.  
On one side, E-cadherin is a cell-adhesion protein that, on top of driving EMT and 
invasive processes, it serves as a buffer to keep β-catenin in the membrane. Given that the 
colon expresses higher levels of E-cadherin than the SI, I hypothesised that a reduction of E-
cadherin in the LI reaches a threshold in the ratio of E-cadherin:β-catenin that enables 
tumour formation, which is smaller than the ratio needed for the same to occur in the SI. In 
the literature, there is controversy whether Rac1b is able or not to modify E-cadherin 
expression. Esufali et al. initially suggested a model whereby Rac1b reduces E-cadherin 
expression in HCT116 cells via stimulation of Slug (Snai2) expression, a negative regulator of 
E-cadherin and a WNT target505. However, just on year later, Lozano et al. argued that only 
Rac1 and Rac3, but not Rac1b, can alter E-cadherin localization and induce junction 
disassembly through their direct interaction with PAK1 in keratinocytes cells551. For the Rac1b 
colonic phenotype, it would be reasonable to think that Rac1b enables misslocalization of E-
cadherin in the cell membrane, thereby disrupting cell-cell adhesion and favouring tumour 
initiation. Given the results from the pre-tumorigenic model and the evidence in the 
literature relating Rac1b and E-cadherin expression, this hypothesis warrants further 
investigations to providing a more definitive conclusion. 
TGF-β is another signalling pathway that has shown activation differences across the 
intestine. Besides, a body of evidence from Ungefroren’s lab and my own data (in the next 
chapter) have demonstrated a compelling link between Rac1b and TGF-β, specifically with 
SMAD4. SMAD4 is a tumour suppressor gene which is mutated in about 20% of all CRCs183. 
Interestingly, Freeman et al. demonstrated that loss of SMAD4 in the context of Apc deletion 
led to enhanced WNT signalling pathway and a consequent increase in tumour number, 
albeit loss of SMAD4 alone couldn’t increase nuclear β-catenin552. Moreover, a recent work 
associated the loss of SMAD4 with colitis, providing evidence that low levels of TGF-β activity 
might facilitate tumorigenesis in an inflammatory context547. Interestingly, a link between 





Rac1b and colitis has already been suggested by Jordan et al., who demonstrated that 
expression of Rac1b increases upon inflammation and its ibuprofen-mediated decreased 
expression reduces tumours originated from colitis-associated cancer (CAC). Bearing all this 
in mind, expression of SMAD4 was tested in the day-31 and tumours samples and presented 
promising results which, as well as with E-cadherin, await further investigation.  
Even though both pathways suggested promising results at the beginning, tumours 
could not validate these changes. Owing that the day-31 model was designed as a strategy 
to evaluate a cleaner cell population with just Rac1b overexpression, the observed 
differences have potentially been driven by Rac1b. However, tumours were the samples that 
showed a phenotypic difference and candidate downstream pathways should be equally 
reflected in those samples. Nevertheless, this study has been quite superficial and a deeper 
analysis should be carried out for any definite conclusion. Despite not showing differences in 
their survival, a permissive tumorigenesis in the colon might allow higher propensity to other 
diseases, especially those related with inflammatory processes. Hence further investigations 
might provide interesting insights with potential therapeutic relevance.  
 
4.4.5 Future work 
Due to time constraints of the project and overlapping with other interesting ongoing 
experiments, further investigations into this phenotype could not be carried out. However, 
deregulation of E-cadherin levels and/or downregulation of TGF-β signalling are feasible 
mechanisms to explain the observed phenotype and their analyses warrant further 
investigation. On one side, protein expression of E-cadherin should be analysed by Western 
blot in both day-31 colons and cohort tumours. Moreover, intestinal epithelial cells could be 
extracted from RAC1BOE induced mice and functional experiments carried out. For instance, 
it would be interesting to fractionate their cellular content into membrane or cytoplasmatic 
fractions and measure E-cadherin expression by Western blot. Additionally, my previous 
BioID experiment demonstrated that Rac1b interacts with a number of cell adhesion 
proteins, such as Occludin or Jam2 (Junctional adhesion molecule B) (Table 4.1). An 
evaluation of their expression might indicate whether Rac1b caused cell membrane 
disruptions that facilitated tumorigenesis.  





 Regarding TGF-β signalling, pathway activity should also be evaluated at the protein 
level by WB. As well as measuring expression of SMAD4 based on Rac1b overexpression, 
functional experiments could also be conducted in ex vivo organoid culture of colonic 
epithelial cells from induced mice. TGF-β1 treatment of organoids induces activation of the 
pathway, which translates into induction of cell death and phosphorylation of its 
downstream effectors SMAD2 and 3. If Rac1b modulates TGF-β activity in the colon, its 
treatment with TGF-β1 ligand may reveal functional differences.  
These experiments might help to clarify the potential implication of these two 
pathways. However, unbiased analysis of Rac1b differential activity in the SI and LI might 
explain more efficiently its mechanistic function, such as a RNAseq analysis comparing SI and 
LI with or without Rac1b overexpression or a BioID experiment comparing SI and LI Rac1b 
interactome. Although interesting, the study of Rac1b functions in other models yielded 




















Chapter 5: Function of Rac1b in tumour progression 
Mutations in the TP53 gene occurs in all cancer types and its loss is implicated in 
leading CRC towards carcinoma progression59. Published literature and our own data have 
demonstrated that loss of TP53 alone is insufficient to initiate intestinal tumorigenesis in 
mouse models553. However, TP53 deficiency in cooperation with activated WNT signalling by 
either loss of Apc or by carcinogen (AOM)-induced carcinogenesis enhances tumorigenesis 
and leads to tumour invasion195,553. Preliminary analysis demonstrated that expression of 
Rac1b increases in Apc and TP53 deficient mice compared to loss of Apc alone (Figure 3.11). 
Besides, my TCGA analysis showed a strong correlation between RAC1B expression and TP53 
mutations (Figure 3.9). Altogether, it suggests that conditional double deletion of Apc and 
TP53 could be a suitable model to assess the potential invasive role of Rac1b. Therefore, 
VillinCreERT2 Apcfl/+ TP53fl/fl (APC P53) mice were crossed with either RAC1BKO or RAC1BOE 
mice. On one side, I aim to address whether Rac1b is required to drive intestinal tumour 
invasion. On the other side, by Rac1b overexpression I will investigate whether it can enhance 
the invasive potential of the model.  
 
5.1 Rac1b deletion does not improve survival when co-deleted with Apc and TP53 
Prior to initiation of the tumour ageing cohort, acute tamoxifen inductions were 
carried out in double homozygous Apc mice in order to validate the efficiency of Rac1b 
deletion in the model. VillinCreERT2 Apcfl/fl TP53fl/fl Rac1b+/+ (APC-/- P53) or VillinCreERT2 Apcfl/fl 
TP53fl/fl Rac1bfl/fl (APC-/- P53 RAC1BKO) mice were acutely induced for 4 days and tissues were 
harvested for molecular analysis. qRT-PCR and WB analysis from the small intestine 
demonstrated an efficient deletion of Rac1b both, at the RNA and protein level (Figure 5.1).  
Therefore, similar to the previous cohort, two cohorts of mice were induced bearing 
the genotypes VillinCreERT2 Apcfl/+ TP53fl/fl Rac1b+/+ (APC P53) or VillinCreERT2 Apcfl/+ TP53fl/fl 
Rac1bfl/fl (APC P53 RAC1BKO). Following tamoxifen induction, symptom surveillance was 
carried by evaluation of pale feet and body weight. Mice started to become symptomatic of 
disease about 90 days after induction and termination was required shortly afterwards. As it 
is illustrated in figure 5.2A, both groups presented a virtually identical survival, 110 days for 





APC P53 and 113 days for APC P53 RAC1BKO. Accordingly, there was no difference on their 
tumorigenesis since APC P53 and APC P53 RAC1BKO mice developed 74 and 59 tumours 
respectively (Figure 5.2B). Interestingly, none of the mice developed any invasive tumour and 
their termination was needed due to the number of tumours originated rather than their 
aggressivity. Thence, in this model, despite expectation, loss of TP53 does not induce tumour 
invasion. This indicates that this model acts as a tumour initiation model rather than a tumour 
invasion and therefore, lack of differences in Rac1b-deficient mice does not account for its 
possible role in invasion. However, knock-out of Rac1b did not reduce tumorigenesis either, 
as it was observed in the previous chapter with APC mice. Bearing in mind that almost half 
of the tumours from the APC RAC1BKO cohort were able to overcome Rac1b deletion, possibly 
by positive selection of the non-recombinant population of cells (Figure 4.2), deletion of 
Rac1b expression was verified by qRT-PCR in both, SI and LI. As it is shown in figure 5.2E, 
virtually all tested mice efficiently knock-downed Rac1b. This might suggest that, in this 
context, Rac1b does not confer an additional advantage to tumoral cells since Rac1b-wild 
type cells did not exert a selective pressure. A possible explanation could be that jointly 
deletion of Apc and TP53 might lead to a threshold of WNT signalling activity whereby 
changes in other genes such as Rac1b are negligible. Nonetheless, this indicates that Rac1b 
is not necessary for Apc- and TP53-driven tumorigenesis and alternative models should be 































Figure 5.1: Validation of Rac1b expression modulation in the APC P53 model. A: qRT-PCR 
for mRac1b from SI tissue of controls (APC-/- P53), Rac1b overexpressing (APC-/- P53 RAC1BOE) 
and Rac1b deficient (APC-/- P53 RAC1BKO) mice. B: qRT-PCR for hRac1b from epithelial 
extractions (EE) of controls and overexpressing mice. C: Western blot for Rac1b and β-actin 
antibodies from EE of experimental mice. The adjacent graph presents densitometry 
quantification of WB bands.  
T-test: **= p≤0.01, ****= p≤0.0001, n.s. = not significant, p> 0.05. N(qRT-PCR) = 5 vs 3 vs 6; 













































































































































Figure 5.2: Deletion of Rac1b does not affect tumorigenesis in Apc- and TP53-deficient 
mice. A: Kaplan-Meier survival plot for APC P53 and APC P53 RAC1BKO induced mice. Log-rank 
test for significance. B and C: tumorigenesis of cohort mice scored by the total number (B) 
and area (C) of tumours per mouse. D: Swiss-roll overview of SI, stained by H&E. An example 
of non-invasive tumour is amplified underneath. E: qRT-PCR for Rac1b comparing SI and LI 
tumours and their matching normal tissue. N(qRT-PCR SI) 6 vs 6; N(qRT-PCR LI) 3 vs 3.  
Mice in the cohort (n): APC P53 = 24, APC P53 RAC1BKO = 18. 
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5.2 Rac1b cooperates with TP53 and APC deletion to increase intestinal tumorigenesis 
In the same way as with the Rac1b-deleted mice, validation of overexpression with 
APC and TP53 deletion was carried out by acute induction of APC-/- and APC-/- RAC1BOE mice 
(VillinCreERT2 Apcfl/+ TP53fl/fl Rosa26+/+ and VillinCreERT2 Apcfl/+ TP53fl/fl Rosa26lsl-Rac1b/lsl-Rac1b 
respectively). qRT-PCR for hRac1b was conducted and showed a robust overexpression, as 
well as when Rac1b was evaluated WB (Figure 5.1). Therefore, overexpression of Rac1b was 
achieved efficiently and mice were subjected for tumour assessment.  
5.2.1 Rac1b overexpression in an ageing cohort of APC P53 mice 
Control (APC P53) and mice with Rac1b overexpression (APC P53 RAC1BOE) were 
tamoxifen induced and closely monitored for endpoint signs. Surprisingly, the first disease 
symptoms in the APC P53 RAC1BOE group were noticeable after 55-65 days from induction, 
substantially earlier than the control mice which were not symptomatic of disease until about 
90 days post-induction. Consequently, APC P53 RAC1BOE mice required to be terminated 
significantly earlier and presented an average survival of 79 days, compared to APC P53 mice 
which show an average survival of 113 days (Figure 5.3A). Despite shortened survival, mice 
in the APC P53 RAC1BOE group developed significantly more tumours than control APC P53 
mice (60 vs 126 tumours respectively, p=0.0054, figure 5.3B). Mice with Rac1b 
overexpression developed lots of small non-invasive adenomas across the intestine, mainly 
originated in the duodenum and the jejunum and much less frequently in the ileum and colon 
(Figure 5.3D). Consequently, very few presented prolapses nor bleeding as signs of their 
performance, and pale feet and weight loss were the best references to control for their 
disease evolution. Both, APC P53 and APC P53 RAC1BOE mice were culled at the same clinical 
endpoint criteria since their overall tumour burden is unchanged (Figure 5.3C). Therefore, I 
can state that Rac1b overexpression together with Apc and TP53 deletion significantly 




























Figure 5.3: Overexpression of RAC1B promotes tumorigenesis and decreases survival in the 
APC P53 model. A: Kaplan-Meier survival graph for induced APC P53 and APC P53 RAC1BOE 
ageing cohort mice (Log-rank test). B: Number of intestinal tumours scored when dissected. 
C: Total area of developed tumours. D: Number of tumours plotted based on their intestinal 
origin. E: Representative picture of a control and Rac1b overexpressing mouse intestines 
when dissected. Tissue was fixed on methacarn to highlight tumoral areas and some tumours 
are marked with arrows. C: SI overview as Swiss-rolls, stained in H&E. Squares mark tumours 
in the section. G: Area of tumours measured on H&E stained Swiss-rolls from 4 and 5 APC 
P53 and APC P53 RAC1BOE mice, respectively. T-test: *= p≤0.05, **= p≤0.01, n.s.= not 
significant, p>0.05. Mice in the cohort (n): APC P53 = 15, APC P53 RAC1BOE = 20. N(area 
tumours) = 4 vs 5. 
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5.2.1.1 Tumour histological study 
Similar to the control animals used for the APC P53 RAC1BKO cohort, mice in this 
experiment demonstrated a rapid tumour initiation phenotype and a lack of tumour invasion. 
Both APC P53 cohorts with either RAC1BKO or RAC1BOE developed comparably and only mice 
with Rac1b overexpression showed a significant difference (decreased survival and increased 
tumour number). In order to mechanistically understand how Rac1b drove this rapid tumour 
formation, a number of analyses were carried out. First, I confirmed Rac1b overexpression 
by qRT-PCR from SI normal tissue and tumours (Figure 5.4A) and WB from SI epithelial 
extractions (EE) (Figure 5.4B) and saw that they maintained expression of human Rac1b over 
time. I then performed some general histological analysis on the tumours for further 
characterisation. Analysis of H&E stained sections revealed that APC P53 mice developed 
larger tumours than mice from APC P53 RAC1BOE group (p=0.033, Figure 5.3G). However, 
these were not invasive since no tumour cells reached either the submucosa or the 
muscularis layers (Figure 5.4C). On the contrary, APC P53 RAC1BOE mice formed lots of small 
adenomas predominantly in the first 20cm of the intestine, with an average size of 0.22mm2. 
They likely originated from the crypts and none of them broke into the submucosa either. 
PAS staining showed a similar pattern of mucus glycoproteins stained and both had a 
comparable DNA damage measured by pH2AX IHC (Figure 5.4D). Since mice were injected 
with a cell proliferation labelling reagent (BrdU) two hours before culling, sections were 
subjected to BrdU+ IHC for proliferation assessment. Scoring was done manually using ImageJ 
and at least 15.000 tumoral cells from 12-18 tumours among different experimental mice 
were used for analysis. As it is shown in Figure 5.4E, there are no differences in their rate of 
proliferation, since both have an almost identical percentage of positive BrdU cells of 37%. 
Same scoring methodology was used to measure their rate of apoptosis by cleaved caspase 
3 staining and again, not significant differences were observed (1.10% in APC P53 and 0.84% 
in APC P53 RAC1BOE tumours, p=0.071, Figure 5.4E). Overall, these reaffirms the lack of 



























    
Figure 5.4: Endpoint tumours do not present morphological differences. A and B: Validation 
of human Rac1b overexpression in cohort mice by both qRT-PCR from SI and SI tumour tissue 
(A) and WB from EE (B). C: Representative H&E staining of SI tumours. Invasive front of the 
tumour is amplified, demonstrating the lack of invasion. D: PAS staining and pH2AX IHC to 
evaluate goblet cell population and DNA damage within tumours, respectively. E: 
Representative images of BrdU and CC3 staining. Positive and total tumour cells were 
manually scored. Proliferation and cell death scores are plotted for each group.  
T-test: **= p≤0.01, ****= p≤0.0001, n.s. = not significant, p>0.05. N (RT-qPCR, WB and 











































































































5.2.1.2 Rac1b overexpression enhances tumour clonogenicity in vitro 
When mice were sampled after culling, tumour adenoma cells were isolated for 
subsequent ex vivo organoid culture in Matrigel. This protocol allows primary tumour 
organoid lines to be established directly from experimental cohort mice. I conducted 
clonogenicity assays on these tumour organoids lines to determine the capacity to form a 
clone from a single tumoral cell. Organoids were digested and sorted through FACS 
(Fluorescence Activated Cell Sorting) to ensure that the resulting cells from digestion will be 
alive, single and in the same number. The latter two characteristics are essential for this assay 
since total number of spheres could be biased if fragments or different number of cells are 
plated. Twenty-five Matrigel drops of 1.000 cells each were plated, and the number of 
spheres formed were measured after 4 days. As it is shown in Figure 5.5, organoids with 
Rac1b overexpression had significantly more clonogenic capacity than APC P53, around 4.5-
fold change more in average (p=0.027). The table with the replicates illustrates the large 
variability of the technique in each repeat, although every time showed the same trend. The 
results given by this assay could be interpreted in two ways: on one side, it might indicate 
that higher levels of Rac1b make the cells more “stem-like” and more capable to grow and 
give rise the different intestinal cell lineages to form a clone. Alternatively, it could also 
suggest that Rac1b provides an advantage to the cells to overcome the harsh process of cell 
digestion and FACS, resulting in more resistant and surviving cells to ultimately form clones. 
Altogether, the assay demonstrates that overexpression of Rac1b enables increased 
tumorigenesis and higher clonogenicity in tumoral cells. Further analyses are required to 






























Figure 5.5: Overexpression of Rac1b confers a major clonogenic capacity to APC P53 
organoids. A: Representative organoid pictures during the clonogenicity assay at day 0, 4 and 
7. B: Summary table of the five replicates, showing the percentage of sphere forming for 
group and the fold change of each experiment. Percentages are plotted in the adjacent 


































5.2.1.3 Intratumour heterogeneity hinders RNAseq analysis 
In order to analyse the cohort by an unbiased approach and elucidate some of the 
Rac1b downstream target genes, RNA from three representative tumours of each cohort was 
sent for RNA sequencing. The results yielded 390 differentially expressed genes, 145 
upregulated and 240 downregulated genes in the APC P53 RAC1BOE group compared to the 
APC P53 (List of genes and detailed FastQC analyses in Appendix 2.3 and 2.5, respectively). 
Data set analysis by PANTHER gene ontology database indicated an involvement of 
inflammation and cell recognition processes. Moreover, most of the candidates seemed to 
be located in the cytoskeleton or the cell membrane (Figure 5.6A), in line with our previous 
RNAseq and BioID analysis from APC mouse model. Looking through the gene set list, some 
interesting targets were picked for further validation, such as Cited1 (WNT target gene, 
positive TGFβ and ERBB2 regulator), IGFBP2 (binding and regulation of insulin growth factor) 
or Klk1 (involved in cell adhesion and extracellular cell matrix remodelling). Validation was 
conducted by qRT-PCR from original RNAseq samples but, surprisingly, very few were 
significantly different. The vast majority of genes analysed showed no differences between 
groups except for Cited1 and Klk1 (Figure 5.6B). After re-analysis of the data, we noticed that 
the FPKM (Fragments Per Kilobase Million) reads presented large variability between 
samples from the same group, which led to false positive significant results (Appendix 2.4). 
Yet there were some interesting targets that I did confirm, but these were not further 
validated when tested in a separate group of tumours (Figure 5.6C), indicating that none of 
these candidates are direct Rac1b effectors. This result, as well as the fact that virtually none 
of the cellular processes were not either up- or down-regulated specifically, suggests that an 

































Figure 5.6: RNA sequencing analysis of endpoint tumours. A: Top up- and down-regulated 
biological processes from RNAseq differentially expressed genes (DEG) comparing APC P53 
and APC P53 RAC1BOE tumours. Gene ontology analyses were performed using Pantherdb. B: 
qRT-PCR validation of five DEG in the sequenced RNA samples. C: qRT-PCR validation of the 
same targets in a larger set of tumour samples.  
T-test: *= p≤0.05, **= p≤0.01, n.s. = not significant, p>0.05. N (RNAseq) = 3 vs 3. N (qRT-PCR 
validation) = 7 vs 6.  
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5.2.2 Pre-tumorigenic model as a strategy to study tumour initiation 
The endpoint tumours have shown high similarity histologically and expression-wise, 
not demonstrating any distinguishable characteristic between genotypes. Yet, there is an 
indubitable difference in the percentage of survival and tumour formation driven by Rac1b 
overexpression. Given that the model emulates an early tumour initiation stage rather than 
an advanced tumour invasion phenotype, analyses of the endpoint tumours might not be the 
most informative source and might hinder to detect early occurring events. High levels of 
Rac1b accelerated and enhanced tumour formation, leading to changes that, perhaps, could 
be more noticeable in the murine intestine before tumours originated. Following this 
rationale, I sought to investigate the function of Rac1b at an early stage of tumorigenesis. 
Therefore, I designed a pre-tumorigenic model with the same genotypes as for the aging 
cohort (APC P53 and APC P53 RAC1BOE) but with a fixed termination day. 31 days after 
induction was chosen as ending point since this is approximately half of the average survival 
for the APC P53 RAC1BOE group. I aimed that by then, some tumours would have started to 
form and either them or the normal intestinal tissue could provide suggestions as to the 
alterations driven by Rac1b.  To ensure the maximum consistency of the intestinal regions 
analysed between mice, a dissection plan was carefully designed (Figure 5.7A). Samples were 
then subjected for histological and molecular analysis.  
 
5.2.2.1 Early adenomas resemble aging cohort phenotype 
When mice were dissected, intestine looked disease-free and virtually no tumours 
were detected macroscopically. I then proceed to conduct a histological and molecular 
characterization of the model. Histologically, there were no major changes by H&E (Figure 
5.7C). Despite being reported that Rac1b could expand the Paneth cell population, neither 
Paneth nor goblet cells were affected, as the Lysozyme IHC and qRT-PCR from the 
corresponding markers show (Figure 5.7C and D). Crypt cells did not present higher nuclear 
β-catenin staining upon Rac1b overexpression and neither there seemed to be more DNA 
damage, measured by pH2AX. Besides, the WNT signalling pathway was not more activated 
in the APC P53 RAC1BOE group, stem cells markers were equally expressed in both groups and 
consequently, proliferation was not increased (Figure 5.7B). However, I did notice some 
tumour-like small lesions in the sections. To confirm that these cells have lost the wild type 





copy of Apc, sections were stained for β-catenin. Nuclear β-catenin staining was detected in 
cells within the lesion, therefore characterizing them as early adenomas or microlesions 
(Figure 5.8C). Moreover, quantification of the lesions from serial sections of the Swiss rolls 
revealed that mice with Rac1b overexpression developed significantly more early adenomas 
compared to the APC P53 group (an average of 65 and 26 microlesions respectively) (p=0.024, 
Figure 5.8B), indicating that the increased tumorigenesis in the aging cohort driven by Rac1b 
is reproducible in a pre-tumorigenic model and noticeable already just 31 days after 
induction. Since I did not observe a phenotype looking at the normal tissue of these mice, I 
decided to repeat a similar histological analysis on the microlesions. Proliferation score 
showed that both groups had an equivalent rate of cell growth, reaffirming again the lack of 
proliferative changes by Rac1b as with the endpoint tumours (34.8% for APC P53 and 34.7% 
for APC P53 RAC1BOE group, Figure 5.8D). However, when apoptosis was measured by CC3+ 
IHC, microlesions from mice with Rac1b overexpression had significantly less cleaved caspase 
3 positive cells than WT group (2.7% vs 1.6% in APC P53 and APC P53 RAC1BOE respectively, 
p=0.002, Figure 5.8D). Moreover, when apoptosis was scored by quantification of apoptotic 
bodies by H&E staining, a similar outcome was observed, validating the reduced cell death in 
these early adenomas with Rac1b overexpression (2.4% vs 1.3% in WTOE and RAC1BOE 
respectively, p<0.0001, Figure 5.8D). Hence, this result would suggest that the increased 
formation of early lesions and following tumours in the APC P53 RAC1BOE group might be due 
to a diminished rate of apoptosis, which would allow transformed cells to pass the cell death 
































Figure 5.7: Characterisation of the day-31 pre-tumorigenic model. A: Schematic 
representation for dissection protocol of day-31 mice. For the SI, the first 3 cm closer to the 
stomach were discarded, and the following was taken to preserve in RNAlater and in liquid 
N2, as well as for parcel fixation. The remaining SI tissue was either for EE or Swiss-roll 
fixation. For the LI, the last cm was discarded and the following was taken for RNAlater and 
N2 preservation and Swiss-roll fixation. B: Staining for BrdU and proliferation score of normal 
intestine. Positive BrdU+ cells were scored in at least 50 half crypts per mouse. C: Histological 
characterization of normal intestine. Tissues were stained for H&E and for lysozyme (Paneth 
cells), pH2AX (DNA damage) and β-catenin IHC. D: qRT-PCR from normal SI tissue for Paneth 
(Lyz1, Defa20) and Goblet cells (Muc2) (i) and stem cells markers (Lgr5, Olfm4, Slc14a1) (ii) 
and WNT/β-catenin target genes (Axin2, Tcf7, Lef1 and Ctnnb1) (iii). T-test: n.s.= not 
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Figure 5.8: Rac1b promotes the early formation of microadenomas and reduces their 
apoptosis. A: Swiss roll overview of day-31 SI tissue stained by H&E. Squares marks the 
microlesions present in section. B: Average of microlesions detected per mouse across serial 
sectioning of tissue. C: Characterisation of microlesions as early adenomas by nuclear β-
catenin IHC. D: Proliferation (BrdU) and cell death (CC3 and apoptotic bodies) scores of 
microlesions. Arrows point to apoptotic cells. Plots presents the average score of at least 5 
microlesions per mouse. 
T-test:  *= p≤0.05, **= p≤0.01, ****= p≤0.0001, n.s. = not significant, p>0.05. N (microlesions) 
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5.2.3 Rac1b confers resistance to cell death through modulation of TGF-β signalling  
An antiapoptotic role has been suggested for Rac1b, either by inducing expression of 
the anti-apoptotic protein MCL1 through AKT2 activation or by stimulating NF-κB activity, 
which induces cell growth but inhibits cell proliferation380,381. Furthermore, over the last 
years, a link between Rac1b and the TGF-β signalling pathway has been suggested. The TGF-
β signalling pathway is a superfamily of cytokines and receptors with a wide range of 
intracellular processes, including cell proliferation regulation, differentiation, invasion and 
apoptosis.  In cancer, it exerts opposite roles based on the tumoral stage. At early stages, 
TGF-β acts as a tumour suppressor by inducing cell cycle arrest and apoptosis in tumoral cells. 
For example, in early colonic mouse adenomas, Apc mutant intestinal cells are more sensitive 
to TGF-β-induced apoptosis than normal epithelial cells, including Lgr5+ cancer initiating stem 
cells554. During CRC progression, there is a selective pressure to diminish TGF-β signalling 
activity and genetic inactivation of its receptors or intracellular mediators such as SMAD4 or 
SMAD3 is detected in 40% to 50% of all adenocarcinomas555. However, high levels of TGF-β 
ligand associates with poor outcome in CRC patients since it facilitates metastasis and cancer 
progression184, hence suggesting a pro-oncogenic role in advanced adenocarcinomas. 
According to Ungefroren et al., Rac1b downregulates TGF-β activity by preventing SMAD3 
phosphorylation, an essential step for initiation of its transcriptional program556. While they 
have mainly focussed attention on the consequences of TGF-β inhibition regarding invasion 
and cell migration, evaluation of its tumour suppressor function upon Rac1b 
deletion/overexpression has not been investigated yet. Furthermore, preliminary proteomic 
studies on epithelial cells from APC P53 and APC P53 RAC1BOE mice suggested a deregulation 
in some SMAD members (data not shown). Since the phenotype observed in the early 
tumoral stage model is a reduction of apoptosis, which would correlate with a TGF-β 
inhibition phenotype, and evidence exists of a crosstalk between Rac1b and TGF-β, I decided 
to assess TGF-β pathway activity in the pre-tumorigenic model. 
 
5.2.3.1 Pre-tumorigenic tissue present different TGF-β activity 
qRT-PCR from day 31 mice SI tissue was carried out for the TGF-β ligands 1 and 2 and 
SMAD4. Consistently, all three markers presented significantly decreased expression in the 
APC P53 RAC1BOE group (Figure 5.9B). SMAD4 is a common mediator for the receptor SMADs 





SMAD2/3 and SMAD1/5/8, which mediates their nuclear translocation by the formation of 
heteromeric complexes. Lower levels of SMAD4 were also observed at the protein level by 
WB, and the same trend was seen when blotting against phosho-SMAD3, a canonical read 
out for TGF-β pathway activity (Figure 5.9A). Altogether, this would suggest that 
overexpression of Rac1b in the small intestine causes a decrease in the activity of TGF-β 
signalling.  
One of the main mediators for TGF-β anti-apoptotic response are the Bcl2 (B-cell 
lymphoma 2) family proteins, which comprises anti- and pro-apoptotic members with shared 
homology in at least one of its four BH domains. Bim is a pro-apoptotic protein of the Bcl2 
subcategory of BH-3-only proteins. Upon apoptotic stimuli, Bim binds to anti-apoptotic Bcl2 
proteins and leads to MOMP-mediated apoptosis (mitochondrial outer membrane 
permeabilization), allowing the release of apoptotic effectors such as Bax or Bak that will lead 
to cleavage-dependent activation of caspases557. TGF-β can induce expression of Bim through 
p-SMAD3-dependent transcription or by ERK-dependent phosphorylation, thereby 
stimulating cell death. Since it was initially discovered as a direct TGF-β apoptotic target in B 
lymphocytes558–561, building evidence has demonstrated Bim as an essential target for TGF-β 
cell death cues. Furthermore, it was shown that Bim expression mediates sensitivity of 
colorectal cancer tumoral cells to TGF-β-induced apoptosis562. In order to assess whether the 
reduced TGF-β activity in the pre-tumorigenic model accounts for the decrease in apoptosis, 
I looked at the levels of the anti-apoptotic TGF-β target gene Bim. qRT-PCR from day-31 
murine intestine demonstrated almost twofold reduction in Bim transcript in the APC P53 
RAC1BOE mice compared to controls (Figure 5.9C). This reduction was also detected at the 
protein level, showing a substantial decrease of the BIMEL isoform in mice with Rac1b 
overexpression, the most abundant isoform (Figure 5.9D). Collectively, these data suggest 
that the low apoptotic microlesions in the APC P53 RAC1BOE group could potentially be a 
consequence of a Rac1b-induced reduction of TGF-β activity and a resultant downregulation 




























Figure 5.9: TGF-β signalling is decreased in Rac1b overexpressing mice. All analyses were 
made on SI epithelial extractions from pre-tumorigenic (day 31) mice. A: WB for SMAD4, 
pSMAD3 and β-actin as housekeeping protein. Densitometry of SMAD4 bands is plotted 
comparing both groups. B: qRT-PCR for SMAD4 and TGF-β ligands 1 and 2. C and D presents 
the downregulation of Bim at the RNA (C) and protein (D) level.  






































































































































































5.2.3.2 Ex vivo organoid culture to study Rac1b-TGF-β modulation 
In order to determine whether TGF-β-induced apoptosis is impaired by Rac1b 
overexpression, I cultured intestinal organoids from the cohort mice as three-dimensional 
organoids embedded in Matrigel. I assumed that to form a tumoral microlesion, cells must 
have lost the remaining copy of the Apc gene, and therefore, the genotype used for modelling 
these lesions in culture was VilCreERT2Apcfl/flTP53fl/fl with or without Rac1b overexpression 
(APC-/- P53 RAC1BOE or APC-/- P53 respectively). Mice were induced, dissected 4 days post 
induction and epithelial cells extracted for either ex vivo organoid culture or RNA and protein 
characterization. As it is shown in Figure 5.10F, mice had a robust overexpression of Rac1b 
and more interestingly, I could also validate the inhibition of Bim by WB in this model. To test 
their TGF-β activity and the efficiency with which they respond to the signal, organoids were 
treated with TGF-β1 ligand for an acute stimulation. This is a commonly used experiment in 
many different 2D cell lines and our lab has confirmed the same procedure in organoids (data 
not published), with 2 hours TGF-β exposure leading to a significant induction of expression 
of TGF-β responsive genes. SMAD7 is an inhibitor of TGF-β receptor 1 (TβR1) but also 
functions as a read out of the pathway, since its expression is increased following TGF-β 
treatment. RNA from organoids treated with TGF-β for 2 hours was extracted and levels of 
TGF-β target gene induction analysed. I found a robust induction of SMAD7 in control APC-/- 
P53 organoids and this was significantly impaired in organoids overexpressing Rac1b 
(p=0.0013, Figure 5.10A). p21 and p15 are Cyclin-dependent Kinase (Cdk) inhibitors which 
are induced by TGF-β to halt cell cycle progression563. They are also early responsive genes, 
and their expression was significantly increased in the control group following acute TGF-β 
treatment (Figure 5.10A). Again, this response was significantly attenuated in organoids with 
Rac1b overexpression (p=0.011). Additionally, similar to the in vivo experiments, the 
expression induction of Bim was also significantly lower in organoids overexpressing Rac1b 
(p=0.024, Figure 5.10A).  Furthermore, treatment of TGF-β during different time points (2, 4, 
6 and 24 hours) and protein analysis confirmed the diminished activation of Bim seen by qRT-
PCR and demonstrated that organoids with Rac1b overexpression never reach Bim induction 
levels observed in APC-/- P53 organoids. This was the case even following 24 hours treatments 
with TGF-β (Figure 5.10B). Accordingly, these data strongly suggest that high levels of Rac1b 
attenuates the response to TGF-β stimuli, resulting in a significant diminution in target genes 
that mediate cell cycle suppression and induce apoptosis.  





I next sought to determine if Rac1b impacts on the physiological outputs of TGF-β 
treatment. In organoids with Apc deletion, treatment with TGF-β causes organoid death 
within 24 hours554. To determine the effect TP53 deletion has on this phenotype, I treated   
APC-/- P53 organoids with TGF-β for an apoptotic assay. Organoids were plated as fragments, 
allowed to form spheres for a day and then treated with increasing concentrations of TGF-β. 
Organoid morphology was scored 24 hours later and classified as either dead (broken 
organoids with dispersed cells and debris) or alive (intact organoids without accumulation of 
debris)439 (Figure 5.10E). At this time point, I observed a clear dose-dependent increase in the 
percentage of dead organoids following TGF-β treatment (Figure 5.10C). Interestingly, the 
proportion of dead organoids was lower in organoids with Rac1b overexpression at all TGF-
β doses, with the clearest differences at 1ng/ml and 3ng/ml (p=0.02 at both doses). To 
confirm organoid death was occurring via induction of apoptosis, I repeated the TGF-β 
treatment for 24 hours exactly as before using 3ng/ml, and the Cell Event™ Caspase3/7 Green 
Detection Reagent from Invitrogen was added for 7 hours before analysis. This reagent has a 
nucleic acid binding dye conjugated to a four amino acid peptide (DEVD), which is cleaved 
when Caspase-3 or -7 are activated, allowing the dye to bind the DNA and releasing a 
fluorescent signal. Thus, organoids containing apoptotic cells emit green light. Photos at 24 
hours were taken and green organoids were scored as area of green pixels relative to total 
organoids area in the Matrigel drop. As is shown in Figure 5.10D, in normal growth conditions 
organoids had equal amounts of cell death (approximately 15%). However, when TGF-β was 
added to the media for 24 hours, cell death increased to ~40% in the APC-/- P53 group but 
only increased slightly to ~20% in the APC-/- P53 RAC1BOE (p=0.028), recapitulating the 
significant decrease in organoid death induction seen before. Therefore, these assays 
demonstrate that overexpression of Rac1b in this organoid system, as in the pre-tumorigenic 
mice models, confers resistance to cell death which is potentially due to a downregulation of 










































































































Figure 5.10: Rac1b impairs TGF-β pathway activation. A: qRT-PCR of early responsive genes 
(SMAD7, Bim, p21, p15) from acute (2 hours) TGF-β treatment in organoids. Total expression 
is the average of three technical replicates within three different cell lines per genotype. B: 
Response of Bim under a TGF-β time course treatment in three organoid cell lines. C: Pictures 
of APC-/- P53 and APC-/- P53 RAC1BOE organoids after 24 hours of TGF-β treatment in the 
media. Graph underneath presents the percentage of cell death. D: Same conditions as in (C) 
but Caspase3/7 Green Detection Reagent was added to the media to allow visualisation of 
cleaved caspase 3. Percentage of cell death was measured by the area of green pixels relative 
to total organoid area. E: Representative picture of a dead organoid (bright field) and 
validation of the reagent (GFP), amplified at 40x. F: Validation of Rac1b overexpression and 
Bim downregulation in the organoid cell lines used for TGF-β treatment. Black and white 
arrows for death and alive organoids, respectively. T-test: *= p≤0.05, **= p≤0.01, ***= 













































































































































































































































































































5.2.3.3 SMAD4 as a potential candidate for Rac1b-dependent TGF-β regulation 
TGF-β is a highly mutated signalling pathway in CRC, favouring tumour initiation 
through inactivating mutations in most of its members. In order to assess whether expression 
of RAC1B may be associated with TGF-β signalling in human samples, an analysis of the COAD 
TCGA dataset was conducted. A pre-defined list of 43 genes integrating the TGF-β pathway 
was used to evaluate COAD tumour samples based on the presence or absence of mutations. 
Analysis of those samples based on RAC1B PSI values showed that samples with lower RAC1B 
PSI (RAC1Blow group) are more likely to present mutations in the TGF-β pathway compared 
to tumours with higher RAC1B PSI (RAC1Bhigh) (Figure 5.11A, p=0.0009).  Altogether, this 
suggests that high RAC1B expression may provide an alternative, non-mutational route, via 
tumours may overcome the tumour suppressive function of TGF-β signalling.   
TGF-β pathway have two mechanisms to induce Bim expression. Upon binding of TGF- 
β1 ligand to receptor, sustained induction of Bim is mediated by p-SMAD3-dependent 
transcription of the transcription factors Runx1 and FOXO3, which will induce a delayed but 
sustained expression of Bim564,565. Parallelly, p-SMAD3 can induce the expression of MKP2, 
which will dephosphorylate and deactivate ERK1/2, therefore preventing ERK1/2-dependent 
degradation of Bim560. Interestingly, TCGA analysis of MPK2 expression revealed that 
RAC1Bhigh tumours express lower levels of MKP2 compared to tumours with high RAC1B 
expression (Figure 5.11B, p≤0.0001). This shows that high levels of RAC1B correlate with 
lower expression of TGF-β target genes, suggesting its mediated downregulation, and 
presents a possible mechanism whereby Rac1b could downregulate Bim expression.  
Even though I have associated a link between Rac1b and the cell death induced by TGF-
β signalling, the mechanism through which this modulation occurs is unknown. SMAD4 is the 
most mutated TGF-β pathway gene in CRC, being altered in about 13% of all CRCs70. Bearing 
in mind the initial downregulation of SMAD4 observed in the pre-tumorigenic intestinal 
tissue at both the RNA and protein level (Figure 5.9), I hypothesised that Rac1b might 
suppress TGF-β signalling by decreasing SMAD4 expression. Interestingly, performing the 
same TCGA analysis looking specifically for mutations in SMAD4 demonstrated that tumours 
harbouring SMAD4 mutations express lower levels of RAC1B compared to SMAD4WT tumours 
(Figure 5.11C, p=0.0004). Hence, this again suggest that tumours with high RAC1B expression 
are not under as strong selective pressure to loss the tumour suppressive functions of 
SMAD4.  





To investigate whether SMAD4 expression is altered following Rac1b overexpression, 
APC-/- P53 and APC-/- P53 RAC1BOE organoid protein lysates were used to analyse SMAD4 
expression by WB. Consistent with my hypothesis, organoids with Rac1b overexpression had 
significantly lower expression of SMAD4 compared to controls (Figure 5.11D). Moreover, IHC 
staining of the endpoint tumours with a SMAD4 antibody showed a decreased 
immunopositivity in samples from the APC P53 RAC1bOE group compared to controls (p=0.01, 
Figure 5.11E). Interestingly, after 2 hours of TGF-β treatment, there was no downregulation 
of pSMAD3 levels by WB (Figure 5.11F). This suggests that phosphorylation of SMAD3 is not 
directly altered by Rac1b overexpression. Altogether, this data points to SMAD4 as a 



































































Figure 5.11: SMAD4 as a potential Rac1b target gene. A: Evaluation of mutations in the TGF-
β pathway by analysing a pre-defined set of genes from CBioPortal and associating the 
presence or absence of mutations in tumours to RAC1B PSI expression (Fisher’s test). B: RSEM 
counts of MKP2 comparing RAC1Blow and RAC1Bhigh TCGA tumours (Mann-Whitney test: 
****= p<0.0001). C: Same as (A) but analysing individually the presence or absence of 
mutations in SMAD4 (Mann-Whitney test: ***= p<0.001). D: Expression of SMAD4 and 
RAC1B in APC-/- and APC-/-RAC1BOE organoids evaluated by WB. E: IHC for SMAD4 of endpoint 
tumour cohort samples. Histoscore comparing APC P53 and APC P53 RAC1BOE is presented 
underneath. F: WB presenting the expression of pSMAD3 of APC-/- and APC-/-RAC1BOE 
organoids treated for 2 hours with TGF-β. Densitometry quantifications of (D) and (F) WB are 
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In this chapter I have outlined the effects of modulating Rac1b expression in a 
theoretically invasive colorectal cancer mouse model, driven by double deletion of Apc and 
TP53.  
First of all, the present model did not lead to tumour invasion in any of the cohorts. 
Therefore, I could not test whether Rac1b is required or can promote invasion using this 
mouse model. Time is a limiting factor for modelling tumour invasion and the speed of the 
current cohort could have been an issue. An ideal mouse model would involve a low 
tumorigenic rate but prolonged survival, allowing tumours to develop and to further progress 
to aggressive carcinomas. Hence, alternative invasive models for studying a loss- and gain-
of-function effect of Rac1b might be more useful and informative than the current one, such 
an orthotopic transplantation of colonic genetic modified organoids or the use of tail vein 
metastatic models. 
The APC P53 model presented an average of 67 tumours and a median survival of 113 
days. Deletion of Rac1b did not prolong survival in this model, as it did when it was depleted 
with Apc alone. p53 is an inhibitor of the WNT signalling pathway and its acute loss along 
with Acpfl/fl enhances the transcription of WNT target genes, hence increasing WNT signalling 
activity566. Therefore, it is possible that APC P53 tumours could have reached a threshold of 
WNT activity that deletion of Rac1b is not sufficient to attenuate tumorigenesis in this 
context. Indeed, mice with Rac1b overexpression did not enhance WNT signalling in this 
context, indicating that Rac1b might not directly modulate the pathway. In fact, this is in line 
with the BioID interactome analysis, which indicated that Rac1b did not interact with any 
core member of the pathway. Hence, deletion of Rac1b in the context of Apc and P53 
deficiency does not reduces tumorigenesis. However, it would be interesting to test if APC 
P53 RAC1BKO mice might confer an enhanced anti-tumorigenic effect if were co-treated with 
an inhibitor of the WNT pathway, EGFR pathway or a chemotherapeutic agent.  
 On the contrary, overexpression of Rac1b in co-operation with Apc and TP53 depletion 
has revealed a very interesting and unknown phenotype: increased tumorigenesis compared 
to the control group and a consequent reduction in survival time after tamoxifen induction. 
Moreover, isolated tumoral cells showed that APC P53 RAC1BOE had an increased clonogenic 
capacity. However, morphological analysis and unbiased analysis by RNAseq of the endpoint 





tumours did not provide much information about Rac1b mechanisms of actions, and I 
therefore sought an alternative approach to understand the mechanism behind these 
findings.  A pre-tumorigenic model with a fixed endpoint was designed for the analysis of 
normal tissue or aberrant crypt foci, aiming to detect at early time points, the intestinal 
alterations driven by Rac1b overexpression. These mice presented early adenomas or 
microlesions which recapitulated the same phenotype as the aging cohort mice, since the 
APC P53 RAC1BOE group had significant more in number compared to controls. Morphological 
analysis by two different means demonstrated that these lesions were less apoptotic. Even 
though the endpoint tumours were not less apoptotic, I did observe that APC P53 RAC1BOE 
organoids performed better in the clonogenicity assay, which is also an indication of a better 
resistance to the harsh process of single cell digestion and FACS and a consequent improved 
survival.  
Due to its anti-apoptotic role while it acts as a tumour suppressor in early tumours, 
and its previous suggested crosstalk with Rac1b, I tested the activity of the TGF-β pathway in 
the pre-tumorigenic model. qRT-PCR of TGF-β ligands and SMAD4 showed reduced 
expression in the SI of APC P53 RAC1BOE mice. Besides, a pro-apoptotic TGF-β target gene 
which has been demonstrated to be a mediator of apoptosis in Apc mutant intestinal cells, 
Bim, was also significantly downregulated. Crypt extraction and 3D organoids culture 
resembled the pre-tumorigenic lesions pattern of expression. For functional analysis of the 
TGF-β pathway, organoids were treated with TGF-β1 ligand. Organoids with high Rac1b were 
less responsive to this treatment and never reached same levels of pathway activation as the 
controls, even after 24 hours of treatment. Other than transcriptionally, I also showed 
phenotypically less TGF-β-induced apoptosis in the APC-/- P53 RAC1BOE organoids by 
measuring death and caspase-3/7 assay.  
Interestingly, TCGA analysis of the colorectal tumours data set revealed a strong 
negative association between RAC1B expression and the presence of mutations within the 
pathway. TCGA tumours that presented at least one genetic alteration among the 43 gene 
list pre-defined by CbioPortal expressed significantly lower levels of RAC1B, measured by its 
PSI. Therefore, this leads to hypothesise that overexpression of RAC1B may be an alternative 
pathway to inactivate TGF-β signalling in colorectal tumours.  
Studies from Ungefroren et al. in PDAC cell lines showed that Rac1b downregulated 
TGF-β through blockage of SMAD2/3 phosphorylation, therefore preventing the complex 





translocating to the nucleus with SMAD4. While preparing this thesis, they have further 
suggested that Rac1b might interact with the G-protein coupled receptor PAR2 and interfere 
with activation of the TβRI/ALK5, hence translating into a decreased activity of the 
pathway404. However, my experiments suggested SMAD4 is a possible candidate to mediate 
Rac1b-dependent regulation. Further, TCGA analysis revealed that tumours with inactivating 
mutations in SMAD4 are less prone to induce RAC1 alternative splicing. My previous 
transcriptomic analysis in pre-tumorigenic intestine tissue demonstrated a significant 
downregulation of SMAD4 mRNA transcript and protein in mice with Rac1b overexpression. 
Further evaluation showed, on one side, that organoids with Rac1b overexpression (which 
presented a TGF-β-induced resistance to cell death) had a decreased expression of SMAD4 
protein. On the other side, histological analysis of endpoint tumours demonstrated lower 
SMAD4+ intensity staining in tumours with Rac1b overexpression. Altogether, these analyses 
strongly point to SMAD4 as a downstream mediator of Rac1b to negatively modulate TGF-β 
activity. 
In summary, I suggest that Rac1b enhances cell transformation by conferring 
resistance to cell death in early transformed tumoral cells, likely via attenuation of TGF-β-
signalling.  
 
5.4 Future work 
Even though the anti-apoptotic role for Rac1b and the involvement of TGF-β seems 
quite plausible, there are some caveats and missing experiments which, due to time, were 
not carried out and would complete this mechanistic hypothesis. On the one hand, since 
SMAD4 is my candidate gene to connect Rac1b and the TGF-β pathway, it would be 
informative to determine whether a physical interaction exists between Rac1b and SMAD4, 
by either immunoprecipitation or co-immunofluorescence. On the other hand, I would like 
to attempt to phenocopy the resistance to TGF-β-induced apoptosis in the organoids by 
downregulating either Bim or SMAD4 in the APC-/- P53 organoids, which would reaffirm these 
two genes as mediators of Rac1b-death resistance. Conversely, overexpression of Bim in the 
APC-/- P53 RAC1BOE organoids would allow us to determine whether Bim regulation mediates 
the observed phenotype. Likewise, it would be interesting to treat APC-/- P53 organoids with 





morpholino to downregulate Rac1b and check whether apoptosis or TGF-β-apoptotic related 
genes increase their expression. 
Interestingly, TCGA data suggest a possible correlation between MKP2 and RAC1B 
expression in tumours. Given that MAPK/ERK pathway constitutes the non-canonical TGF-β 
signalling pathway, it would be interesting to validate whether Rac1b-dependent Bim 
downregulation occurs via downregulation of TGF-β/SMAD signalling or via ERK1/2 signalling 
activation. Moreover, ERK1/2 controls SMADs signalling through inhibition of p-SMAD3, 
suggesting another possible mechanism through which SMADs signalling could be 
downregulated. Inhibition of ERK1/2 by either treating the organoids with ERKi or by CRISPR 
followed by treatment with TGF-β would potentially reveal which pathway is essential for 
Bim inhibition. 
Besides, an essential point to cover was whether Rac1b-driven resistance to apoptosis 
is specific to TGF-β or it is a general trait to any other cell death stimuli. Other people from 
the lab addressed this question by treating APC-/- P53 and APC-/- P53 RAC1bOE organoids with 
oxaliplatin. Survival score by Resazurin cell viability assay revealed no differences between 
genotypes, indicating that, at least in this model, resistance to cell death is a specific trait 
induced by TGF-β signalling. 
Finally, I would like to screen Rac1b function in invasive human CRC organoids and test 
whether it maintains its inhibitory role among TGF-β or it switches along TGF-β to cooperate 
with its oncogenic activities.  
These experiments would help to complete the suggested anti-apoptotic Rac1b role 
and elucidate whether Rac1b might be a good target to tackle therapeutically CRC at another 













Chapter 6: Discussion 
6.1 Summary 
In this thesis, I have described Rac1b functional roles in both normal and transformed 
murine intestine, and presented evidence for Rac1b tumour-related functions in human 
cancers, with special focus on CRC.  
Initially, epithelial fractionation and RNA in situ experiments allowed the quantification 
and visualisation of Rac1b transcript in the intestine. I identified a crypt base preferential 
location for Rac1b, which gradually decreases towards the topmost villus region. In 
physiological conditions Rac1b is expressed at low levels and its expression increases and 
expands across the crypt-villus axis upon Apc loss. This does not necessarily define Rac1b 
splicing as a WNT target gene, as many other factors in conjunction with Apc are 
dysregulated. However, it indicates a potential role for Rac1b in processes leading to 
hyperplastic conditions, such as cancer. TCGA data analyses showed that seven out of twenty 
tumour types expressed significantly higher RAC1B PSI compared to matched normal 
samples (including CHOL, COAD, LIHC, LUAD, LUSC, READ, STAD and THCA). Interestingly, CRC 
is one of the cancers with the highest fold increase. Further analyses within the COAD data 
set revealed that RAC1B expression associates with poor clinical outcome, being more highly 
expressed in advanced and invasive tumours and correlating with lower disease-free survival 
and overall survival. Moreover, its expression defines a subset of Wnt activated CRC tumours 
within the CMS stratification.  
Functional analyses demonstrated that deletion of Rac1b in an Apc-driven adenoma 
mouse model improves survival and decreases intestinal tumorigenesis. Potential molecular 
mechanisms include modulation of EGFR signalling and downregulation of the WNT signalling 
pathway, either through EGFR-dependent or -independent processes. Importantly, Rac1b 
depletion sensitises both mouse and human organoids to EGFRi treatment, pointing to a 
therapeutic benefit for Rac1b deletion. On the contrary, its overexpression in the same 
mouse model enhances tumorigenesis but is restricted to the large intestine. This phenotype 
did not lead to survival changes and the underlying mechanisms are unknown.  
In a different mutational context, overexpression of Rac1b with Apc and TP53 
deficiency leads to an increased tumorigenesis and significant reduced survival. Mice bearing 





Rac1b overexpression developed a rapid tumour initiation, potentially driven by a 
downregulation of TGF-β-dependent induction of apoptosis. Downregulation of SMAD4 and 
Bim stand as potential Rac1b target candidates, the latter being also a mediator of EGFRi-
induced apoptosis. 
Altogether, these data suggest Rac1b as a pro-tumorigenic gene and provide evidence 
for a beneficial clinical outcome if deleted. These results are discussed in further detail below.  
 
6.2 Rac1b is not required for intestinal homeostasis 
When Rac1b was acutely deleted in the murine intestine, no phenotypic changes were 
observed, indicating that its expression is not required during physiological conditions. This 
is not entirely unexpected, given the low basal expression of Rac1b. Therefore, it would 
suggest that environmental or genetic events are necessary to promote its expression and to 
drive its functional roles. In contrast, Li et al. showed that deletion of Rac1b in normal rat 
colonic mucosa decreases expression of the anti-apoptotic protein MCL1 through AKT2 
activation380. MCL1 expression was not assessed in my model and given that apoptosis in 
normal cells is virtually undetectable, I cannot verify whether Rac1b-AKT2-MCL1 activation 
also occurs. 
When Rac1b was overexpressed, no gross phenotypic changes were observed either. 
This is contrary to Kotelevets et al. observation, who detected an increased in proliferation 
and WNT activity using the same model409. Some differences might account for it, such as the 
duration of the experiment or the mouse genetic background. Nonetheless, high 
overexpression of Rac1b on its own is insufficient to initiate tumorigenesis408,409, as I also 
observed after 1-year overexpression of Rac1b with p53 deletion (data not shown). The levels 
of overexpression acquired with this model are comparable to the expression of Rac1b in 
advanced tumours and such levels of expression will likely not be achieved in physiological 
conditions. Therefore, the lack of effect in both of these models reinforces the requirement 
of other oncogenic drivers to translate into a functional impact.  
 





6.3 Rac1b as a promoter of tumorigenesis 
The principal outcome from this thesis is the pro-tumorigenic role of Rac1b, which is 
validated in two different mouse models and in a large set of human expression data. 
Interestingly, these models have led to distinct molecular mechanisms underlying Rac1b 
function (Figure 6).  
Loss of Apc is an initiating event in CRC and occurs in about 85% of all CRCs.  When 
Rac1b is deleted in a benign adenoma model driven by Apc deficiency, it decreases 
tumorigenesis and significantly prolongs mice survival. Interestingly, about half of the knock-
out tumours did not show Rac1b deletion, probably due to positive selection of cells lacking 
efficient Cre deletion of the Rac1b allele. These observations strongly indicate that tumoral 
cells benefit from increased Rac1b expression. Indeed, BaseScope and qRT-PCR experiments 
show that Rac1b expression is significantly increased upon deletion of Apc compared to 
healthy tissue, suggesting a deregulation of the alternative splicing machinery during Apc-
driven cellular transformation (Figure 6, number 1). The lab has shown that a large 
proportion of splicing factors are deregulated following Apc deletion in the murine intestine 
(unpublished data). Among them is SRSF1, which has previously been identified as a key 
positive regulator of Rac1b AS. However, our own preliminary studies differ from previous 
studies. On one side, Jordan and colleagues proposed a model where SRSF1 promotes exon 
3b inclusion while SRSF3 prevents it412. Likewise, upstream activation of signalling pathways 
controls the expression of splicing factors. An example for this is WNT signalling which drives 
SRSF3 expression therefore indicating high WNT activity inhibits Rac1b expression567. On the 
other side, further experiments showed that Rac1b expression correlated with B-RAFV600E-
driven tumours568. However, in other experiments carried out in the lab deletion of SRSF1 or 
SRSF3 in the murine intestine had no effect on Rac1b expression (data not shown). Moreover, 
our observations that Apc loss leads to an increased Rac1b expression further suggests that 
the WNT signalling in fact positively controls Rac1b AS. Apart from in vivo mouse 
experiments, whole-exome sequencing data from the TCGA database supports my 
hypothesis. Expression analyses demonstrate a strong positive correlation between RAC1B 
expression and WNT activated CRC and a strong negative correlation with B-RAF mutated 
tumours. Furthermore, MSI status, which along with B-RAF mutation constitute the driving 
traits for tumours developed through the serrated route, is also negatively associated with 
RAC1B. Stratification of CRC tumours according to the consensus molecular subtypes (CMS) 





classification showed that RAC1B and the CMS1 (MSI, B-RAFmut rich, immunologic) are 
negatively correlated. Therefore, previous assumptions about Rac1b regulation based on cell 
models appear to be not completely accurate and warrant further in vivo validation. Studying 
the splicing factors that lead to Rac1b expression is out of the scope of the current project, 
but their investigation will provide interesting insights into both Rac1b and other possible 
cancer-related alternatively spliced isoforms.  
Tumours developed from APC RAC1bKO mice showed decreased proliferation and 
downregulation of WNT signalling, identified by RNAseq and validated by qRT-PCR. 
Modulation of the WNT pathway by Rac1b has also been suggested in the literature, 
especially from Bapat’s lab. They suggest that Rac1b can localise to the nucleus and promote 
the transcription of β-catenin target genes386,387. Its nuclear location could be plausible given 
the NLS sequence within the PBR region of Rac1b, which targets both its membrane and 
nuclear location264. However, modulation of the WNT pathway upstream of β-catenin is 
something we think unlikely for a number of reasons. Firstly, nuclear staining of β-catenin 
does not decrease upon Rac1b deletion. Secondly, the GTP-bound state would be expected 
to cause Rac1b to localise near to the membrane, where small GTPases are activated. Finally, 
my BioID protein interactome experiment, on top of suggesting a membrane preferential 
location of Rac1b, did not present any core member of the WNT pathway as a Rac1b 
interacting partner. Some resultant proteins might influence its signalling, such as Cyclin Y, 
which phosphorylates LRP6 and primes the receptor for activation upon Wnt ligand 
binding468. The possible regulation of Wnt signalling by Rac1b via Cyclin Y warrants further 
investigation. The NLS might be a conserved motif from other Ras small GTPases such as the 
Ran family, with an active nuclear function. Rac1 has a nuclear location with an important 
role in cell cycle progression, but further investigations are needed for the potential nuclear 
role of Rac1b.  
The positive correlation between RAC1B expression and CMS2 (canonical, WNT driven) 
reinforced the WNT signature observed in the APC RAC1bKO mice. However, its modulation 
may be an indirect rather than a direct effect, according to the BioID interactome. ERBB1 and 
ERBB2 were identified as interacting proteins and due to the enrichment of several 
membrane bound RTKs became the focus for further analysis. These RTKs activate diverse 
kinase signalling cascades such as MAPK and PI3K signalling and are frequently overactivated 
and mutated in cancer. Functional studies revealed that downregulation of Rac1b attenuates 





the activation of EGFR downstream signalling, evaluated by phosphorylation of EGFR, ERK1/2 
and AKT (Figure 6, number 3). Importantly, the strongest difference in activation was 
observed after 10 minutes upon ligand stimulation, when receptor-ligand dimers are 
potentially internalised at the early endosomes and either enter into the lysosomal 
degradation route or are recycled back to the plasma membrane. Signalling pathway 
modulation could be achieved at the receptor level, whereby shifting their internalisation 
fate from the degradation to the recycle route would increase the quantity and availability 
of free receptors at the plasma membrane. Related literature suggests a role for Rac1b in 
driving such modulation. On one side, Rac1 mediates vesicle endocytosis through its effector 
synaptojanin 2, whose overexpression and copy number gains promotes EGFR recycling to 
the cell surface and associates with metastatic breast cancer569,570. Moreover, other Rho 
GTPases mediate EGFR internalisation, such as RhoB, whose location at the late endosomes 
reduces receptor degradation247. Indeed, its overexpression in lung cancer associates with 
EGFRi resistance, whereby RhoB sustains phosphorylated EGFR at the plasma membrane and 
activates AKT signalling571. On the other side, several Rac1b interacting proteins are involved 
in both Rac1-related actin dynamics and in EGFR signalling regulation. One of the caveats of 
BioID is that some of the resultant proteins may not be direct interactors but neighbour 
proteins. However, this also provides a more comprehensive interactome landscape and 
identifies protein networks rather than single interactions. An interesting protein is WASF2, 
which mediates actin polymerisation through activation of the Arp2/3 complex and promotes 
invasion in breast cancer cells through constitutive EGFR endosomal recycling572. Likewise, 
Asap1 also supports this hypothesis. Several studies have suggested its pro-tumorigenic role 
based on enhanced EGFR recycling475,528,532 and one of its effectors, Arf6, has already been 
shown to interact with Rac1b and promote endosomal recycling in neurons535. The 
abundance of membrane proteins, as well as actin-related proteins in the BioID dataset, 
might indicate that both Rac1 and Rac1b could localise in the vicinity of EGFR and ERBB2, its 
main heterodimer partner, and promote their activity by facilitating their recycling dynamics 
(Figure 6, number 4). However, Rac1b might perform this process more efficiently due to its 
levels and GEF-independent activation.  The phenotype observed was a delayed and lower 
EGFR signalling response, pointing to a loss of efficiency in this process upon Rac1b loss. 
Targeting of RTK degradation route is a current approach for attenuating aberrantly activated 
signalling pathways. Therefore, characterising whether Rac1b is involved during receptor 
endocytosis adds a new potentially druggable target to modify this process.  





Furthermore, downregulation of EGFR signalling could also account for the decreased 
activation of the WNT pathway. Given their cooperative role in promoting CRC 
tumorigenesis, mutations in the WNT and Ras pathways are among the most prevalent 
events. Both pathways can be simultaneously activated upon WNT ligand binding, given that 
the β-catenin destruction complex also promotes phosphorylation and degradation of Ras478. 
A positive feedback loop might exist from ERK, whose activation stabilises β-catenin in the 
cytoplasm573,574. Moreover, a recent work has shown that EGFR is required for FZD9B 
phosphorylation, an essential step to mediate internalization of WNT receptor and to 
conduct signal transduction in hematopoietic cells479. Altogether, this indicates that due to 
the cross-activity of both pathways, downregulation of one will likely interfere into the others 
activity. I cannot discard that Rac1b directly modulates WNT signalling (Figure 6, number 2), 
but the interactome data rather points to an indirect consequence following the modulation 
of other pathways such as EGFR.  
 Signalling output seems to be largely context dependent. Whilst co-deletion of Apc 
and Rac1b led to this interesting phenotype, no effect was observed when it was deleted in 
an Apc- and TP53-deletion model. One of the hypotheses includes the levels of WNT activity. 
Acute induction of this model showed that TP53 induced a subtle but significant increase in  
the transcription of WNT target genes566. Besides, it has recently been demonstrated that 
p53 represses the transcription of some WNT ligands (WNT1, WNT6 and WNT7A) and its loss 
induces their cell-autonomous secretion in cancer cells, leading to an enhanced WNT 
activity575. This could suggest that APC P53 RAC1bKO tumoral cells might reach a threshold of 
WNT activation where deletion of Rac1b alone is not enough to counteract it. A suggestive 
event is the cellular response upon knocking-out Rac1b: whereas almost half of the tumours 
analysed of the APC RAC1bKO cohort overcame Rac1b deletion, all APC P53 RAC1bKO tumours 
maintained its knock-out throughout tumorigenesis. This indicates that, in this context, 
expression of Rac1b does not exert a positive selective pressure. Although mice did not 
present a different phenotype, subtle molecular changes might have occurred. Further 
characterization could be interesting, especially to explore a potential synergism of Rac1b 
deletion under therapeutic treatments. However, a large part of the project was invested in 
describing other co-occurring mouse models, such as the APC P53 with Rac1b 
overexpression. 





Overexpression of Rac1b in this same model substantially decreased survival as a result 
of increased tumorigenesis. These mice modelled a tumour initiation phenotype whose 
enhanced tumorigenesis was validated in two different cohorts: an ageing and a pre-
tumorigenic time point cohort. Interestingly, the latter developed small micro lesions which 
nuclear β-catenin staining characterised as early adenomas. Histological analysis revealed a 
decreased rate of apoptosis in the APC P53 RAC1bOE group, which likely allowed the 
progression of transformed cells and their evolution towards adenomas. Even though the 
endpoint tumours did not present an anti-apoptotic phenotype, clonogenicity experiments 
from isolated tumoral cells demonstrated a higher clonogenic rate, which also indicates that 
these tumours were more resistant to the stressful conditions of this assay than controls. 
Mechanistically, dysregulation of TGF-β signalling appeared as a feasible explanation for a 
number of reasons. Initially, a previous MS analysis from intestinal epithelial fractions of pre-
tumorigenic mice pointed to some SMADs members being downregulated (data not shown). 
Moreover, TCGA analyses demonstrated that tumours with high RAC1B expression bear 
fewer inactivating mutations in the TGF-β pathway, indicating that these tumours might 
utilise RAC1B to downregulate the pathway. Furthermore, consistent studies from 
Ungefroren and colleagues have associated RAC1B expression and lower TGF-β activity403,550. 
Expression analysis in the pre-tumorigenic tissue showed a downregulation in some TGF-β 
core members, such as SMAD4, its ligands TGF-β1 and 2 and importantly, a decrease in its 
pro-apoptotic target Bim (Figure 6, number 5). Moreover, acutely deleted APC-/- P53 RAC1bOE 
organoids recapitulated this phenotype and were more resistant to cell death upon TGF-β 
stimulation. Interestingly, resistance to cell death was a specific response from TGF-β, since 
treatment with oxaliplatin did not show any difference. Expression and histologic analyses 
point to SMAD4 as the candidate gene through which Rac1b might downregulate the 
pathway, but direct evidence of this is lacking (Figure 6, number 6). Although the molecular 
mechanism through which Rac1b modulates the pathway is unknown, decreased expression 
of Bim was consistently observed when Rac1b was highly expressed. Indeed, stimulation of 
TGF-β for 24 hours showed that Bim never reached the same expression levels as the control 
organoids. This is of relevance, especially due to the EGFR modulation observed in the 
previous cohort. Inhibitors of EGFR mediate cell death through expression of Bim, since 
activated ERK1/2 phosphorylates Bim and promotes its degradation. Interestingly, TGF-β can 
induce Bim expression directing its transcription (delayed but sustained expression) or 
through the expression of the phosphatase MKP2 (rapid response), which deactivates ERK 





and prevents its mediated Bim degradation560. Therefore, Rac1b-driven downregulation of 
the TGF-β pathway could also enhance EGFR signalling and favour its resistance to inhibitors 
(Figure 6, number 7). TCGA analyses showed that RAC1Bhigh tumours expressed lower levels 
of MKP2, once again suggesting the lower activation of the pathway through one of its 
targeted genes. However, these are aspects that warrant further investigation since non-
canonical TGF-β activation was not assessed during my thesis and I did not determine 
whether MKP2 was downregulated in my models.  
Aside from modulating SMAD4 expression, an alternative hypothesis might include 
TGF-β receptor recycling regulation, similar to what I have speculated for EGFR. However, it 
is shown that clathrin-dependent endocytic recycle of TGF-β would enhance its activity, since 
endosomal internalisation is required for SMAD activation576,577. Thence, it would not explain 
why Rac1b downregulates the pathway. Alternative internalisation routes exist, such as the 
endocytosis mediated by lipid-rafts. These facilitate receptor degradation, switching off the 
signal. TβRs localised at cholesterol-rich lipid rafts associate with the non-canonical/MAPK 
mediated TGF-β signalling578. If an endocytic modulator role was identified for Rac1b, 
investigating whether it affects TβR internalisation would be of interest. Hints of Rac1b-
mediated receptor regulation have also been suggested by Ungefroren et al., whose recent 
data points to the G protein coupled-receptor Par2 as a Rac1b effector for TβRI/ALK5 
downregulation404. Despite my signalling output being similar to theirs, the cellular function 
is different. In their cell model, TGF-β induces cell migration and deletion of RAC1B translates 
into a decreased invasion403,550. TGF-β response largely depends on the mutational 
background of the tumoral cell. For instance, Apc-only deleted organoids die upon TGF-β 
treatment (data from the lab). Co-deletion of TP53 delays death response but virtually no 
clones survive after 48 hours of TGF-β in the media. However, triple mutant AKP organoids 
(Apc, K-Ras and TP53) partially overcome the tumour suppressor function of TGF-β and a 
proportion of cells undergo EMT as a response of TGF-β stimuli (unpublished data). It is yet 
unknown whether Rac1b might inhibit the oncogenic functions of TGF-β or would switch 
along with it, promoting invasion. Bearing in mind the positive association of Rac1b with 
invasive and metastatic tumours, it might suggest that it would functionally cooperate with 
TGF-β. The dual response of TGF-β is greatly influenced by the stroma. Most of the TGF-β 
ligands in advanced tumours are secreted from the stroma and this context-dependent 
situation might potentially promote its oncogenic switch184. The TGF-β-driven oncogenic role 
of Rac1b might require a stromal component and this might explain why Ungefroren et al. 





observe a suppressive role of Rac1b during tumour cell invasion in their experiments. 
Moreover, a large body of evidence involves Rac1b in invasive processes, especially through 
MMP3- and E-cadherin-dependent EMT induction390,395. Therefore, the interconnection 


















Figure 6: Pro-tumorigenic functions of Rac1b.  Upon Apc loss, the destruction complex (DC) 
cannot associate and free cytoplasmic β-catenin translocates to the nucleus, where it binds 
to TCF/LEF transcription factors and initiates the transcription of WNT target genes. (1) In 
this scenario, levels of Rac1b increase. (2) It has been described that Rac1b might promote 
WNT signalling through interacting with Dvl. However, I have not observed evidence for this 
interaction or any other interaction with the DC or WNT receptors. (3) Rac1b is required to 
maintain EGFR phosphorylation and activation of its downstream pathways, such as AKT and 
ERK. (4) There are some hints that Rac1b could activate EGFR by promoting its membrane 
recycling and preventing its lysosomal degradation, although functional evidence is required. 
Interestingly, EGFR can promote WNT signalling by phosphorylating FZD9B and recruiting the 
DC to the plasma membrane. EGFR can also potentiate Rac1b expression by targeting for 
ubiquitylation its negative splicing regulator HnRNP A1. (5) In parallel, Rac1b downregulates 
TGF-β signalling as observed by the decrease of its target genes Bim, p21 and p15 and 
SMAD4. (6) Mechanistically, it could inhibit SMAD4 directly although evidence is required. 
(7) Moreover, downregulation of Bim could also be achieved by the downregulation of the 
TGF-β target gene MKP2, which would inhibit ERK and prevent Bim degradation. Altogether, 
through EGFR and WNT activation and TGF-β downregulation, Rac1b expression results in an 
increased proliferation and a reduced cell death in tumoral cells.  
Green and red arrows indicate positive and negative stimulation, respectively. Black arrows 
correspond to processes described elsewhere. Dashed arrows are processes that require 
further evidence.   
 





6.4 Therapeutic benefit of targeting Rac1b 
Rac1b-deficient mouse organoids and inhibition of Rac1b with a specifically designed 
antisense morpholino in human CRC organoids conferred an enhanced sensitivity to EGFRi in 
both systems. This is in apparent contradiction with the positive correlation of Rac1b with 
the CMS2 subtype, which is associated with a good response to EGFR mAbs such as 
cetuximab. However, I have shown that RAC1B expression increases in invasive and 
metastatic tumours. Further analyses showed that RAC1B expression stratifies CMS2 
tumours within two subtypes: RAC1Blow and good survival or RAC1Bhigh with poor survival and 
high WNT activity. Interestingly, the later presents a survival as poor as the CMS4, the worst 
prognostic CMS type. This Rac1b-driven substratification is highly similar to a previous 
classification attempt conducted by Sadanandam and colleagues202. They identified a 
subtype termed the transit-amplifying group (TA), whose traits largely correspond to those 
from the CMS2. Interestingly, response to cetuximab stratifies the TA subgroup into 
cetuximab-sensitive (TA-CS) or cetuximab-resistant (TA-RS) tumours. Given the treatment 
sensitivity acquired when Rac1b is deleted and the survival curve of CMS2-RAC1Blow, it seems 
feasible to think that RAC1B expression correlates with tumoral treatment response. At 
present, analyses are being undertaken to determine whether RAC1B expression correlates 
with expression markers of cetuximab resistance in the TCGA cohort. Altogether, this could 
indicate that RAC1B expression in CMS2 tumours might predict the tumour clinical response 
to treatment. 
EGFR acquired resistance is virtually an unavoidable event. To date, up to 70% of CRC 
tumours present mutations in members of the EGFR signalling pathway579. Even so, 
resistance is also acquired without the presence of these genetic drivers. Recently, a non-
genetic mechanism has been proposed whereby tumours might undergo a transcriptomic 
switch from CMS2 to CMS4 subtype to develop cetuximab resistance580. In line with this, 
hyperactivation of other signalling pathways might confer resistant traits. For example, it has 
been shown that concomitantly with EGFR signalling inhibition, WNT signalling increases and 
its enhanced activity is responsible for acquired cetuximab resistance171,581. Both studies 
suggest that co-treatment with a WNT signalling inhibitor might sensitise resilient tumour 
cells. Other pathways that become hyperactivated upon cell-autonomous activation of EGFR 
include Rac1 signalling. Indeed, EGFR promotes Rac1 signalling through Akt-dependent 
Tiam1 activation, indicating their cross-activity582. A number of studies have demonstrated a 





synergetic effect when Rac1 activity is targeted along with EGFR501,502. However, direct 
targeting of Rac1 is therapeutically challenging given its ubiquitous location and multimodal 
function. Alternative strategies might include targeting of GEFs or GAPs to downregulate its 
activity, but previously I have outlined how their context-dependent function might lead to 
undesired effects348,349,532. Given the specific tumour-related role of Rac1b and the lack of 
physiological functions, its deletion is foreseen to be well-tolerated with fewer collateral 
effects. Furthermore, its deletion could simultaneously lead to the decrease of both EGFR 
and WNT signalling, potentially preventing the resistant response of the WNT pathway. 
Besides, a positive feedback loop seems to exist between EGFR and Rac1b expression, 
whereby EGFR promotes exon 3b inclusion583. Hence, EGFR targets Rac1b expression to 
promote tumorigenesis and Rac1b participates in mediating its oncogenic function. An 
important aspect still to be considered is whether Rac1b might also sensitise tumours mutant 
for K-RAS. K-RAS mutation is the main genetic hallmark for EGFR mAbs response and one of 
the few molecular parameters considered for clinical decision making, since K-Rasmut tumours 
are intrinsically resistant. The pro-apoptotic protein Bim is the main mediator for EGFR-
mediated apoptosis and its expression can identify the tumoral response to kinases 
inhibitors, such as EGFRi or MEKi584. Recently, it was shown that the use of a BH3-only 
mimetics induces cell death to CRC adenoma organoids. Importantly, this mimetic eventually 
sensitised K-Rasmut tumours as well585. Given that Rac1b downregulates Bim expression, its 
deletion might also favour to sensitise K-Rasmut tumours. Hence, it is of paramount 
importance to describe whether this subset of patients (that accounts for up to the half of 
CRCs) might benefit from RAC1B inhibition.  
Despite my efforts in determining the potential therapeutic benefit for Rac1b, its 
inhibition would be unlikely to be beneficial as a single therapy. Although its expression is 
required for a full oncogenic outcome, its deletion did not completely prevent either 
tumorigenesis nor EGFR or WNT signal. Moreover, its depletion in models with a higher 
mutational load such as the APC P53 model did not result in survival improvement. This is 
consistent with the data obtained with RAC1B knock-out in human organoids. While benign 
organoids presented a growth defect upon Rac1b-morpholino treatment, invasive 
carcinomas were only affected when co-treated with an EGFRi. This agrees with the current 
philosophy for anti-cancer treatment, which includes the targeting of more than one gene 
using more than one inhibitor agent (multi-target drug approach). Therefore, while Rac1b 
inhibition might confer anti-cancer properties, its effect might only be observed clinically 





when combined with other agents. I suggest that combined treatment of EGFRi and Rac1b-
morpholino might affect tumour performance and potentially avoid or expand the time to 
relapse. Furthermore, I also provide evidence for a prognostic role of RAC1B, whose 
expression might anticipate therapy response and aid treatment decision.  
 
6.6 Concluding remarks 
Since it was discovered 20 years ago, Rac1b has largely been recognised as a tumour-
related isoform but in vivo investigation of its function was missing. Here, I have provided 
evidence for a tumour-specific role of Rac1b. Whilst its expression is not required for 
physiological intestinal homeostasis, Rac1b promotes tumorigenesis. Tumours without 
Rac1b expression perform poorly, while higher levels of Rac1b enhance cell transformation. 
Human data indicate a possible role for Rac1b during invasion and metastatic disease, albeit 
its function awaits in vivo evaluation. Importantly, Rac1b might be involved in treatment 
resistance processes, since depletion of its expression sensitises tumour organoids to EGFR 
inhibitors. Therefore, these data present Rac1b as a potential druggable target and as an 
indicator of malignant disease. Further studies are required to validate these findings and 
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Appendix 2: RNAseq results 


















































Table appendix 2.1: List of significant upregulated and downregulated genes comparing 
APC and APC RAC1BKO tumours. BaseMean is the average of all normalised count values. 
Log2FC (log2 fold change) is the change in gene expression reported on a logarithmic scale 
to base 2. Significant changes are evaluated by adjusted p values below 0.05. 
Downregulated genes 

















Per base sequence quality (A), per sequence quality scores (B) and per base sequence content 




































































































































































































































Table appendix 2.2: List of significant upregulated and downregulated genes comparing 
APC P53 and APC P53 RAC1BOE tumours. BaseMean is the average of all normalised count 
values. Log2FC (log2 fold change) is the change in gene expression reported on a logarithmic 
scale to base 2. Significant changes are evaluated by adjusted p values below 0.05. 
Downregulated genes 



























































Table appendix 2.3: Individual expression data from APC P53 and APC P53 RAC1BOE 
tumours. Gene names and FPKM (fragments kilobase per million reads mapped) values 
shown individually per each tumour, demonstrating the variability within groups. AP: APC 
P53; APR: APC P53 RAC1BOE. 
Downregulated genes 
















Per base sequence quality (A), per sequence quality scores (B) and per base sequence content 
































































































APC P53 RAC1BOE_1: 
A. B. 
C. 
APC P53 RAC1BOE_2: 
A. B. 
C. 



































APC P53 RAC1BOE_3: 
A. B. 
C. 

































Table continues in the next page. 




























Table appendix 3: List of genes within each dataset utilised for GSEA. The 
“SANSOM_APC_TARGETS” list are genes up-regulated after Cre-lox knockout of APC 
(GeneID=324) in the small intestine. The “SANSOM_WNT_PATHWAY_REQUIRE_MYC” list are 
Wnt target genes up-regulated after Cre-lox knockout of APC (GeneID=324) in the small 
intestine that require functional MYC (GeneID=4609). The “Lrg5 high vs low study C” list is 
derived from the supplementary data (Table S1) of the Merlos-Suarez et al. paper from 2011 
(murine Lgr5 refined ISC signature). The “Direct and functional βcatenin target genes in 
SW480” is derived from the supplementay data (Table S1) of the Watanabe et al. paper from 
2014 (combined analysis of βcatenin target genes in SW480 cancer cells by CHIPseq and 
siRNA depletion.  































Table appendix 4: Extended BioID protein list. Protein IDs, protein names and genes names 
from the significantly different BioID hits. It is also shown the percentage of sequence 
coverage, the molecular weight and length of proteins and the MS counts per condition and 
total MS counts per protein.  
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